data_2lwz_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lwz _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.627 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.435 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.13 -91.6 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.45 -0.781 . . . . 0.0 110.608 -178.789 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.435 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.7 m120 -101.57 26.2 7.59 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.366 -0.834 . . . . 0.0 109.886 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.627 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -95.55 158.03 15.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.371 -0.831 . . . . 0.0 109.567 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.423 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.3 OUTLIER -91.57 132.0 36.61 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.66 -0.65 . . . . 0.0 110.587 -178.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.18 136.14 35.89 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -151.62 125.01 8.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.276 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.5 -146.65 40.91 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.1 m -46.85 -32.47 3.76 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.369 -1.077 . . . . 0.0 110.163 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -48.88 -50.49 34.72 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.991 -1.068 . . . . 0.0 108.728 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.9 tp -56.04 -54.44 44.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.473 -0.767 . . . . 0.0 109.519 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.53 -66.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.261 -0.9 . . . . 0.0 110.04 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.482 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 49.2 mt-10 -47.46 -28.61 2.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.208 -0.932 . . . . 0.0 109.388 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.497 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.16 -54.51 5.92 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.36 -0.838 . . . . 0.0 109.297 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.78 -35.28 43.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.367 -1.458 . . . . 0.0 108.581 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -49.31 -49.14 45.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.385 -0.822 . . . . 0.0 110.289 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.489 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 4.2 mp -68.62 -50.96 47.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.558 -1.339 . . . . 0.0 108.592 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -50.65 -58.81 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-O 121.482 0.658 . . . . 0.0 109.847 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.31 -23.72 54.31 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.67 -125.99 27.67 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -78.75 -14.0 59.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.384 -1.068 . . . . 0.0 110.463 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 22.7 mtt180 -58.07 -26.88 63.09 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.973 -1.079 . . . . 0.0 109.647 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.56 155.99 5.61 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.63 173.01 17.58 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.324 . . . . 0.0 110.413 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 32.3 p90 -116.62 140.18 49.68 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -80.49 170.24 16.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.63 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 9.8 t -65.01 175.6 1.5 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.995 -1.066 . . . . 0.0 110.219 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.63 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -43.52 150.22 0.54 Allowed Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 121.497 -0.752 . . . . 0.0 110.115 -178.584 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo . . . . . 0 N--CA 1.484 0.93 0 C-N-CA 122.252 1.968 . . . . 0.0 110.658 179.478 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.53 -25.62 74.85 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.15 -56.38 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.212 0 O-C-N 121.056 -1.261 . . . . 0.0 110.45 -179.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.524 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.1 t -62.42 -64.18 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.94 -1.1 . . . . 0.0 111.4 -177.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.517 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.9 mt-10 -55.8 -46.36 78.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.873 -1.142 . . . . 0.0 110.355 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 62.1 tp60 -47.99 -56.65 7.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.074 -1.016 . . . . 0.0 110.101 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 59.0 m -84.71 -28.25 26.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 111.072 -178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.415 ' N ' ' O ' ' A' ' 39' ' ' VAL . 52.4 t -83.49 -52.24 6.67 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.733 -1.229 . . . . 0.0 109.231 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.517 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t-80 -70.46 -27.89 64.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.346 -0.846 . . . . 0.0 109.231 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.9 m -136.92 159.85 40.63 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.437 -0.79 . . . . 0.0 109.431 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 7.7 mm -82.8 99.7 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.307 -0.87 . . . . 0.0 109.088 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.9 p -91.15 150.83 21.22 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.094 -1.003 . . . . 0.0 109.32 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.5 167.45 14.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.232 -0.918 . . . . 0.0 109.112 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.77 -34.81 67.97 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.06 -57.53 3.32 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.867 0.841 . . . . 0.0 110.025 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -59.73 -42.48 93.24 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.3 mt -62.02 -32.25 72.71 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -69.91 -9.54 55.34 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -75.86 -28.56 58.22 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.824 -0.548 . . . . 0.0 109.702 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.457 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.4 m-85 -102.13 6.89 41.09 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.372 -0.83 . . . . 0.0 109.948 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 65.0 m -80.29 111.18 16.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.023 -1.048 . . . . 0.0 109.282 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.955 -1.021 . . . . 0.0 109.437 179.97 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.632 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.426 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -101.61 -91.93 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.383 -0.823 . . . . 0.0 110.851 -178.566 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.426 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.8 m120 -101.21 26.03 7.56 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.403 -0.811 . . . . 0.0 109.807 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.94 160.84 14.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.384 -0.822 . . . . 0.0 109.483 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -95.95 136.77 35.95 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.577 -0.702 . . . . 0.0 110.092 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -98.38 136.11 39.0 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.16 124.76 9.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.933 . . . . 0.0 109.236 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.71 -147.34 41.66 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.6 m -45.94 -32.59 2.79 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.393 -1.063 . . . . 0.0 110.197 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -48.68 -49.99 35.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.978 -1.077 . . . . 0.0 108.753 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 22.6 tp -57.33 -51.79 67.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.411 -0.805 . . . . 0.0 109.484 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.8 t -49.08 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 110.065 -179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 53.2 mt-10 -47.47 -28.45 2.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.406 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.497 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.08 -54.94 5.5 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.377 -0.827 . . . . 0.0 109.206 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.37 -35.63 39.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.402 -1.436 . . . . 0.0 108.772 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -49.35 -50.02 41.74 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.355 -0.841 . . . . 0.0 110.422 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.497 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.3 mp -67.68 -50.7 56.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.612 -1.305 . . . . 0.0 108.595 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -51.25 -59.19 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.485 0.66 . . . . 0.0 110.318 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 22.8 m -76.59 -23.26 53.46 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.419 -0.801 . . . . 0.0 109.932 -178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.11 -129.58 27.77 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.352 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -73.43 -16.71 61.31 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.437 -1.037 . . . . 0.0 110.589 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 49.0 mtp180 -54.95 -28.54 52.03 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 109.426 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.8 156.31 6.06 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 107.799 -2.12 . . . . 0.0 107.799 -178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -156.27 172.68 18.05 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.835 -1.391 . . . . 0.0 110.44 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.554 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 31.5 p90 -116.57 127.24 54.32 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -67.58 172.14 5.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.442 ' HG1' ' H ' ' A' ' 28' ' ' ASP . 10.2 t -62.6 174.39 1.02 Allowed 'General case' 0 C--N 1.295 -1.762 0 O-C-N 120.641 -1.287 . . . . 0.0 109.359 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.442 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -43.58 150.74 0.51 Allowed Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.341 -0.849 . . . . 0.0 110.409 -177.829 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo . . . . . 0 N--CA 1.484 0.947 0 C-N-CA 122.111 1.874 . . . . 0.0 110.421 179.297 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.477 ' O ' ' N ' ' A' ' 38' ' ' ILE . 12.0 ptt180 . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.86 -22.98 0.11 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.56 -54.27 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 O-C-N 120.978 -1.307 . . . . 0.0 109.787 179.924 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.18 -64.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.057 -1.027 . . . . 0.0 111.76 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -58.57 -41.35 85.49 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.768 -1.208 . . . . 0.0 110.884 -178.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.2 tp60 -50.58 -55.95 13.95 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.972 -1.08 . . . . 0.0 109.553 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 81.6 m -85.23 -26.55 26.63 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 111.222 -178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.405 ' N ' ' O ' ' A' ' 39' ' ' VAL . 49.1 t -83.94 -52.62 6.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.604 -1.31 . . . . 0.0 109.821 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.6 t60 -68.99 -29.41 67.61 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.248 -0.907 . . . . 0.0 109.175 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -137.14 157.89 45.68 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.55 -0.719 . . . . 0.0 109.572 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.3 mm -78.96 119.07 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.38 -0.825 . . . . 0.0 108.822 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.9 p -111.03 156.57 21.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.364 -0.835 . . . . 0.0 109.687 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 p -88.97 166.79 13.68 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.37 -0.831 . . . . 0.0 109.395 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.7 mt -59.65 -32.53 70.54 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.53 -57.68 3.45 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.802 0.81 . . . . 0.0 110.123 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -60.82 -42.46 97.74 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 119.799 -0.76 . . . . 0.0 108.959 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.6 mt -61.42 -26.03 67.6 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.17 -8.55 57.28 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -79.8 -26.34 40.6 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.848 -0.532 . . . . 0.0 109.926 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -100.0 6.1 45.11 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.266 -0.896 . . . . 0.0 110.448 -179.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.425 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 85.1 m -76.39 111.6 12.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.921 -1.112 . . . . 0.0 109.403 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 25.5 t-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.457 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.646 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.432 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -105.13 -91.88 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.508 -0.745 . . . . 0.0 110.678 -178.514 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.432 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.2 m120 -98.98 25.41 6.72 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.303 -0.873 . . . . 0.0 109.745 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.646 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.99 160.47 14.44 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 109.512 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.2 p-80 -96.2 138.7 33.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.613 -0.68 . . . . 0.0 110.101 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.94 134.09 44.44 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.43 124.86 10.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -0.947 . . . . 0.0 109.203 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.74 -148.48 43.38 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -45.07 -32.26 1.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.322 -1.105 . . . . 0.0 110.22 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -48.79 -50.3 34.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.944 -1.098 . . . . 0.0 108.755 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.04 -54.65 44.35 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.482 -0.762 . . . . 0.0 109.579 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 t -46.58 -66.3 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.303 -0.873 . . . . 0.0 110.067 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 65.6 mt-10 -47.81 -27.83 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.491 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.65 -54.47 5.85 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.319 -0.863 . . . . 0.0 109.14 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.61 -35.3 41.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.402 -1.437 . . . . 0.0 108.626 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.44 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.6 t80 -49.32 -49.6 43.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.306 -0.871 . . . . 0.0 110.37 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.507 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 4.0 mp -68.36 -50.88 50.04 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.533 -1.355 . . . . 0.0 108.607 179.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -50.54 -58.72 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 CA-C-O 121.511 0.672 . . . . 0.0 109.602 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.03 -23.69 55.16 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.497 -0.752 . . . . 0.0 109.749 -179.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 52.91 -131.08 40.66 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -75.69 -11.52 60.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.345 -1.091 . . . . 0.0 110.158 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.401 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -58.21 -27.76 64.2 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.092 -1.005 . . . . 0.0 109.488 -179.453 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.72 155.22 5.28 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -156.51 172.73 18.03 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.936 -1.332 . . . . 0.0 110.277 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 33.8 p90 -115.74 137.39 52.13 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -77.13 171.13 15.31 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -63.89 175.02 1.27 Allowed 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.798 -1.189 . . . . 0.0 109.9 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -43.14 148.39 0.61 Allowed Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.494 -0.754 . . . . 0.0 110.229 -178.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo . . . . . 0 N--CA 1.483 0.909 0 C-N-CA 122.128 1.885 . . . . 0.0 110.409 179.326 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.9 ptm180 . . . . . 0 N--CA 1.486 1.358 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.7 -24.27 76.42 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.9 -55.3 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.261 0 O-C-N 121.098 -1.236 . . . . 0.0 110.349 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -63.54 -64.27 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.024 -1.047 . . . . 0.0 111.278 -177.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 44' ' ' HIS . 30.2 mt-10 -55.01 -45.74 75.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.373 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -48.74 -57.63 6.02 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.099 -1.0 . . . . 0.0 110.304 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 45' ' ' SER . 59.0 m -84.88 -25.36 28.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.173 -0.955 . . . . 0.0 111.435 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 48.3 t -84.24 -52.34 6.31 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.535 -1.353 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.421 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.9 t60 -68.91 -26.77 65.26 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.22 -0.925 . . . . 0.0 109.195 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 12.6 t -136.71 173.32 11.83 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.458 -0.776 . . . . 0.0 109.473 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.65 99.6 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.3 p -91.53 152.49 20.29 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.126 -0.984 . . . . 0.0 109.72 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -86.67 166.7 15.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.326 -0.859 . . . . 0.0 109.32 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.8 mt -57.39 -34.91 69.35 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -43.97 -57.19 3.46 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.862 0.839 . . . . 0.0 109.978 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.71 -42.59 93.41 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.4 mt -61.89 -32.36 72.73 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.98 -9.61 55.76 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -75.88 -28.15 58.02 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.799 -0.563 . . . . 0.0 109.664 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 7.9 m-85 -102.86 6.99 39.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.407 -0.808 . . . . 0.0 109.95 -179.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 62.2 m -79.26 108.23 12.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.984 -1.072 . . . . 0.0 109.456 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.548 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.645 ' H3 ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.437 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -101.92 -91.69 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -0.812 . . . . 0.0 110.607 -178.738 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.437 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.3 m120 -101.73 26.08 7.82 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.351 -0.843 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.645 ' NE2' ' H3 ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.59 160.16 14.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 109.708 -179.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -92.05 134.61 34.67 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.53 0.681 . . . . 0.0 110.541 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.4 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.4 mp -98.53 130.69 45.1 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -149.12 125.06 10.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.107 179.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.63 -148.34 43.36 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -45.02 -32.64 1.75 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.394 -1.062 . . . . 0.0 110.321 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -48.87 -50.31 35.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.004 -1.06 . . . . 0.0 108.745 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.5 tp -57.13 -55.05 39.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.404 -0.81 . . . . 0.0 109.562 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -46.31 -66.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.313 -0.867 . . . . 0.0 109.945 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 34.4 mt-10 -47.69 -26.67 1.62 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 -179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.501 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.07 -54.31 5.65 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.365 -0.834 . . . . 0.0 109.082 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.71 -34.48 39.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.372 -1.455 . . . . 0.0 108.658 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.8 t80 -50.49 -49.59 55.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.301 -0.874 . . . . 0.0 110.336 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.492 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 4.2 mp -68.26 -50.29 54.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.591 -1.318 . . . . 0.0 108.556 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.5 t -50.68 -59.38 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.522 0.677 . . . . 0.0 109.745 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.05 -23.64 55.1 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 -178.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.48 -123.78 20.2 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -80.28 -16.56 54.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.355 -1.085 . . . . 0.0 110.584 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 15.8 mtt180 -55.92 -27.12 50.78 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.053 -1.029 . . . . 0.0 109.52 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.5 6.05 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -156.57 172.96 17.64 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.895 -1.356 . . . . 0.0 110.357 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.547 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 34.0 p90 -116.77 135.81 53.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -76.18 170.91 15.4 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.52 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 10.1 t -64.29 174.73 1.52 Allowed 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.807 -1.183 . . . . 0.0 110.027 -179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.52 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.2 OUTLIER -44.28 148.58 0.82 Allowed Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.43 -0.794 . . . . 0.0 109.998 -178.53 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 C-N-CA 122.118 1.878 . . . . 0.0 110.425 179.385 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.0 mtm180 . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.72 -25.89 73.94 Favored Glycine 0 N--CA 1.487 2.056 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.533 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.89 -56.28 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 O-C-N 121.026 -1.279 . . . . 0.0 110.559 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -61.98 -64.41 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 120.906 -1.121 . . . . 0.0 111.574 -177.1 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' HIS . 76.1 mt-10 -56.09 -46.17 79.16 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.932 -1.105 . . . . 0.0 110.341 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 52.0 tt0 -48.31 -56.55 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.11 -0.993 . . . . 0.0 110.298 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 62.4 m -84.79 -27.16 27.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.135 -0.978 . . . . 0.0 111.331 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.412 ' N ' ' O ' ' A' ' 39' ' ' VAL . 51.1 t -83.01 -52.23 6.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.72 -1.238 . . . . 0.0 109.163 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.464 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.7 t-80 -69.32 -27.5 65.43 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.178 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 m -137.01 159.95 40.37 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.424 -0.797 . . . . 0.0 109.594 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.8 mm -83.41 99.59 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.264 -0.897 . . . . 0.0 108.933 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.0 p -90.63 147.31 23.38 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.059 -1.026 . . . . 0.0 109.482 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -81.62 166.56 20.08 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.6 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.4 mt -56.41 -34.24 66.55 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -44.31 -57.42 3.51 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.924 0.869 . . . . 0.0 109.982 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.0 -42.29 93.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 81.4 mt -62.36 -32.34 73.12 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -69.74 -9.51 54.76 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -75.7 -28.34 58.57 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.753 -0.592 . . . . 0.0 109.613 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.3 m-85 -101.48 6.0 42.19 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.35 -0.844 . . . . 0.0 110.035 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.405 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 88.6 m -80.45 110.52 15.99 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.933 -1.104 . . . . 0.0 109.217 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.405 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 17.3 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.633 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.432 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -99.55 -91.51 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.432 -0.793 . . . . 0.0 110.582 -178.756 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.432 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.1 m120 -103.86 27.14 7.84 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.491 -0.756 . . . . 0.0 109.798 -179.219 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.95 161.22 14.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.456 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.481 ' CD2' ' H ' ' A' ' 5' ' ' HIS . 8.6 p80 -92.94 134.73 34.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.619 -0.676 . . . . 0.0 110.593 -178.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -98.99 131.0 45.37 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.35 125.15 11.89 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.165 -0.96 . . . . 0.0 109.301 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.17 -149.24 43.86 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.2 m -44.91 -31.86 1.41 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.255 -1.144 . . . . 0.0 110.226 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -48.19 -50.5 28.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.064 -1.023 . . . . 0.0 108.824 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.8 tp -57.14 -55.21 37.72 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.474 -0.766 . . . . 0.0 109.501 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.12 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.273 -0.892 . . . . 0.0 110.033 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.5 mt-10 -47.57 -29.12 2.63 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.485 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.78 -54.59 5.92 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.291 -0.881 . . . . 0.0 109.209 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.27 -35.67 38.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.433 -1.417 . . . . 0.0 108.71 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -49.31 -49.41 44.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.873 . . . . 0.0 110.403 -179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.511 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 3.9 mp -68.82 -50.55 49.08 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.589 -1.319 . . . . 0.0 108.581 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -51.03 -59.14 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.503 0.668 . . . . 0.0 110.13 -179.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.2 m -76.42 -23.69 53.99 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.507 -0.746 . . . . 0.0 109.743 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.57 -133.44 46.96 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -74.87 -13.05 60.51 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.423 -1.045 . . . . 0.0 110.196 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.11 -26.77 51.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.166 -0.959 . . . . 0.0 109.258 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 155.75 5.58 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 108.462 -1.855 . . . . 0.0 108.462 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -156.43 172.52 18.37 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.982 -1.305 . . . . 0.0 110.091 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 35.0 p90 -115.8 133.45 56.02 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -72.66 171.9 11.67 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.522 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 8.3 t -63.36 174.53 1.22 Allowed 'General case' 0 C--N 1.298 -1.666 0 O-C-N 120.768 -1.207 . . . . 0.0 109.722 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.522 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -43.88 147.06 0.93 Allowed Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.483 -0.761 . . . . 0.0 110.231 -177.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo . . . . . 0 N--CA 1.483 0.88 0 C-N-CA 122.032 1.821 . . . . 0.0 110.3 179.286 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.6 ptt180 . . . . . 0 N--CA 1.487 1.396 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.43 -22.88 74.81 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 121.014 -1.286 . . . . 0.0 110.252 -179.702 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.7 t -62.59 -64.27 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.044 -1.035 . . . . 0.0 111.249 -177.29 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.495 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.0 mt-10 -54.99 -48.78 72.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.014 -1.054 . . . . 0.0 110.431 -178.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 52.7 tp60 -46.32 -57.2 4.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.075 -1.016 . . . . 0.0 110.458 -179.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 60.3 m -84.75 -26.48 27.58 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 111.278 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.3 t -83.19 -51.33 7.58 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.677 -1.264 . . . . 0.0 109.25 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.52 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.3 t-80 -72.61 -26.61 61.75 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.353 -0.842 . . . . 0.0 109.621 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.92 158.83 43.57 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.311 -0.868 . . . . 0.0 109.838 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 10.4 mm -81.25 99.51 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.347 -0.846 . . . . 0.0 109.171 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -92.17 149.9 21.22 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.018 -1.051 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -83.84 166.46 17.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.25 -0.906 . . . . 0.0 109.336 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.2 mt -57.63 -33.61 68.45 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -43.72 -57.85 3.0 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.917 0.865 . . . . 0.0 109.979 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -59.95 -42.68 94.58 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.8 mt -61.72 -27.2 68.54 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -75.33 -8.54 56.94 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -79.51 -26.33 41.57 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.811 -0.555 . . . . 0.0 109.995 -179.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 13.8 m-85 -101.05 5.67 43.08 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.283 -0.886 . . . . 0.0 110.398 -179.257 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.3 m -79.29 111.39 15.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.928 -1.108 . . . . 0.0 109.631 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.568 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.623 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.43 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.38 -91.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.479 -0.763 . . . . 0.0 110.572 -178.68 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.43 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.2 m120 -101.45 25.94 7.81 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.382 -0.824 . . . . 0.0 109.879 -179.267 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.623 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.64 159.82 14.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.356 -0.84 . . . . 0.0 109.671 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -92.2 137.17 32.59 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.483 0.659 . . . . 0.0 110.568 -179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -100.83 131.12 46.87 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -148.03 125.02 11.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -147.7 41.99 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -45.99 -32.3 2.7 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.328 -1.101 . . . . 0.0 110.225 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -48.43 -50.08 32.54 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.054 -1.029 . . . . 0.0 108.722 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.2 tp -57.21 -54.39 47.36 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.45 -0.781 . . . . 0.0 109.519 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.7 t -46.93 -66.32 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.284 -0.885 . . . . 0.0 109.951 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 41.4 mt-10 -48.03 -24.41 1.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.139 -0.976 . . . . 0.0 109.377 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.5 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -83.29 -54.43 5.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.339 -0.851 . . . . 0.0 109.035 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -52.23 -33.26 40.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.429 -1.42 . . . . 0.0 108.542 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -51.17 -49.85 60.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.344 -0.848 . . . . 0.0 110.2 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.487 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.3 mp -68.23 -50.55 53.27 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.578 -1.326 . . . . 0.0 108.597 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -50.54 -58.79 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.504 0.669 . . . . 0.0 109.723 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.03 -23.27 52.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.582 -0.699 . . . . 0.0 109.893 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.19 -126.27 18.33 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -77.39 -14.96 59.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.313 -1.11 . . . . 0.0 110.282 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.8 mtp180 -55.31 -27.95 50.33 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.088 -1.007 . . . . 0.0 109.424 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.66 154.55 4.83 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.509 -1.836 . . . . 0.0 108.509 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.79 173.01 17.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.897 -1.355 . . . . 0.0 110.372 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.4 p90 -117.96 136.46 53.49 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -77.25 170.37 16.65 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 t -64.62 175.34 1.45 Allowed 'General case' 0 C--N 1.298 -1.654 0 O-C-N 120.973 -1.079 . . . . 0.0 110.016 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -44.33 148.55 0.84 Allowed Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 109.967 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo . . . . . 0 N--CA 1.484 0.939 0 C-N-CA 122.118 1.879 . . . . 0.0 110.3 179.415 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 . . . . . 0 N--CA 1.485 1.318 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.2 -24.41 71.36 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.76 -56.41 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 121.024 -1.28 . . . . 0.0 110.287 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.34 -64.41 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.028 -1.045 . . . . 0.0 111.352 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.422 ' O ' ' N ' ' A' ' 44' ' ' HIS . 56.4 mt-10 -55.52 -45.45 77.15 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.056 -1.028 . . . . 0.0 110.457 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -49.6 -56.45 9.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.087 -1.008 . . . . 0.0 110.212 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 64.5 m -84.99 -26.12 27.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.18 -0.95 . . . . 0.0 111.339 -178.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.438 ' N ' ' O ' ' A' ' 39' ' ' VAL . 46.2 t -83.06 -51.33 7.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.723 -1.236 . . . . 0.0 109.295 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.5 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.5 t-80 -72.1 -25.67 61.84 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.283 -0.885 . . . . 0.0 109.376 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -136.81 157.78 45.97 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.363 -0.836 . . . . 0.0 109.623 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 8.6 mm -82.11 99.22 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.374 -0.829 . . . . 0.0 108.891 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.5 p -91.28 150.62 21.24 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.097 -1.002 . . . . 0.0 109.54 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.421 ' H ' ' HG ' ' A' ' 48' ' ' SER . 2.3 p -84.1 166.83 17.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.199 179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -57.44 -33.6 68.11 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.42 -57.81 3.33 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.811 0.815 . . . . 0.0 110.081 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 11.5 mt-30 -60.13 -41.86 93.55 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.9 mt -61.98 -31.99 72.41 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.04 -9.57 55.78 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -75.68 -28.33 58.63 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.759 -0.588 . . . . 0.0 109.557 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.437 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 12.9 m-85 -100.99 5.1 43.0 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.33 -0.856 . . . . 0.0 110.151 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.419 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 96.8 m -80.15 109.6 14.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.92 -1.112 . . . . 0.0 109.086 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.419 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 23.3 t-20 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.084 -0.96 . . . . 0.0 109.391 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.631 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.445 ' H ' ' H3 ' ' A' ' 1' ' ' PHE . 0.6 OUTLIER -94.7 -91.36 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.373 -0.829 . . . . 0.0 110.791 -178.495 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.42 ' H ' HG21 ' A' ' 2' ' ' VAL . 5.2 m120 -105.65 25.73 10.42 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.408 -0.807 . . . . 0.0 110.028 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 3.3 pt20 -95.91 158.07 15.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.278 -0.889 . . . . 0.0 109.625 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.5 p80 -90.68 137.01 32.69 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.696 -0.627 . . . . 0.0 110.217 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.401 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -96.21 122.57 39.21 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.8 m -139.69 125.65 19.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.291 -0.881 . . . . 0.0 109.331 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.38 -149.81 46.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -44.54 -29.55 0.74 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.353 -1.086 . . . . 0.0 110.235 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -49.18 -51.24 33.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.034 -1.041 . . . . 0.0 108.874 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 21.7 tp -55.8 -51.36 67.72 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.401 -0.812 . . . . 0.0 109.365 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -49.61 -66.22 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 0.0 109.714 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.481 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 38.8 mt-10 -47.49 -26.91 1.53 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.379 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.49 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.53 -55.49 4.82 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.407 -0.808 . . . . 0.0 109.148 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.1 mt -51.3 -33.64 29.79 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.268 -1.52 . . . . 0.0 108.737 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.436 ' O ' ' N ' ' A' ' 20' ' ' GLY . 54.8 t80 -50.94 -50.35 57.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 110.228 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.481 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.6 mp -67.66 -50.53 57.35 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.575 -1.328 . . . . 0.0 108.605 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -50.42 -58.95 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.514 0.673 . . . . 0.0 109.816 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.8 m -76.71 -23.38 53.12 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.541 -0.724 . . . . 0.0 109.867 -178.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 48.42 -123.31 9.8 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -79.07 -13.28 59.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.304 -1.115 . . . . 0.0 110.298 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -57.81 -27.67 63.35 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.085 -1.009 . . . . 0.0 109.561 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 154.73 4.75 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.68 172.85 17.86 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.773 -1.428 . . . . 0.0 110.484 -179.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.9 p90 -118.14 129.98 55.84 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.3 t80 -70.69 171.12 10.97 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 t -64.12 174.91 1.39 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 120.826 -1.171 . . . . 0.0 109.644 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -42.29 150.38 0.4 Allowed Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.449 -0.782 . . . . 0.0 110.339 -178.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo . . . . . 0 N--CA 1.484 0.961 0 C-N-CA 122.068 1.845 . . . . 0.0 110.439 179.377 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.605 HH11 ' CG ' ' A' ' 36' ' ' ARG . 0.6 OUTLIER . . . . . 0 N--CA 1.484 1.273 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.96 -24.53 0.09 OUTLIER Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.5 -55.55 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 120.977 -1.308 . . . . 0.0 109.91 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.8 t -62.49 -64.26 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.052 -1.03 . . . . 0.0 112.1 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -59.38 -37.71 78.64 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.832 -1.168 . . . . 0.0 110.856 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.419 ' O ' ' OG ' ' A' ' 45' ' ' SER . 49.6 tt0 -54.49 -56.26 20.57 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.819 -1.175 . . . . 0.0 109.409 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 67.2 m -85.78 -24.03 27.0 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.324 -0.86 . . . . 0.0 111.297 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 39' ' ' VAL . 45.4 t -83.9 -52.62 6.21 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.635 -1.291 . . . . 0.0 109.771 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.4 t-80 -69.77 -26.3 64.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.203 -0.936 . . . . 0.0 109.278 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 0.7 OUTLIER -136.88 161.17 36.74 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.376 -0.828 . . . . 0.0 109.483 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.7 mm -84.59 99.79 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.4 p -90.99 153.96 19.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.065 -1.022 . . . . 0.0 109.726 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.19 167.95 15.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.312 -0.867 . . . . 0.0 109.056 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.1 mt -59.74 -33.34 71.53 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.919 0.866 . . . . 0.0 108.669 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -44.34 -57.74 3.34 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.777 0.798 . . . . 0.0 110.286 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -61.06 -41.73 97.18 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 119.773 -0.771 . . . . 0.0 108.964 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.3 mt -61.56 -31.31 71.34 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.64 -9.64 57.49 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -75.64 -28.06 58.64 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.746 -0.596 . . . . 0.0 109.569 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.429 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.8 m-85 -101.22 5.64 42.66 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.333 -0.854 . . . . 0.0 110.072 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 90.0 m -80.35 109.47 14.86 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.916 -1.115 . . . . 0.0 109.27 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.454 -179.961 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.63 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.417 HG22 ' H ' ' A' ' 3' ' ' ASN . 0.3 OUTLIER -98.32 -91.29 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.366 -0.834 . . . . 0.0 110.503 -178.827 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.488 ' N ' ' OD1' ' A' ' 3' ' ' ASN . 1.1 m-20 -106.35 27.53 8.64 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.534 -0.729 . . . . 0.0 109.899 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.63 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.79 159.96 14.82 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.343 -0.848 . . . . 0.0 109.335 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 14.8 p-80 -90.65 131.46 36.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.616 -0.677 . . . . 0.0 110.693 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD23 ' CE1' ' A' ' 1' ' ' PHE . 0.8 OUTLIER -94.01 127.28 39.71 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.021 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.2 m -142.68 125.51 16.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.233 -0.917 . . . . 0.0 109.343 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.33 -150.45 47.06 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.9 m -43.67 -29.92 0.56 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -1.032 . . . . 0.0 110.383 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 24.4 m-20 -50.01 -51.31 42.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.991 -1.068 . . . . 0.0 108.951 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.5 tp -54.8 -53.52 54.15 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.313 -0.867 . . . . 0.0 109.148 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 t -47.91 -66.07 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.356 -0.84 . . . . 0.0 109.963 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 45.3 mt-10 -47.82 -28.51 2.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.349 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.488 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.72 -54.89 5.63 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.352 -0.843 . . . . 0.0 109.123 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.0 mt -51.64 -35.29 41.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.35 -1.469 . . . . 0.0 108.661 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.8 t80 -49.32 -49.53 43.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 110.298 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.49 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.5 mp -68.53 -51.27 44.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.67 -1.269 . . . . 0.0 108.609 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -50.33 -58.41 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 121.525 0.678 . . . . 0.0 109.59 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -76.58 -23.53 53.51 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.558 -0.714 . . . . 0.0 109.98 -178.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.91 -122.07 10.79 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.3 mt-10 -80.47 -16.47 54.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.307 -1.113 . . . . 0.0 110.357 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.41 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -55.89 -28.16 55.34 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.551 -179.524 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 156.25 5.68 Favored Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -156.58 172.73 18.05 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.842 -1.387 . . . . 0.0 110.477 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.535 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 31.0 p90 -117.76 139.46 51.03 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -78.47 170.97 15.79 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t -64.6 174.55 1.72 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.869 -1.144 . . . . 0.0 110.523 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -46.36 148.53 1.59 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.586 -0.696 . . . . 0.0 110.098 -178.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo . . . . . 0 N--CA 1.486 1.071 0 C-N-CA 122.347 2.031 . . . . 0.0 110.962 179.715 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.488 HH11 ' HG2' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.6 -23.82 66.58 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.537 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.95 -56.41 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.234 0 O-C-N 121.096 -1.238 . . . . 0.0 110.393 -179.716 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.04 -64.35 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.026 . . . . 0.0 111.436 -177.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -55.04 -48.55 73.29 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.856 -1.152 . . . . 0.0 110.411 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.445 ' O ' ' OG ' ' A' ' 45' ' ' SER . 50.2 tt0 -45.93 -58.32 3.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.195 -0.94 . . . . 0.0 110.451 -179.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 68.6 m -85.34 -27.02 26.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.154 -0.966 . . . . 0.0 111.511 -178.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.417 ' N ' ' O ' ' A' ' 39' ' ' VAL . 42.6 t -83.38 -52.32 6.64 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.733 -1.229 . . . . 0.0 109.598 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.438 ' N ' ' O ' ' A' ' 40' ' ' GLU . 12.3 t60 -70.94 -26.59 63.25 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 0.9 OUTLIER -136.88 161.84 34.89 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.324 -0.86 . . . . 0.0 109.676 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.8 mm -83.36 99.69 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.585 -0.697 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -92.4 160.12 15.24 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.05 -1.031 . . . . 0.0 109.741 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.07 167.31 11.87 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.91 -32.58 69.67 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.35 -57.24 3.63 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.702 0.763 . . . . 0.0 110.14 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -61.35 -42.37 98.59 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.924 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.3 mt -61.08 -31.93 71.59 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.42 -9.6 56.81 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.937 -1.135 . . . . 0.0 107.937 179.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -77.0 -27.67 54.78 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.778 -0.576 . . . . 0.0 109.689 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.1 m-85 -102.29 6.23 40.37 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.402 -0.811 . . . . 0.0 109.957 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 65.4 m -78.41 103.3 8.26 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.994 -1.066 . . . . 0.0 109.403 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.4 t-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.456 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.638 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.442 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -104.39 -91.67 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.616 -178.695 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.442 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.4 m120 -100.02 25.8 7.04 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.349 -0.844 . . . . 0.0 109.777 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.638 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.93 160.05 14.66 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.384 -0.823 . . . . 0.0 109.522 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -94.88 136.29 35.36 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.57 -0.706 . . . . 0.0 110.178 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.51 130.17 44.61 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.8 m -143.92 125.18 14.62 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.306 -0.871 . . . . 0.0 109.255 179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.18 -150.62 47.58 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.9 m -43.77 -30.5 0.66 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.418 -1.048 . . . . 0.0 110.322 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -48.94 -50.51 35.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.967 -1.083 . . . . 0.0 108.856 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.9 tp -55.42 -54.86 38.48 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.359 -0.838 . . . . 0.0 109.235 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.75 -66.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.391 -0.818 . . . . 0.0 110.057 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.48 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 35.2 mt-10 -47.87 -27.85 2.32 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.191 -0.943 . . . . 0.0 109.341 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.495 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.69 -54.57 5.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.336 -0.852 . . . . 0.0 109.164 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.64 -34.96 40.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.364 -1.46 . . . . 0.0 108.599 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.9 t80 -49.64 -49.48 47.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.359 -0.838 . . . . 0.0 110.389 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.48 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.3 mp -68.55 -50.76 49.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.525 -1.36 . . . . 0.0 108.578 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -50.6 -58.87 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-O 121.506 0.67 . . . . 0.0 109.718 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.48 -23.56 53.81 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.486 -0.759 . . . . 0.0 109.819 -178.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 53.51 -130.17 41.71 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -76.83 -13.07 60.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -1.105 . . . . 0.0 110.114 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.406 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.3 OUTLIER -56.69 -27.62 59.24 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.107 -0.996 . . . . 0.0 109.368 -179.533 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 155.59 5.5 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -156.54 172.93 17.7 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.932 -1.334 . . . . 0.0 110.074 -179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.3 p90 -116.02 138.65 51.02 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -78.87 171.28 15.41 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -64.33 174.95 1.45 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.927 -1.108 . . . . 0.0 110.338 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.92 149.95 1.44 Allowed Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.497 -0.752 . . . . 0.0 110.301 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 N--CA 1.484 0.965 0 C-N-CA 122.206 1.937 . . . . 0.0 110.508 179.276 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.415 ' HG3' HH11 ' A' ' 36' ' ' ARG . 17.6 mtm-85 . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.93 -25.66 74.2 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.18 -56.01 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.327 0 O-C-N 121.035 -1.273 . . . . 0.0 110.645 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.526 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -62.39 -63.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.946 -1.096 . . . . 0.0 111.495 -177.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' HIS . 70.1 mt-10 -55.97 -47.81 76.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.84 -1.163 . . . . 0.0 110.285 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.3 tt0 -46.41 -57.44 4.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.999 -1.063 . . . . 0.0 110.426 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 61.0 m -84.69 -27.95 26.7 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.124 -0.985 . . . . 0.0 111.083 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.451 ' N ' ' O ' ' A' ' 39' ' ' VAL . 49.3 t -83.49 -52.1 6.79 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.809 -1.182 . . . . 0.0 109.349 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' GLU . 16.0 t60 -69.77 -28.23 65.59 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.241 -0.912 . . . . 0.0 109.077 179.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 m -137.04 160.73 38.08 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.403 -0.811 . . . . 0.0 109.505 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -83.13 99.94 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 p -91.45 152.05 20.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.012 -1.055 . . . . 0.0 109.563 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.92 167.42 14.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.307 -0.871 . . . . 0.0 109.121 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.95 -34.51 68.09 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.625 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -44.15 -56.97 3.68 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.816 0.817 . . . . 0.0 109.979 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.3 mt-30 -60.33 -42.64 96.08 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 81.9 mt -62.05 -32.6 73.13 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.55 -9.47 54.1 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -76.06 -28.03 57.47 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.79 -0.569 . . . . 0.0 109.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.6 m-85 -102.57 6.71 39.97 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.368 -0.832 . . . . 0.0 109.992 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' O ' ' A' ' 57' ' ' ASN . 67.3 m -79.81 104.01 10.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 109.33 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.431 ' O ' ' O ' ' A' ' 56' ' ' CYS . 24.9 t-20 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.511 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.644 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.428 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -100.28 -91.42 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.437 -0.789 . . . . 0.0 110.425 -178.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.428 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 5.0 m120 -104.54 27.64 7.73 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.477 -0.764 . . . . 0.0 109.801 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.54 159.79 14.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.26 -0.9 . . . . 0.0 109.523 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.0 OUTLIER -90.26 131.94 35.8 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.602 0.715 . . . . 0.0 110.866 -178.637 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -97.51 132.56 43.08 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -148.98 124.89 10.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.15 -0.969 . . . . 0.0 109.222 179.287 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.43 -147.43 42.28 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.8 m -44.9 -33.17 1.87 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.376 -1.073 . . . . 0.0 110.205 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.3 -49.85 41.94 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.003 -1.061 . . . . 0.0 108.815 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.0 tp -58.08 -57.02 14.67 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.0 t -45.07 -65.94 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.34 -0.85 . . . . 0.0 109.974 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.491 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.7 mt-10 -47.54 -30.44 3.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.494 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -77.62 -54.58 6.22 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 109.223 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -50.92 -36.53 38.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.522 -1.361 . . . . 0.0 108.665 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -48.84 -49.8 37.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.399 -0.813 . . . . 0.0 110.396 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.524 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.6 mp -68.26 -50.73 51.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.524 -1.36 . . . . 0.0 108.579 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -50.89 -59.33 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.456 0.646 . . . . 0.0 110.087 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -23.45 54.21 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.512 -0.743 . . . . 0.0 109.809 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.98 -129.03 30.97 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.204 -1.159 . . . . 0.0 110.204 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -76.49 -15.04 59.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -1.106 . . . . 0.0 110.182 -179.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.514 ' NH1' ' OE2' ' A' ' 53' ' ' GLU . 33.8 mtp180 -54.69 -27.61 41.64 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.032 -1.043 . . . . 0.0 109.087 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.13 5.23 Favored Glycine 0 N--CA 1.486 2.0 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 -179.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.39 172.33 18.69 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.889 -1.36 . . . . 0.0 110.214 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.3 p90 -117.53 135.07 54.19 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -73.18 171.65 12.58 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.587 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 6.8 t -63.36 174.71 1.16 Allowed 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.773 -1.204 . . . . 0.0 109.749 -178.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.587 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -42.22 146.33 0.68 Allowed Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.201 -178.134 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo . . . . . 0 N--CA 1.484 0.92 0 C-N-CA 122.081 1.854 . . . . 0.0 110.723 179.688 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.66 -24.21 77.1 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.09 -55.12 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.23 0 O-C-N 121.056 -1.261 . . . . 0.0 110.393 -179.635 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.522 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.12 -64.34 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.013 -1.054 . . . . 0.0 111.559 -177.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 44' ' ' HIS . 73.0 mt-10 -56.55 -44.78 81.26 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.95 -1.094 . . . . 0.0 110.483 -178.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.438 ' O ' ' OG ' ' A' ' 45' ' ' SER . 56.5 tp60 -48.86 -56.94 7.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.065 -1.022 . . . . 0.0 110.06 -179.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 56.6 m -84.83 -27.26 26.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.105 -0.997 . . . . 0.0 111.08 -178.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.9 t -83.46 -52.35 6.58 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.672 -1.267 . . . . 0.0 109.448 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 40' ' ' GLU . 2.1 t-160 -70.14 -28.85 65.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.327 -0.858 . . . . 0.0 108.84 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 1.3 p -136.61 162.38 33.29 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.334 -0.853 . . . . 0.0 109.542 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.428 HG22 HD12 ' A' ' 46' ' ' ILE . 15.2 mm -84.09 99.75 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.608 -0.682 . . . . 0.0 109.662 -179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.0 p -92.28 146.53 23.64 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.13 -0.981 . . . . 0.0 109.342 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.72 167.61 18.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.232 -0.918 . . . . 0.0 109.212 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.593 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.3 mt -57.08 -34.25 68.1 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -43.67 -57.25 3.28 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.874 0.845 . . . . 0.0 110.138 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -60.33 -41.87 94.44 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 78.2 mt -62.73 -28.27 69.85 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.514 ' OE2' ' NH1' ' A' ' 22' ' ' ARG . 1.8 tm-20 -74.26 -8.72 57.2 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -78.84 -26.96 44.16 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.875 -0.515 . . . . 0.0 109.946 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.421 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 14.5 m-85 -100.31 5.63 44.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.253 -0.905 . . . . 0.0 110.38 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 72.7 m -82.69 111.27 18.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.843 -1.161 . . . . 0.0 109.462 179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 57' ' ' ASN . 62.7 t-20 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.819 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.633 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.436 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -101.13 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 110.697 -178.658 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.436 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.8 m120 -102.97 26.58 7.99 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 109.807 -179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.52 161.88 13.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.331 -0.855 . . . . 0.0 109.443 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -94.27 136.5 34.49 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.639 0.733 . . . . 0.0 110.32 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.64 131.89 45.34 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.8 125.31 11.7 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.192 -0.943 . . . . 0.0 109.186 179.334 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -149.14 44.34 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.8 m -44.96 -31.61 1.34 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.373 -1.075 . . . . 0.0 110.335 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -48.73 -50.04 35.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.966 -1.084 . . . . 0.0 108.761 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.0 -54.57 45.24 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.458 -0.776 . . . . 0.0 109.534 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.66 -66.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 110.096 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 50.8 mt-10 -47.67 -27.63 2.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.387 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.501 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.08 -54.49 5.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.392 -0.818 . . . . 0.0 109.17 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.92 -34.81 43.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.398 -1.439 . . . . 0.0 108.585 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 20' ' ' GLY . 57.2 t80 -49.94 -50.04 47.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.327 -0.858 . . . . 0.0 110.231 -179.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.492 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.4 mp -67.68 -50.81 55.78 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.573 -1.329 . . . . 0.0 108.64 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -50.62 -58.98 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.543 0.687 . . . . 0.0 109.759 -179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.23 -23.76 54.57 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.528 -0.732 . . . . 0.0 109.768 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.8 -127.2 30.91 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -78.98 -11.67 60.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.409 -1.054 . . . . 0.0 110.028 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.61 -27.18 62.52 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.162 -0.961 . . . . 0.0 109.287 -179.568 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 154.8 5.01 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -156.47 172.52 18.38 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.859 -1.377 . . . . 0.0 110.278 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.2 p90 -116.95 132.57 56.67 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -72.26 171.44 12.11 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.563 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 7.8 t -63.73 174.56 1.36 Allowed 'General case' 0 C--N 1.297 -1.69 0 O-C-N 120.706 -1.246 . . . . 0.0 109.669 -179.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.563 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -43.88 147.35 0.89 Allowed Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.398 -0.814 . . . . 0.0 110.078 -178.16 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo . . . . . 0 N--CA 1.484 0.951 0 C-N-CA 122.102 1.868 . . . . 0.0 110.429 179.474 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' HG3' HH11 ' A' ' 36' ' ' ARG . 13.5 mtm-85 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.43 -24.13 76.22 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.91 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 O-C-N 121.006 -1.291 . . . . 0.0 110.437 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.4 t -62.02 -64.18 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.038 -1.038 . . . . 0.0 111.521 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.443 ' O ' ' N ' ' A' ' 44' ' ' HIS . 83.9 mt-10 -55.84 -46.3 78.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.908 -1.12 . . . . 0.0 110.485 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.9 tp60 -48.14 -56.5 7.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.059 -1.026 . . . . 0.0 110.299 -179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 45' ' ' SER . 58.5 m -85.15 -26.36 26.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.143 -0.973 . . . . 0.0 111.271 -178.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.9 t -83.4 -52.4 6.56 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.608 -1.307 . . . . 0.0 109.418 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.443 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.1 t-80 -69.47 -26.68 64.69 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.874 . . . . 0.0 109.339 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -137.04 173.31 11.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.338 -0.851 . . . . 0.0 109.827 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -93.17 100.04 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.4 p -93.78 145.03 24.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.016 -1.053 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -80.53 166.53 21.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.882 . . . . 0.0 109.35 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -56.81 -34.36 67.62 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.45 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -44.03 -57.29 3.44 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.904 0.859 . . . . 0.0 109.943 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -59.89 -42.94 94.89 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.9 mt -61.83 -31.91 72.19 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.23 -9.68 56.58 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -75.83 -28.33 58.23 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.803 -0.561 . . . . 0.0 109.598 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 6.9 m-85 -102.72 7.01 39.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.406 -0.808 . . . . 0.0 109.984 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 60.5 m -78.58 108.6 12.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.96 -1.087 . . . . 0.0 109.409 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 57' ' ' ASN . 2.1 t-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.483 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.644 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.445 HG22 ' H ' ' A' ' 3' ' ' ASN . 1.1 m -102.73 -91.99 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.506 -0.746 . . . . 0.0 110.762 -178.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.445 ' H ' HG22 ' A' ' 2' ' ' VAL . 3.7 m120 -99.59 25.3 7.24 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.232 -0.917 . . . . 0.0 109.883 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.95 157.35 15.94 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.83 . . . . 0.0 109.635 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.5 p-80 -92.69 135.9 33.7 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.574 0.702 . . . . 0.0 109.957 -179.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.53 136.03 38.52 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -151.67 125.16 8.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.303 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -146.49 40.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.7 m -47.84 -31.83 5.45 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -1.086 . . . . 0.0 110.209 -179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -49.03 -49.83 39.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.881 -1.137 . . . . 0.0 108.645 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.6 tp -56.67 -55.09 38.49 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.415 -0.803 . . . . 0.0 109.401 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -46.41 -66.04 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.283 -0.886 . . . . 0.0 110.001 -179.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.1 mt-10 -47.51 -28.8 2.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.368 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.486 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.02 -54.61 5.84 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 109.173 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.4 mt -51.26 -34.93 34.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.509 -1.369 . . . . 0.0 108.667 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.6 t80 -49.96 -48.79 51.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 110.394 -179.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.513 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 3.7 mp -69.55 -50.71 42.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.495 -1.378 . . . . 0.0 108.529 179.315 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -50.86 -59.09 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 121.512 0.673 . . . . 0.0 110.02 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.4 m -76.04 -23.98 55.15 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.441 -0.787 . . . . 0.0 109.699 -178.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.42 -133.55 46.34 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -75.5 -12.13 60.17 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.325 -1.103 . . . . 0.0 109.963 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -56.32 -26.93 54.03 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.002 -179.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.86 154.72 5.11 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.5 172.91 17.72 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.999 -1.295 . . . . 0.0 110.079 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 32.6 p90 -117.38 139.79 50.41 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.48 170.43 16.59 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.647 ' HG1' ' H ' ' A' ' 28' ' ' ASP . 7.5 t -64.73 174.94 1.61 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.947 -1.095 . . . . 0.0 110.069 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.647 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.2 OUTLIER -42.54 148.56 0.52 Allowed Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.651 -0.655 . . . . 0.0 110.135 -178.711 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 N--CA 1.487 1.091 0 C-N-CA 122.255 1.97 . . . . 0.0 110.995 179.911 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.0 -25.74 72.9 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.39 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.31 0 O-C-N 121.057 -1.261 . . . . 0.0 110.385 -179.601 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 2.9 t -63.46 -63.91 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.962 -1.086 . . . . 0.0 111.461 -177.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.444 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.4 mt-10 -55.62 -46.18 77.43 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.864 -1.147 . . . . 0.0 110.43 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -48.39 -56.77 7.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 110.204 -179.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 73.0 m -85.1 -28.07 25.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 111.427 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 53.9 t -83.29 -52.33 6.66 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.66 -1.275 . . . . 0.0 109.295 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.444 ' N ' ' O ' ' A' ' 40' ' ' GLU . 5.8 t60 -69.55 -27.04 64.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.066 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.7 m -137.17 157.4 46.76 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.496 -0.753 . . . . 0.0 109.49 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -81.55 99.73 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.6 p -89.51 163.84 15.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.998 -1.064 . . . . 0.0 109.697 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -96.18 166.84 11.55 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.416 -0.802 . . . . 0.0 109.186 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.601 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.59 -33.29 69.82 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -44.76 -57.86 3.45 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.791 0.805 . . . . 0.0 110.236 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -61.07 -40.84 95.22 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.061 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 76.1 mt -62.41 -25.09 67.76 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 179.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.66 -9.03 58.75 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -78.96 -26.82 43.51 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.783 -0.573 . . . . 0.0 109.705 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 17.2 m-85 -99.73 4.39 45.43 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.348 -0.845 . . . . 0.0 110.339 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.406 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 71.0 m -82.84 111.22 18.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.883 -1.136 . . . . 0.0 109.367 179.639 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.406 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.9 t-20 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.058 -0.972 . . . . 0.0 109.377 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.636 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.444 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -102.85 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.445 -0.784 . . . . 0.0 110.536 -178.856 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.444 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.7 m120 -101.5 26.77 6.91 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.393 -0.817 . . . . 0.0 109.892 -179.318 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.636 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.0 pt20 -95.23 160.79 14.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -92.87 134.77 34.75 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.514 0.673 . . . . 0.0 110.67 -178.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -99.49 132.56 44.74 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.262 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -148.49 125.1 11.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.094 -1.004 . . . . 0.0 109.332 179.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -148.52 43.26 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.3 m -45.11 -32.28 1.72 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.347 -1.09 . . . . 0.0 110.245 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -48.54 -50.52 31.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.991 -1.068 . . . . 0.0 108.823 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.8 tp -57.08 -54.79 42.76 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.434 -0.791 . . . . 0.0 109.505 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -46.56 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.294 -0.879 . . . . 0.0 109.991 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 46.9 mt-10 -47.59 -29.31 2.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.923 . . . . 0.0 109.397 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.495 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.42 -54.58 6.02 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.375 -0.828 . . . . 0.0 109.363 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.12 -36.1 38.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.456 -1.402 . . . . 0.0 108.794 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -49.43 -49.0 46.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.341 -0.849 . . . . 0.0 110.482 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.503 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 3.9 mp -69.02 -50.32 49.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.61 -1.306 . . . . 0.0 108.496 179.381 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -51.03 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.504 0.669 . . . . 0.0 110.113 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.3 m -75.52 -23.63 56.72 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.495 -0.753 . . . . 0.0 109.821 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.47 -126.76 25.09 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -77.45 -15.49 59.29 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.395 -1.062 . . . . 0.0 110.186 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -54.85 -27.9 45.81 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.174 -0.953 . . . . 0.0 109.409 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.79 154.88 5.13 Favored Glycine 0 N--CA 1.487 2.033 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.38 172.53 18.34 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.918 -1.342 . . . . 0.0 110.269 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 31.5 p90 -118.01 129.28 55.49 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -68.62 171.45 7.62 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 178.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.598 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 10.0 t -63.41 174.45 1.27 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 120.74 -1.225 . . . . 0.0 109.468 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.598 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.2 OUTLIER -44.59 147.64 1.03 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.182 -178.124 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo . . . . . 0 N--CA 1.483 0.883 0 C-N-CA 122.098 1.865 . . . . 0.0 110.158 179.179 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 . . . . . 0 N--CA 1.488 1.435 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.59 -21.84 65.74 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.28 -55.53 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 O-C-N 121.024 -1.28 . . . . 0.0 110.052 -179.714 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -62.2 -63.84 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.023 -1.048 . . . . 0.0 111.094 -177.526 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.456 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.9 mt-10 -54.74 -48.49 72.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.989 -1.069 . . . . 0.0 110.557 -178.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.0 tt0 -47.22 -56.58 6.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.069 -1.019 . . . . 0.0 110.493 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 45' ' ' SER . 57.1 m -84.66 -26.51 27.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.228 -0.92 . . . . 0.0 111.363 -178.588 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.3 t -83.77 -52.39 6.44 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.642 -1.286 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.4 t-80 -68.96 -27.29 65.6 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.235 -0.916 . . . . 0.0 109.23 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.436 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.6 t -137.23 173.17 11.97 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.416 -0.803 . . . . 0.0 109.88 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 9.7 mm -92.3 99.85 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.561 -0.712 . . . . 0.0 109.315 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.8 p -93.0 143.3 26.37 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.014 -1.054 . . . . 0.0 109.39 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -79.39 166.45 22.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.447 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.0 mt -56.36 -34.11 66.33 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.06 -57.49 3.35 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 121.87 0.843 . . . . 0.0 109.971 179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.9 mt-30 -60.06 -42.15 93.9 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.8 mt -62.79 -29.05 70.41 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.11 -8.9 57.81 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -78.43 -26.89 46.41 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.853 -0.529 . . . . 0.0 109.864 -179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.422 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 15.3 m-85 -100.75 5.24 43.57 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.265 -0.897 . . . . 0.0 110.227 -179.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 71.6 m -83.35 111.48 19.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.97 -1.081 . . . . 0.0 109.49 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.441 179.959 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.631 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.422 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -101.99 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.421 -0.799 . . . . 0.0 110.678 -178.616 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.422 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.7 m120 -102.02 25.57 8.59 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.429 -0.794 . . . . 0.0 109.991 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.97 160.18 14.59 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.468 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 9.8 p80 -92.95 136.19 33.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.514 -0.741 . . . . 0.0 110.552 -178.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.403 HD23 ' CE1' ' A' ' 1' ' ' PHE . 1.0 OUTLIER -97.35 127.06 42.99 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.304 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 82.2 m -142.89 125.29 15.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.296 -0.878 . . . . 0.0 109.348 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.17 -149.31 45.61 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.5 m -44.92 -30.84 1.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.421 -1.047 . . . . 0.0 110.284 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -48.7 -50.61 32.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.927 -1.108 . . . . 0.0 108.787 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.9 tp -55.42 -53.99 49.29 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -47.04 -66.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.837 . . . . 0.0 109.899 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 72.5 mt-10 -47.79 -26.77 1.74 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.371 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.494 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.02 -54.73 5.3 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.384 -0.823 . . . . 0.0 109.131 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.84 -34.28 39.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.406 -1.434 . . . . 0.0 108.581 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.6 t80 -50.16 -49.85 50.88 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.366 -0.834 . . . . 0.0 110.179 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.485 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.4 mp -68.27 -50.76 51.59 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.584 -1.323 . . . . 0.0 108.681 179.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -50.52 -58.64 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.5 0.667 . . . . 0.0 109.757 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -77.0 -23.34 52.23 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 -178.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 46.95 -120.78 5.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -80.22 -13.7 59.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.299 -1.118 . . . . 0.0 110.15 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -57.95 -28.27 64.17 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.112 -0.992 . . . . 0.0 109.528 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.59 154.19 4.57 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -156.87 172.95 17.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.886 -1.361 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.8 p90 -119.15 139.51 51.68 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -80.52 169.82 17.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.931 -1.106 . . . . 0.0 108.143 179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.2 t -65.59 175.71 1.74 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.117 -0.989 . . . . 0.0 110.404 -179.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -45.22 149.87 0.88 Allowed Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.459 -0.776 . . . . 0.0 109.895 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo . . . . . 0 N--CA 1.484 0.95 0 C-N-CA 122.178 1.919 . . . . 0.0 110.581 179.421 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.92 -25.73 73.02 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.08 -56.33 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.061 -1.258 . . . . 0.0 110.46 -179.67 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -62.27 -64.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 120.961 -1.087 . . . . 0.0 111.637 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 44' ' ' HIS . 62.4 mt-10 -55.79 -46.79 77.9 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.85 -1.157 . . . . 0.0 110.331 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.0 tt0 -47.67 -57.49 5.45 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.086 -1.009 . . . . 0.0 110.167 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 63.1 m -84.77 -26.7 27.39 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.137 -0.977 . . . . 0.0 111.101 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.455 ' N ' ' O ' ' A' ' 39' ' ' VAL . 45.0 t -83.25 -52.3 6.7 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.826 -1.171 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.503 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.1 t-80 -71.24 -26.46 62.92 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.231 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.2 m -136.83 157.91 45.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.39 -0.819 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -82.27 99.73 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.242 -0.911 . . . . 0.0 109.013 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.7 p -90.75 151.62 21.14 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.137 -0.977 . . . . 0.0 109.375 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -85.08 166.49 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.02 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -56.54 -34.04 66.67 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -44.44 -57.5 3.52 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.855 0.835 . . . . 0.0 110.023 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.07 -42.35 94.37 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.9 mt -62.29 -31.8 72.44 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.89 -9.46 54.96 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -75.54 -28.37 59.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.799 -0.563 . . . . 0.0 109.712 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.1 m-85 -102.03 6.32 41.03 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.333 -0.854 . . . . 0.0 110.018 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 73.4 m -80.4 109.0 14.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.93 -1.106 . . . . 0.0 109.358 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.417 ' OXT' ' OD1' ' A' ' 57' ' ' ASN . 53.7 t-20 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.514 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.667 ' H2 ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -104.04 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.407 -0.808 . . . . 0.0 110.726 -178.661 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.43 ' H ' HG22 ' A' ' 2' ' ' VAL . 5.2 m120 -101.66 25.85 8.04 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.409 -0.807 . . . . 0.0 109.936 -179.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.667 ' NE2' ' H2 ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.88 160.2 14.59 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.321 -0.862 . . . . 0.0 109.85 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' A' ' 5' ' ' HIS . 0.1 OUTLIER -92.76 132.09 37.26 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.643 -0.661 . . . . 0.0 110.441 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -95.4 132.8 40.06 Favored 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -149.12 125.24 10.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.033 -1.042 . . . . 0.0 109.327 179.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.88 -147.4 41.49 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -45.89 -32.07 2.47 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.362 -1.081 . . . . 0.0 110.194 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -49.27 -51.06 36.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.092 . . . . 0.0 108.762 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 21.3 tp -56.1 -51.64 67.16 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.4 -0.812 . . . . 0.0 109.391 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 t -49.44 -66.28 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.219 -0.926 . . . . 0.0 109.968 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.4 mt-10 -47.56 -26.42 1.44 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.412 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.493 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.03 -54.64 5.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.323 -0.861 . . . . 0.0 109.058 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.85 -33.94 38.4 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.412 -1.43 . . . . 0.0 108.635 179.452 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.2 t80 -50.58 -50.06 54.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.926 . . . . 0.0 110.236 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.496 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 4.3 mp -67.78 -50.82 54.95 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.534 -1.354 . . . . 0.0 108.547 179.387 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -50.7 -59.01 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 CA-C-O 121.527 0.68 . . . . 0.0 109.668 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -75.87 -23.54 55.63 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.48 -0.763 . . . . 0.0 109.819 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.02 -130.64 44.05 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -77.1 -14.44 59.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -1.094 . . . . 0.0 110.087 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.88 -27.8 45.53 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.149 -0.969 . . . . 0.0 109.327 -179.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.76 156.39 6.07 Favored Glycine 0 N--CA 1.485 1.964 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.41 172.93 17.65 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.022 -1.281 . . . . 0.0 110.243 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 33.9 p90 -115.73 132.84 56.52 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -73.23 171.75 12.42 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 t -63.55 173.93 1.5 Allowed 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 118.578 -1.249 . . . . 0.0 109.302 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -44.41 148.82 0.81 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.199 -0.938 . . . . 0.0 110.139 -178.088 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo . . . . . 0 N--CA 1.484 0.958 0 C-N-CA 122.086 1.857 . . . . 0.0 110.682 179.577 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.02 -21.86 54.2 Favored Glycine 0 N--CA 1.491 2.36 0 O-C-N 121.133 -0.98 . . . . 0.0 110.911 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -100.31 -54.24 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 120.879 -1.366 . . . . 0.0 110.457 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.525 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -61.42 -63.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 111.704 -177.116 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.417 ' HG3' ' N ' ' A' ' 41' ' ' GLN . 0.9 OUTLIER -58.52 -38.15 77.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 111.079 -178.101 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -55.6 -53.68 53.43 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.833 -1.167 . . . . 0.0 109.195 -179.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 60.3 m -85.76 -26.73 25.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 110.769 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.433 ' N ' ' O ' ' A' ' 39' ' ' VAL . 51.8 t -83.86 -52.5 6.32 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.701 -1.249 . . . . 0.0 109.541 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.412 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.6 t60 -71.39 -26.41 62.77 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.207 -0.933 . . . . 0.0 109.174 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.7 m -137.06 160.28 39.4 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.363 -0.835 . . . . 0.0 109.645 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.2 mm -83.21 100.28 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.49 -0.756 . . . . 0.0 109.221 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -93.0 147.75 22.57 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.105 -0.997 . . . . 0.0 109.683 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.7 167.76 17.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -58.4 -34.04 70.3 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -44.1 -57.12 3.57 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 121.797 0.808 . . . . 0.0 110.154 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 9.8 mt-30 -61.59 -41.63 97.7 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.0 mt -61.84 -31.69 71.97 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.48 -9.79 57.47 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -75.5 -28.31 59.13 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.816 -0.552 . . . . 0.0 109.571 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.438 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.5 m-85 -101.83 7.04 41.81 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.399 -0.813 . . . . 0.0 110.017 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 65.4 m -80.43 106.39 12.41 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.897 -1.127 . . . . 0.0 109.398 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.65 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.632 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.444 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.0 -91.83 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.476 -0.765 . . . . 0.0 110.34 -179.082 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.698 ' N ' HD21 ' A' ' 3' ' ' ASN . 0.0 OUTLIER -101.94 27.4 6.57 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.465 -0.772 . . . . 0.0 110.074 -179.323 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.7 pt20 -95.28 157.66 15.8 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.232 -0.917 . . . . 0.0 109.166 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -90.2 132.05 35.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.582 -0.699 . . . . 0.0 110.718 -178.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.1 130.5 41.78 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.5 m -143.5 125.27 15.07 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.24 -0.913 . . . . 0.0 109.388 179.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.16 -150.04 46.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -44.66 -30.34 0.91 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.412 -1.052 . . . . 0.0 110.284 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -48.67 -50.14 34.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.953 -1.092 . . . . 0.0 108.791 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.3 tp -55.76 -55.71 29.18 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.451 -0.781 . . . . 0.0 109.172 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -45.8 -65.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.385 -0.822 . . . . 0.0 109.946 -179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 84.8 mt-10 -47.73 -29.68 3.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.436 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.496 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.31 -54.45 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.84 . . . . 0.0 109.239 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -51.34 -35.88 40.32 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.496 -1.378 . . . . 0.0 108.712 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.6 t80 -49.4 -48.84 46.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.414 -0.804 . . . . 0.0 110.461 -179.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.521 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.38 -50.45 46.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.488 -1.383 . . . . 0.0 108.539 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -50.84 -59.23 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 CA-C-O 121.558 0.694 . . . . 0.0 110.23 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -24.04 54.23 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.402 -0.811 . . . . 0.0 109.804 -178.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.37 -126.19 23.2 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -77.32 -14.54 59.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -1.077 . . . . 0.0 110.28 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.52 -27.6 57.8 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.36 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.53 154.51 4.69 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -156.52 172.6 18.27 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.923 -1.34 . . . . 0.0 110.418 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.3 p90 -118.29 138.75 52.17 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -77.45 170.83 15.87 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.617 ' HG1' ' H ' ' A' ' 28' ' ' ASP . 7.6 t -64.3 175.29 1.35 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.869 -1.144 . . . . 0.0 109.807 -179.276 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.617 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -42.15 148.03 0.52 Allowed Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.492 -0.755 . . . . 0.0 110.295 -178.229 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo . . . . . 0 N--CA 1.484 0.952 0 C-N-CA 122.091 1.861 . . . . 0.0 110.462 179.469 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.573 HH11 ' CG ' ' A' ' 36' ' ' ARG . 1.4 mtt-85 . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.85 -25.99 74.02 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.52 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.21 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.315 0 O-C-N 121.002 -1.293 . . . . 0.0 110.436 -179.502 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.52 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.25 -64.52 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.133 . . . . 0.0 111.564 -177.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' HIS . 35.4 mt-10 -55.94 -45.74 78.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.854 -1.154 . . . . 0.0 110.295 -178.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.461 ' NE2' ' OE1' ' A' ' 51' ' ' GLN . 53.0 tt0 -47.48 -57.87 4.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.084 -1.01 . . . . 0.0 110.15 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 68.1 m -84.83 -27.0 27.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.156 -0.965 . . . . 0.0 111.02 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.467 ' N ' ' O ' ' A' ' 39' ' ' VAL . 47.8 t -83.32 -51.44 7.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.845 -1.16 . . . . 0.0 109.429 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.519 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.0 t60 -73.47 -26.16 60.79 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.339 -0.851 . . . . 0.0 109.48 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -136.86 157.69 46.18 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.4 -0.813 . . . . 0.0 109.876 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.405 HD12 HG23 ' A' ' 46' ' ' ILE . 11.5 mm -79.95 99.56 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.461 -0.774 . . . . 0.0 109.229 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.6 p -92.57 154.9 18.14 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.056 -1.027 . . . . 0.0 109.637 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -88.85 166.5 13.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.296 -0.878 . . . . 0.0 108.988 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.7 mt -58.4 -32.78 68.94 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.39 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.28 -57.31 3.55 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.804 0.811 . . . . 0.0 110.159 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.461 ' OE1' ' NE2' ' A' ' 41' ' ' GLN . 24.6 mt-30 -61.68 -42.04 98.38 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.71 -0.796 . . . . 0.0 108.998 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 74.6 mt -61.29 -24.93 66.76 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.71 -8.74 58.39 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -79.67 -26.78 40.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.794 -0.566 . . . . 0.0 109.849 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 16.3 m-85 -99.06 4.62 47.12 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.282 -0.886 . . . . 0.0 110.31 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 70.9 m -81.26 111.34 17.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.939 -1.101 . . . . 0.0 109.496 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.64 179.993 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.628 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.453 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -99.77 -91.57 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.353 -0.842 . . . . 0.0 110.197 -179.124 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.488 ' OD1' ' N ' ' A' ' 3' ' ' ASN . 1.3 p-10 -104.33 28.22 7.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.671 -0.643 . . . . 0.0 109.431 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.628 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.75 157.41 15.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.163 -0.96 . . . . 0.0 109.123 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -89.0 131.73 35.05 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.526 0.679 . . . . 0.0 110.713 -178.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.1 mp -97.16 132.44 42.94 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -149.24 125.36 10.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.189 -0.944 . . . . 0.0 109.278 179.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.72 -146.51 40.31 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.7 m -46.75 -32.5 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.365 -1.079 . . . . 0.0 110.155 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -49.0 -50.44 35.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.965 -1.084 . . . . 0.0 108.783 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.1 tp -56.9 -55.73 30.71 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.394 -0.816 . . . . 0.0 109.529 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.6 t -46.13 -66.15 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.342 -0.849 . . . . 0.0 110.085 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 75.8 mt-10 -47.94 -26.75 1.85 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.197 -0.939 . . . . 0.0 109.298 -179.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.488 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.08 -54.21 5.74 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.333 -0.854 . . . . 0.0 109.088 179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.87 -34.77 42.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.361 -1.462 . . . . 0.0 108.536 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 20' ' ' GLY . 58.0 t80 -49.82 -49.59 48.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.374 -0.828 . . . . 0.0 110.358 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.501 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.58 -50.66 49.99 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.584 -1.322 . . . . 0.0 108.598 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -50.67 -58.88 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.49 0.662 . . . . 0.0 109.703 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -76.51 -23.48 53.72 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.526 -0.734 . . . . 0.0 109.9 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.94 -127.08 31.16 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.12 -14.96 59.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.402 -1.057 . . . . 0.0 110.101 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.1 mtp180 -54.95 -28.99 55.61 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.098 -1.001 . . . . 0.0 109.171 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.91 5.73 Favored Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.5 172.72 18.05 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.907 -1.349 . . . . 0.0 110.174 -179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.09 137.65 51.94 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -75.96 171.95 13.56 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -63.13 174.37 1.17 Allowed 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.762 -1.211 . . . . 0.0 109.812 -178.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.45 147.37 1.03 Allowed Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.369 -0.832 . . . . 0.0 110.096 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo . . . . . 0 N--CA 1.484 0.915 0 C-N-CA 122.107 1.871 . . . . 0.0 110.315 179.352 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.524 ' CD ' ' H ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.85 -26.66 58.19 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.93 -55.8 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.335 0 O-C-N 120.895 -1.356 . . . . 0.0 110.566 -179.461 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.8 t -63.26 -64.39 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.905 -1.122 . . . . 0.0 111.295 -177.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 44' ' ' HIS . 80.9 mt-10 -54.47 -47.54 72.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.89 -1.131 . . . . 0.0 110.277 -178.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 48.5 tt0 -46.68 -58.52 3.77 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.155 -0.966 . . . . 0.0 110.417 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 45' ' ' SER . 60.7 m -84.87 -25.88 27.71 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.131 -0.981 . . . . 0.0 111.435 -178.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.419 ' N ' ' O ' ' A' ' 39' ' ' VAL . 47.3 t -83.61 -51.71 7.07 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.58 -1.325 . . . . 0.0 109.068 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.477 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t60 -68.13 -27.9 66.85 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.419 -0.8 . . . . 0.0 109.341 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 14.2 t -137.35 173.14 12.0 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.353 -0.842 . . . . 0.0 110.188 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.2 mm -91.82 99.43 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.0 p -93.92 152.99 18.46 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.074 -1.016 . . . . 0.0 109.548 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.28 167.54 13.47 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.902 . . . . 0.0 109.125 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.4 -34.53 68.98 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -43.67 -57.01 3.4 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.852 0.834 . . . . 0.0 110.038 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.1 mt-30 -60.1 -42.19 94.13 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.1 mt -62.54 -32.39 73.33 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.86 -9.24 54.12 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -76.34 -27.64 56.56 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.9 m-85 -102.11 6.64 40.99 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 95.7 m -80.95 105.2 12.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.842 -1.161 . . . . 0.0 109.154 179.567 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.431 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.4 t-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.635 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.446 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.9 OUTLIER -104.5 -91.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.751 . . . . 0.0 110.574 -178.767 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.446 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.0 m120 -99.95 25.82 6.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.283 -0.886 . . . . 0.0 109.742 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.635 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.72 159.14 15.13 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.308 -0.87 . . . . 0.0 109.494 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -93.36 134.46 35.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.616 -0.678 . . . . 0.0 110.283 -179.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.4 HD22 ' CE1' ' A' ' 1' ' ' PHE . 0.9 OUTLIER -95.94 127.94 42.4 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.465 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 76.2 m -143.51 125.48 15.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.892 . . . . 0.0 109.263 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.11 -149.57 46.11 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -44.84 -30.21 0.94 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -1.032 . . . . 0.0 110.347 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -49.12 -50.89 35.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.895 -1.128 . . . . 0.0 108.818 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.0 tp -55.16 -52.11 64.35 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.361 -0.837 . . . . 0.0 109.198 179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 t -49.15 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 109.896 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 28.4 mt-10 -47.9 -25.75 1.44 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.447 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.496 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.57 -54.9 5.03 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.282 -0.887 . . . . 0.0 109.063 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.65 -34.35 37.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.335 -1.478 . . . . 0.0 108.595 179.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.422 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.5 t80 -50.23 -49.92 51.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.326 -0.859 . . . . 0.0 110.275 -179.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.487 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.5 mp -67.91 -50.85 53.77 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.65 -1.281 . . . . 0.0 108.626 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -50.52 -58.68 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 CA-C-O 121.511 0.672 . . . . 0.0 109.854 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -77.03 -23.12 52.13 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.483 -0.761 . . . . 0.0 109.997 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 47.7 -122.27 7.61 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -79.13 -15.3 58.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 0.0 110.275 -179.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.2 mtp180 -56.62 -28.35 60.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.123 -0.985 . . . . 0.0 109.491 -179.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.49 155.06 4.95 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.399 -1.881 . . . . 0.0 108.399 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -156.68 172.74 18.07 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.898 -1.354 . . . . 0.0 110.449 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 30.5 p90 -118.4 133.93 55.47 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -73.41 171.18 13.58 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -64.29 175.1 1.39 Allowed 'General case' 0 C--N 1.296 -1.756 0 O-C-N 120.961 -1.087 . . . . 0.0 109.698 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.51 151.87 0.45 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.423 -0.798 . . . . 0.0 110.121 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 N--CA 1.484 0.94 0 C-N-CA 122.004 1.803 . . . . 0.0 110.259 179.421 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 38' ' ' ILE . 16.6 mtm-85 . . . . . 0 N--CA 1.484 1.257 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.9 -23.98 0.08 OUTLIER Glycine 0 N--CA 1.49 2.286 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.4 -55.61 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.152 -1.204 . . . . 0.0 109.97 179.674 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.7 t -62.69 -64.15 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.087 -1.008 . . . . 0.0 112.069 -176.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -59.93 -39.59 86.0 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.727 -1.233 . . . . 0.0 110.719 -178.241 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.2 tt0 -51.26 -56.71 11.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.877 -1.139 . . . . 0.0 109.477 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 68.9 m -85.46 -26.58 26.25 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.381 -0.824 . . . . 0.0 111.045 -179.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.436 ' N ' ' O ' ' A' ' 39' ' ' VAL . 46.3 t -84.07 -52.4 6.32 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.706 -1.246 . . . . 0.0 109.673 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.427 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.2 t60 -69.99 -26.97 64.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.114 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 0.3 OUTLIER -136.78 160.58 38.42 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.484 -0.76 . . . . 0.0 109.107 179.818 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.9 mm -84.65 99.73 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -90.42 164.18 14.39 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.065 -1.022 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.535 ' H ' ' HG ' ' A' ' 48' ' ' SER . 2.4 p -96.82 166.77 11.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.36 -0.838 . . . . 0.0 109.007 179.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -57.68 -34.34 69.31 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -44.08 -57.85 3.16 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.86 0.838 . . . . 0.0 110.014 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 7.8 mt-30 -59.8 -42.57 93.73 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -179.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 81.2 mt -62.21 -32.08 72.7 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.91 -9.26 54.35 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -76.21 -28.04 57.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.788 -0.57 . . . . 0.0 109.649 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.2 m-85 -101.83 6.21 41.45 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.354 -0.841 . . . . 0.0 110.102 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 88.6 m -79.8 106.74 12.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.939 -1.101 . . . . 0.0 109.323 179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.41 179.967 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.63 ' H3 ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.436 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.6 -91.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.404 -0.81 . . . . 0.0 110.626 -178.68 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.436 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.6 m120 -101.05 25.6 7.92 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 -179.239 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.63 ' NE2' ' H3 ' ' A' ' 1' ' ' PHE . 2.5 pt20 -96.0 158.54 15.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.36 -0.837 . . . . 0.0 109.635 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.1 p-80 -92.04 135.89 33.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.635 -0.665 . . . . 0.0 110.255 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.2 mp -97.05 126.55 42.27 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 76.5 m -142.35 125.14 16.0 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.292 -0.88 . . . . 0.0 109.241 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.9 -148.74 45.18 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.354 -1.098 . . . . 0.0 110.354 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -44.67 -31.08 1.05 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.383 -1.069 . . . . 0.0 110.349 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -49.01 -50.66 34.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.946 -1.097 . . . . 0.0 108.841 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.1 tp -55.53 -54.01 49.32 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.405 -0.809 . . . . 0.0 109.283 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -47.43 -66.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.012 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 52.0 mt-10 -47.72 -26.92 1.73 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.343 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.498 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.81 -54.93 5.17 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.467 -0.771 . . . . 0.0 109.188 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.54 -34.06 34.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.394 -1.441 . . . . 0.0 108.603 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.46 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.7 t80 -50.48 -50.75 51.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.276 -179.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.492 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.3 -50.8 58.76 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.532 -1.355 . . . . 0.0 108.658 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -50.43 -59.01 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.569 0.7 . . . . 0.0 109.668 -179.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.72 -23.27 53.08 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.539 -0.725 . . . . 0.0 109.92 -178.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.02 -123.2 10.55 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.57 -15.12 58.24 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -1.114 . . . . 0.0 110.084 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -55.15 -28.81 55.52 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.15 -0.969 . . . . 0.0 109.337 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.47 154.66 4.72 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -156.57 172.9 17.74 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 120.901 -1.352 . . . . 0.0 110.434 -179.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.541 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.7 p90 -118.11 138.27 52.37 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -77.67 170.61 16.27 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.495 ' HG1' ' H ' ' A' ' 28' ' ' ASP . 9.3 t -64.68 175.0 1.56 Allowed 'General case' 0 C--N 1.299 -1.617 0 O-C-N 120.998 -1.064 . . . . 0.0 110.111 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.495 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -45.11 148.4 1.05 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.41 -0.806 . . . . 0.0 110.03 -178.678 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo . . . . . 0 N--CA 1.484 0.964 0 C-N-CA 122.121 1.881 . . . . 0.0 110.573 179.465 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.697 ' N ' ' HE ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.406 ' N ' ' HE ' ' A' ' 36' ' ' ARG . . . -56.23 -28.6 54.89 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.63 -55.98 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 O-C-N 120.929 -1.336 . . . . 0.0 110.704 -179.283 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.11 -64.24 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.911 -1.118 . . . . 0.0 111.421 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -54.46 -47.8 72.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.773 -1.204 . . . . 0.0 110.3 -178.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -47.13 -58.97 3.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.08 -1.013 . . . . 0.0 110.459 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 45' ' ' SER . 60.0 m -84.54 -25.56 28.65 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -0.946 . . . . 0.0 111.307 -178.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.463 ' N ' ' O ' ' A' ' 39' ' ' VAL . 45.4 t -83.96 -52.3 6.45 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.65 -1.281 . . . . 0.0 109.214 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.48 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.9 t-80 -67.44 -28.88 68.26 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.32 -0.863 . . . . 0.0 109.243 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -136.9 173.28 11.87 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.379 -0.826 . . . . 0.0 109.704 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 3.6 mm -92.56 99.66 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.6 p -91.75 151.68 20.51 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.063 -1.023 . . . . 0.0 109.632 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -84.97 166.34 16.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.233 -0.917 . . . . 0.0 109.223 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.2 -34.18 68.25 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -44.22 -57.42 3.46 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.914 0.864 . . . . 0.0 110.014 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.83 -42.67 94.08 Favored 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.0 mt -62.01 -32.39 72.87 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.6 -9.77 55.47 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -75.73 -27.85 58.31 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.781 -0.575 . . . . 0.0 109.584 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.9 m-85 -101.85 5.5 41.07 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.373 -0.829 . . . . 0.0 110.056 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.2 m -79.95 111.14 16.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.901 -1.124 . . . . 0.0 109.449 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.447 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.642 ' H1 ' ' NE2' ' A' ' 4' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.443 ' H ' ' H3 ' ' A' ' 1' ' ' PHE . 0.7 OUTLIER -98.57 -91.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.369 -0.832 . . . . 0.0 110.803 -178.37 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ASN . . . . . 0.426 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.6 m120 -104.17 25.92 9.45 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.401 -0.812 . . . . 0.0 109.988 -179.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . 0.642 ' NE2' ' H1 ' ' A' ' 1' ' ' PHE . 3.2 pt20 -95.85 157.95 15.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.247 -0.908 . . . . 0.0 109.672 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 3.0 p-80 -91.25 133.52 35.33 Favored 'General case' 0 N--CA 1.489 1.494 0 CA-C-O 121.405 0.622 . . . . 0.0 110.134 -179.335 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -92.9 125.22 37.39 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.1 m -140.79 125.45 17.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.907 . . . . 0.0 109.264 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.46 -150.75 47.32 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.9 m -44.21 -29.36 0.63 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -1.058 . . . . 0.0 110.263 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -48.77 -50.49 33.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.982 -1.074 . . . . 0.0 108.859 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.4 tp -55.94 -54.48 44.22 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.438 -0.789 . . . . 0.0 109.207 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.71 -66.17 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.358 -0.839 . . . . 0.0 109.901 -179.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 86.7 mt-10 -47.63 -27.98 2.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.177 -0.952 . . . . 0.0 109.291 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.495 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.74 -55.32 5.09 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 109.181 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.47 -34.07 33.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.311 -1.493 . . . . 0.0 108.649 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -50.44 -49.27 55.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 110.165 -179.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.488 ' H ' ' CD1' ' A' ' 17' ' ' LEU . 4.4 mp -68.76 -51.06 45.22 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.535 -1.353 . . . . 0.0 108.619 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.9 t -50.39 -58.56 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 121.523 0.678 . . . . 0.0 109.698 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.3 -23.81 54.35 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.485 -0.759 . . . . 0.0 109.693 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.33 -131.83 45.89 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -76.62 -11.25 59.83 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.37 -1.077 . . . . 0.0 110.121 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -57.84 -26.98 62.77 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.076 -1.015 . . . . 0.0 109.35 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.87 155.68 5.72 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 -179.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.74 173.0 17.62 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.921 -1.341 . . . . 0.0 110.227 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.551 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 37.5 p90 -115.26 137.25 52.24 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -78.13 171.01 15.67 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.64 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 7.1 t -64.13 175.11 1.33 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.853 -1.154 . . . . 0.0 109.975 -179.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.64 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -42.42 147.71 0.58 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.521 -0.737 . . . . 0.0 110.3 -178.25 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo . . . . . 0 N--CA 1.484 0.946 0 C-N-CA 122.18 1.92 . . . . 0.0 110.493 179.503 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 . . . . . 0 N--CA 1.486 1.375 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.06 -24.41 73.81 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.41 -55.99 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.001 -1.293 . . . . 0.0 110.051 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.6 t -61.97 -64.38 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.01 -1.056 . . . . 0.0 111.32 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.475 ' O ' ' N ' ' A' ' 44' ' ' HIS . 51.2 mt-10 -55.24 -47.49 75.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.946 -1.096 . . . . 0.0 110.613 -178.725 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -47.3 -57.78 4.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.051 -1.03 . . . . 0.0 110.303 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 70.9 m -84.81 -26.0 27.76 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.203 -0.935 . . . . 0.0 111.177 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.1 t -83.1 -52.27 6.78 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.746 -1.221 . . . . 0.0 109.42 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.497 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 11.8 t-80 -71.15 -26.08 62.84 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.357 -0.839 . . . . 0.0 109.39 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.94 157.85 45.81 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.443 -0.785 . . . . 0.0 109.625 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.2 mm -82.03 99.59 5.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.357 -0.839 . . . . 0.0 108.785 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.7 p -91.14 158.43 16.64 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.106 -0.996 . . . . 0.0 109.781 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.6 p -89.81 166.61 13.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.308 -0.87 . . . . 0.0 108.96 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.607 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -58.78 -33.27 70.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.54 -57.56 3.53 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 121.716 0.769 . . . . 0.0 110.238 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -61.06 -41.8 97.29 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 119.665 -0.814 . . . . 0.0 108.918 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.7 mt -61.28 -30.77 70.68 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.48 -9.72 58.64 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -75.99 -28.19 57.71 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.756 -0.59 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.426 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 9.9 m-85 -101.55 6.1 42.06 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.357 -0.839 . . . . 0.0 110.02 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 66.7 m -79.81 107.49 12.63 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.866 -1.147 . . . . 0.0 109.345 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 28.1 t-20 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.094 -0.955 . . . . 0.0 109.453 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.627 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.435 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.13 -91.6 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.45 -0.781 . . . . 0.0 110.608 -178.789 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.435 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.7 m120 -101.57 26.2 7.59 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.366 -0.834 . . . . 0.0 109.886 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.627 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -95.55 158.03 15.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.371 -0.831 . . . . 0.0 109.567 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.423 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.3 OUTLIER -91.57 132.0 36.61 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.66 -0.65 . . . . 0.0 110.587 -178.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.18 136.14 35.89 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -151.62 125.01 8.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.276 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.5 -146.65 40.91 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.1 m -46.85 -32.47 3.76 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.369 -1.077 . . . . 0.0 110.163 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -48.88 -50.49 34.72 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.991 -1.068 . . . . 0.0 108.728 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.9 tp -56.04 -54.44 44.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.473 -0.767 . . . . 0.0 109.519 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.53 -66.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.261 -0.9 . . . . 0.0 110.04 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.482 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 49.2 mt-10 -47.46 -28.61 2.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.208 -0.932 . . . . 0.0 109.388 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.497 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.16 -54.51 5.92 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.36 -0.838 . . . . 0.0 109.297 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.78 -35.28 43.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.367 -1.458 . . . . 0.0 108.581 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -49.31 -49.14 45.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.385 -0.822 . . . . 0.0 110.289 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.489 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.62 -50.96 47.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.558 -1.339 . . . . 0.0 108.592 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -50.65 -58.81 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-O 121.482 0.658 . . . . 0.0 109.847 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.31 -23.72 54.31 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.67 -125.99 27.67 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -78.75 -14.0 59.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.384 -1.068 . . . . 0.0 110.463 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 22.7 mtt180 -58.07 -26.88 63.09 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.973 -1.079 . . . . 0.0 109.647 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.56 155.99 5.61 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.63 173.01 17.58 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.324 . . . . 0.0 110.413 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.62 140.18 49.68 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -80.49 170.24 16.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.63 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 9.8 t -65.01 175.6 1.5 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.995 -1.066 . . . . 0.0 110.219 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.63 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -43.52 150.22 0.54 Allowed Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 121.497 -0.752 . . . . 0.0 110.115 -178.584 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -78.25 -6.32 15.58 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 122.252 1.968 . . . . 0.0 110.658 179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.538 ' C ' ' H ' ' A' ' 32' ' ' GLY . 41.7 p -53.77 -40.99 66.7 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.039 -1.038 . . . . 0.0 111.169 -177.248 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.42 -15.95 0.39 Allowed Glycine 0 N--CA 1.494 2.501 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.432 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.538 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.27 -21.21 23.14 Favored Glycine 0 N--CA 1.5 2.914 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.494 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.15 54.43 0.17 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.582 -1.807 . . . . 0.0 108.582 179.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.517 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 Cg_endo -68.75 -174.14 0.68 Allowed 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.985 1.79 . . . . 0.0 110.102 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.553 ' C ' ' H ' ' A' ' 37' ' ' GLY . 46.7 ttt180 -56.23 86.92 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.517 ' N ' ' O ' ' A' ' 34' ' ' PRO . 0.8 OUTLIER -59.15 -2.48 0.27 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.091 -1.006 . . . . 0.0 108.525 179.914 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -71.53 -25.62 74.85 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.15 -56.38 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.212 0 O-C-N 121.056 -1.261 . . . . 0.0 110.45 -179.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.524 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.1 t -62.42 -64.18 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.94 -1.1 . . . . 0.0 111.4 -177.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.517 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.9 mt-10 -55.8 -46.36 78.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.873 -1.142 . . . . 0.0 110.355 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 62.1 tp60 -47.99 -56.65 7.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.074 -1.016 . . . . 0.0 110.101 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 59.0 m -84.71 -28.25 26.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 111.072 -178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.415 ' N ' ' O ' ' A' ' 39' ' ' VAL . 52.4 t -83.49 -52.24 6.67 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.733 -1.229 . . . . 0.0 109.231 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.517 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t-80 -70.46 -27.89 64.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.346 -0.846 . . . . 0.0 109.231 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.9 m -136.92 159.85 40.63 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.437 -0.79 . . . . 0.0 109.431 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 7.7 mm -82.8 99.7 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.307 -0.87 . . . . 0.0 109.088 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.9 p -91.15 150.83 21.22 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.094 -1.003 . . . . 0.0 109.32 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.5 167.45 14.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.232 -0.918 . . . . 0.0 109.112 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.77 -34.81 67.97 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.06 -57.53 3.32 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.867 0.841 . . . . 0.0 110.025 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -59.73 -42.48 93.24 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.3 mt -62.02 -32.25 72.71 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -69.91 -9.54 55.34 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -75.86 -28.56 58.22 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.824 -0.548 . . . . 0.0 109.702 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.457 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.4 m-85 -102.13 6.89 41.09 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.372 -0.83 . . . . 0.0 109.948 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 65.0 m -80.29 111.18 16.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.023 -1.048 . . . . 0.0 109.282 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.955 -1.021 . . . . 0.0 109.437 179.97 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.632 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.426 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -101.61 -91.93 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.383 -0.823 . . . . 0.0 110.851 -178.566 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.426 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.8 m120 -101.21 26.03 7.56 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.403 -0.811 . . . . 0.0 109.807 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.94 160.84 14.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.384 -0.822 . . . . 0.0 109.483 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -95.95 136.77 35.95 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.577 -0.702 . . . . 0.0 110.092 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -98.38 136.11 39.0 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.16 124.76 9.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.933 . . . . 0.0 109.236 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.71 -147.34 41.66 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.6 m -45.94 -32.59 2.79 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.393 -1.063 . . . . 0.0 110.197 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -48.68 -49.99 35.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.978 -1.077 . . . . 0.0 108.753 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 22.6 tp -57.33 -51.79 67.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.411 -0.805 . . . . 0.0 109.484 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.8 t -49.08 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 110.065 -179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 53.2 mt-10 -47.47 -28.45 2.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.406 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.497 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.08 -54.94 5.5 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.377 -0.827 . . . . 0.0 109.206 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.37 -35.63 39.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.402 -1.436 . . . . 0.0 108.772 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -49.35 -50.02 41.74 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.355 -0.841 . . . . 0.0 110.422 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.497 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.3 mp -67.68 -50.7 56.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.612 -1.305 . . . . 0.0 108.595 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -51.25 -59.19 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.485 0.66 . . . . 0.0 110.318 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 22.8 m -76.59 -23.26 53.46 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.419 -0.801 . . . . 0.0 109.932 -178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.11 -129.58 27.77 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.352 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -73.43 -16.71 61.31 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.437 -1.037 . . . . 0.0 110.589 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 49.0 mtp180 -54.95 -28.54 52.03 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 109.426 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.8 156.31 6.06 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 107.799 -2.12 . . . . 0.0 107.799 -178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -156.27 172.68 18.05 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.835 -1.391 . . . . 0.0 110.44 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.554 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -116.57 127.24 54.32 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -67.58 172.14 5.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.611 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.2 t -62.6 174.39 1.02 Allowed 'General case' 0 C--N 1.295 -1.762 0 O-C-N 120.641 -1.287 . . . . 0.0 109.359 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.442 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -43.58 150.74 0.51 Allowed Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.341 -0.849 . . . . 0.0 110.409 -177.829 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -77.82 -7.09 16.41 Favored 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.111 1.874 . . . . 0.0 110.421 179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.1 p -53.99 -40.86 67.3 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.128 -0.983 . . . . 0.0 111.136 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.74 -15.78 0.45 Allowed Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.382 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.545 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.74 -23.89 17.08 Favored Glycine 0 N--CA 1.499 2.862 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.489 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -170.56 55.68 0.19 Allowed Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 30.8 Cg_endo -72.29 -175.01 1.57 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 121.914 1.742 . . . . 0.0 110.178 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.611 ' N ' ' OG1' ' A' ' 27' ' ' THR . 6.0 ttt-85 -61.53 85.48 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 178.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.477 ' O ' ' N ' ' A' ' 38' ' ' ILE . 12.0 ptt180 -59.33 -28.39 66.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.052 -1.03 . . . . 0.0 108.225 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.86 -22.98 0.11 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.56 -54.27 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 O-C-N 120.978 -1.307 . . . . 0.0 109.787 179.924 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.18 -64.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.057 -1.027 . . . . 0.0 111.76 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -58.57 -41.35 85.49 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.768 -1.208 . . . . 0.0 110.884 -178.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.2 tp60 -50.58 -55.95 13.95 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.972 -1.08 . . . . 0.0 109.553 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 81.6 m -85.23 -26.55 26.63 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 111.222 -178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.405 ' N ' ' O ' ' A' ' 39' ' ' VAL . 49.1 t -83.94 -52.62 6.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.604 -1.31 . . . . 0.0 109.821 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.6 t60 -68.99 -29.41 67.61 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.248 -0.907 . . . . 0.0 109.175 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -137.14 157.89 45.68 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.55 -0.719 . . . . 0.0 109.572 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.3 mm -78.96 119.07 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.38 -0.825 . . . . 0.0 108.822 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.9 p -111.03 156.57 21.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.364 -0.835 . . . . 0.0 109.687 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 p -88.97 166.79 13.68 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.37 -0.831 . . . . 0.0 109.395 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.7 mt -59.65 -32.53 70.54 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.53 -57.68 3.45 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.802 0.81 . . . . 0.0 110.123 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -60.82 -42.46 97.74 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 119.799 -0.76 . . . . 0.0 108.959 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.6 mt -61.42 -26.03 67.6 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.17 -8.55 57.28 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -79.8 -26.34 40.6 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.848 -0.532 . . . . 0.0 109.926 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -100.0 6.1 45.11 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.266 -0.896 . . . . 0.0 110.448 -179.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.425 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 85.1 m -76.39 111.6 12.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.921 -1.112 . . . . 0.0 109.403 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 25.5 t-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.457 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.646 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.432 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -105.13 -91.88 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.508 -0.745 . . . . 0.0 110.678 -178.514 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.432 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.2 m120 -98.98 25.41 6.72 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.303 -0.873 . . . . 0.0 109.745 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.646 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.99 160.47 14.44 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 109.512 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.2 p-80 -96.2 138.7 33.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.613 -0.68 . . . . 0.0 110.101 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.94 134.09 44.44 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.43 124.86 10.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -0.947 . . . . 0.0 109.203 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.74 -148.48 43.38 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -45.07 -32.26 1.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.322 -1.105 . . . . 0.0 110.22 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -48.79 -50.3 34.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.944 -1.098 . . . . 0.0 108.755 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.04 -54.65 44.35 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.482 -0.762 . . . . 0.0 109.579 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 t -46.58 -66.3 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.303 -0.873 . . . . 0.0 110.067 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 65.6 mt-10 -47.81 -27.83 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.491 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.65 -54.47 5.85 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.319 -0.863 . . . . 0.0 109.14 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.61 -35.3 41.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.402 -1.437 . . . . 0.0 108.626 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.44 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.6 t80 -49.32 -49.6 43.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.306 -0.871 . . . . 0.0 110.37 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.507 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.0 mp -68.36 -50.88 50.04 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.533 -1.355 . . . . 0.0 108.607 179.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -50.54 -58.72 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 CA-C-O 121.511 0.672 . . . . 0.0 109.602 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.03 -23.69 55.16 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.497 -0.752 . . . . 0.0 109.749 -179.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 52.91 -131.08 40.66 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -75.69 -11.52 60.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.345 -1.091 . . . . 0.0 110.158 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.401 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -58.21 -27.76 64.2 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.092 -1.005 . . . . 0.0 109.488 -179.453 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.72 155.22 5.28 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -156.51 172.73 18.03 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.936 -1.332 . . . . 0.0 110.277 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.8 p90 -115.74 137.39 52.13 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -77.13 171.13 15.31 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.573 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.0 t -63.89 175.02 1.27 Allowed 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.798 -1.189 . . . . 0.0 109.9 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -43.14 148.39 0.61 Allowed Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.494 -0.754 . . . . 0.0 110.229 -178.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -78.39 -6.5 15.56 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.128 1.885 . . . . 0.0 110.409 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' C ' ' H ' ' A' ' 32' ' ' GLY . 38.1 p -54.04 -40.92 67.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.028 -1.045 . . . . 0.0 110.98 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.82 -15.7 0.47 Allowed Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.691 -1.243 . . . . 0.0 110.332 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.545 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.79 -17.26 36.16 Favored Glycine 0 N--CA 1.499 2.837 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.91 55.02 0.12 Allowed Glycine 0 N--CA 1.485 1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.7 Cg_endo -68.86 -175.19 0.88 Allowed 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 121.898 1.732 . . . . 0.0 110.231 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.573 ' N ' ' OG1' ' A' ' 27' ' ' THR . 41.4 ttt180 -58.04 86.47 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 34' ' ' PRO . 6.9 ptm180 -59.75 -2.01 0.33 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.023 -1.048 . . . . 0.0 108.667 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.561 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -72.7 -24.27 76.42 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.9 -55.3 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.261 0 O-C-N 121.098 -1.236 . . . . 0.0 110.349 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -63.54 -64.27 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.024 -1.047 . . . . 0.0 111.278 -177.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 44' ' ' HIS . 30.2 mt-10 -55.01 -45.74 75.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.373 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -48.74 -57.63 6.02 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.099 -1.0 . . . . 0.0 110.304 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 45' ' ' SER . 59.0 m -84.88 -25.36 28.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.173 -0.955 . . . . 0.0 111.435 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 48.3 t -84.24 -52.34 6.31 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.535 -1.353 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.421 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.9 t60 -68.91 -26.77 65.26 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.22 -0.925 . . . . 0.0 109.195 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 12.6 t -136.71 173.32 11.83 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.458 -0.776 . . . . 0.0 109.473 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.65 99.6 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.3 p -91.53 152.49 20.29 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.126 -0.984 . . . . 0.0 109.72 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -86.67 166.7 15.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.326 -0.859 . . . . 0.0 109.32 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.8 mt -57.39 -34.91 69.35 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -43.97 -57.19 3.46 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.862 0.839 . . . . 0.0 109.978 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.71 -42.59 93.41 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.4 mt -61.89 -32.36 72.73 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.98 -9.61 55.76 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -75.88 -28.15 58.02 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.799 -0.563 . . . . 0.0 109.664 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 7.9 m-85 -102.86 6.99 39.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.407 -0.808 . . . . 0.0 109.95 -179.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 62.2 m -79.26 108.23 12.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.984 -1.072 . . . . 0.0 109.456 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.548 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.645 ' H3 ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.437 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -101.92 -91.69 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -0.812 . . . . 0.0 110.607 -178.738 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.437 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.3 m120 -101.73 26.08 7.82 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.351 -0.843 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.645 ' NE2' ' H3 ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.59 160.16 14.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 109.708 -179.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -92.05 134.61 34.67 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.53 0.681 . . . . 0.0 110.541 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.4 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.4 mp -98.53 130.69 45.1 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -149.12 125.06 10.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.107 179.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.63 -148.34 43.36 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -45.02 -32.64 1.75 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.394 -1.062 . . . . 0.0 110.321 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -48.87 -50.31 35.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.004 -1.06 . . . . 0.0 108.745 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.5 tp -57.13 -55.05 39.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.404 -0.81 . . . . 0.0 109.562 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -46.31 -66.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.313 -0.867 . . . . 0.0 109.945 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 34.4 mt-10 -47.69 -26.67 1.62 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 -179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.501 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.07 -54.31 5.65 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.365 -0.834 . . . . 0.0 109.082 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.71 -34.48 39.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.372 -1.455 . . . . 0.0 108.658 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.8 t80 -50.49 -49.59 55.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.301 -0.874 . . . . 0.0 110.336 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.492 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.26 -50.29 54.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.591 -1.318 . . . . 0.0 108.556 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.5 t -50.68 -59.38 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.522 0.677 . . . . 0.0 109.745 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.05 -23.64 55.1 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 -178.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.48 -123.78 20.2 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -80.28 -16.56 54.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.355 -1.085 . . . . 0.0 110.584 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 15.8 mtt180 -55.92 -27.12 50.78 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.053 -1.029 . . . . 0.0 109.52 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.5 6.05 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -156.57 172.96 17.64 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.895 -1.356 . . . . 0.0 110.357 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.547 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.0 p90 -116.77 135.81 53.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -76.18 170.91 15.4 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.576 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.1 t -64.29 174.73 1.52 Allowed 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.807 -1.183 . . . . 0.0 110.027 -179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.52 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.2 OUTLIER -44.28 148.58 0.82 Allowed Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.43 -0.794 . . . . 0.0 109.998 -178.53 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -78.17 -6.43 15.71 Favored 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.118 1.878 . . . . 0.0 110.425 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' C ' ' H ' ' A' ' 32' ' ' GLY . 39.6 p -54.05 -40.94 67.56 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.111 -0.993 . . . . 0.0 111.176 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.85 -15.86 0.47 Allowed Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.328 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.545 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.1 -18.55 31.21 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -173.99 54.89 0.14 Allowed Glycine 0 N--CA 1.485 1.952 0 N-CA-C 108.416 -1.874 . . . . 0.0 108.416 179.208 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.3 Cg_endo -70.17 -175.19 1.17 Allowed 'Trans proline' 0 C--N 1.318 -1.052 0 C-N-CA 121.855 1.703 . . . . 0.0 110.127 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.576 ' N ' ' OG1' ' A' ' 27' ' ' THR . 4.6 ttt-85 -57.9 86.67 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 34' ' ' PRO . 45.0 mtm180 -59.37 -6.24 0.96 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.984 -1.072 . . . . 0.0 108.169 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.533 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.72 -25.89 73.94 Favored Glycine 0 N--CA 1.487 2.056 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.533 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.89 -56.28 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 O-C-N 121.026 -1.279 . . . . 0.0 110.559 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -61.98 -64.41 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 120.906 -1.121 . . . . 0.0 111.574 -177.1 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' HIS . 76.1 mt-10 -56.09 -46.17 79.16 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.932 -1.105 . . . . 0.0 110.341 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 52.0 tt0 -48.31 -56.55 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.11 -0.993 . . . . 0.0 110.298 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 62.4 m -84.79 -27.16 27.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.135 -0.978 . . . . 0.0 111.331 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.412 ' N ' ' O ' ' A' ' 39' ' ' VAL . 51.1 t -83.01 -52.23 6.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.72 -1.238 . . . . 0.0 109.163 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.464 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.7 t-80 -69.32 -27.5 65.43 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.178 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 m -137.01 159.95 40.37 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.424 -0.797 . . . . 0.0 109.594 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.8 mm -83.41 99.59 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.264 -0.897 . . . . 0.0 108.933 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.0 p -90.63 147.31 23.38 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.059 -1.026 . . . . 0.0 109.482 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -81.62 166.56 20.08 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.6 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.4 mt -56.41 -34.24 66.55 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -44.31 -57.42 3.51 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.924 0.869 . . . . 0.0 109.982 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.0 -42.29 93.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 81.4 mt -62.36 -32.34 73.12 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -69.74 -9.51 54.76 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -75.7 -28.34 58.57 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.753 -0.592 . . . . 0.0 109.613 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.3 m-85 -101.48 6.0 42.19 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.35 -0.844 . . . . 0.0 110.035 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.405 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 88.6 m -80.45 110.52 15.99 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.933 -1.104 . . . . 0.0 109.217 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.405 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 17.3 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.633 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.432 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -99.55 -91.51 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.432 -0.793 . . . . 0.0 110.582 -178.756 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.432 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.1 m120 -103.86 27.14 7.84 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.491 -0.756 . . . . 0.0 109.798 -179.219 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.95 161.22 14.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.456 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.481 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 8.6 p80 -92.94 134.73 34.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.619 -0.676 . . . . 0.0 110.593 -178.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -98.99 131.0 45.37 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.35 125.15 11.89 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.165 -0.96 . . . . 0.0 109.301 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.17 -149.24 43.86 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.2 m -44.91 -31.86 1.41 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.255 -1.144 . . . . 0.0 110.226 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -48.19 -50.5 28.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.064 -1.023 . . . . 0.0 108.824 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.8 tp -57.14 -55.21 37.72 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.474 -0.766 . . . . 0.0 109.501 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.12 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.273 -0.892 . . . . 0.0 110.033 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.5 mt-10 -47.57 -29.12 2.63 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.485 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.78 -54.59 5.92 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.291 -0.881 . . . . 0.0 109.209 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.27 -35.67 38.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.433 -1.417 . . . . 0.0 108.71 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -49.31 -49.41 44.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.873 . . . . 0.0 110.403 -179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.511 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -68.82 -50.55 49.08 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.589 -1.319 . . . . 0.0 108.581 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -51.03 -59.14 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.503 0.668 . . . . 0.0 110.13 -179.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.2 m -76.42 -23.69 53.99 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.507 -0.746 . . . . 0.0 109.743 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.57 -133.44 46.96 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -74.87 -13.05 60.51 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.423 -1.045 . . . . 0.0 110.196 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.11 -26.77 51.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.166 -0.959 . . . . 0.0 109.258 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 155.75 5.58 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 108.462 -1.855 . . . . 0.0 108.462 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -156.43 172.52 18.37 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.982 -1.305 . . . . 0.0 110.091 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.0 p90 -115.8 133.45 56.02 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -72.66 171.9 11.67 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.586 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 8.3 t -63.36 174.53 1.22 Allowed 'General case' 0 C--N 1.298 -1.666 0 O-C-N 120.768 -1.207 . . . . 0.0 109.722 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.522 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -43.88 147.06 0.93 Allowed Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.483 -0.761 . . . . 0.0 110.231 -177.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -77.64 -6.32 16.08 Favored 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 122.032 1.821 . . . . 0.0 110.3 179.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.549 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.0 p -53.91 -41.0 67.18 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.181 -0.949 . . . . 0.0 110.839 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.48 -15.78 0.41 Allowed Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.433 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.549 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.8 -14.32 46.92 Favored Glycine 0 N--CA 1.499 2.882 0 N-CA-C 109.043 -1.623 . . . . 0.0 109.043 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.469 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.99 55.95 0.1 OUTLIER Glycine 0 N--CA 1.484 1.848 0 N-CA-C 108.173 -1.971 . . . . 0.0 108.173 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.469 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.2 Cg_endo -69.52 -175.54 1.13 Allowed 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.742 1.628 . . . . 0.0 110.206 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.586 ' N ' ' OG1' ' A' ' 27' ' ' THR . 4.3 ttt-85 -59.68 86.45 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.44 ' N ' ' O ' ' A' ' 34' ' ' PRO . 12.6 ptt180 -60.16 -1.01 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.04 -1.038 . . . . 0.0 108.746 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.562 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -75.43 -22.88 74.81 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 121.014 -1.286 . . . . 0.0 110.252 -179.702 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.7 t -62.59 -64.27 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.044 -1.035 . . . . 0.0 111.249 -177.29 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.495 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.0 mt-10 -54.99 -48.78 72.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.014 -1.054 . . . . 0.0 110.431 -178.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 52.7 tp60 -46.32 -57.2 4.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.075 -1.016 . . . . 0.0 110.458 -179.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 60.3 m -84.75 -26.48 27.58 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 111.278 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.3 t -83.19 -51.33 7.58 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.677 -1.264 . . . . 0.0 109.25 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.52 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.3 t-80 -72.61 -26.61 61.75 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.353 -0.842 . . . . 0.0 109.621 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.92 158.83 43.57 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.311 -0.868 . . . . 0.0 109.838 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 10.4 mm -81.25 99.51 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.347 -0.846 . . . . 0.0 109.171 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -92.17 149.9 21.22 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.018 -1.051 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -83.84 166.46 17.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.25 -0.906 . . . . 0.0 109.336 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.2 mt -57.63 -33.61 68.45 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -43.72 -57.85 3.0 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.917 0.865 . . . . 0.0 109.979 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -59.95 -42.68 94.58 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.8 mt -61.72 -27.2 68.54 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -75.33 -8.54 56.94 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -79.51 -26.33 41.57 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.811 -0.555 . . . . 0.0 109.995 -179.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 13.8 m-85 -101.05 5.67 43.08 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.283 -0.886 . . . . 0.0 110.398 -179.257 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.3 m -79.29 111.39 15.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.928 -1.108 . . . . 0.0 109.631 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.568 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.623 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.43 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.38 -91.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.479 -0.763 . . . . 0.0 110.572 -178.68 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.43 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.2 m120 -101.45 25.94 7.81 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.382 -0.824 . . . . 0.0 109.879 -179.267 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.623 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.64 159.82 14.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.356 -0.84 . . . . 0.0 109.671 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -92.2 137.17 32.59 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.483 0.659 . . . . 0.0 110.568 -179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -100.83 131.12 46.87 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -148.03 125.02 11.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -147.7 41.99 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -45.99 -32.3 2.7 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.328 -1.101 . . . . 0.0 110.225 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -48.43 -50.08 32.54 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.054 -1.029 . . . . 0.0 108.722 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.2 tp -57.21 -54.39 47.36 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.45 -0.781 . . . . 0.0 109.519 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.7 t -46.93 -66.32 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.284 -0.885 . . . . 0.0 109.951 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 41.4 mt-10 -48.03 -24.41 1.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.139 -0.976 . . . . 0.0 109.377 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.5 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -83.29 -54.43 5.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.339 -0.851 . . . . 0.0 109.035 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -52.23 -33.26 40.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.429 -1.42 . . . . 0.0 108.542 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -51.17 -49.85 60.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.344 -0.848 . . . . 0.0 110.2 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.487 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.3 mp -68.23 -50.55 53.27 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.578 -1.326 . . . . 0.0 108.597 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -50.54 -58.79 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.504 0.669 . . . . 0.0 109.723 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.03 -23.27 52.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.582 -0.699 . . . . 0.0 109.893 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.19 -126.27 18.33 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -77.39 -14.96 59.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.313 -1.11 . . . . 0.0 110.282 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.8 mtp180 -55.31 -27.95 50.33 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.088 -1.007 . . . . 0.0 109.424 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.66 154.55 4.83 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.509 -1.836 . . . . 0.0 108.509 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.79 173.01 17.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.897 -1.355 . . . . 0.0 110.372 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.4 p90 -117.96 136.46 53.49 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -77.25 170.37 16.65 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.587 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.3 t -64.62 175.34 1.45 Allowed 'General case' 0 C--N 1.298 -1.654 0 O-C-N 120.973 -1.079 . . . . 0.0 110.016 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -44.33 148.55 0.84 Allowed Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 109.967 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -77.35 -6.1 16.14 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.118 1.879 . . . . 0.0 110.3 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.547 ' C ' ' H ' ' A' ' 32' ' ' GLY . 48.8 p -53.79 -41.17 66.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.149 -0.969 . . . . 0.0 111.084 -177.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.28 -16.14 0.36 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.525 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -97.26 -18.52 28.53 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.486 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.97 55.49 0.16 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.382 -1.887 . . . . 0.0 108.382 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.6 Cg_endo -70.86 -175.25 1.35 Allowed 'Trans proline' 0 C--N 1.318 -1.067 0 C-N-CA 121.841 1.694 . . . . 0.0 110.189 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.587 ' N ' ' OG1' ' A' ' 27' ' ' THR . 7.5 ttt-85 -56.67 86.3 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 34' ' ' PRO . 10.9 ptt180 -60.1 0.16 0.18 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.984 -1.072 . . . . 0.0 108.843 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.576 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -75.2 -24.41 71.36 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.76 -56.41 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 121.024 -1.28 . . . . 0.0 110.287 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.34 -64.41 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.028 -1.045 . . . . 0.0 111.352 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.422 ' O ' ' N ' ' A' ' 44' ' ' HIS . 56.4 mt-10 -55.52 -45.45 77.15 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.056 -1.028 . . . . 0.0 110.457 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -49.6 -56.45 9.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.087 -1.008 . . . . 0.0 110.212 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 64.5 m -84.99 -26.12 27.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.18 -0.95 . . . . 0.0 111.339 -178.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.438 ' N ' ' O ' ' A' ' 39' ' ' VAL . 46.2 t -83.06 -51.33 7.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.723 -1.236 . . . . 0.0 109.295 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.5 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.5 t-80 -72.1 -25.67 61.84 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.283 -0.885 . . . . 0.0 109.376 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -136.81 157.78 45.97 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.363 -0.836 . . . . 0.0 109.623 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 8.6 mm -82.11 99.22 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.374 -0.829 . . . . 0.0 108.891 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.5 p -91.28 150.62 21.24 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.097 -1.002 . . . . 0.0 109.54 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.421 ' H ' ' HG ' ' A' ' 48' ' ' SER . 2.3 p -84.1 166.83 17.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.199 179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -57.44 -33.6 68.11 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.42 -57.81 3.33 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.811 0.815 . . . . 0.0 110.081 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 11.5 mt-30 -60.13 -41.86 93.55 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.9 mt -61.98 -31.99 72.41 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.04 -9.57 55.78 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -75.68 -28.33 58.63 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.759 -0.588 . . . . 0.0 109.557 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.437 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 12.9 m-85 -100.99 5.1 43.0 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.33 -0.856 . . . . 0.0 110.151 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.419 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 96.8 m -80.15 109.6 14.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.92 -1.112 . . . . 0.0 109.086 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.419 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 23.3 t-20 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.084 -0.96 . . . . 0.0 109.391 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.631 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.445 ' H ' ' H3 ' ' A' ' 1' ' ' PHE . 0.6 OUTLIER -94.7 -91.36 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.373 -0.829 . . . . 0.0 110.791 -178.495 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.42 ' H ' HG21 ' A' ' 2' ' ' VAL . 5.2 m120 -105.65 25.73 10.42 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.408 -0.807 . . . . 0.0 110.028 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 3.3 pt20 -95.91 158.07 15.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.278 -0.889 . . . . 0.0 109.625 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.5 p80 -90.68 137.01 32.69 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.696 -0.627 . . . . 0.0 110.217 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.401 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -96.21 122.57 39.21 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.8 m -139.69 125.65 19.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.291 -0.881 . . . . 0.0 109.331 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.38 -149.81 46.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -44.54 -29.55 0.74 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.353 -1.086 . . . . 0.0 110.235 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -49.18 -51.24 33.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.034 -1.041 . . . . 0.0 108.874 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 21.7 tp -55.8 -51.36 67.72 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.401 -0.812 . . . . 0.0 109.365 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -49.61 -66.22 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 0.0 109.714 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.481 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 38.8 mt-10 -47.49 -26.91 1.53 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.379 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.49 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.53 -55.49 4.82 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.407 -0.808 . . . . 0.0 109.148 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.1 mt -51.3 -33.64 29.79 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.268 -1.52 . . . . 0.0 108.737 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.436 ' O ' ' N ' ' A' ' 20' ' ' GLY . 54.8 t80 -50.94 -50.35 57.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 110.228 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.481 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.6 mp -67.66 -50.53 57.35 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.575 -1.328 . . . . 0.0 108.605 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -50.42 -58.95 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.514 0.673 . . . . 0.0 109.816 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.8 m -76.71 -23.38 53.12 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.541 -0.724 . . . . 0.0 109.867 -178.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 48.42 -123.31 9.8 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -79.07 -13.28 59.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.304 -1.115 . . . . 0.0 110.298 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -57.81 -27.67 63.35 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.085 -1.009 . . . . 0.0 109.561 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 154.73 4.75 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.68 172.85 17.86 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.773 -1.428 . . . . 0.0 110.484 -179.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.9 p90 -118.14 129.98 55.84 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.3 t80 -70.69 171.12 10.97 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.591 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.8 t -64.12 174.91 1.39 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 120.826 -1.171 . . . . 0.0 109.644 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -42.29 150.38 0.4 Allowed Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.449 -0.782 . . . . 0.0 110.339 -178.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -78.35 -6.78 15.77 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.068 1.845 . . . . 0.0 110.439 179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.53 ' C ' ' H ' ' A' ' 32' ' ' GLY . 37.7 p -54.09 -40.68 67.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.128 -0.982 . . . . 0.0 111.166 -177.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.09 -15.45 0.54 Allowed Glycine 0 N--CA 1.493 2.475 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.347 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -94.95 -25.8 13.94 Favored Glycine 0 N--CA 1.5 2.902 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.5 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -169.91 54.9 0.2 Allowed Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.502 ' O ' ' N ' ' A' ' 36' ' ' ARG . 24.9 Cg_endo -70.89 -174.95 1.25 Allowed 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.041 1.828 . . . . 0.0 110.369 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.591 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.9 ttt-85 -57.6 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.605 HH11 ' CG ' ' A' ' 36' ' ' ARG . 0.6 OUTLIER -58.32 -30.77 66.95 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.918 -1.114 . . . . 0.0 108.368 -179.65 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.96 -24.53 0.09 OUTLIER Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.5 -55.55 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 120.977 -1.308 . . . . 0.0 109.91 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.8 t -62.49 -64.26 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.052 -1.03 . . . . 0.0 112.1 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -59.38 -37.71 78.64 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.832 -1.168 . . . . 0.0 110.856 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.419 ' O ' ' OG ' ' A' ' 45' ' ' SER . 49.6 tt0 -54.49 -56.26 20.57 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.819 -1.175 . . . . 0.0 109.409 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 67.2 m -85.78 -24.03 27.0 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.324 -0.86 . . . . 0.0 111.297 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 39' ' ' VAL . 45.4 t -83.9 -52.62 6.21 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.635 -1.291 . . . . 0.0 109.771 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.4 t-80 -69.77 -26.3 64.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.203 -0.936 . . . . 0.0 109.278 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 0.7 OUTLIER -136.88 161.17 36.74 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.376 -0.828 . . . . 0.0 109.483 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.7 mm -84.59 99.79 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.4 p -90.99 153.96 19.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.065 -1.022 . . . . 0.0 109.726 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.19 167.95 15.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.312 -0.867 . . . . 0.0 109.056 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.1 mt -59.74 -33.34 71.53 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.919 0.866 . . . . 0.0 108.669 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -44.34 -57.74 3.34 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.777 0.798 . . . . 0.0 110.286 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -61.06 -41.73 97.18 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 119.773 -0.771 . . . . 0.0 108.964 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.3 mt -61.56 -31.31 71.34 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.64 -9.64 57.49 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -75.64 -28.06 58.64 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.746 -0.596 . . . . 0.0 109.569 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.429 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.8 m-85 -101.22 5.64 42.66 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.333 -0.854 . . . . 0.0 110.072 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 90.0 m -80.35 109.47 14.86 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.916 -1.115 . . . . 0.0 109.27 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.454 -179.961 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.63 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.417 HG22 ' H ' ' A' ' 3' ' ' ASN . 0.3 OUTLIER -98.32 -91.29 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.366 -0.834 . . . . 0.0 110.503 -178.827 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.488 ' N ' ' OD1' ' A' ' 3' ' ' ASN . 1.1 m-20 -106.35 27.53 8.64 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.534 -0.729 . . . . 0.0 109.899 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.63 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.79 159.96 14.82 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.343 -0.848 . . . . 0.0 109.335 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 14.8 p-80 -90.65 131.46 36.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.616 -0.677 . . . . 0.0 110.693 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD23 ' CE1' ' A' ' 1' ' ' PHE . 0.8 OUTLIER -94.01 127.28 39.71 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.021 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.2 m -142.68 125.51 16.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.233 -0.917 . . . . 0.0 109.343 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.33 -150.45 47.06 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.9 m -43.67 -29.92 0.56 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -1.032 . . . . 0.0 110.383 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 24.4 m-20 -50.01 -51.31 42.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.991 -1.068 . . . . 0.0 108.951 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.5 tp -54.8 -53.52 54.15 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.313 -0.867 . . . . 0.0 109.148 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 t -47.91 -66.07 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.356 -0.84 . . . . 0.0 109.963 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 45.3 mt-10 -47.82 -28.51 2.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.349 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.72 -54.89 5.63 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.352 -0.843 . . . . 0.0 109.123 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.0 mt -51.64 -35.29 41.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.35 -1.469 . . . . 0.0 108.661 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.8 t80 -49.32 -49.53 43.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 110.298 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.49 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.5 mp -68.53 -51.27 44.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.67 -1.269 . . . . 0.0 108.609 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -50.33 -58.41 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 121.525 0.678 . . . . 0.0 109.59 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -76.58 -23.53 53.51 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.558 -0.714 . . . . 0.0 109.98 -178.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.91 -122.07 10.79 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.3 mt-10 -80.47 -16.47 54.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.307 -1.113 . . . . 0.0 110.357 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.41 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -55.89 -28.16 55.34 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.551 -179.524 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 156.25 5.68 Favored Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -156.58 172.73 18.05 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.842 -1.387 . . . . 0.0 110.477 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.0 p90 -117.76 139.46 51.03 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -78.47 170.97 15.79 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.586 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.5 t -64.6 174.55 1.72 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.869 -1.144 . . . . 0.0 110.523 -178.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -46.36 148.53 1.59 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.586 -0.696 . . . . 0.0 110.098 -178.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.69 -6.23 15.97 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.347 2.031 . . . . 0.0 110.962 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' C ' ' H ' ' A' ' 32' ' ' GLY . 53.2 p -53.17 -40.93 64.71 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.921 -1.112 . . . . 0.0 110.844 -177.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.32 -16.18 0.36 Allowed Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.594 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.545 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.49 -14.08 45.55 Favored Glycine 0 N--CA 1.499 2.899 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.481 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.84 55.87 0.1 OUTLIER Glycine 0 N--CA 1.483 1.803 0 N-CA-C 108.132 -1.987 . . . . 0.0 108.132 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.7 Cg_endo -69.48 -175.29 1.04 Allowed 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 121.694 1.596 . . . . 0.0 109.927 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.586 ' N ' ' OG1' ' A' ' 27' ' ' THR . 1.1 ttt-85 -56.68 86.02 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.529 ' N ' ' O ' ' A' ' 34' ' ' PRO . 0.0 OUTLIER -60.63 0.66 0.18 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.005 -1.059 . . . . 0.0 108.857 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.567 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -77.6 -23.82 66.58 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.537 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.95 -56.41 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.234 0 O-C-N 121.096 -1.238 . . . . 0.0 110.393 -179.716 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.04 -64.35 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.026 . . . . 0.0 111.436 -177.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -55.04 -48.55 73.29 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.856 -1.152 . . . . 0.0 110.411 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.445 ' O ' ' OG ' ' A' ' 45' ' ' SER . 50.2 tt0 -45.93 -58.32 3.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.195 -0.94 . . . . 0.0 110.451 -179.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 68.6 m -85.34 -27.02 26.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.154 -0.966 . . . . 0.0 111.511 -178.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.417 ' N ' ' O ' ' A' ' 39' ' ' VAL . 42.6 t -83.38 -52.32 6.64 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.733 -1.229 . . . . 0.0 109.598 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.438 ' N ' ' O ' ' A' ' 40' ' ' GLU . 12.3 t60 -70.94 -26.59 63.25 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 0.9 OUTLIER -136.88 161.84 34.89 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.324 -0.86 . . . . 0.0 109.676 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.8 mm -83.36 99.69 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.585 -0.697 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -92.4 160.12 15.24 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.05 -1.031 . . . . 0.0 109.741 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.07 167.31 11.87 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.91 -32.58 69.67 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.35 -57.24 3.63 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.702 0.763 . . . . 0.0 110.14 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -61.35 -42.37 98.59 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.924 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.3 mt -61.08 -31.93 71.59 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.42 -9.6 56.81 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.937 -1.135 . . . . 0.0 107.937 179.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -77.0 -27.67 54.78 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.778 -0.576 . . . . 0.0 109.689 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.1 m-85 -102.29 6.23 40.37 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.402 -0.811 . . . . 0.0 109.957 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 65.4 m -78.41 103.3 8.26 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.994 -1.066 . . . . 0.0 109.403 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.4 t-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.456 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.638 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.442 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -104.39 -91.67 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.616 -178.695 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.442 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.4 m120 -100.02 25.8 7.04 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.349 -0.844 . . . . 0.0 109.777 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.638 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.93 160.05 14.66 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.384 -0.823 . . . . 0.0 109.522 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -94.88 136.29 35.36 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.57 -0.706 . . . . 0.0 110.178 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.51 130.17 44.61 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.8 m -143.92 125.18 14.62 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.306 -0.871 . . . . 0.0 109.255 179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.18 -150.62 47.58 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.9 m -43.77 -30.5 0.66 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.418 -1.048 . . . . 0.0 110.322 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -48.94 -50.51 35.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.967 -1.083 . . . . 0.0 108.856 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.9 tp -55.42 -54.86 38.48 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.359 -0.838 . . . . 0.0 109.235 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.75 -66.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.391 -0.818 . . . . 0.0 110.057 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.48 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 35.2 mt-10 -47.87 -27.85 2.32 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.191 -0.943 . . . . 0.0 109.341 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.495 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.69 -54.57 5.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.336 -0.852 . . . . 0.0 109.164 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.64 -34.96 40.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.364 -1.46 . . . . 0.0 108.599 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.9 t80 -49.64 -49.48 47.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.359 -0.838 . . . . 0.0 110.389 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.48 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.3 mp -68.55 -50.76 49.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.525 -1.36 . . . . 0.0 108.578 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -50.6 -58.87 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-O 121.506 0.67 . . . . 0.0 109.718 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.48 -23.56 53.81 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.486 -0.759 . . . . 0.0 109.819 -178.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 53.51 -130.17 41.71 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -76.83 -13.07 60.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -1.105 . . . . 0.0 110.114 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.406 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.3 OUTLIER -56.69 -27.62 59.24 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.107 -0.996 . . . . 0.0 109.368 -179.533 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 155.59 5.5 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -156.54 172.93 17.7 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.932 -1.334 . . . . 0.0 110.074 -179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.3 p90 -116.02 138.65 51.02 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -78.87 171.28 15.41 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.578 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 8.8 t -64.33 174.95 1.45 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.927 -1.108 . . . . 0.0 110.338 -178.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.92 149.95 1.44 Allowed Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.497 -0.752 . . . . 0.0 110.301 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -78.54 -6.31 15.33 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.206 1.937 . . . . 0.0 110.508 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.553 ' C ' ' H ' ' A' ' 32' ' ' GLY . 42.8 p -53.76 -41.04 66.71 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.094 -1.004 . . . . 0.0 111.129 -177.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.63 -15.86 0.43 Allowed Glycine 0 N--CA 1.493 2.474 0 C-N-CA 119.638 -1.268 . . . . 0.0 110.309 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.62 -17.02 34.69 Favored Glycine 0 N--CA 1.499 2.844 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.49 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.55 54.91 0.12 Allowed Glycine 0 N--CA 1.484 1.836 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.508 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.2 Cg_endo -69.51 -175.58 1.14 Allowed 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.782 1.655 . . . . 0.0 109.996 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.578 ' N ' ' OG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -57.34 85.86 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.654 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.508 ' N ' ' O ' ' A' ' 34' ' ' PRO . 17.6 mtm-85 -59.64 -6.81 1.26 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.921 -1.112 . . . . 0.0 108.195 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.516 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.93 -25.66 74.2 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.18 -56.01 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.327 0 O-C-N 121.035 -1.273 . . . . 0.0 110.645 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.526 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -62.39 -63.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.946 -1.096 . . . . 0.0 111.495 -177.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' HIS . 70.1 mt-10 -55.97 -47.81 76.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.84 -1.163 . . . . 0.0 110.285 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.3 tt0 -46.41 -57.44 4.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.999 -1.063 . . . . 0.0 110.426 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 61.0 m -84.69 -27.95 26.7 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.124 -0.985 . . . . 0.0 111.083 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.451 ' N ' ' O ' ' A' ' 39' ' ' VAL . 49.3 t -83.49 -52.1 6.79 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.809 -1.182 . . . . 0.0 109.349 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' GLU . 16.0 t60 -69.77 -28.23 65.59 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.241 -0.912 . . . . 0.0 109.077 179.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 m -137.04 160.73 38.08 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.403 -0.811 . . . . 0.0 109.505 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -83.13 99.94 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 p -91.45 152.05 20.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.012 -1.055 . . . . 0.0 109.563 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.92 167.42 14.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.307 -0.871 . . . . 0.0 109.121 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.95 -34.51 68.09 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.625 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -44.15 -56.97 3.68 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.816 0.817 . . . . 0.0 109.979 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.3 mt-30 -60.33 -42.64 96.08 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 81.9 mt -62.05 -32.6 73.13 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.55 -9.47 54.1 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -76.06 -28.03 57.47 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.79 -0.569 . . . . 0.0 109.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.6 m-85 -102.57 6.71 39.97 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.368 -0.832 . . . . 0.0 109.992 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' O ' ' A' ' 57' ' ' ASN . 67.3 m -79.81 104.01 10.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 109.33 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.431 ' O ' ' O ' ' A' ' 56' ' ' CYS . 24.9 t-20 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.511 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.644 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.428 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -100.28 -91.42 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.437 -0.789 . . . . 0.0 110.425 -178.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.428 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 5.0 m120 -104.54 27.64 7.73 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.477 -0.764 . . . . 0.0 109.801 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.54 159.79 14.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.26 -0.9 . . . . 0.0 109.523 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.0 OUTLIER -90.26 131.94 35.8 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.602 0.715 . . . . 0.0 110.866 -178.637 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -97.51 132.56 43.08 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -148.98 124.89 10.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.15 -0.969 . . . . 0.0 109.222 179.287 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.43 -147.43 42.28 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.8 m -44.9 -33.17 1.87 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.376 -1.073 . . . . 0.0 110.205 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.3 -49.85 41.94 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.003 -1.061 . . . . 0.0 108.815 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.0 tp -58.08 -57.02 14.67 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.0 t -45.07 -65.94 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.34 -0.85 . . . . 0.0 109.974 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.491 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.7 mt-10 -47.54 -30.44 3.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.494 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -77.62 -54.58 6.22 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 109.223 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -50.92 -36.53 38.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.522 -1.361 . . . . 0.0 108.665 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -48.84 -49.8 37.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.399 -0.813 . . . . 0.0 110.396 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.524 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.6 mp -68.26 -50.73 51.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.524 -1.36 . . . . 0.0 108.579 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -50.89 -59.33 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.456 0.646 . . . . 0.0 110.087 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -23.45 54.21 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.512 -0.743 . . . . 0.0 109.809 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.98 -129.03 30.97 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.204 -1.159 . . . . 0.0 110.204 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -76.49 -15.04 59.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -1.106 . . . . 0.0 110.182 -179.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.514 ' NH1' ' OE2' ' A' ' 53' ' ' GLU . 33.8 mtp180 -54.69 -27.61 41.64 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.032 -1.043 . . . . 0.0 109.087 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.13 5.23 Favored Glycine 0 N--CA 1.486 2.0 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 -179.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.39 172.33 18.69 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.889 -1.36 . . . . 0.0 110.214 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.3 p90 -117.53 135.07 54.19 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -73.18 171.65 12.58 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.587 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 6.8 t -63.36 174.71 1.16 Allowed 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.773 -1.204 . . . . 0.0 109.749 -178.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.587 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -42.22 146.33 0.68 Allowed Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.201 -178.134 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -77.05 -6.91 17.03 Favored 'Trans proline' 0 N--CA 1.484 0.92 0 C-N-CA 122.081 1.854 . . . . 0.0 110.723 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.541 ' C ' ' H ' ' A' ' 32' ' ' GLY . 33.6 p -54.25 -40.9 68.18 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.023 -1.048 . . . . 0.0 110.842 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.59 -15.83 0.43 Allowed Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.822 -1.18 . . . . 0.0 110.512 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.541 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.09 -13.87 47.68 Favored Glycine 0 N--CA 1.5 2.925 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.47 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.79 56.22 0.1 OUTLIER Glycine 0 N--CA 1.484 1.877 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.47 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.5 Cg_endo -70.0 -175.22 1.14 Allowed 'Trans proline' 0 C--N 1.32 -0.973 0 C-N-CA 121.815 1.677 . . . . 0.0 110.352 -178.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.568 ' N ' ' OG1' ' A' ' 27' ' ' THR . 46.6 ttt180 -60.49 86.93 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 34' ' ' PRO . 1.3 ppt_? -59.31 -2.98 0.35 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.851 -1.155 . . . . 0.0 108.757 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.531 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -70.66 -24.21 77.1 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.09 -55.12 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.23 0 O-C-N 121.056 -1.261 . . . . 0.0 110.393 -179.635 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.522 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.12 -64.34 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.013 -1.054 . . . . 0.0 111.559 -177.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 44' ' ' HIS . 73.0 mt-10 -56.55 -44.78 81.26 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.95 -1.094 . . . . 0.0 110.483 -178.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.438 ' O ' ' OG ' ' A' ' 45' ' ' SER . 56.5 tp60 -48.86 -56.94 7.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.065 -1.022 . . . . 0.0 110.06 -179.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 56.6 m -84.83 -27.26 26.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.105 -0.997 . . . . 0.0 111.08 -178.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.9 t -83.46 -52.35 6.58 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.672 -1.267 . . . . 0.0 109.448 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 40' ' ' GLU . 2.1 t-160 -70.14 -28.85 65.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.327 -0.858 . . . . 0.0 108.84 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 1.3 p -136.61 162.38 33.29 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.334 -0.853 . . . . 0.0 109.542 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.428 HG22 HD12 ' A' ' 46' ' ' ILE . 15.2 mm -84.09 99.75 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.608 -0.682 . . . . 0.0 109.662 -179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.0 p -92.28 146.53 23.64 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.13 -0.981 . . . . 0.0 109.342 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.72 167.61 18.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.232 -0.918 . . . . 0.0 109.212 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.593 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.3 mt -57.08 -34.25 68.1 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -43.67 -57.25 3.28 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.874 0.845 . . . . 0.0 110.138 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -60.33 -41.87 94.44 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 78.2 mt -62.73 -28.27 69.85 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.514 ' OE2' ' NH1' ' A' ' 22' ' ' ARG . 1.8 tm-20 -74.26 -8.72 57.2 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -78.84 -26.96 44.16 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.875 -0.515 . . . . 0.0 109.946 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.421 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 14.5 m-85 -100.31 5.63 44.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.253 -0.905 . . . . 0.0 110.38 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 72.7 m -82.69 111.27 18.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.843 -1.161 . . . . 0.0 109.462 179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 57' ' ' ASN . 62.7 t-20 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.819 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.633 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 . . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.436 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -101.13 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 110.697 -178.658 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.436 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.8 m120 -102.97 26.58 7.99 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 109.807 -179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.52 161.88 13.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.331 -0.855 . . . . 0.0 109.443 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -94.27 136.5 34.49 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.639 0.733 . . . . 0.0 110.32 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.64 131.89 45.34 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.8 125.31 11.7 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.192 -0.943 . . . . 0.0 109.186 179.334 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -149.14 44.34 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.8 m -44.96 -31.61 1.34 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.373 -1.075 . . . . 0.0 110.335 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -48.73 -50.04 35.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.966 -1.084 . . . . 0.0 108.761 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.0 -54.57 45.24 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.458 -0.776 . . . . 0.0 109.534 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.66 -66.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 110.096 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 50.8 mt-10 -47.67 -27.63 2.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.387 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.501 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.08 -54.49 5.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.392 -0.818 . . . . 0.0 109.17 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.92 -34.81 43.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.398 -1.439 . . . . 0.0 108.585 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 20' ' ' GLY . 57.2 t80 -49.94 -50.04 47.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.327 -0.858 . . . . 0.0 110.231 -179.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.492 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.4 mp -67.68 -50.81 55.78 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.573 -1.329 . . . . 0.0 108.64 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -50.62 -58.98 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.543 0.687 . . . . 0.0 109.759 -179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.23 -23.76 54.57 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.528 -0.732 . . . . 0.0 109.768 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.8 -127.2 30.91 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -78.98 -11.67 60.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.409 -1.054 . . . . 0.0 110.028 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.61 -27.18 62.52 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.162 -0.961 . . . . 0.0 109.287 -179.568 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 154.8 5.01 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -156.47 172.52 18.38 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.859 -1.377 . . . . 0.0 110.278 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.2 p90 -116.95 132.57 56.67 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -72.26 171.44 12.11 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.8 t -63.73 174.56 1.36 Allowed 'General case' 0 C--N 1.297 -1.69 0 O-C-N 120.706 -1.246 . . . . 0.0 109.669 -179.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.563 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -43.88 147.35 0.89 Allowed Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.398 -0.814 . . . . 0.0 110.078 -178.16 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -77.69 -6.25 15.99 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 C-N-CA 122.102 1.868 . . . . 0.0 110.429 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.546 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.2 p -53.95 -40.91 67.23 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.083 -1.011 . . . . 0.0 110.984 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.486 ' N ' ' HG1' ' A' ' 30' ' ' THR . . . 67.57 -15.95 0.42 Allowed Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.409 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.546 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.88 -15.26 43.18 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.478 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.21 55.53 0.1 Allowed Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.8 Cg_endo -69.96 -175.62 1.27 Allowed 'Trans proline' 0 C--N 1.319 -1.016 0 C-N-CA 121.857 1.705 . . . . 0.0 110.239 -179.108 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.583 ' N ' ' OG1' ' A' ' 27' ' ' THR . 2.9 ttt-85 -58.96 86.08 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.469 ' N ' ' O ' ' A' ' 34' ' ' PRO . 13.5 mtm-85 -59.57 -5.49 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.97 -1.082 . . . . 0.0 108.367 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.532 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -69.43 -24.13 76.22 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.91 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 O-C-N 121.006 -1.291 . . . . 0.0 110.437 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.4 t -62.02 -64.18 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.038 -1.038 . . . . 0.0 111.521 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.443 ' O ' ' N ' ' A' ' 44' ' ' HIS . 83.9 mt-10 -55.84 -46.3 78.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.908 -1.12 . . . . 0.0 110.485 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.9 tp60 -48.14 -56.5 7.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.059 -1.026 . . . . 0.0 110.299 -179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 45' ' ' SER . 58.5 m -85.15 -26.36 26.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.143 -0.973 . . . . 0.0 111.271 -178.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.9 t -83.4 -52.4 6.56 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.608 -1.307 . . . . 0.0 109.418 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.443 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.1 t-80 -69.47 -26.68 64.69 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.874 . . . . 0.0 109.339 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -137.04 173.31 11.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.338 -0.851 . . . . 0.0 109.827 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -93.17 100.04 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.4 p -93.78 145.03 24.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.016 -1.053 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -80.53 166.53 21.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.882 . . . . 0.0 109.35 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -56.81 -34.36 67.62 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.45 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -44.03 -57.29 3.44 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.904 0.859 . . . . 0.0 109.943 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -59.89 -42.94 94.89 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.9 mt -61.83 -31.91 72.19 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.23 -9.68 56.58 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -75.83 -28.33 58.23 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.803 -0.561 . . . . 0.0 109.598 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 6.9 m-85 -102.72 7.01 39.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.406 -0.808 . . . . 0.0 109.984 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 60.5 m -78.58 108.6 12.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.96 -1.087 . . . . 0.0 109.409 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 57' ' ' ASN . 2.1 t-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.483 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.644 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 . . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.445 HG22 ' H ' ' A' ' 3' ' ' ASN . 1.1 m -102.73 -91.99 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.506 -0.746 . . . . 0.0 110.762 -178.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.445 ' H ' HG22 ' A' ' 2' ' ' VAL . 3.7 m120 -99.59 25.3 7.24 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.232 -0.917 . . . . 0.0 109.883 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.95 157.35 15.94 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.83 . . . . 0.0 109.635 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.5 p-80 -92.69 135.9 33.7 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.574 0.702 . . . . 0.0 109.957 -179.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.53 136.03 38.52 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -151.67 125.16 8.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.303 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -146.49 40.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.7 m -47.84 -31.83 5.45 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -1.086 . . . . 0.0 110.209 -179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -49.03 -49.83 39.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.881 -1.137 . . . . 0.0 108.645 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.6 tp -56.67 -55.09 38.49 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.415 -0.803 . . . . 0.0 109.401 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -46.41 -66.04 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.283 -0.886 . . . . 0.0 110.001 -179.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.1 mt-10 -47.51 -28.8 2.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.368 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.486 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.02 -54.61 5.84 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 109.173 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.4 mt -51.26 -34.93 34.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.509 -1.369 . . . . 0.0 108.667 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.6 t80 -49.96 -48.79 51.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 110.394 -179.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.513 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.55 -50.71 42.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.495 -1.378 . . . . 0.0 108.529 179.315 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -50.86 -59.09 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 121.512 0.673 . . . . 0.0 110.02 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.4 m -76.04 -23.98 55.15 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.441 -0.787 . . . . 0.0 109.699 -178.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.42 -133.55 46.34 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -75.5 -12.13 60.17 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.325 -1.103 . . . . 0.0 109.963 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -56.32 -26.93 54.03 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.002 -179.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.86 154.72 5.11 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.5 172.91 17.72 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.999 -1.295 . . . . 0.0 110.079 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.546 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.6 p90 -117.38 139.79 50.41 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.48 170.43 16.59 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.647 ' HG1' ' H ' ' A' ' 28' ' ' ASP . 7.5 t -64.73 174.94 1.61 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.947 -1.095 . . . . 0.0 110.069 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.647 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.2 OUTLIER -42.54 148.56 0.52 Allowed Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.651 -0.655 . . . . 0.0 110.135 -178.711 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.47 -6.32 16.21 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.255 1.97 . . . . 0.0 110.995 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.536 ' C ' ' H ' ' A' ' 32' ' ' GLY . 52.0 p -53.49 -40.79 65.65 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.995 -1.065 . . . . 0.0 111.0 -177.237 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.64 -15.68 0.44 Allowed Glycine 0 N--CA 1.495 2.57 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.647 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.05 -20.02 27.01 Favored Glycine 0 N--CA 1.5 2.935 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.502 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -173.4 54.69 0.15 Allowed Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.277 -1.929 . . . . 0.0 108.277 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.516 ' O ' ' N ' ' A' ' 36' ' ' ARG . 17.4 Cg_endo -67.81 -173.95 0.54 Allowed 'Trans proline' 0 C--N 1.319 -1.026 0 C-N-CA 121.915 1.743 . . . . 0.0 110.5 -179.071 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.569 ' C ' ' H ' ' A' ' 37' ' ' GLY . 38.8 ttt180 -56.24 87.1 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.516 ' N ' ' O ' ' A' ' 34' ' ' PRO . 2.1 ptp180 -58.99 -1.55 0.18 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.107 -0.995 . . . . 0.0 108.68 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.569 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -73.0 -25.74 72.9 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.39 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.31 0 O-C-N 121.057 -1.261 . . . . 0.0 110.385 -179.601 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 2.9 t -63.46 -63.91 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.962 -1.086 . . . . 0.0 111.461 -177.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.444 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.4 mt-10 -55.62 -46.18 77.43 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.864 -1.147 . . . . 0.0 110.43 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -48.39 -56.77 7.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 110.204 -179.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 73.0 m -85.1 -28.07 25.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 111.427 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 53.9 t -83.29 -52.33 6.66 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.66 -1.275 . . . . 0.0 109.295 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.444 ' N ' ' O ' ' A' ' 40' ' ' GLU . 5.8 t60 -69.55 -27.04 64.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.066 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.7 m -137.17 157.4 46.76 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.496 -0.753 . . . . 0.0 109.49 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -81.55 99.73 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.6 p -89.51 163.84 15.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.998 -1.064 . . . . 0.0 109.697 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -96.18 166.84 11.55 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.416 -0.802 . . . . 0.0 109.186 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.601 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.59 -33.29 69.82 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -44.76 -57.86 3.45 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.791 0.805 . . . . 0.0 110.236 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -61.07 -40.84 95.22 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.061 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 76.1 mt -62.41 -25.09 67.76 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 179.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.66 -9.03 58.75 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -78.96 -26.82 43.51 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.783 -0.573 . . . . 0.0 109.705 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 17.2 m-85 -99.73 4.39 45.43 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.348 -0.845 . . . . 0.0 110.339 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.406 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 71.0 m -82.84 111.22 18.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.883 -1.136 . . . . 0.0 109.367 179.639 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.406 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.9 t-20 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.058 -0.972 . . . . 0.0 109.377 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.636 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.444 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -102.85 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.445 -0.784 . . . . 0.0 110.536 -178.856 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.444 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.7 m120 -101.5 26.77 6.91 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.393 -0.817 . . . . 0.0 109.892 -179.318 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.636 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.0 pt20 -95.23 160.79 14.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -92.87 134.77 34.75 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.514 0.673 . . . . 0.0 110.67 -178.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -99.49 132.56 44.74 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.262 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -148.49 125.1 11.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.094 -1.004 . . . . 0.0 109.332 179.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -148.52 43.26 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.3 m -45.11 -32.28 1.72 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.347 -1.09 . . . . 0.0 110.245 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -48.54 -50.52 31.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.991 -1.068 . . . . 0.0 108.823 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.8 tp -57.08 -54.79 42.76 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.434 -0.791 . . . . 0.0 109.505 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -46.56 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.294 -0.879 . . . . 0.0 109.991 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 46.9 mt-10 -47.59 -29.31 2.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.923 . . . . 0.0 109.397 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.495 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.42 -54.58 6.02 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.375 -0.828 . . . . 0.0 109.363 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.12 -36.1 38.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.456 -1.402 . . . . 0.0 108.794 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -49.43 -49.0 46.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.341 -0.849 . . . . 0.0 110.482 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.503 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -69.02 -50.32 49.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.61 -1.306 . . . . 0.0 108.496 179.381 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -51.03 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.504 0.669 . . . . 0.0 110.113 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.3 m -75.52 -23.63 56.72 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.495 -0.753 . . . . 0.0 109.821 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.47 -126.76 25.09 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -77.45 -15.49 59.29 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.395 -1.062 . . . . 0.0 110.186 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -54.85 -27.9 45.81 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.174 -0.953 . . . . 0.0 109.409 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.79 154.88 5.13 Favored Glycine 0 N--CA 1.487 2.033 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.38 172.53 18.34 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.918 -1.342 . . . . 0.0 110.269 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -118.01 129.28 55.49 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -68.62 171.45 7.62 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 178.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.598 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 10.0 t -63.41 174.45 1.27 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 120.74 -1.225 . . . . 0.0 109.468 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.598 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.2 OUTLIER -44.59 147.64 1.03 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.182 -178.124 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -78.18 -6.29 15.62 Favored 'Trans proline' 0 N--CA 1.483 0.883 0 C-N-CA 122.098 1.865 . . . . 0.0 110.158 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.537 ' C ' ' H ' ' A' ' 32' ' ' GLY . 39.0 p -53.85 -40.95 66.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 110.99 -177.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.73 -15.74 0.45 Allowed Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.773 -1.203 . . . . 0.0 110.399 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.537 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.54 -16.2 40.68 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.476 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -176.74 55.53 0.11 Allowed Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.476 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 17.7 Cg_endo -69.39 -175.44 1.07 Allowed 'Trans proline' 0 C--N 1.318 -1.037 0 C-N-CA 121.774 1.65 . . . . 0.0 110.143 -179.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.59 ' N ' ' OG1' ' A' ' 27' ' ' THR . 33.7 ttt180 -59.84 86.19 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 178.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 34' ' ' PRO . 1.8 ptp180 -61.58 3.08 0.14 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.054 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -79.59 -21.84 65.74 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.28 -55.53 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 O-C-N 121.024 -1.28 . . . . 0.0 110.052 -179.714 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -62.2 -63.84 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.023 -1.048 . . . . 0.0 111.094 -177.526 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.456 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.9 mt-10 -54.74 -48.49 72.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.989 -1.069 . . . . 0.0 110.557 -178.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.0 tt0 -47.22 -56.58 6.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.069 -1.019 . . . . 0.0 110.493 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 45' ' ' SER . 57.1 m -84.66 -26.51 27.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.228 -0.92 . . . . 0.0 111.363 -178.588 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.3 t -83.77 -52.39 6.44 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.642 -1.286 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.4 t-80 -68.96 -27.29 65.6 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.235 -0.916 . . . . 0.0 109.23 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.436 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.6 t -137.23 173.17 11.97 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.416 -0.803 . . . . 0.0 109.88 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 9.7 mm -92.3 99.85 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.561 -0.712 . . . . 0.0 109.315 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.8 p -93.0 143.3 26.37 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.014 -1.054 . . . . 0.0 109.39 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -79.39 166.45 22.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.447 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.0 mt -56.36 -34.11 66.33 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.06 -57.49 3.35 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 121.87 0.843 . . . . 0.0 109.971 179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.9 mt-30 -60.06 -42.15 93.9 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.8 mt -62.79 -29.05 70.41 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.11 -8.9 57.81 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -78.43 -26.89 46.41 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.853 -0.529 . . . . 0.0 109.864 -179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.422 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 15.3 m-85 -100.75 5.24 43.57 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.265 -0.897 . . . . 0.0 110.227 -179.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 71.6 m -83.35 111.48 19.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.97 -1.081 . . . . 0.0 109.49 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.441 179.959 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.631 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.422 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -101.99 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.421 -0.799 . . . . 0.0 110.678 -178.616 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.422 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.7 m120 -102.02 25.57 8.59 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.429 -0.794 . . . . 0.0 109.991 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.97 160.18 14.59 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.468 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 9.8 p80 -92.95 136.19 33.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.514 -0.741 . . . . 0.0 110.552 -178.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.403 HD23 ' CE1' ' A' ' 1' ' ' PHE . 1.0 OUTLIER -97.35 127.06 42.99 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.304 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 82.2 m -142.89 125.29 15.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.296 -0.878 . . . . 0.0 109.348 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.17 -149.31 45.61 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.5 m -44.92 -30.84 1.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.421 -1.047 . . . . 0.0 110.284 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -48.7 -50.61 32.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.927 -1.108 . . . . 0.0 108.787 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.9 tp -55.42 -53.99 49.29 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -47.04 -66.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.837 . . . . 0.0 109.899 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 72.5 mt-10 -47.79 -26.77 1.74 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.371 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.494 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.02 -54.73 5.3 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.384 -0.823 . . . . 0.0 109.131 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.84 -34.28 39.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.406 -1.434 . . . . 0.0 108.581 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.6 t80 -50.16 -49.85 50.88 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.366 -0.834 . . . . 0.0 110.179 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.485 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.4 mp -68.27 -50.76 51.59 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.584 -1.323 . . . . 0.0 108.681 179.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -50.52 -58.64 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.5 0.667 . . . . 0.0 109.757 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -77.0 -23.34 52.23 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 -178.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 46.95 -120.78 5.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -80.22 -13.7 59.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.299 -1.118 . . . . 0.0 110.15 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -57.95 -28.27 64.17 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.112 -0.992 . . . . 0.0 109.528 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.59 154.19 4.57 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -156.87 172.95 17.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.886 -1.361 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.8 p90 -119.15 139.51 51.68 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -80.52 169.82 17.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.931 -1.106 . . . . 0.0 108.143 179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.579 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.2 t -65.59 175.71 1.74 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.117 -0.989 . . . . 0.0 110.404 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -45.22 149.87 0.88 Allowed Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.459 -0.776 . . . . 0.0 109.895 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -78.4 -6.13 15.35 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.178 1.919 . . . . 0.0 110.581 179.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.552 ' C ' ' H ' ' A' ' 32' ' ' GLY . 42.5 p -53.67 -40.97 66.38 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.125 -0.985 . . . . 0.0 111.231 -177.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.57 -15.92 0.42 Allowed Glycine 0 N--CA 1.494 2.531 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.352 179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.52 -20.14 25.58 Favored Glycine 0 N--CA 1.499 2.852 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.508 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.82 54.3 0.16 Allowed Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.656 -1.778 . . . . 0.0 108.656 179.11 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.528 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.6 Cg_endo -69.17 -174.46 0.79 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 121.969 1.779 . . . . 0.0 110.075 -179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.579 ' N ' ' OG1' ' A' ' 27' ' ' THR . 2.8 ttt-85 -56.34 86.52 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' N ' ' O ' ' A' ' 34' ' ' PRO . 7.0 ptm180 -59.61 -1.73 0.28 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.049 -1.032 . . . . 0.0 108.722 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.555 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -72.92 -25.73 73.02 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.08 -56.33 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.061 -1.258 . . . . 0.0 110.46 -179.67 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -62.27 -64.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 120.961 -1.087 . . . . 0.0 111.637 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 44' ' ' HIS . 62.4 mt-10 -55.79 -46.79 77.9 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.85 -1.157 . . . . 0.0 110.331 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.0 tt0 -47.67 -57.49 5.45 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.086 -1.009 . . . . 0.0 110.167 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 63.1 m -84.77 -26.7 27.39 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.137 -0.977 . . . . 0.0 111.101 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.455 ' N ' ' O ' ' A' ' 39' ' ' VAL . 45.0 t -83.25 -52.3 6.7 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.826 -1.171 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.503 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.1 t-80 -71.24 -26.46 62.92 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.231 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.2 m -136.83 157.91 45.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.39 -0.819 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -82.27 99.73 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.242 -0.911 . . . . 0.0 109.013 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.7 p -90.75 151.62 21.14 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.137 -0.977 . . . . 0.0 109.375 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -85.08 166.49 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.02 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -56.54 -34.04 66.67 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -44.44 -57.5 3.52 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.855 0.835 . . . . 0.0 110.023 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.07 -42.35 94.37 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.9 mt -62.29 -31.8 72.44 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.89 -9.46 54.96 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -75.54 -28.37 59.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.799 -0.563 . . . . 0.0 109.712 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.1 m-85 -102.03 6.32 41.03 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.333 -0.854 . . . . 0.0 110.018 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 73.4 m -80.4 109.0 14.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.93 -1.106 . . . . 0.0 109.358 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.417 ' OXT' ' OD1' ' A' ' 57' ' ' ASN . 53.7 t-20 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.514 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.667 ' H2 ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -104.04 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.407 -0.808 . . . . 0.0 110.726 -178.661 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.43 ' H ' HG22 ' A' ' 2' ' ' VAL . 5.2 m120 -101.66 25.85 8.04 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.409 -0.807 . . . . 0.0 109.936 -179.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.667 ' NE2' ' H2 ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.88 160.2 14.59 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.321 -0.862 . . . . 0.0 109.85 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 5' ' ' HIS . 0.1 OUTLIER -92.76 132.09 37.26 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.643 -0.661 . . . . 0.0 110.441 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -95.4 132.8 40.06 Favored 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -149.12 125.24 10.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.033 -1.042 . . . . 0.0 109.327 179.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.88 -147.4 41.49 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -45.89 -32.07 2.47 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.362 -1.081 . . . . 0.0 110.194 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -49.27 -51.06 36.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.092 . . . . 0.0 108.762 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 21.3 tp -56.1 -51.64 67.16 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.4 -0.812 . . . . 0.0 109.391 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 t -49.44 -66.28 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.219 -0.926 . . . . 0.0 109.968 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.4 mt-10 -47.56 -26.42 1.44 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.412 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.493 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.03 -54.64 5.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.323 -0.861 . . . . 0.0 109.058 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.85 -33.94 38.4 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.412 -1.43 . . . . 0.0 108.635 179.452 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.2 t80 -50.58 -50.06 54.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.926 . . . . 0.0 110.236 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.496 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.78 -50.82 54.95 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.534 -1.354 . . . . 0.0 108.547 179.387 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -50.7 -59.01 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 CA-C-O 121.527 0.68 . . . . 0.0 109.668 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -75.87 -23.54 55.63 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.48 -0.763 . . . . 0.0 109.819 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.02 -130.64 44.05 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -77.1 -14.44 59.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -1.094 . . . . 0.0 110.087 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.88 -27.8 45.53 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.149 -0.969 . . . . 0.0 109.327 -179.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.76 156.39 6.07 Favored Glycine 0 N--CA 1.485 1.964 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.41 172.93 17.65 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.022 -1.281 . . . . 0.0 110.243 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.9 p90 -115.73 132.84 56.52 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -73.23 171.75 12.42 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.614 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.2 t -63.55 173.93 1.5 Allowed 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 118.578 -1.249 . . . . 0.0 109.302 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -44.41 148.82 0.81 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.199 -0.938 . . . . 0.0 110.139 -178.088 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -78.07 -6.54 15.87 Favored 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.086 1.857 . . . . 0.0 110.682 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.549 ' C ' ' H ' ' A' ' 32' ' ' GLY . 44.3 p -54.18 -40.86 67.93 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.949 -1.094 . . . . 0.0 111.186 -177.319 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.88 -15.76 0.48 Allowed Glycine 0 N--CA 1.493 2.439 0 C-N-CA 119.703 -1.237 . . . . 0.0 110.231 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.549 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.91 -15.93 37.66 Favored Glycine 0 N--CA 1.5 2.919 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.484 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.85 55.29 0.12 Allowed Glycine 0 N--CA 1.484 1.892 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.539 ' O ' ' N ' ' A' ' 36' ' ' ARG . 22.4 Cg_endo -71.14 -175.46 1.5 Allowed 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 121.833 1.688 . . . . 0.0 109.866 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.614 ' N ' ' OG1' ' A' ' 27' ' ' THR . 8.3 ttt-85 -57.05 86.26 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.539 ' N ' ' O ' ' A' ' 34' ' ' PRO . 6.8 ptm180 -62.25 6.31 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.138 -0.976 . . . . 0.0 109.181 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.591 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -85.02 -21.86 54.2 Favored Glycine 0 N--CA 1.491 2.36 0 O-C-N 121.133 -0.98 . . . . 0.0 110.911 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -100.31 -54.24 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 120.879 -1.366 . . . . 0.0 110.457 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.525 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -61.42 -63.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 111.704 -177.116 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.417 ' HG3' ' N ' ' A' ' 41' ' ' GLN . 0.9 OUTLIER -58.52 -38.15 77.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 111.079 -178.101 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -55.6 -53.68 53.43 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.833 -1.167 . . . . 0.0 109.195 -179.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 60.3 m -85.76 -26.73 25.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 110.769 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.433 ' N ' ' O ' ' A' ' 39' ' ' VAL . 51.8 t -83.86 -52.5 6.32 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.701 -1.249 . . . . 0.0 109.541 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.412 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.6 t60 -71.39 -26.41 62.77 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.207 -0.933 . . . . 0.0 109.174 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.7 m -137.06 160.28 39.4 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.363 -0.835 . . . . 0.0 109.645 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.2 mm -83.21 100.28 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.49 -0.756 . . . . 0.0 109.221 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -93.0 147.75 22.57 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.105 -0.997 . . . . 0.0 109.683 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.7 167.76 17.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -58.4 -34.04 70.3 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -44.1 -57.12 3.57 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 121.797 0.808 . . . . 0.0 110.154 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 9.8 mt-30 -61.59 -41.63 97.7 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 79.0 mt -61.84 -31.69 71.97 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.48 -9.79 57.47 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -75.5 -28.31 59.13 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.816 -0.552 . . . . 0.0 109.571 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.438 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.5 m-85 -101.83 7.04 41.81 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.399 -0.813 . . . . 0.0 110.017 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 65.4 m -80.43 106.39 12.41 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.897 -1.127 . . . . 0.0 109.398 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.65 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.632 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.444 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.0 -91.83 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.476 -0.765 . . . . 0.0 110.34 -179.082 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.698 ' N ' HD21 ' A' ' 3' ' ' ASN . 0.0 OUTLIER -101.94 27.4 6.57 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.465 -0.772 . . . . 0.0 110.074 -179.323 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.7 pt20 -95.28 157.66 15.8 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.232 -0.917 . . . . 0.0 109.166 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -90.2 132.05 35.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.582 -0.699 . . . . 0.0 110.718 -178.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.1 130.5 41.78 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.5 m -143.5 125.27 15.07 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.24 -0.913 . . . . 0.0 109.388 179.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.16 -150.04 46.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -44.66 -30.34 0.91 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.412 -1.052 . . . . 0.0 110.284 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -48.67 -50.14 34.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.953 -1.092 . . . . 0.0 108.791 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.3 tp -55.76 -55.71 29.18 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.451 -0.781 . . . . 0.0 109.172 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -45.8 -65.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.385 -0.822 . . . . 0.0 109.946 -179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 84.8 mt-10 -47.73 -29.68 3.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.436 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.496 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.31 -54.45 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.84 . . . . 0.0 109.239 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -51.34 -35.88 40.32 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.496 -1.378 . . . . 0.0 108.712 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.6 t80 -49.4 -48.84 46.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.414 -0.804 . . . . 0.0 110.461 -179.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.521 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.38 -50.45 46.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.488 -1.383 . . . . 0.0 108.539 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -50.84 -59.23 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 CA-C-O 121.558 0.694 . . . . 0.0 110.23 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -24.04 54.23 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.402 -0.811 . . . . 0.0 109.804 -178.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.37 -126.19 23.2 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -77.32 -14.54 59.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -1.077 . . . . 0.0 110.28 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.52 -27.6 57.8 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.36 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.53 154.51 4.69 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -156.52 172.6 18.27 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.923 -1.34 . . . . 0.0 110.418 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.3 p90 -118.29 138.75 52.17 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -77.45 170.83 15.87 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.617 ' HG1' ' H ' ' A' ' 28' ' ' ASP . 7.6 t -64.3 175.29 1.35 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.869 -1.144 . . . . 0.0 109.807 -179.276 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.617 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -42.15 148.03 0.52 Allowed Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.492 -0.755 . . . . 0.0 110.295 -178.229 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -77.36 -6.52 16.45 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.091 1.861 . . . . 0.0 110.462 179.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.552 ' C ' ' H ' ' A' ' 32' ' ' GLY . 40.2 p -54.02 -41.16 67.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.095 -1.003 . . . . 0.0 111.096 -177.357 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.53 -15.89 0.41 Allowed Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.655 -1.259 . . . . 0.0 110.311 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.35 -19.05 31.36 Favored Glycine 0 N--CA 1.499 2.839 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.55 54.95 0.13 Allowed Glycine 0 N--CA 1.484 1.899 0 N-CA-C 108.449 -1.86 . . . . 0.0 108.449 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.491 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.3 Cg_endo -68.82 -174.71 0.77 Allowed 'Trans proline' 0 C--N 1.319 -0.993 0 C-N-CA 121.868 1.712 . . . . 0.0 110.416 -179.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.544 ' N ' ' OG1' ' A' ' 27' ' ' THR . 41.2 ttt180 -57.46 87.93 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.573 HH11 ' CG ' ' A' ' 36' ' ' ARG . 1.4 mtt-85 -59.1 -5.88 0.76 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.967 -1.083 . . . . 0.0 108.384 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.85 -25.99 74.02 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.52 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.21 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.315 0 O-C-N 121.002 -1.293 . . . . 0.0 110.436 -179.502 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.52 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.25 -64.52 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.133 . . . . 0.0 111.564 -177.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' HIS . 35.4 mt-10 -55.94 -45.74 78.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.854 -1.154 . . . . 0.0 110.295 -178.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.461 ' NE2' ' OE1' ' A' ' 51' ' ' GLN . 53.0 tt0 -47.48 -57.87 4.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.084 -1.01 . . . . 0.0 110.15 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 68.1 m -84.83 -27.0 27.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.156 -0.965 . . . . 0.0 111.02 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.467 ' N ' ' O ' ' A' ' 39' ' ' VAL . 47.8 t -83.32 -51.44 7.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.845 -1.16 . . . . 0.0 109.429 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.519 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.0 t60 -73.47 -26.16 60.79 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.339 -0.851 . . . . 0.0 109.48 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -136.86 157.69 46.18 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.4 -0.813 . . . . 0.0 109.876 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.405 HD12 HG23 ' A' ' 46' ' ' ILE . 11.5 mm -79.95 99.56 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.461 -0.774 . . . . 0.0 109.229 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.6 p -92.57 154.9 18.14 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.056 -1.027 . . . . 0.0 109.637 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -88.85 166.5 13.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.296 -0.878 . . . . 0.0 108.988 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.7 mt -58.4 -32.78 68.94 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.39 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.28 -57.31 3.55 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.804 0.811 . . . . 0.0 110.159 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.461 ' OE1' ' NE2' ' A' ' 41' ' ' GLN . 24.6 mt-30 -61.68 -42.04 98.38 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.71 -0.796 . . . . 0.0 108.998 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 74.6 mt -61.29 -24.93 66.76 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.71 -8.74 58.39 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -79.67 -26.78 40.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.794 -0.566 . . . . 0.0 109.849 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 16.3 m-85 -99.06 4.62 47.12 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.282 -0.886 . . . . 0.0 110.31 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 70.9 m -81.26 111.34 17.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.939 -1.101 . . . . 0.0 109.496 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.64 179.993 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.628 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.453 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -99.77 -91.57 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.353 -0.842 . . . . 0.0 110.197 -179.124 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.488 ' OD1' ' N ' ' A' ' 3' ' ' ASN . 1.3 p-10 -104.33 28.22 7.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.671 -0.643 . . . . 0.0 109.431 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.628 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.75 157.41 15.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.163 -0.96 . . . . 0.0 109.123 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -89.0 131.73 35.05 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.526 0.679 . . . . 0.0 110.713 -178.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.1 mp -97.16 132.44 42.94 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -149.24 125.36 10.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.189 -0.944 . . . . 0.0 109.278 179.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.72 -146.51 40.31 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.7 m -46.75 -32.5 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.365 -1.079 . . . . 0.0 110.155 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -49.0 -50.44 35.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.965 -1.084 . . . . 0.0 108.783 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.1 tp -56.9 -55.73 30.71 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.394 -0.816 . . . . 0.0 109.529 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.6 t -46.13 -66.15 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.342 -0.849 . . . . 0.0 110.085 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 75.8 mt-10 -47.94 -26.75 1.85 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.197 -0.939 . . . . 0.0 109.298 -179.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.08 -54.21 5.74 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.333 -0.854 . . . . 0.0 109.088 179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.87 -34.77 42.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.361 -1.462 . . . . 0.0 108.536 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 20' ' ' GLY . 58.0 t80 -49.82 -49.59 48.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.374 -0.828 . . . . 0.0 110.358 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.501 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.58 -50.66 49.99 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.584 -1.322 . . . . 0.0 108.598 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -50.67 -58.88 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.49 0.662 . . . . 0.0 109.703 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -76.51 -23.48 53.72 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.526 -0.734 . . . . 0.0 109.9 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.94 -127.08 31.16 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.12 -14.96 59.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.402 -1.057 . . . . 0.0 110.101 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.1 mtp180 -54.95 -28.99 55.61 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.098 -1.001 . . . . 0.0 109.171 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.91 5.73 Favored Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.5 172.72 18.05 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.907 -1.349 . . . . 0.0 110.174 -179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.09 137.65 51.94 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -75.96 171.95 13.56 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.571 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.0 t -63.13 174.37 1.17 Allowed 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.762 -1.211 . . . . 0.0 109.812 -178.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.45 147.37 1.03 Allowed Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.369 -0.832 . . . . 0.0 110.096 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -77.5 -6.48 16.3 Favored 'Trans proline' 0 N--CA 1.484 0.915 0 C-N-CA 122.107 1.871 . . . . 0.0 110.315 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.553 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.2 p -54.1 -41.06 67.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.104 -0.998 . . . . 0.0 110.904 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.25 -15.88 0.37 Allowed Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.389 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.35 -14.22 45.5 Favored Glycine 0 N--CA 1.498 2.808 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.52 ' O ' ' NH2' ' A' ' 36' ' ' ARG . . . -177.73 56.33 0.1 OUTLIER Glycine 0 N--CA 1.484 1.839 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.47 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 20.6 Cg_endo -70.7 -175.08 1.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 121.793 1.662 . . . . 0.0 109.886 -179.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.571 ' N ' ' OG1' ' A' ' 27' ' ' THR . 43.8 ttt180 -63.4 87.93 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.524 ' CD ' ' H ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER -58.63 -13.91 6.98 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.78 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.404 ' N ' ' C ' ' A' ' 35' ' ' ARG . . . -57.85 -26.66 58.19 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.437 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.93 -55.8 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.335 0 O-C-N 120.895 -1.356 . . . . 0.0 110.566 -179.461 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.8 t -63.26 -64.39 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.905 -1.122 . . . . 0.0 111.295 -177.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 44' ' ' HIS . 80.9 mt-10 -54.47 -47.54 72.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.89 -1.131 . . . . 0.0 110.277 -178.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 48.5 tt0 -46.68 -58.52 3.77 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.155 -0.966 . . . . 0.0 110.417 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 45' ' ' SER . 60.7 m -84.87 -25.88 27.71 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.131 -0.981 . . . . 0.0 111.435 -178.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.419 ' N ' ' O ' ' A' ' 39' ' ' VAL . 47.3 t -83.61 -51.71 7.07 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.58 -1.325 . . . . 0.0 109.068 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.477 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t60 -68.13 -27.9 66.85 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.419 -0.8 . . . . 0.0 109.341 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 14.2 t -137.35 173.14 12.0 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.353 -0.842 . . . . 0.0 110.188 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.2 mm -91.82 99.43 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.0 p -93.92 152.99 18.46 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.074 -1.016 . . . . 0.0 109.548 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.28 167.54 13.47 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.902 . . . . 0.0 109.125 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.4 -34.53 68.98 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -43.67 -57.01 3.4 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.852 0.834 . . . . 0.0 110.038 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.1 mt-30 -60.1 -42.19 94.13 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.1 mt -62.54 -32.39 73.33 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.86 -9.24 54.12 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -76.34 -27.64 56.56 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.9 m-85 -102.11 6.64 40.99 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 95.7 m -80.95 105.2 12.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.842 -1.161 . . . . 0.0 109.154 179.567 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.431 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.4 t-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.635 ' N ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.446 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.9 OUTLIER -104.5 -91.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.751 . . . . 0.0 110.574 -178.767 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.446 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.0 m120 -99.95 25.82 6.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.283 -0.886 . . . . 0.0 109.742 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.635 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.72 159.14 15.13 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.308 -0.87 . . . . 0.0 109.494 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -93.36 134.46 35.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.616 -0.678 . . . . 0.0 110.283 -179.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.4 HD22 ' CE1' ' A' ' 1' ' ' PHE . 0.9 OUTLIER -95.94 127.94 42.4 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.465 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 76.2 m -143.51 125.48 15.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.892 . . . . 0.0 109.263 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.11 -149.57 46.11 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -44.84 -30.21 0.94 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -1.032 . . . . 0.0 110.347 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -49.12 -50.89 35.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.895 -1.128 . . . . 0.0 108.818 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.0 tp -55.16 -52.11 64.35 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.361 -0.837 . . . . 0.0 109.198 179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 t -49.15 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 109.896 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 28.4 mt-10 -47.9 -25.75 1.44 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.447 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.496 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.57 -54.9 5.03 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.282 -0.887 . . . . 0.0 109.063 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.65 -34.35 37.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.335 -1.478 . . . . 0.0 108.595 179.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.422 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.5 t80 -50.23 -49.92 51.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.326 -0.859 . . . . 0.0 110.275 -179.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.487 ' CD1' ' O ' ' A' ' 13' ' ' GLU . 4.5 mp -67.91 -50.85 53.77 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.65 -1.281 . . . . 0.0 108.626 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -50.52 -58.68 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 CA-C-O 121.511 0.672 . . . . 0.0 109.854 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -77.03 -23.12 52.13 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.483 -0.761 . . . . 0.0 109.997 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 47.7 -122.27 7.61 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -79.13 -15.3 58.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 0.0 110.275 -179.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.2 mtp180 -56.62 -28.35 60.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.123 -0.985 . . . . 0.0 109.491 -179.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.49 155.06 4.95 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.399 -1.881 . . . . 0.0 108.399 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -156.68 172.74 18.07 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.898 -1.354 . . . . 0.0 110.449 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 30.5 p90 -118.4 133.93 55.47 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -73.41 171.18 13.58 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.588 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.0 t -64.29 175.1 1.39 Allowed 'General case' 0 C--N 1.296 -1.756 0 O-C-N 120.961 -1.087 . . . . 0.0 109.698 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.51 151.87 0.45 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.423 -0.798 . . . . 0.0 110.121 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -78.69 -6.59 15.36 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.004 1.803 . . . . 0.0 110.259 179.421 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.529 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.7 p -53.64 -40.59 65.97 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.172 -0.955 . . . . 0.0 111.291 -177.384 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.14 -15.53 0.54 Allowed Glycine 0 N--CA 1.495 2.579 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.259 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -94.17 -31.82 7.81 Favored Glycine 0 N--CA 1.499 2.868 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.518 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -166.25 53.58 0.25 Allowed Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.83 -1.708 . . . . 0.0 108.83 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.528 ' O ' ' N ' ' A' ' 36' ' ' ARG . 24.5 Cg_endo -70.3 -173.6 0.83 Allowed 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 122.041 1.827 . . . . 0.0 109.924 -179.499 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.588 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.7 ttt-85 -57.01 85.95 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' N ' ' O ' ' A' ' 34' ' ' PRO . 16.6 mtm-85 -59.12 -29.54 67.46 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.045 -1.034 . . . . 0.0 108.281 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.9 -23.98 0.08 OUTLIER Glycine 0 N--CA 1.49 2.286 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.4 -55.61 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.152 -1.204 . . . . 0.0 109.97 179.674 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.7 t -62.69 -64.15 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.087 -1.008 . . . . 0.0 112.069 -176.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -59.93 -39.59 86.0 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.727 -1.233 . . . . 0.0 110.719 -178.241 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.2 tt0 -51.26 -56.71 11.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.877 -1.139 . . . . 0.0 109.477 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 68.9 m -85.46 -26.58 26.25 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.381 -0.824 . . . . 0.0 111.045 -179.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.436 ' N ' ' O ' ' A' ' 39' ' ' VAL . 46.3 t -84.07 -52.4 6.32 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.706 -1.246 . . . . 0.0 109.673 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.427 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.2 t60 -69.99 -26.97 64.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.114 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 41' ' ' GLN . 0.3 OUTLIER -136.78 160.58 38.42 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.484 -0.76 . . . . 0.0 109.107 179.818 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.9 mm -84.65 99.73 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -90.42 164.18 14.39 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.065 -1.022 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.535 ' H ' ' HG ' ' A' ' 48' ' ' SER . 2.4 p -96.82 166.77 11.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.36 -0.838 . . . . 0.0 109.007 179.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -57.68 -34.34 69.31 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -44.08 -57.85 3.16 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.86 0.838 . . . . 0.0 110.014 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 7.8 mt-30 -59.8 -42.57 93.73 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -179.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 81.2 mt -62.21 -32.08 72.7 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.91 -9.26 54.35 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -76.21 -28.04 57.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.788 -0.57 . . . . 0.0 109.649 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.2 m-85 -101.83 6.21 41.45 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.354 -0.841 . . . . 0.0 110.102 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 88.6 m -79.8 106.74 12.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.939 -1.101 . . . . 0.0 109.323 179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.41 179.967 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.63 ' H3 ' ' NE2' ' A' ' 4' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.436 ' CG2' ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.6 -91.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.404 -0.81 . . . . 0.0 110.626 -178.68 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.436 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.6 m120 -101.05 25.6 7.92 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 -179.239 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.63 ' NE2' ' H3 ' ' A' ' 1' ' ' PHE . 2.5 pt20 -96.0 158.54 15.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.36 -0.837 . . . . 0.0 109.635 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.1 p-80 -92.04 135.89 33.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.635 -0.665 . . . . 0.0 110.255 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.2 mp -97.05 126.55 42.27 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 76.5 m -142.35 125.14 16.0 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.292 -0.88 . . . . 0.0 109.241 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.9 -148.74 45.18 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.354 -1.098 . . . . 0.0 110.354 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -44.67 -31.08 1.05 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.383 -1.069 . . . . 0.0 110.349 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -49.01 -50.66 34.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.946 -1.097 . . . . 0.0 108.841 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 19.1 tp -55.53 -54.01 49.32 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.405 -0.809 . . . . 0.0 109.283 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -47.43 -66.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.012 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 52.0 mt-10 -47.72 -26.92 1.73 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.343 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.498 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.81 -54.93 5.17 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.467 -0.771 . . . . 0.0 109.188 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.54 -34.06 34.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.394 -1.441 . . . . 0.0 108.603 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.46 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.7 t80 -50.48 -50.75 51.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.276 -179.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.492 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.3 -50.8 58.76 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.532 -1.355 . . . . 0.0 108.658 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -50.43 -59.01 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.569 0.7 . . . . 0.0 109.668 -179.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.72 -23.27 53.08 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.539 -0.725 . . . . 0.0 109.92 -178.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.02 -123.2 10.55 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.57 -15.12 58.24 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -1.114 . . . . 0.0 110.084 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -55.15 -28.81 55.52 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.15 -0.969 . . . . 0.0 109.337 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.47 154.66 4.72 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -156.57 172.9 17.74 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 120.901 -1.352 . . . . 0.0 110.434 -179.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.541 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.7 p90 -118.11 138.27 52.37 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -77.67 170.61 16.27 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.565 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.3 t -64.68 175.0 1.56 Allowed 'General case' 0 C--N 1.299 -1.617 0 O-C-N 120.998 -1.064 . . . . 0.0 110.111 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.495 ' H ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -45.11 148.4 1.05 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.41 -0.806 . . . . 0.0 110.03 -178.678 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -77.73 -6.23 15.94 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.121 1.881 . . . . 0.0 110.573 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.55 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.0 p -53.88 -41.1 67.18 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.077 -1.014 . . . . 0.0 111.215 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.58 -15.76 0.43 Allowed Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.604 -1.284 . . . . 0.0 110.398 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.97 -17.71 31.63 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.501 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.58 54.64 0.13 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.157 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.2 Cg_endo -69.98 -174.61 0.98 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 121.866 1.711 . . . . 0.0 109.802 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.565 ' N ' ' OG1' ' A' ' 27' ' ' THR . 38.4 ttt180 -60.31 89.18 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.697 ' N ' ' HE ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER -58.52 -16.64 16.31 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.795 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.406 ' N ' ' HE ' ' A' ' 36' ' ' ARG . . . -56.23 -28.6 54.89 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.63 -55.98 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 O-C-N 120.929 -1.336 . . . . 0.0 110.704 -179.283 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.11 -64.24 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.911 -1.118 . . . . 0.0 111.421 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -54.46 -47.8 72.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.773 -1.204 . . . . 0.0 110.3 -178.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -47.13 -58.97 3.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.08 -1.013 . . . . 0.0 110.459 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 45' ' ' SER . 60.0 m -84.54 -25.56 28.65 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -0.946 . . . . 0.0 111.307 -178.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.463 ' N ' ' O ' ' A' ' 39' ' ' VAL . 45.4 t -83.96 -52.3 6.45 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.65 -1.281 . . . . 0.0 109.214 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.48 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.9 t-80 -67.44 -28.88 68.26 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.32 -0.863 . . . . 0.0 109.243 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -136.9 173.28 11.87 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.379 -0.826 . . . . 0.0 109.704 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 3.6 mm -92.56 99.66 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.6 p -91.75 151.68 20.51 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.063 -1.023 . . . . 0.0 109.632 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -84.97 166.34 16.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.233 -0.917 . . . . 0.0 109.223 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.2 -34.18 68.25 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -44.22 -57.42 3.46 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.914 0.864 . . . . 0.0 110.014 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.83 -42.67 94.08 Favored 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 80.0 mt -62.01 -32.39 72.87 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.6 -9.77 55.47 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -75.73 -27.85 58.31 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.781 -0.575 . . . . 0.0 109.584 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.9 m-85 -101.85 5.5 41.07 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.373 -0.829 . . . . 0.0 110.056 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.2 m -79.95 111.14 16.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.901 -1.124 . . . . 0.0 109.449 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.447 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.642 ' H1 ' ' NE2' ' A' ' 4' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.443 ' H ' ' H3 ' ' A' ' 1' ' ' PHE . 0.7 OUTLIER -98.57 -91.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.369 -0.832 . . . . 0.0 110.803 -178.37 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.426 ' H ' ' CG2' ' A' ' 2' ' ' VAL . 4.6 m120 -104.17 25.92 9.45 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.401 -0.812 . . . . 0.0 109.988 -179.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.642 ' NE2' ' H1 ' ' A' ' 1' ' ' PHE . 3.2 pt20 -95.85 157.95 15.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.247 -0.908 . . . . 0.0 109.672 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 3.0 p-80 -91.25 133.52 35.33 Favored 'General case' 0 N--CA 1.489 1.494 0 CA-C-O 121.405 0.622 . . . . 0.0 110.134 -179.335 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -92.9 125.22 37.39 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.1 m -140.79 125.45 17.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.907 . . . . 0.0 109.264 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.46 -150.75 47.32 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.9 m -44.21 -29.36 0.63 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -1.058 . . . . 0.0 110.263 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -48.77 -50.49 33.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.982 -1.074 . . . . 0.0 108.859 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 20.4 tp -55.94 -54.48 44.22 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.438 -0.789 . . . . 0.0 109.207 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.71 -66.17 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.358 -0.839 . . . . 0.0 109.901 -179.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 86.7 mt-10 -47.63 -27.98 2.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.177 -0.952 . . . . 0.0 109.291 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.495 ' CB ' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.74 -55.32 5.09 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 109.181 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.47 -34.07 33.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.311 -1.493 . . . . 0.0 108.649 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -50.44 -49.27 55.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 110.165 -179.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.488 ' CD1' ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.76 -51.06 45.22 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.535 -1.353 . . . . 0.0 108.619 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.9 t -50.39 -58.56 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 121.523 0.678 . . . . 0.0 109.698 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.3 -23.81 54.35 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.485 -0.759 . . . . 0.0 109.693 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.33 -131.83 45.89 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -76.62 -11.25 59.83 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.37 -1.077 . . . . 0.0 110.121 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -57.84 -26.98 62.77 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.076 -1.015 . . . . 0.0 109.35 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.87 155.68 5.72 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 -179.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.74 173.0 17.62 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.921 -1.341 . . . . 0.0 110.227 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.551 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 37.5 p90 -115.26 137.25 52.24 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -78.13 171.01 15.67 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.64 ' HG1' ' N ' ' A' ' 28' ' ' ASP . 7.1 t -64.13 175.11 1.33 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.853 -1.154 . . . . 0.0 109.975 -179.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.64 ' N ' ' HG1' ' A' ' 27' ' ' THR . 0.1 OUTLIER -42.42 147.71 0.58 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.521 -0.737 . . . . 0.0 110.3 -178.25 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -77.24 -6.41 16.47 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.18 1.92 . . . . 0.0 110.493 179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.549 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.1 p -53.98 -41.06 67.47 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.137 -0.977 . . . . 0.0 110.96 -177.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.59 -15.83 0.43 Allowed Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.388 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.549 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.24 -18.38 31.4 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.497 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.04 55.04 0.14 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 179.229 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.497 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.6 Cg_endo -69.29 -175.03 0.92 Allowed 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.874 1.716 . . . . 0.0 110.423 -179.128 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.577 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.4 ttt-85 -56.93 86.58 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.488 ' N ' ' O ' ' A' ' 34' ' ' PRO . 7.1 ptm180 -59.71 -1.72 0.29 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.016 -1.052 . . . . 0.0 108.605 179.687 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.564 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -74.06 -24.41 73.81 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.41 -55.99 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.001 -1.293 . . . . 0.0 110.051 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.6 t -61.97 -64.38 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.01 -1.056 . . . . 0.0 111.32 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.475 ' O ' ' N ' ' A' ' 44' ' ' HIS . 51.2 mt-10 -55.24 -47.49 75.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.946 -1.096 . . . . 0.0 110.613 -178.725 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -47.3 -57.78 4.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.051 -1.03 . . . . 0.0 110.303 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 70.9 m -84.81 -26.0 27.76 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.203 -0.935 . . . . 0.0 111.177 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.1 t -83.1 -52.27 6.78 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.746 -1.221 . . . . 0.0 109.42 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.497 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 11.8 t-80 -71.15 -26.08 62.84 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.357 -0.839 . . . . 0.0 109.39 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.94 157.85 45.81 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.443 -0.785 . . . . 0.0 109.625 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.2 mm -82.03 99.59 5.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.357 -0.839 . . . . 0.0 108.785 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.7 p -91.14 158.43 16.64 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.106 -0.996 . . . . 0.0 109.781 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.6 p -89.81 166.61 13.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.308 -0.87 . . . . 0.0 108.96 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.607 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -58.78 -33.27 70.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.54 -57.56 3.53 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 121.716 0.769 . . . . 0.0 110.238 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -61.06 -41.8 97.29 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 119.665 -0.814 . . . . 0.0 108.918 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 77.7 mt -61.28 -30.77 70.68 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.48 -9.72 58.64 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -75.99 -28.19 57.71 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.756 -0.59 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.426 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 9.9 m-85 -101.55 6.1 42.06 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.357 -0.839 . . . . 0.0 110.02 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 66.7 m -79.81 107.49 12.63 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.866 -1.147 . . . . 0.0 109.345 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 28.1 t-20 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.094 -0.955 . . . . 0.0 109.453 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.615 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.13 -91.6 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.45 -0.781 . . . . 0.0 110.608 -178.789 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.615 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.57 26.2 7.59 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.366 -0.834 . . . . 0.0 109.886 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.47 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -95.55 158.03 15.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.371 -0.831 . . . . 0.0 109.567 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.423 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.3 OUTLIER -91.57 132.0 36.61 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.66 -0.65 . . . . 0.0 110.587 -178.927 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -95.18 136.14 35.89 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.147 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.477 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -151.62 125.01 8.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.276 179.31 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.5 -146.65 40.91 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.1 m -46.85 -32.47 3.76 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.369 -1.077 . . . . 0.0 110.163 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.477 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 8.2 m-20 -48.88 -50.49 34.72 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.991 -1.068 . . . . 0.0 108.728 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -56.04 -54.44 44.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.473 -0.767 . . . . 0.0 109.519 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.53 -66.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.261 -0.9 . . . . 0.0 110.04 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.482 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 49.2 mt-10 -47.46 -28.61 2.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.208 -0.932 . . . . 0.0 109.388 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.16 -54.51 5.92 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.36 -0.838 . . . . 0.0 109.297 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.78 -35.28 43.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.367 -1.458 . . . . 0.0 108.581 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -49.31 -49.14 45.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.385 -0.822 . . . . 0.0 110.289 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.782 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.62 -50.96 47.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.558 -1.339 . . . . 0.0 108.592 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.0 t -50.65 -58.81 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-O 121.482 0.658 . . . . 0.0 109.847 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.31 -23.72 54.31 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.67 -125.99 27.67 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -78.75 -14.0 59.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.384 -1.068 . . . . 0.0 110.463 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 22.7 mtt180 -58.07 -26.88 63.09 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.973 -1.079 . . . . 0.0 109.647 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.56 155.99 5.61 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.63 173.01 17.58 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.324 . . . . 0.0 110.413 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.62 140.18 49.68 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -80.49 170.24 16.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 t -65.01 175.6 1.5 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.995 -1.066 . . . . 0.0 110.219 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.52 150.22 0.54 Allowed Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 121.497 -0.752 . . . . 0.0 110.115 -178.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo . . . . . 0 N--CA 1.484 0.93 0 C-N-CA 122.252 1.968 . . . . 0.0 110.658 179.478 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.53 -25.62 74.85 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.15 -56.38 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.212 0 O-C-N 121.056 -1.261 . . . . 0.0 110.45 -179.714 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.524 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.1 t -62.42 -64.18 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.94 -1.1 . . . . 0.0 111.4 -177.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.517 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.9 mt-10 -55.8 -46.36 78.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.873 -1.142 . . . . 0.0 110.355 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 62.1 tp60 -47.99 -56.65 7.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.074 -1.016 . . . . 0.0 110.101 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.71 -28.25 26.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 111.072 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 52.4 t -83.49 -52.24 6.67 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.733 -1.229 . . . . 0.0 109.231 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.517 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t-80 -70.46 -27.89 64.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.346 -0.846 . . . . 0.0 109.231 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.9 m -136.92 159.85 40.63 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.437 -0.79 . . . . 0.0 109.431 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 7.7 mm -82.8 99.7 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.307 -0.87 . . . . 0.0 109.088 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.9 p -91.15 150.83 21.22 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.094 -1.003 . . . . 0.0 109.32 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.5 167.45 14.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.232 -0.918 . . . . 0.0 109.112 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.77 -34.81 67.97 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.06 -57.53 3.32 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.867 0.841 . . . . 0.0 110.025 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -59.73 -42.48 93.24 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -62.02 -32.25 72.71 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -69.91 -9.54 55.34 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -75.86 -28.56 58.22 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.824 -0.548 . . . . 0.0 109.702 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.457 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.4 m-85 -102.13 6.89 41.09 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.372 -0.83 . . . . 0.0 109.948 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.0 m -80.29 111.18 16.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.023 -1.048 . . . . 0.0 109.282 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.8 t30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.955 -1.021 . . . . 0.0 109.437 179.97 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -101.61 -91.93 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.383 -0.823 . . . . 0.0 110.851 -178.566 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -101.21 26.03 7.56 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.403 -0.811 . . . . 0.0 109.807 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.46 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.94 160.84 14.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.384 -0.822 . . . . 0.0 109.483 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.449 ' HB3' HD13 ' A' ' 46' ' ' ILE . 4.4 p-80 -95.95 136.77 35.95 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.577 -0.702 . . . . 0.0 110.092 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -98.38 136.11 39.0 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.597 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -150.16 124.76 9.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.933 . . . . 0.0 109.236 179.003 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.71 -147.34 41.66 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.6 m -45.94 -32.59 2.79 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.393 -1.063 . . . . 0.0 110.197 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.68 -49.99 35.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.978 -1.077 . . . . 0.0 108.753 179.866 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 38' ' ' ILE . 22.6 tp -57.33 -51.79 67.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.411 -0.805 . . . . 0.0 109.484 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.8 t -49.08 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 110.065 -179.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 53.2 mt-10 -47.47 -28.45 2.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.406 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.08 -54.94 5.5 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.377 -0.827 . . . . 0.0 109.206 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.37 -35.63 39.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.402 -1.436 . . . . 0.0 108.772 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -49.35 -50.02 41.74 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.355 -0.841 . . . . 0.0 110.422 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.794 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.68 -50.7 56.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.612 -1.305 . . . . 0.0 108.595 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -51.25 -59.19 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.485 0.66 . . . . 0.0 110.318 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 22.8 m -76.59 -23.26 53.46 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.419 -0.801 . . . . 0.0 109.932 -178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.11 -129.58 27.77 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.352 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -73.43 -16.71 61.31 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.437 -1.037 . . . . 0.0 110.589 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 49.0 mtp180 -54.95 -28.54 52.03 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 109.426 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.8 156.31 6.06 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 107.799 -2.12 . . . . 0.0 107.799 -178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -156.27 172.68 18.05 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.835 -1.391 . . . . 0.0 110.44 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.554 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -116.57 127.24 54.32 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -67.58 172.14 5.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.2 t -62.6 174.39 1.02 Allowed 'General case' 0 C--N 1.295 -1.762 0 O-C-N 120.641 -1.287 . . . . 0.0 109.359 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.58 150.74 0.51 Allowed Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.341 -0.849 . . . . 0.0 110.409 -177.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo . . . . . 0 N--CA 1.484 0.947 0 C-N-CA 122.111 1.874 . . . . 0.0 110.421 179.297 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.477 ' O ' ' N ' ' A' ' 38' ' ' ILE . 12.0 ptt180 . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.86 -22.98 0.11 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.56 -54.27 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 O-C-N 120.978 -1.307 . . . . 0.0 109.787 179.924 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.18 -64.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.057 -1.027 . . . . 0.0 111.76 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -58.57 -41.35 85.49 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.768 -1.208 . . . . 0.0 110.884 -178.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.2 tp60 -50.58 -55.95 13.95 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.972 -1.08 . . . . 0.0 109.553 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.459 ' SG ' HD21 ' A' ' 52' ' ' LEU . 81.6 m -85.23 -26.55 26.63 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 111.222 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.1 t -83.94 -52.62 6.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.604 -1.31 . . . . 0.0 109.821 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.6 t60 -68.99 -29.41 67.61 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.248 -0.907 . . . . 0.0 109.175 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -137.14 157.89 45.68 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.55 -0.719 . . . . 0.0 109.572 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.449 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.3 mm -78.96 119.07 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.38 -0.825 . . . . 0.0 108.822 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.9 p -111.03 156.57 21.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.364 -0.835 . . . . 0.0 109.687 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 p -88.97 166.79 13.68 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.37 -0.831 . . . . 0.0 109.395 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.7 mt -59.65 -32.53 70.54 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.53 -57.68 3.45 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.802 0.81 . . . . 0.0 110.123 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -60.82 -42.46 97.74 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 119.799 -0.76 . . . . 0.0 108.959 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.488 HD22 HD11 ' A' ' 11' ' ' LEU . 77.6 mt -61.42 -26.03 67.6 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.17 -8.55 57.28 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -79.8 -26.34 40.6 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.848 -0.532 . . . . 0.0 109.926 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -100.0 6.1 45.11 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.266 -0.896 . . . . 0.0 110.448 -179.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.425 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 85.1 m -76.39 111.6 12.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.921 -1.112 . . . . 0.0 109.403 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 25.5 t-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.457 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -105.13 -91.88 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.508 -0.745 . . . . 0.0 110.678 -178.514 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -98.98 25.41 6.72 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.303 -0.873 . . . . 0.0 109.745 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.483 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.99 160.47 14.44 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 109.512 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HB3' HD13 ' A' ' 46' ' ' ILE . 2.2 p-80 -96.2 138.7 33.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.613 -0.68 . . . . 0.0 110.101 -179.225 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -100.94 134.09 44.44 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -149.43 124.86 10.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -0.947 . . . . 0.0 109.203 179.065 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.74 -148.48 43.38 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -45.07 -32.26 1.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.322 -1.105 . . . . 0.0 110.22 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.2 m-20 -48.79 -50.3 34.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.944 -1.098 . . . . 0.0 108.755 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -57.04 -54.65 44.35 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.482 -0.762 . . . . 0.0 109.579 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.5 t -46.58 -66.3 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.303 -0.873 . . . . 0.0 110.067 -179.249 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 65.6 mt-10 -47.81 -27.83 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.65 -54.47 5.85 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.319 -0.863 . . . . 0.0 109.14 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.61 -35.3 41.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.402 -1.437 . . . . 0.0 108.626 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.44 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.6 t80 -49.32 -49.6 43.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.306 -0.871 . . . . 0.0 110.37 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.0 mp -68.36 -50.88 50.04 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.533 -1.355 . . . . 0.0 108.607 179.358 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.0 t -50.54 -58.72 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 CA-C-O 121.511 0.672 . . . . 0.0 109.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.03 -23.69 55.16 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.497 -0.752 . . . . 0.0 109.749 -179.004 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 52.91 -131.08 40.66 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -75.69 -11.52 60.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.345 -1.091 . . . . 0.0 110.158 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.409 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -58.21 -27.76 64.2 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.092 -1.005 . . . . 0.0 109.488 -179.453 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.72 155.22 5.28 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -156.51 172.73 18.03 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.936 -1.332 . . . . 0.0 110.277 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.8 p90 -115.74 137.39 52.13 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -77.13 171.13 15.31 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -63.89 175.02 1.27 Allowed 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.798 -1.189 . . . . 0.0 109.9 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -43.14 148.39 0.61 Allowed Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.494 -0.754 . . . . 0.0 110.229 -178.23 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo . . . . . 0 N--CA 1.483 0.909 0 C-N-CA 122.128 1.885 . . . . 0.0 110.409 179.326 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.9 ptm180 . . . . . 0 N--CA 1.486 1.358 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.7 -24.27 76.42 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.9 -55.3 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.261 0 O-C-N 121.098 -1.236 . . . . 0.0 110.349 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -63.54 -64.27 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.024 -1.047 . . . . 0.0 111.278 -177.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 44' ' ' HIS . 30.2 mt-10 -55.01 -45.74 75.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.373 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -48.74 -57.63 6.02 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.099 -1.0 . . . . 0.0 110.304 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.503 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.88 -25.36 28.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.173 -0.955 . . . . 0.0 111.435 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 48.3 t -84.24 -52.34 6.31 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.535 -1.353 . . . . 0.0 109.537 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.421 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.9 t60 -68.91 -26.77 65.26 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.22 -0.925 . . . . 0.0 109.195 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 12.6 t -136.71 173.32 11.83 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.458 -0.776 . . . . 0.0 109.473 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.407 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.0 mm -94.65 99.6 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.3 p -91.53 152.49 20.29 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.126 -0.984 . . . . 0.0 109.72 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -86.67 166.7 15.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.326 -0.859 . . . . 0.0 109.32 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.8 mt -57.39 -34.91 69.35 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -43.97 -57.19 3.46 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.862 0.839 . . . . 0.0 109.978 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.71 -42.59 93.41 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.503 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.4 mt -61.89 -32.36 72.73 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.98 -9.61 55.76 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -75.88 -28.15 58.02 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.799 -0.563 . . . . 0.0 109.664 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 7.9 m-85 -102.86 6.99 39.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.407 -0.808 . . . . 0.0 109.95 -179.616 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 62.2 m -79.26 108.23 12.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.984 -1.072 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.474 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 1.6 t30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.548 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -101.92 -91.69 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -0.812 . . . . 0.0 110.607 -178.738 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.3 m120 -101.73 26.08 7.82 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.351 -0.843 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.457 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -95.59 160.16 14.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 109.708 -179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -92.05 134.61 34.67 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.53 0.681 . . . . 0.0 110.541 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.4 mp -98.53 130.69 45.1 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.07 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.12 125.06 10.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.107 179.377 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.63 -148.34 43.36 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -45.02 -32.64 1.75 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.394 -1.062 . . . . 0.0 110.321 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.87 -50.31 35.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.004 -1.06 . . . . 0.0 108.745 179.841 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.534 HD21 HD12 ' A' ' 38' ' ' ILE . 18.5 tp -57.13 -55.05 39.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.404 -0.81 . . . . 0.0 109.562 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -46.31 -66.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.313 -0.867 . . . . 0.0 109.945 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 34.4 mt-10 -47.69 -26.67 1.62 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 -179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.07 -54.31 5.65 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.365 -0.834 . . . . 0.0 109.082 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.71 -34.48 39.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.372 -1.455 . . . . 0.0 108.658 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.8 t80 -50.49 -49.59 55.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.301 -0.874 . . . . 0.0 110.336 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.797 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.26 -50.29 54.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.591 -1.318 . . . . 0.0 108.556 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.5 t -50.68 -59.38 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.522 0.677 . . . . 0.0 109.745 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.05 -23.64 55.1 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 -178.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.48 -123.78 20.2 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -80.28 -16.56 54.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.355 -1.085 . . . . 0.0 110.584 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 15.8 mtt180 -55.92 -27.12 50.78 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.053 -1.029 . . . . 0.0 109.52 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.5 6.05 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -156.57 172.96 17.64 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.895 -1.356 . . . . 0.0 110.357 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.547 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.0 p90 -116.77 135.81 53.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -76.18 170.91 15.4 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.1 t -64.29 174.73 1.52 Allowed 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.807 -1.183 . . . . 0.0 110.027 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.28 148.58 0.82 Allowed Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.43 -0.794 . . . . 0.0 109.998 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 C-N-CA 122.118 1.878 . . . . 0.0 110.425 179.385 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.0 mtm180 . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.72 -25.89 73.94 Favored Glycine 0 N--CA 1.487 2.056 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.534 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -101.89 -56.28 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 O-C-N 121.026 -1.279 . . . . 0.0 110.559 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -61.98 -64.41 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 120.906 -1.121 . . . . 0.0 111.574 -177.1 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' HIS . 76.1 mt-10 -56.09 -46.17 79.16 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.932 -1.105 . . . . 0.0 110.341 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -48.31 -56.55 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.11 -0.993 . . . . 0.0 110.298 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.572 ' SG ' HD21 ' A' ' 52' ' ' LEU . 62.4 m -84.79 -27.16 27.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.135 -0.978 . . . . 0.0 111.331 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.1 t -83.01 -52.23 6.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.72 -1.238 . . . . 0.0 109.163 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.464 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.7 t-80 -69.32 -27.5 65.43 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.178 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 m -137.01 159.95 40.37 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.424 -0.797 . . . . 0.0 109.594 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.8 mm -83.41 99.59 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.264 -0.897 . . . . 0.0 108.933 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.0 p -90.63 147.31 23.38 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.059 -1.026 . . . . 0.0 109.482 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -81.62 166.56 20.08 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.6 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.4 mt -56.41 -34.24 66.55 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -44.31 -57.42 3.51 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.924 0.869 . . . . 0.0 109.982 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -60.0 -42.29 93.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.572 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.4 mt -62.36 -32.34 73.12 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -69.74 -9.51 54.76 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -75.7 -28.34 58.57 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.753 -0.592 . . . . 0.0 109.613 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.3 m-85 -101.48 6.0 42.19 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.35 -0.844 . . . . 0.0 110.035 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -80.45 110.52 15.99 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.933 -1.104 . . . . 0.0 109.217 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.409 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 1.8 t30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -99.55 -91.51 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.432 -0.793 . . . . 0.0 110.582 -178.756 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.1 m120 -103.86 27.14 7.84 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.491 -0.756 . . . . 0.0 109.798 -179.219 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.469 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -94.95 161.22 14.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.456 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -92.94 134.73 34.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.619 -0.676 . . . . 0.0 110.593 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.413 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -98.99 131.0 45.37 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.289 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.481 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.35 125.15 11.89 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.165 -0.96 . . . . 0.0 109.301 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.17 -149.24 43.86 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.2 m -44.91 -31.86 1.41 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.255 -1.144 . . . . 0.0 110.226 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.481 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.19 -50.5 28.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.064 -1.023 . . . . 0.0 108.824 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.14 -55.21 37.72 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.474 -0.766 . . . . 0.0 109.501 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.12 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.273 -0.892 . . . . 0.0 110.033 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.5 mt-10 -47.57 -29.12 2.63 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.78 -54.59 5.92 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.291 -0.881 . . . . 0.0 109.209 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.27 -35.67 38.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.433 -1.417 . . . . 0.0 108.71 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -49.31 -49.41 44.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.873 . . . . 0.0 110.403 -179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.811 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -68.82 -50.55 49.08 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.589 -1.319 . . . . 0.0 108.581 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -51.03 -59.14 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.503 0.668 . . . . 0.0 110.13 -179.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.2 m -76.42 -23.69 53.99 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.507 -0.746 . . . . 0.0 109.743 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.57 -133.44 46.96 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -74.87 -13.05 60.51 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.423 -1.045 . . . . 0.0 110.196 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.404 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.11 -26.77 51.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.166 -0.959 . . . . 0.0 109.258 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 155.75 5.58 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 108.462 -1.855 . . . . 0.0 108.462 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -156.43 172.52 18.37 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.982 -1.305 . . . . 0.0 110.091 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.0 p90 -115.8 133.45 56.02 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -72.66 171.9 11.67 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.3 t -63.36 174.53 1.22 Allowed 'General case' 0 C--N 1.298 -1.666 0 O-C-N 120.768 -1.207 . . . . 0.0 109.722 -179.037 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.06 0.93 Allowed Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.483 -0.761 . . . . 0.0 110.231 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo . . . . . 0 N--CA 1.483 0.88 0 C-N-CA 122.032 1.821 . . . . 0.0 110.3 179.286 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.6 ptt180 . . . . . 0 N--CA 1.487 1.396 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.43 -22.88 74.81 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 121.014 -1.286 . . . . 0.0 110.252 -179.702 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.7 t -62.59 -64.27 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.044 -1.035 . . . . 0.0 111.249 -177.29 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.495 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.0 mt-10 -54.99 -48.78 72.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.014 -1.054 . . . . 0.0 110.431 -178.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 52.7 tp60 -46.32 -57.2 4.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.075 -1.016 . . . . 0.0 110.458 -179.228 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.518 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -84.75 -26.48 27.58 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 111.278 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.3 t -83.19 -51.33 7.58 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.677 -1.264 . . . . 0.0 109.25 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.517 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.3 t-80 -72.61 -26.61 61.75 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.353 -0.842 . . . . 0.0 109.621 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.92 158.83 43.57 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.311 -0.868 . . . . 0.0 109.838 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 10.4 mm -81.25 99.51 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.347 -0.846 . . . . 0.0 109.171 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -92.17 149.9 21.22 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.018 -1.051 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -83.84 166.46 17.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.25 -0.906 . . . . 0.0 109.336 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.2 mt -57.63 -33.61 68.45 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -43.72 -57.85 3.0 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.917 0.865 . . . . 0.0 109.979 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -59.95 -42.68 94.58 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.518 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.8 mt -61.72 -27.2 68.54 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.25 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -75.33 -8.54 56.94 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -79.51 -26.33 41.57 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.811 -0.555 . . . . 0.0 109.995 -179.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 13.8 m-85 -101.05 5.67 43.08 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.283 -0.886 . . . . 0.0 110.398 -179.257 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.3 m -79.29 111.39 15.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.928 -1.108 . . . . 0.0 109.631 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.568 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.38 -91.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.479 -0.763 . . . . 0.0 110.572 -178.68 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -101.45 25.94 7.81 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.382 -0.824 . . . . 0.0 109.879 -179.267 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.64 159.82 14.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.356 -0.84 . . . . 0.0 109.671 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -92.2 137.17 32.59 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.483 0.659 . . . . 0.0 110.568 -179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -100.83 131.12 46.87 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.475 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.03 125.02 11.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 179.308 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -147.7 41.99 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -45.99 -32.3 2.7 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.328 -1.101 . . . . 0.0 110.225 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.475 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.9 OUTLIER -48.43 -50.08 32.54 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.054 -1.029 . . . . 0.0 108.722 179.805 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.493 HD11 HD22 ' A' ' 52' ' ' LEU . 20.2 tp -57.21 -54.39 47.36 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.45 -0.781 . . . . 0.0 109.519 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.7 t -46.93 -66.32 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.284 -0.885 . . . . 0.0 109.951 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 41.4 mt-10 -48.03 -24.41 1.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.139 -0.976 . . . . 0.0 109.377 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -83.29 -54.43 5.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.339 -0.851 . . . . 0.0 109.035 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -52.23 -33.26 40.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.429 -1.42 . . . . 0.0 108.542 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -51.17 -49.85 60.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.344 -0.848 . . . . 0.0 110.2 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.783 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.23 -50.55 53.27 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.578 -1.326 . . . . 0.0 108.597 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.1 t -50.54 -58.79 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.504 0.669 . . . . 0.0 109.723 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.03 -23.27 52.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.582 -0.699 . . . . 0.0 109.893 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.19 -126.27 18.33 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -77.39 -14.96 59.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.313 -1.11 . . . . 0.0 110.282 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.8 mtp180 -55.31 -27.95 50.33 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.088 -1.007 . . . . 0.0 109.424 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.66 154.55 4.83 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.509 -1.836 . . . . 0.0 108.509 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.79 173.01 17.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.897 -1.355 . . . . 0.0 110.372 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.4 p90 -117.96 136.46 53.49 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -77.25 170.37 16.65 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 t -64.62 175.34 1.45 Allowed 'General case' 0 C--N 1.298 -1.654 0 O-C-N 120.973 -1.079 . . . . 0.0 110.016 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -44.33 148.55 0.84 Allowed Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 109.967 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo . . . . . 0 N--CA 1.484 0.939 0 C-N-CA 122.118 1.879 . . . . 0.0 110.3 179.415 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 . . . . . 0 N--CA 1.485 1.318 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.2 -24.41 71.36 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.76 -56.41 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 121.024 -1.28 . . . . 0.0 110.287 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.34 -64.41 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.028 -1.045 . . . . 0.0 111.352 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -55.52 -45.45 77.15 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.056 -1.028 . . . . 0.0 110.457 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.5 tt0 -49.6 -56.45 9.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.087 -1.008 . . . . 0.0 110.212 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.543 ' SG ' HD21 ' A' ' 52' ' ' LEU . 64.5 m -84.99 -26.12 27.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.18 -0.95 . . . . 0.0 111.339 -178.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.06 -51.33 7.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.723 -1.236 . . . . 0.0 109.295 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.494 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.5 t-80 -72.1 -25.67 61.84 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.283 -0.885 . . . . 0.0 109.376 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -136.81 157.78 45.97 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.363 -0.836 . . . . 0.0 109.623 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 8.6 mm -82.11 99.22 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.374 -0.829 . . . . 0.0 108.891 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.5 p -91.28 150.62 21.24 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.097 -1.002 . . . . 0.0 109.54 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -84.1 166.83 17.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.199 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -57.44 -33.6 68.11 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.42 -57.81 3.33 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.811 0.815 . . . . 0.0 110.081 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -60.13 -41.86 93.55 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.543 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.9 mt -61.98 -31.99 72.41 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.031 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 49' ' ' LEU . 0.6 OUTLIER -70.04 -9.57 55.78 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 179.289 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -75.68 -28.33 58.63 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.759 -0.588 . . . . 0.0 109.557 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.437 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 12.9 m-85 -100.99 5.1 43.0 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.33 -0.856 . . . . 0.0 110.151 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.44 ' SG ' HG12 ' A' ' 18' ' ' VAL . 96.8 m -80.15 109.6 14.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.92 -1.112 . . . . 0.0 109.086 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.419 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 23.3 t-20 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.084 -0.96 . . . . 0.0 109.391 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.575 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -94.7 -91.36 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.373 -0.829 . . . . 0.0 110.791 -178.495 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.575 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -105.65 25.73 10.42 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.408 -0.807 . . . . 0.0 110.028 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.91 158.07 15.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.278 -0.889 . . . . 0.0 109.625 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.436 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 12.5 p80 -90.68 137.01 32.69 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.696 -0.627 . . . . 0.0 110.217 -179.275 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -96.21 122.57 39.21 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.8 m -139.69 125.65 19.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.291 -0.881 . . . . 0.0 109.331 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.38 -149.81 46.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -44.54 -29.55 0.74 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.353 -1.086 . . . . 0.0 110.235 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 9.9 m-20 -49.18 -51.24 33.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.034 -1.041 . . . . 0.0 108.874 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.515 HD11 HD22 ' A' ' 52' ' ' LEU . 21.7 tp -55.8 -51.36 67.72 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.401 -0.812 . . . . 0.0 109.365 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -49.61 -66.22 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 0.0 109.714 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.481 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 38.8 mt-10 -47.49 -26.91 1.53 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.379 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.53 -55.49 4.82 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.407 -0.808 . . . . 0.0 109.148 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.1 mt -51.3 -33.64 29.79 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.268 -1.52 . . . . 0.0 108.737 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.436 ' O ' ' N ' ' A' ' 20' ' ' GLY . 54.8 t80 -50.94 -50.35 57.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 110.228 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.776 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.6 mp -67.66 -50.53 57.35 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.575 -1.328 . . . . 0.0 108.605 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.434 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.5 t -50.42 -58.95 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.514 0.673 . . . . 0.0 109.816 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.8 m -76.71 -23.38 53.12 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.541 -0.724 . . . . 0.0 109.867 -178.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 48.42 -123.31 9.8 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -79.07 -13.28 59.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.304 -1.115 . . . . 0.0 110.298 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -57.81 -27.67 63.35 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.085 -1.009 . . . . 0.0 109.561 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 154.73 4.75 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.68 172.85 17.86 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.773 -1.428 . . . . 0.0 110.484 -179.328 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.9 p90 -118.14 129.98 55.84 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.3 t80 -70.69 171.12 10.97 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 t -64.12 174.91 1.39 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 120.826 -1.171 . . . . 0.0 109.644 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -42.29 150.38 0.4 Allowed Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.449 -0.782 . . . . 0.0 110.339 -178.075 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo . . . . . 0 N--CA 1.484 0.961 0 C-N-CA 122.068 1.845 . . . . 0.0 110.439 179.377 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.621 HH11 ' CG ' ' A' ' 36' ' ' ARG . 0.6 OUTLIER . . . . . 0 N--CA 1.484 1.273 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.96 -24.53 0.09 OUTLIER Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.5 -55.55 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 120.977 -1.308 . . . . 0.0 109.91 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.8 t -62.49 -64.26 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.052 -1.03 . . . . 0.0 112.1 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -59.38 -37.71 78.64 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.832 -1.168 . . . . 0.0 110.856 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -54.49 -56.26 20.57 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.819 -1.175 . . . . 0.0 109.409 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.618 ' SG ' HD21 ' A' ' 52' ' ' LEU . 67.2 m -85.78 -24.03 27.0 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.324 -0.86 . . . . 0.0 111.297 -179.161 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.9 -52.62 6.21 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.635 -1.291 . . . . 0.0 109.771 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.515 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.4 t-80 -69.77 -26.3 64.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.203 -0.936 . . . . 0.0 109.278 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.88 161.17 36.74 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.376 -0.828 . . . . 0.0 109.483 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.7 mm -84.59 99.79 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.4 p -90.99 153.96 19.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.065 -1.022 . . . . 0.0 109.726 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.19 167.95 15.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.312 -0.867 . . . . 0.0 109.056 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.1 mt -59.74 -33.34 71.53 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.919 0.866 . . . . 0.0 108.669 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -44.34 -57.74 3.34 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.777 0.798 . . . . 0.0 110.286 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -61.06 -41.73 97.18 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 119.773 -0.771 . . . . 0.0 108.964 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.618 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.56 -31.31 71.34 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.64 -9.64 57.49 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -75.64 -28.06 58.64 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.746 -0.596 . . . . 0.0 109.569 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.429 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.8 m-85 -101.22 5.64 42.66 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.333 -0.854 . . . . 0.0 110.072 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.434 ' SG ' HG12 ' A' ' 18' ' ' VAL . 90.0 m -80.35 109.47 14.86 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.916 -1.115 . . . . 0.0 109.27 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.452 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 2.1 t30 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.454 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.553 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.3 OUTLIER -98.32 -91.29 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.366 -0.834 . . . . 0.0 110.503 -178.827 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.553 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.1 m-20 -106.35 27.53 8.64 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.534 -0.729 . . . . 0.0 109.899 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.447 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -94.79 159.96 14.82 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.343 -0.848 . . . . 0.0 109.335 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 14.8 p-80 -90.65 131.46 36.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.616 -0.677 . . . . 0.0 110.693 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.411 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -94.01 127.28 39.71 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.021 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.435 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.2 m -142.68 125.51 16.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.233 -0.917 . . . . 0.0 109.343 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.33 -150.45 47.06 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.9 m -43.67 -29.92 0.56 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -1.032 . . . . 0.0 110.383 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 24.4 m-20 -50.01 -51.31 42.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.991 -1.068 . . . . 0.0 108.951 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -54.8 -53.52 54.15 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.313 -0.867 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 t -47.91 -66.07 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.356 -0.84 . . . . 0.0 109.963 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 45.3 mt-10 -47.82 -28.51 2.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.349 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.72 -54.89 5.63 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.352 -0.843 . . . . 0.0 109.123 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.0 mt -51.64 -35.29 41.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.35 -1.469 . . . . 0.0 108.661 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.8 t80 -49.32 -49.53 43.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 110.298 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.748 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -68.53 -51.27 44.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.67 -1.269 . . . . 0.0 108.609 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.448 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.33 -58.41 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 121.525 0.678 . . . . 0.0 109.59 -179.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -76.58 -23.53 53.51 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.558 -0.714 . . . . 0.0 109.98 -178.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.91 -122.07 10.79 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.3 mt-10 -80.47 -16.47 54.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.307 -1.113 . . . . 0.0 110.357 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.43 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -55.89 -28.16 55.34 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.551 -179.524 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 156.25 5.68 Favored Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -156.58 172.73 18.05 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.842 -1.387 . . . . 0.0 110.477 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.0 p90 -117.76 139.46 51.03 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -78.47 170.97 15.79 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t -64.6 174.55 1.72 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.869 -1.144 . . . . 0.0 110.523 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -46.36 148.53 1.59 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.586 -0.696 . . . . 0.0 110.098 -178.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo . . . . . 0 N--CA 1.486 1.071 0 C-N-CA 122.347 2.031 . . . . 0.0 110.962 179.715 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.52 HH11 ' HG2' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.6 -23.82 66.58 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.537 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.95 -56.41 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.234 0 O-C-N 121.096 -1.238 . . . . 0.0 110.393 -179.716 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.04 -64.35 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.026 . . . . 0.0 111.436 -177.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -55.04 -48.55 73.29 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.856 -1.152 . . . . 0.0 110.411 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -45.93 -58.32 3.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.195 -0.94 . . . . 0.0 110.451 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.6 m -85.34 -27.02 26.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.154 -0.966 . . . . 0.0 111.511 -178.573 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 42.6 t -83.38 -52.32 6.64 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.733 -1.229 . . . . 0.0 109.598 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.438 ' N ' ' O ' ' A' ' 40' ' ' GLU . 64.1 t-80 -70.94 -26.59 63.25 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.88 161.84 34.89 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.324 -0.86 . . . . 0.0 109.676 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.8 mm -83.36 99.69 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.585 -0.697 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -92.4 160.12 15.24 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.05 -1.031 . . . . 0.0 109.741 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.07 167.31 11.87 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.91 -32.58 69.67 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.517 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.35 -57.24 3.63 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.702 0.763 . . . . 0.0 110.14 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -61.35 -42.37 98.59 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.924 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.08 -31.93 71.59 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.42 -9.6 56.81 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.937 -1.135 . . . . 0.0 107.937 179.332 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -77.0 -27.67 54.78 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.778 -0.576 . . . . 0.0 109.689 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.1 m-85 -102.29 6.23 40.37 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.402 -0.811 . . . . 0.0 109.957 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.448 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -78.41 103.3 8.26 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.994 -1.066 . . . . 0.0 109.403 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.4 t-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.456 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -104.39 -91.67 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.616 -178.695 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.619 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.4 m120 -100.02 25.8 7.04 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.349 -0.844 . . . . 0.0 109.777 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.528 ' CD ' ' H2 ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.93 160.05 14.66 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.384 -0.823 . . . . 0.0 109.522 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -94.88 136.29 35.36 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.57 -0.706 . . . . 0.0 110.178 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.405 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -97.51 130.17 44.61 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.639 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 72.8 m -143.92 125.18 14.62 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.306 -0.871 . . . . 0.0 109.255 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.18 -150.62 47.58 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.9 m -43.77 -30.5 0.66 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.418 -1.048 . . . . 0.0 110.322 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 4.6 m-20 -48.94 -50.51 35.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.967 -1.083 . . . . 0.0 108.856 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 18.9 tp -55.42 -54.86 38.48 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.359 -0.838 . . . . 0.0 109.235 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.75 -66.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.391 -0.818 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.48 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 35.2 mt-10 -47.87 -27.85 2.32 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.191 -0.943 . . . . 0.0 109.341 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.69 -54.57 5.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.336 -0.852 . . . . 0.0 109.164 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.64 -34.96 40.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.364 -1.46 . . . . 0.0 108.599 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.9 t80 -49.64 -49.48 47.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.359 -0.838 . . . . 0.0 110.389 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.789 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.55 -50.76 49.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.525 -1.36 . . . . 0.0 108.578 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.6 -58.87 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-O 121.506 0.67 . . . . 0.0 109.718 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.48 -23.56 53.81 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.486 -0.759 . . . . 0.0 109.819 -178.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 53.51 -130.17 41.71 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -76.83 -13.07 60.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -1.105 . . . . 0.0 110.114 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.415 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.3 OUTLIER -56.69 -27.62 59.24 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.107 -0.996 . . . . 0.0 109.368 -179.533 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 155.59 5.5 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -156.54 172.93 17.7 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.932 -1.334 . . . . 0.0 110.074 -179.426 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.3 p90 -116.02 138.65 51.02 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -78.87 171.28 15.41 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -64.33 174.95 1.45 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.927 -1.108 . . . . 0.0 110.338 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.92 149.95 1.44 Allowed Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.497 -0.752 . . . . 0.0 110.301 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 N--CA 1.484 0.965 0 C-N-CA 122.206 1.937 . . . . 0.0 110.508 179.276 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.429 ' HG3' HH11 ' A' ' 36' ' ' ARG . 17.6 mtm-85 . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.93 -25.66 74.2 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.18 -56.01 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.327 0 O-C-N 121.035 -1.273 . . . . 0.0 110.645 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.526 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -62.39 -63.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.946 -1.096 . . . . 0.0 111.495 -177.06 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' HIS . 70.1 mt-10 -55.97 -47.81 76.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.84 -1.163 . . . . 0.0 110.285 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -46.41 -57.44 4.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.999 -1.063 . . . . 0.0 110.426 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.559 ' SG ' HD21 ' A' ' 52' ' ' LEU . 61.0 m -84.69 -27.95 26.7 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.124 -0.985 . . . . 0.0 111.083 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.3 t -83.49 -52.1 6.79 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.809 -1.182 . . . . 0.0 109.349 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' GLU . 16.0 t60 -69.77 -28.23 65.59 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.241 -0.912 . . . . 0.0 109.077 179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 m -137.04 160.73 38.08 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.403 -0.811 . . . . 0.0 109.505 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -83.13 99.94 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 p -91.45 152.05 20.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.012 -1.055 . . . . 0.0 109.563 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.92 167.42 14.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.307 -0.871 . . . . 0.0 109.121 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.95 -34.51 68.09 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.625 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -44.15 -56.97 3.68 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.816 0.817 . . . . 0.0 109.979 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -60.33 -42.64 96.08 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.559 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.9 mt -62.05 -32.6 73.13 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.55 -9.47 54.1 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -76.06 -28.03 57.47 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.79 -0.569 . . . . 0.0 109.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.6 m-85 -102.57 6.71 39.97 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.368 -0.832 . . . . 0.0 109.992 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.464 ' SG ' HG12 ' A' ' 18' ' ' VAL . 67.3 m -79.81 104.01 10.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 109.33 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.431 ' O ' ' O ' ' A' ' 56' ' ' CYS . 24.9 t-20 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.511 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.584 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -100.28 -91.42 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.437 -0.789 . . . . 0.0 110.425 -178.938 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.584 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.0 m120 -104.54 27.64 7.73 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.477 -0.764 . . . . 0.0 109.801 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 1.9 pt20 -94.54 159.79 14.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.26 -0.9 . . . . 0.0 109.523 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.0 OUTLIER -90.26 131.94 35.8 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.602 0.715 . . . . 0.0 110.866 -178.637 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.51 132.56 43.08 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.957 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.98 124.89 10.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.15 -0.969 . . . . 0.0 109.222 179.287 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.43 -147.43 42.28 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.8 m -44.9 -33.17 1.87 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.376 -1.073 . . . . 0.0 110.205 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -49.3 -49.85 41.94 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.003 -1.061 . . . . 0.0 108.815 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.548 HD21 HD12 ' A' ' 38' ' ' ILE . 19.0 tp -58.08 -57.02 14.67 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 21.0 t -45.07 -65.94 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.34 -0.85 . . . . 0.0 109.974 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.491 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.7 mt-10 -47.54 -30.44 3.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -77.62 -54.58 6.22 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 109.223 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -50.92 -36.53 38.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.522 -1.361 . . . . 0.0 108.665 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -48.84 -49.8 37.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.399 -0.813 . . . . 0.0 110.396 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.841 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.6 mp -68.26 -50.73 51.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.524 -1.36 . . . . 0.0 108.579 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -50.89 -59.33 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.456 0.646 . . . . 0.0 110.087 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -23.45 54.21 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.512 -0.743 . . . . 0.0 109.809 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.98 -129.03 30.97 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.204 -1.159 . . . . 0.0 110.204 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -76.49 -15.04 59.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -1.106 . . . . 0.0 110.182 -179.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.514 ' NH1' ' OE2' ' A' ' 53' ' ' GLU . 33.8 mtp180 -54.69 -27.61 41.64 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.032 -1.043 . . . . 0.0 109.087 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.13 5.23 Favored Glycine 0 N--CA 1.486 2.0 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 -179.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.39 172.33 18.69 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.889 -1.36 . . . . 0.0 110.214 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.3 p90 -117.53 135.07 54.19 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -73.18 171.65 12.58 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.8 t -63.36 174.71 1.16 Allowed 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.773 -1.204 . . . . 0.0 109.749 -178.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.22 146.33 0.68 Allowed Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.201 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo . . . . . 0 N--CA 1.484 0.92 0 C-N-CA 122.081 1.854 . . . . 0.0 110.723 179.688 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.66 -24.21 77.1 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.548 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.09 -55.12 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.23 0 O-C-N 121.056 -1.261 . . . . 0.0 110.393 -179.635 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.522 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.12 -64.34 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.013 -1.054 . . . . 0.0 111.559 -177.091 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 44' ' ' HIS . 73.0 mt-10 -56.55 -44.78 81.26 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.95 -1.094 . . . . 0.0 110.483 -178.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.5 tp60 -48.86 -56.94 7.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.065 -1.022 . . . . 0.0 110.06 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.511 ' SG ' HD21 ' A' ' 52' ' ' LEU . 56.6 m -84.83 -27.26 26.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.105 -0.997 . . . . 0.0 111.08 -178.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.9 t -83.46 -52.35 6.58 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.672 -1.267 . . . . 0.0 109.448 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 40' ' ' GLU . 2.1 t-160 -70.14 -28.85 65.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.327 -0.858 . . . . 0.0 108.84 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.3 p -136.61 162.38 33.29 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.334 -0.853 . . . . 0.0 109.542 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.2 mm -84.09 99.75 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.608 -0.682 . . . . 0.0 109.662 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.0 p -92.28 146.53 23.64 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.13 -0.981 . . . . 0.0 109.342 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.72 167.61 18.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.232 -0.918 . . . . 0.0 109.212 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.593 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.3 mt -57.08 -34.25 68.1 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -43.67 -57.25 3.28 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.874 0.845 . . . . 0.0 110.138 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -60.33 -41.87 94.44 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.511 HD21 ' SG ' ' A' ' 42' ' ' CYS . 78.2 mt -62.73 -28.27 69.85 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.514 ' OE2' ' NH1' ' A' ' 22' ' ' ARG . 1.8 tm-20 -74.26 -8.72 57.2 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.184 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -78.84 -26.96 44.16 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.875 -0.515 . . . . 0.0 109.946 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.421 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 14.5 m-85 -100.31 5.63 44.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.253 -0.905 . . . . 0.0 110.38 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 72.7 m -82.69 111.27 18.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.843 -1.161 . . . . 0.0 109.462 179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 57' ' ' ASN . 62.7 t-20 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.819 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.594 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -101.13 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 110.697 -178.658 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.594 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -102.97 26.58 7.99 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 109.807 -179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.466 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.52 161.88 13.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.331 -0.855 . . . . 0.0 109.443 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -94.27 136.5 34.49 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.639 0.733 . . . . 0.0 110.32 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 0.8 OUTLIER -99.64 131.89 45.34 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.461 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.8 125.31 11.7 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.192 -0.943 . . . . 0.0 109.186 179.334 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -149.14 44.34 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.8 m -44.96 -31.61 1.34 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.373 -1.075 . . . . 0.0 110.335 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.461 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -48.73 -50.04 35.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.966 -1.084 . . . . 0.0 108.761 179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -57.0 -54.57 45.24 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.458 -0.776 . . . . 0.0 109.534 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.411 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.66 -66.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 110.096 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 50.8 mt-10 -47.67 -27.63 2.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.387 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.08 -54.49 5.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.392 -0.818 . . . . 0.0 109.17 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.92 -34.81 43.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.398 -1.439 . . . . 0.0 108.585 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 20' ' ' GLY . 57.2 t80 -49.94 -50.04 47.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.327 -0.858 . . . . 0.0 110.231 -179.524 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -67.68 -50.81 55.78 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.573 -1.329 . . . . 0.0 108.64 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.3 t -50.62 -58.98 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.543 0.687 . . . . 0.0 109.759 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.23 -23.76 54.57 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.528 -0.732 . . . . 0.0 109.768 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.8 -127.2 30.91 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -78.98 -11.67 60.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.409 -1.054 . . . . 0.0 110.028 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.407 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -57.61 -27.18 62.52 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.162 -0.961 . . . . 0.0 109.287 -179.568 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 154.8 5.01 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.225 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -156.47 172.52 18.38 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.859 -1.377 . . . . 0.0 110.278 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.2 p90 -116.95 132.57 56.67 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -72.26 171.44 12.11 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.8 t -63.73 174.56 1.36 Allowed 'General case' 0 C--N 1.297 -1.69 0 O-C-N 120.706 -1.246 . . . . 0.0 109.669 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.35 0.89 Allowed Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.398 -0.814 . . . . 0.0 110.078 -178.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo . . . . . 0 N--CA 1.484 0.951 0 C-N-CA 122.102 1.868 . . . . 0.0 110.429 179.474 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.424 ' HG3' HH11 ' A' ' 36' ' ' ARG . 13.5 mtm-85 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.43 -24.13 76.22 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.91 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 O-C-N 121.006 -1.291 . . . . 0.0 110.437 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.4 t -62.02 -64.18 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.038 -1.038 . . . . 0.0 111.521 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.443 ' O ' ' N ' ' A' ' 44' ' ' HIS . 83.9 mt-10 -55.84 -46.3 78.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.908 -1.12 . . . . 0.0 110.485 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.9 tp60 -48.14 -56.5 7.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.059 -1.026 . . . . 0.0 110.299 -179.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.552 ' SG ' HD21 ' A' ' 52' ' ' LEU . 58.5 m -85.15 -26.36 26.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.143 -0.973 . . . . 0.0 111.271 -178.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.9 t -83.4 -52.4 6.56 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.608 -1.307 . . . . 0.0 109.418 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.443 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.1 t-80 -69.47 -26.68 64.69 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.874 . . . . 0.0 109.339 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -137.04 173.31 11.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.338 -0.851 . . . . 0.0 109.827 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -93.17 100.04 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.4 p -93.78 145.03 24.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.016 -1.053 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -80.53 166.53 21.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.882 . . . . 0.0 109.35 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -56.81 -34.36 67.62 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.45 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -44.03 -57.29 3.44 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.904 0.859 . . . . 0.0 109.943 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -59.89 -42.94 94.89 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.552 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.9 mt -61.83 -31.91 72.19 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.23 -9.68 56.58 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -75.83 -28.33 58.23 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.803 -0.561 . . . . 0.0 109.598 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 6.9 m-85 -102.72 7.01 39.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.406 -0.808 . . . . 0.0 109.984 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 60.5 m -78.58 108.6 12.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.96 -1.087 . . . . 0.0 109.409 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 39.7 t30 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.483 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.622 HG23 ' H ' ' A' ' 3' ' ' ASN . 1.1 m -102.73 -91.99 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.506 -0.746 . . . . 0.0 110.762 -178.542 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.622 ' H ' HG23 ' A' ' 2' ' ' VAL . 3.7 m120 -99.59 25.3 7.24 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.232 -0.917 . . . . 0.0 109.883 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.492 ' CD ' ' H2 ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.95 157.35 15.94 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.83 . . . . 0.0 109.635 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.421 ' HB3' HD13 ' A' ' 46' ' ' ILE . 3.5 p-80 -92.69 135.9 33.7 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.574 0.702 . . . . 0.0 109.957 -179.189 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.418 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -97.53 136.03 38.52 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.472 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -151.67 125.16 8.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.303 179.4 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -146.49 40.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.7 m -47.84 -31.83 5.45 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -1.086 . . . . 0.0 110.209 -179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.472 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.2 m-20 -49.03 -49.83 39.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.881 -1.137 . . . . 0.0 108.645 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 38' ' ' ILE . 19.6 tp -56.67 -55.09 38.49 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.415 -0.803 . . . . 0.0 109.401 179.674 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -46.41 -66.04 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.283 -0.886 . . . . 0.0 110.001 -179.428 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.1 mt-10 -47.51 -28.8 2.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.368 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.02 -54.61 5.84 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 109.173 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.4 mt -51.26 -34.93 34.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.509 -1.369 . . . . 0.0 108.667 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.6 t80 -49.96 -48.79 51.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 110.394 -179.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.82 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.55 -50.71 42.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.495 -1.378 . . . . 0.0 108.529 179.315 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -50.86 -59.09 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 121.512 0.673 . . . . 0.0 110.02 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.4 m -76.04 -23.98 55.15 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.441 -0.787 . . . . 0.0 109.699 -178.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.42 -133.55 46.34 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -75.5 -12.13 60.17 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.325 -1.103 . . . . 0.0 109.963 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -56.32 -26.93 54.03 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.002 -179.544 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.86 154.72 5.11 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.5 172.91 17.72 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.999 -1.295 . . . . 0.0 110.079 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.546 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.6 p90 -117.38 139.79 50.41 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.48 170.43 16.59 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.5 t -64.73 174.94 1.61 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.947 -1.095 . . . . 0.0 110.069 -179.207 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.54 148.56 0.52 Allowed Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.651 -0.655 . . . . 0.0 110.135 -178.711 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 N--CA 1.487 1.091 0 C-N-CA 122.255 1.97 . . . . 0.0 110.995 179.911 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.0 -25.74 72.9 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.39 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.31 0 O-C-N 121.057 -1.261 . . . . 0.0 110.385 -179.601 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 2.9 t -63.46 -63.91 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.962 -1.086 . . . . 0.0 111.461 -177.332 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.444 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.4 mt-10 -55.62 -46.18 77.43 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.864 -1.147 . . . . 0.0 110.43 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -48.39 -56.77 7.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 110.204 -179.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.494 ' SG ' HD21 ' A' ' 52' ' ' LEU . 73.0 m -85.1 -28.07 25.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 111.427 -178.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 53.9 t -83.29 -52.33 6.66 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.66 -1.275 . . . . 0.0 109.295 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.444 ' N ' ' O ' ' A' ' 40' ' ' GLU . 5.8 t60 -69.55 -27.04 64.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.066 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.7 m -137.17 157.4 46.76 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.496 -0.753 . . . . 0.0 109.49 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.421 HD13 ' HB3' ' A' ' 5' ' ' HIS . 5.8 mm -81.55 99.73 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.6 p -89.51 163.84 15.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.998 -1.064 . . . . 0.0 109.697 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -96.18 166.84 11.55 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.416 -0.802 . . . . 0.0 109.186 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.601 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.59 -33.29 69.82 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -44.76 -57.86 3.45 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.791 0.805 . . . . 0.0 110.236 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -61.07 -40.84 95.22 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.061 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.494 HD21 ' SG ' ' A' ' 42' ' ' CYS . 76.1 mt -62.41 -25.09 67.76 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.66 -9.03 58.75 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -78.96 -26.82 43.51 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.783 -0.573 . . . . 0.0 109.705 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 17.2 m-85 -99.73 4.39 45.43 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.348 -0.845 . . . . 0.0 110.339 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.406 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 71.0 m -82.84 111.22 18.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.883 -1.136 . . . . 0.0 109.367 179.639 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.438 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 1.2 t30 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.058 -0.972 . . . . 0.0 109.377 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.598 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -102.85 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.445 -0.784 . . . . 0.0 110.536 -178.856 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.598 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.5 26.77 6.91 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.393 -0.817 . . . . 0.0 109.892 -179.318 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.472 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.0 pt20 -95.23 160.79 14.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -92.87 134.77 34.75 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.514 0.673 . . . . 0.0 110.67 -178.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -99.49 132.56 44.74 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.262 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.47 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -148.49 125.1 11.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.094 -1.004 . . . . 0.0 109.332 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -148.52 43.26 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.3 m -45.11 -32.28 1.72 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.347 -1.09 . . . . 0.0 110.245 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.47 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.54 -50.52 31.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.991 -1.068 . . . . 0.0 108.823 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.08 -54.79 42.76 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.434 -0.791 . . . . 0.0 109.505 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -46.56 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.294 -0.879 . . . . 0.0 109.991 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 46.9 mt-10 -47.59 -29.31 2.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.923 . . . . 0.0 109.397 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.42 -54.58 6.02 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.375 -0.828 . . . . 0.0 109.363 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.12 -36.1 38.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.456 -1.402 . . . . 0.0 108.794 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -49.43 -49.0 46.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.341 -0.849 . . . . 0.0 110.482 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.816 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -69.02 -50.32 49.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.61 -1.306 . . . . 0.0 108.496 179.381 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -51.03 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.504 0.669 . . . . 0.0 110.113 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.3 m -75.52 -23.63 56.72 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.495 -0.753 . . . . 0.0 109.821 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.47 -126.76 25.09 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -77.45 -15.49 59.29 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.395 -1.062 . . . . 0.0 110.186 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -54.85 -27.9 45.81 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.174 -0.953 . . . . 0.0 109.409 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.79 154.88 5.13 Favored Glycine 0 N--CA 1.487 2.033 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.38 172.53 18.34 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.918 -1.342 . . . . 0.0 110.269 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -118.01 129.28 55.49 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -68.62 171.45 7.62 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 178.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -63.41 174.45 1.27 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 120.74 -1.225 . . . . 0.0 109.468 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.59 147.64 1.03 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.182 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo . . . . . 0 N--CA 1.483 0.883 0 C-N-CA 122.098 1.865 . . . . 0.0 110.158 179.179 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 . . . . . 0 N--CA 1.488 1.435 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.59 -21.84 65.74 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.28 -55.53 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 O-C-N 121.024 -1.28 . . . . 0.0 110.052 -179.714 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -62.2 -63.84 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.023 -1.048 . . . . 0.0 111.094 -177.526 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.456 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.9 mt-10 -54.74 -48.49 72.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.989 -1.069 . . . . 0.0 110.557 -178.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -47.22 -56.58 6.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.069 -1.019 . . . . 0.0 110.493 -179.149 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.526 ' SG ' HD21 ' A' ' 52' ' ' LEU . 57.1 m -84.66 -26.51 27.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.228 -0.92 . . . . 0.0 111.363 -178.588 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.3 t -83.77 -52.39 6.44 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.642 -1.286 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.4 t-80 -68.96 -27.29 65.6 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.235 -0.916 . . . . 0.0 109.23 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.436 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.6 t -137.23 173.17 11.97 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.416 -0.803 . . . . 0.0 109.88 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 9.7 mm -92.3 99.85 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.561 -0.712 . . . . 0.0 109.315 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.8 p -93.0 143.3 26.37 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.014 -1.054 . . . . 0.0 109.39 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -79.39 166.45 22.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.447 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.0 mt -56.36 -34.11 66.33 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.06 -57.49 3.35 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 121.87 0.843 . . . . 0.0 109.971 179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -60.06 -42.15 93.9 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.526 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.8 mt -62.79 -29.05 70.41 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.127 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.11 -8.9 57.81 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -78.43 -26.89 46.41 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.853 -0.529 . . . . 0.0 109.864 -179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.422 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 15.3 m-85 -100.75 5.24 43.57 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.265 -0.897 . . . . 0.0 110.227 -179.281 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 71.6 m -83.35 111.48 19.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.97 -1.081 . . . . 0.0 109.49 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 52.6 t30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.441 179.959 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.998 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.59 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -101.99 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.421 -0.799 . . . . 0.0 110.678 -178.616 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.59 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -102.02 25.57 8.59 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.429 -0.794 . . . . 0.0 109.991 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.449 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.97 160.18 14.59 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.548 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 9.8 p80 -92.95 136.19 33.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.514 -0.741 . . . . 0.0 110.552 -178.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.35 127.06 42.99 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.304 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 82.2 m -142.89 125.29 15.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.296 -0.878 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.17 -149.31 45.61 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.5 m -44.92 -30.84 1.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.421 -1.047 . . . . 0.0 110.284 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.437 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 17.3 m-20 -48.7 -50.61 32.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.927 -1.108 . . . . 0.0 108.787 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.492 HD11 HD22 ' A' ' 52' ' ' LEU . 19.9 tp -55.42 -53.99 49.29 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -47.04 -66.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.837 . . . . 0.0 109.899 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 72.5 mt-10 -47.79 -26.77 1.74 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.371 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.998 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.02 -54.73 5.3 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.384 -0.823 . . . . 0.0 109.131 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.84 -34.28 39.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.406 -1.434 . . . . 0.0 108.581 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.6 t80 -50.16 -49.85 50.88 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.366 -0.834 . . . . 0.0 110.179 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.78 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.27 -50.76 51.59 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.584 -1.323 . . . . 0.0 108.681 179.407 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.6 t -50.52 -58.64 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.5 0.667 . . . . 0.0 109.757 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -77.0 -23.34 52.23 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 -178.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 46.95 -120.78 5.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.673 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -80.22 -13.7 59.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.299 -1.118 . . . . 0.0 110.15 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -57.95 -28.27 64.17 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.112 -0.992 . . . . 0.0 109.528 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.59 154.19 4.57 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -156.87 172.95 17.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.886 -1.361 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.8 p90 -119.15 139.51 51.68 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -80.52 169.82 17.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.931 -1.106 . . . . 0.0 108.143 179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.2 t -65.59 175.71 1.74 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.117 -0.989 . . . . 0.0 110.404 -179.217 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -45.22 149.87 0.88 Allowed Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.459 -0.776 . . . . 0.0 109.895 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo . . . . . 0 N--CA 1.484 0.95 0 C-N-CA 122.178 1.919 . . . . 0.0 110.581 179.421 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.92 -25.73 73.02 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.08 -56.33 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.061 -1.258 . . . . 0.0 110.46 -179.67 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -62.27 -64.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 120.961 -1.087 . . . . 0.0 111.637 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 44' ' ' HIS . 62.4 mt-10 -55.79 -46.79 77.9 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.85 -1.157 . . . . 0.0 110.331 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 -47.67 -57.49 5.45 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.086 -1.009 . . . . 0.0 110.167 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.598 ' SG ' HD21 ' A' ' 52' ' ' LEU . 63.1 m -84.77 -26.7 27.39 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.137 -0.977 . . . . 0.0 111.101 -178.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.0 t -83.25 -52.3 6.7 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.826 -1.171 . . . . 0.0 109.481 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.502 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.1 t-80 -71.24 -26.46 62.92 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.231 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.2 m -136.83 157.91 45.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.39 -0.819 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -82.27 99.73 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.242 -0.911 . . . . 0.0 109.013 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.7 p -90.75 151.62 21.14 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.137 -0.977 . . . . 0.0 109.375 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -85.08 166.49 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.02 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -56.54 -34.04 66.67 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -44.44 -57.5 3.52 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.855 0.835 . . . . 0.0 110.023 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -60.07 -42.35 94.37 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.598 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.9 mt -62.29 -31.8 72.44 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.13 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.89 -9.46 54.96 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -75.54 -28.37 59.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.799 -0.563 . . . . 0.0 109.712 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.1 m-85 -102.03 6.32 41.03 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.333 -0.854 . . . . 0.0 110.018 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 73.4 m -80.4 109.0 14.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.93 -1.106 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.417 ' OXT' ' OD1' ' A' ' 57' ' ' ASN . 53.7 t-20 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.514 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -104.04 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.407 -0.808 . . . . 0.0 110.726 -178.661 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -101.66 25.85 8.04 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.409 -0.807 . . . . 0.0 109.936 -179.06 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.447 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.88 160.2 14.59 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.321 -0.862 . . . . 0.0 109.85 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' A' ' 5' ' ' HIS . 0.1 OUTLIER -92.76 132.09 37.26 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.643 -0.661 . . . . 0.0 110.441 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -95.4 132.8 40.06 Favored 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.027 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.486 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -149.12 125.24 10.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.033 -1.042 . . . . 0.0 109.327 179.244 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.88 -147.4 41.49 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -45.89 -32.07 2.47 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.362 -1.081 . . . . 0.0 110.194 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.486 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.0 m-20 -49.27 -51.06 36.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.092 . . . . 0.0 108.762 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.512 HD21 HD12 ' A' ' 38' ' ' ILE . 21.3 tp -56.1 -51.64 67.16 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.4 -0.812 . . . . 0.0 109.391 179.763 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 t -49.44 -66.28 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.219 -0.926 . . . . 0.0 109.968 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.4 mt-10 -47.56 -26.42 1.44 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.412 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.03 -54.64 5.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.323 -0.861 . . . . 0.0 109.058 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.85 -33.94 38.4 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.412 -1.43 . . . . 0.0 108.635 179.452 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.2 t80 -50.58 -50.06 54.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.926 . . . . 0.0 110.236 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.78 -50.82 54.95 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.534 -1.354 . . . . 0.0 108.547 179.387 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.435 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.4 t -50.7 -59.01 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 CA-C-O 121.527 0.68 . . . . 0.0 109.668 -179.441 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -75.87 -23.54 55.63 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.48 -0.763 . . . . 0.0 109.819 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.02 -130.64 44.05 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -77.1 -14.44 59.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -1.094 . . . . 0.0 110.087 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.408 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.3 OUTLIER -54.88 -27.8 45.53 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.149 -0.969 . . . . 0.0 109.327 -179.628 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.76 156.39 6.07 Favored Glycine 0 N--CA 1.485 1.964 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.41 172.93 17.65 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.022 -1.281 . . . . 0.0 110.243 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.9 p90 -115.73 132.84 56.52 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -73.23 171.75 12.42 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 t -63.55 173.93 1.5 Allowed 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 118.578 -1.249 . . . . 0.0 109.302 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -44.41 148.82 0.81 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.199 -0.938 . . . . 0.0 110.139 -178.088 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo . . . . . 0 N--CA 1.484 0.958 0 C-N-CA 122.086 1.857 . . . . 0.0 110.682 179.577 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.02 -21.86 54.2 Favored Glycine 0 N--CA 1.491 2.36 0 O-C-N 121.133 -0.98 . . . . 0.0 110.911 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -100.31 -54.24 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 120.879 -1.366 . . . . 0.0 110.457 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.525 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -61.42 -63.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 111.704 -177.116 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -58.52 -38.15 77.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 111.079 -178.101 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -55.6 -53.68 53.43 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.833 -1.167 . . . . 0.0 109.195 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.63 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -85.76 -26.73 25.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 110.769 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.8 t -83.86 -52.5 6.32 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.701 -1.249 . . . . 0.0 109.541 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.412 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.6 t60 -71.39 -26.41 62.77 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.207 -0.933 . . . . 0.0 109.174 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.7 m -137.06 160.28 39.4 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.363 -0.835 . . . . 0.0 109.645 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.2 mm -83.21 100.28 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.49 -0.756 . . . . 0.0 109.221 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -93.0 147.75 22.57 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.105 -0.997 . . . . 0.0 109.683 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.7 167.76 17.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -58.4 -34.04 70.3 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -44.1 -57.12 3.57 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 121.797 0.808 . . . . 0.0 110.154 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -61.59 -41.63 97.7 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.63 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.0 mt -61.84 -31.69 71.97 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.48 -9.79 57.47 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -75.5 -28.31 59.13 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.816 -0.552 . . . . 0.0 109.571 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.438 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.5 m-85 -101.83 7.04 41.81 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.399 -0.813 . . . . 0.0 110.017 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.435 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -80.43 106.39 12.41 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.897 -1.127 . . . . 0.0 109.398 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.65 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.994 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.601 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.0 -91.83 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.476 -0.765 . . . . 0.0 110.34 -179.082 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.601 ' H ' HG23 ' A' ' 2' ' ' VAL . 24.6 p-10 -101.94 27.4 6.57 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.465 -0.772 . . . . 0.0 110.074 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.478 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 1.9 pt20 -95.28 157.66 15.8 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.232 -0.917 . . . . 0.0 109.166 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -90.2 132.05 35.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.582 -0.699 . . . . 0.0 110.718 -178.722 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -95.1 130.5 41.78 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.184 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.424 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.5 m -143.5 125.27 15.07 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.24 -0.913 . . . . 0.0 109.388 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.16 -150.04 46.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -44.66 -30.34 0.91 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.412 -1.052 . . . . 0.0 110.284 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.424 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.67 -50.14 34.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.953 -1.092 . . . . 0.0 108.791 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.51 HD21 HD12 ' A' ' 38' ' ' ILE . 20.3 tp -55.76 -55.71 29.18 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.451 -0.781 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 19.3 t -45.8 -65.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.385 -0.822 . . . . 0.0 109.946 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 84.8 mt-10 -47.73 -29.68 3.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.436 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.994 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.31 -54.45 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.84 . . . . 0.0 109.239 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -51.34 -35.88 40.32 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.496 -1.378 . . . . 0.0 108.712 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.6 t80 -49.4 -48.84 46.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.414 -0.804 . . . . 0.0 110.461 -179.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.832 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.38 -50.45 46.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.488 -1.383 . . . . 0.0 108.539 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -50.84 -59.23 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 CA-C-O 121.558 0.694 . . . . 0.0 110.23 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -24.04 54.23 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.402 -0.811 . . . . 0.0 109.804 -178.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.37 -126.19 23.2 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -77.32 -14.54 59.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -1.077 . . . . 0.0 110.28 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.406 ' HB3' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.52 -27.6 57.8 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.36 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.53 154.51 4.69 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -156.52 172.6 18.27 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.923 -1.34 . . . . 0.0 110.418 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.3 p90 -118.29 138.75 52.17 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -77.45 170.83 15.87 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.6 t -64.3 175.29 1.35 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.869 -1.144 . . . . 0.0 109.807 -179.276 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.15 148.03 0.52 Allowed Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.492 -0.755 . . . . 0.0 110.295 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo . . . . . 0 N--CA 1.484 0.952 0 C-N-CA 122.091 1.861 . . . . 0.0 110.462 179.469 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.585 HH11 ' CG ' ' A' ' 36' ' ' ARG . 1.4 mtt-85 . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.85 -25.99 74.02 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.52 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.21 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.315 0 O-C-N 121.002 -1.293 . . . . 0.0 110.436 -179.502 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.52 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.25 -64.52 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.133 . . . . 0.0 111.564 -177.05 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' HIS . 35.4 mt-10 -55.94 -45.74 78.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.854 -1.154 . . . . 0.0 110.295 -178.836 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 -47.48 -57.87 4.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.084 -1.01 . . . . 0.0 110.15 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.568 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.1 m -84.83 -27.0 27.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.156 -0.965 . . . . 0.0 111.02 -178.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.8 t -83.32 -51.44 7.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.845 -1.16 . . . . 0.0 109.429 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.519 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.0 t60 -73.47 -26.16 60.79 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.339 -0.851 . . . . 0.0 109.48 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -136.86 157.69 46.18 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.4 -0.813 . . . . 0.0 109.876 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.5 mm -79.95 99.56 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.461 -0.774 . . . . 0.0 109.229 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.6 p -92.57 154.9 18.14 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.056 -1.027 . . . . 0.0 109.637 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -88.85 166.5 13.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.296 -0.878 . . . . 0.0 108.988 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.7 mt -58.4 -32.78 68.94 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.39 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.28 -57.31 3.55 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.804 0.811 . . . . 0.0 110.159 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -61.68 -42.04 98.38 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.71 -0.796 . . . . 0.0 108.998 -179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.568 HD21 ' SG ' ' A' ' 42' ' ' CYS . 74.6 mt -61.29 -24.93 66.76 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.71 -8.74 58.39 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -79.67 -26.78 40.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.794 -0.566 . . . . 0.0 109.849 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 16.3 m-85 -99.06 4.62 47.12 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.282 -0.886 . . . . 0.0 110.31 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 70.9 m -81.26 111.34 17.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.939 -1.101 . . . . 0.0 109.496 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.64 179.993 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -99.77 -91.57 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.353 -0.842 . . . . 0.0 110.197 -179.124 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.3 p-10 -104.33 28.22 7.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.671 -0.643 . . . . 0.0 109.431 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.458 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 1.9 pt20 -94.75 157.41 15.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.163 -0.96 . . . . 0.0 109.123 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.6 p-80 -89.0 131.73 35.05 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.526 0.679 . . . . 0.0 110.713 -178.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.1 mp -97.16 132.44 42.94 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.483 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.24 125.36 10.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.189 -0.944 . . . . 0.0 109.278 179.286 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.72 -146.51 40.31 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.7 m -46.75 -32.5 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.365 -1.079 . . . . 0.0 110.155 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.483 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.0 -50.44 35.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.965 -1.084 . . . . 0.0 108.783 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.526 HD21 HD12 ' A' ' 38' ' ' ILE . 18.1 tp -56.9 -55.73 30.71 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.394 -0.816 . . . . 0.0 109.529 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 12' ' ' VAL . 15.6 t -46.13 -66.15 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.342 -0.849 . . . . 0.0 110.085 -179.41 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 75.8 mt-10 -47.94 -26.75 1.85 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.197 -0.939 . . . . 0.0 109.298 -179.644 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.08 -54.21 5.74 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.333 -0.854 . . . . 0.0 109.088 179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.87 -34.77 42.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.361 -1.462 . . . . 0.0 108.536 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 20' ' ' GLY . 58.0 t80 -49.82 -49.59 48.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.374 -0.828 . . . . 0.0 110.358 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.777 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.58 -50.66 49.99 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.584 -1.322 . . . . 0.0 108.598 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.428 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.67 -58.88 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.49 0.662 . . . . 0.0 109.703 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -76.51 -23.48 53.72 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.526 -0.734 . . . . 0.0 109.9 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.94 -127.08 31.16 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.12 -14.96 59.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.402 -1.057 . . . . 0.0 110.101 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.1 mtp180 -54.95 -28.99 55.61 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.098 -1.001 . . . . 0.0 109.171 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.91 5.73 Favored Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.5 172.72 18.05 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.907 -1.349 . . . . 0.0 110.174 -179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.09 137.65 51.94 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -75.96 171.95 13.56 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -63.13 174.37 1.17 Allowed 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.762 -1.211 . . . . 0.0 109.812 -178.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.45 147.37 1.03 Allowed Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.369 -0.832 . . . . 0.0 110.096 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo . . . . . 0 N--CA 1.484 0.915 0 C-N-CA 122.107 1.871 . . . . 0.0 110.315 179.352 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.525 HH11 ' HG2' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.85 -26.66 58.19 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.93 -55.8 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.335 0 O-C-N 120.895 -1.356 . . . . 0.0 110.566 -179.461 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.8 t -63.26 -64.39 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.905 -1.122 . . . . 0.0 111.295 -177.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 44' ' ' HIS . 80.9 mt-10 -54.47 -47.54 72.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.89 -1.131 . . . . 0.0 110.277 -178.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -46.68 -58.52 3.77 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.155 -0.966 . . . . 0.0 110.417 -179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.47 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.7 m -84.87 -25.88 27.71 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.131 -0.981 . . . . 0.0 111.435 -178.644 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.3 t -83.61 -51.71 7.07 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.58 -1.325 . . . . 0.0 109.068 179.793 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.477 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t60 -68.13 -27.9 66.85 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.419 -0.8 . . . . 0.0 109.341 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 14.2 t -137.35 173.14 12.0 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.353 -0.842 . . . . 0.0 110.188 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.2 mm -91.82 99.43 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.0 p -93.92 152.99 18.46 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.074 -1.016 . . . . 0.0 109.548 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.28 167.54 13.47 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.902 . . . . 0.0 109.125 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.4 -34.53 68.98 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -43.67 -57.01 3.4 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.852 0.834 . . . . 0.0 110.038 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -60.1 -42.19 94.13 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.485 HD22 HD11 ' A' ' 11' ' ' LEU . 80.1 mt -62.54 -32.39 73.33 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.86 -9.24 54.12 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -76.34 -27.64 56.56 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.9 m-85 -102.11 6.64 40.99 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 95.7 m -80.95 105.2 12.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.842 -1.161 . . . . 0.0 109.154 179.567 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.431 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.4 t-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.633 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.9 OUTLIER -104.5 -91.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.751 . . . . 0.0 110.574 -178.767 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.633 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.0 m120 -99.95 25.82 6.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.283 -0.886 . . . . 0.0 109.742 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.483 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.72 159.14 15.13 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.308 -0.87 . . . . 0.0 109.494 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -93.36 134.46 35.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.616 -0.678 . . . . 0.0 110.283 -179.208 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -95.94 127.94 42.4 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.465 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.436 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.2 m -143.51 125.48 15.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.892 . . . . 0.0 109.263 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.11 -149.57 46.11 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -44.84 -30.21 0.94 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -1.032 . . . . 0.0 110.347 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.436 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.7 m-20 -49.12 -50.89 35.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.895 -1.128 . . . . 0.0 108.818 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.556 HD21 HD12 ' A' ' 38' ' ' ILE . 20.0 tp -55.16 -52.11 64.35 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.361 -0.837 . . . . 0.0 109.198 179.637 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 t -49.15 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 109.896 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 28.4 mt-10 -47.9 -25.75 1.44 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.447 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.57 -54.9 5.03 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.282 -0.887 . . . . 0.0 109.063 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.65 -34.35 37.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.335 -1.478 . . . . 0.0 108.595 179.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.422 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.5 t80 -50.23 -49.92 51.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.326 -0.859 . . . . 0.0 110.275 -179.494 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -67.91 -50.85 53.77 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.65 -1.281 . . . . 0.0 108.626 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.9 t -50.52 -58.68 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 CA-C-O 121.511 0.672 . . . . 0.0 109.854 -179.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -77.03 -23.12 52.13 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.483 -0.761 . . . . 0.0 109.997 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 47.7 -122.27 7.61 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -79.13 -15.3 58.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 0.0 110.275 -179.25 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.2 mtp180 -56.62 -28.35 60.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.123 -0.985 . . . . 0.0 109.491 -179.481 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.49 155.06 4.95 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.399 -1.881 . . . . 0.0 108.399 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -156.68 172.74 18.07 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.898 -1.354 . . . . 0.0 110.449 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 30.5 p90 -118.4 133.93 55.47 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -73.41 171.18 13.58 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -64.29 175.1 1.39 Allowed 'General case' 0 C--N 1.296 -1.756 0 O-C-N 120.961 -1.087 . . . . 0.0 109.698 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.51 151.87 0.45 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.423 -0.798 . . . . 0.0 110.121 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 N--CA 1.484 0.94 0 C-N-CA 122.004 1.803 . . . . 0.0 110.259 179.421 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 38' ' ' ILE . 16.6 mtm-85 . . . . . 0 N--CA 1.484 1.257 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.9 -23.98 0.08 OUTLIER Glycine 0 N--CA 1.49 2.286 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.556 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.4 -55.61 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.152 -1.204 . . . . 0.0 109.97 179.674 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.7 t -62.69 -64.15 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.087 -1.008 . . . . 0.0 112.069 -176.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -59.93 -39.59 86.0 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.727 -1.233 . . . . 0.0 110.719 -178.241 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -51.26 -56.71 11.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.877 -1.139 . . . . 0.0 109.477 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.9 m -85.46 -26.58 26.25 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.381 -0.824 . . . . 0.0 111.045 -179.21 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.3 t -84.07 -52.4 6.32 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.706 -1.246 . . . . 0.0 109.673 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.427 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.2 t60 -69.99 -26.97 64.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.114 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -136.78 160.58 38.42 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.484 -0.76 . . . . 0.0 109.107 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.9 mm -84.65 99.73 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -90.42 164.18 14.39 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.065 -1.022 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -96.82 166.77 11.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.36 -0.838 . . . . 0.0 109.007 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -57.68 -34.34 69.31 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -44.08 -57.85 3.16 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.86 0.838 . . . . 0.0 110.014 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -59.8 -42.57 93.73 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.2 mt -62.21 -32.08 72.7 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.91 -9.26 54.35 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -76.21 -28.04 57.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.788 -0.57 . . . . 0.0 109.649 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.2 m-85 -101.83 6.21 41.45 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.354 -0.841 . . . . 0.0 110.102 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.462 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -79.8 106.74 12.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.939 -1.101 . . . . 0.0 109.323 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.41 179.967 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.62 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.6 -91.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.404 -0.81 . . . . 0.0 110.626 -178.68 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.62 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -101.05 25.6 7.92 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 -179.239 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.479 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -96.0 158.54 15.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.36 -0.837 . . . . 0.0 109.635 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.1 p-80 -92.04 135.89 33.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.635 -0.665 . . . . 0.0 110.255 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -97.05 126.55 42.27 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.425 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.5 m -142.35 125.14 16.0 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.292 -0.88 . . . . 0.0 109.241 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.9 -148.74 45.18 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.354 -1.098 . . . . 0.0 110.354 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -44.67 -31.08 1.05 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.383 -1.069 . . . . 0.0 110.349 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.425 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.01 -50.66 34.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.946 -1.097 . . . . 0.0 108.841 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 38' ' ' ILE . 19.1 tp -55.53 -54.01 49.32 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.405 -0.809 . . . . 0.0 109.283 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.415 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.7 t -47.43 -66.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.012 -179.516 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 52.0 mt-10 -47.72 -26.92 1.73 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.343 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.81 -54.93 5.17 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.467 -0.771 . . . . 0.0 109.188 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.54 -34.06 34.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.394 -1.441 . . . . 0.0 108.603 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.46 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.7 t80 -50.48 -50.75 51.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.276 -179.612 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.3 -50.8 58.76 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.532 -1.355 . . . . 0.0 108.658 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.457 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.43 -59.01 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.569 0.7 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.72 -23.27 53.08 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.539 -0.725 . . . . 0.0 109.92 -178.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.02 -123.2 10.55 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.57 -15.12 58.24 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -1.114 . . . . 0.0 110.084 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -55.15 -28.81 55.52 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.15 -0.969 . . . . 0.0 109.337 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.47 154.66 4.72 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -156.57 172.9 17.74 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 120.901 -1.352 . . . . 0.0 110.434 -179.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.541 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.7 p90 -118.11 138.27 52.37 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -77.67 170.61 16.27 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 t -64.68 175.0 1.56 Allowed 'General case' 0 C--N 1.299 -1.617 0 O-C-N 120.998 -1.064 . . . . 0.0 110.111 -179.241 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -45.11 148.4 1.05 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.41 -0.806 . . . . 0.0 110.03 -178.678 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo . . . . . 0 N--CA 1.484 0.964 0 C-N-CA 122.121 1.881 . . . . 0.0 110.573 179.465 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.727 ' N ' ' HE ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.442 ' N ' ' HE ' ' A' ' 36' ' ' ARG . . . -56.23 -28.6 54.89 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.63 -55.98 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 O-C-N 120.929 -1.336 . . . . 0.0 110.704 -179.283 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.11 -64.24 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.911 -1.118 . . . . 0.0 111.421 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -54.46 -47.8 72.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.773 -1.204 . . . . 0.0 110.3 -178.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -47.13 -58.97 3.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.08 -1.013 . . . . 0.0 110.459 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.0 m -84.54 -25.56 28.65 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -0.946 . . . . 0.0 111.307 -178.736 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.96 -52.3 6.45 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.65 -1.281 . . . . 0.0 109.214 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.48 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.9 t-80 -67.44 -28.88 68.26 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.32 -0.863 . . . . 0.0 109.243 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -136.9 173.28 11.87 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.379 -0.826 . . . . 0.0 109.704 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 3.6 mm -92.56 99.66 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.6 p -91.75 151.68 20.51 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.063 -1.023 . . . . 0.0 109.632 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -84.97 166.34 16.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.233 -0.917 . . . . 0.0 109.223 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.2 -34.18 68.25 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.485 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -44.22 -57.42 3.46 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.914 0.864 . . . . 0.0 110.014 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.83 -42.67 94.08 Favored 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.0 mt -62.01 -32.39 72.87 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.046 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.6 -9.77 55.47 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -75.73 -27.85 58.31 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.781 -0.575 . . . . 0.0 109.584 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.9 m-85 -101.85 5.5 41.07 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.373 -0.829 . . . . 0.0 110.056 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.457 ' SG ' HG12 ' A' ' 18' ' ' VAL . 89.2 m -79.95 111.14 16.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.901 -1.124 . . . . 0.0 109.449 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.447 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -98.57 -91.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.369 -0.832 . . . . 0.0 110.803 -178.37 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -104.17 25.92 9.45 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.401 -0.812 . . . . 0.0 109.988 -179.086 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLN . . . . . 0.465 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.85 157.95 15.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.247 -0.908 . . . . 0.0 109.672 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 3.0 p-80 -91.25 133.52 35.33 Favored 'General case' 0 N--CA 1.489 1.494 0 CA-C-O 121.405 0.622 . . . . 0.0 110.134 -179.335 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.408 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -92.9 125.22 37.39 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.519 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.1 m -140.79 125.45 17.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.907 . . . . 0.0 109.264 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.46 -150.75 47.32 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.9 m -44.21 -29.36 0.63 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -1.058 . . . . 0.0 110.263 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.77 -50.49 33.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.982 -1.074 . . . . 0.0 108.859 179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.495 HD11 HD22 ' A' ' 52' ' ' LEU . 20.4 tp -55.94 -54.48 44.22 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.438 -0.789 . . . . 0.0 109.207 179.736 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.71 -66.17 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.358 -0.839 . . . . 0.0 109.901 -179.513 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 86.7 mt-10 -47.63 -27.98 2.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.177 -0.952 . . . . 0.0 109.291 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.74 -55.32 5.09 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 109.181 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.47 -34.07 33.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.311 -1.493 . . . . 0.0 108.649 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -50.44 -49.27 55.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 110.165 -179.662 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.76 -51.06 45.22 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.535 -1.353 . . . . 0.0 108.619 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.418 HG12 ' SG ' ' A' ' 56' ' ' CYS . 39.9 t -50.39 -58.56 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 121.523 0.678 . . . . 0.0 109.698 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.3 -23.81 54.35 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.485 -0.759 . . . . 0.0 109.693 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.33 -131.83 45.89 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.799 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -76.62 -11.25 59.83 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.37 -1.077 . . . . 0.0 110.121 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -57.84 -26.98 62.77 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.076 -1.015 . . . . 0.0 109.35 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.87 155.68 5.72 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 -179.255 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.74 173.0 17.62 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.921 -1.341 . . . . 0.0 110.227 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.551 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 37.5 p90 -115.26 137.25 52.24 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -78.13 171.01 15.67 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t -64.13 175.11 1.33 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.853 -1.154 . . . . 0.0 109.975 -179.088 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.42 147.71 0.58 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.521 -0.737 . . . . 0.0 110.3 -178.25 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo . . . . . 0 N--CA 1.484 0.946 0 C-N-CA 122.18 1.92 . . . . 0.0 110.493 179.503 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 . . . . . 0 N--CA 1.486 1.375 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.06 -24.41 73.81 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.41 -55.99 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.001 -1.293 . . . . 0.0 110.051 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.6 t -61.97 -64.38 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.01 -1.056 . . . . 0.0 111.32 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 51.2 mt-10 -55.24 -47.49 75.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.946 -1.096 . . . . 0.0 110.613 -178.725 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -47.3 -57.78 4.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.051 -1.03 . . . . 0.0 110.303 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.573 ' SG ' HD21 ' A' ' 52' ' ' LEU . 70.9 m -84.81 -26.0 27.76 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.203 -0.935 . . . . 0.0 111.177 -178.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.1 t -83.1 -52.27 6.78 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.746 -1.221 . . . . 0.0 109.42 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 11.8 t-80 -71.15 -26.08 62.84 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.357 -0.839 . . . . 0.0 109.39 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.94 157.85 45.81 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.443 -0.785 . . . . 0.0 109.625 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.2 mm -82.03 99.59 5.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.357 -0.839 . . . . 0.0 108.785 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.7 p -91.14 158.43 16.64 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.106 -0.996 . . . . 0.0 109.781 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.6 p -89.81 166.61 13.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.308 -0.87 . . . . 0.0 108.96 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.607 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -58.78 -33.27 70.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.54 -57.56 3.53 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 121.716 0.769 . . . . 0.0 110.238 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -61.06 -41.8 97.29 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 119.665 -0.814 . . . . 0.0 108.918 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.573 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.7 mt -61.28 -30.77 70.68 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.008 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.48 -9.72 58.64 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -75.99 -28.19 57.71 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.756 -0.59 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.426 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 9.9 m-85 -101.55 6.1 42.06 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.357 -0.839 . . . . 0.0 110.02 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 66.7 m -79.81 107.49 12.63 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.866 -1.147 . . . . 0.0 109.345 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 28.1 t-20 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.094 -0.955 . . . . 0.0 109.453 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.615 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.13 -91.6 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.45 -0.781 . . . . 0.0 110.608 -178.789 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.615 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.57 26.2 7.59 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.366 -0.834 . . . . 0.0 109.886 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.47 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -95.55 158.03 15.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.371 -0.831 . . . . 0.0 109.567 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.423 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.3 OUTLIER -91.57 132.0 36.61 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.66 -0.65 . . . . 0.0 110.587 -178.927 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -95.18 136.14 35.89 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.147 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.477 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -151.62 125.01 8.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.276 179.31 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.5 -146.65 40.91 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.1 m -46.85 -32.47 3.76 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.369 -1.077 . . . . 0.0 110.163 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.477 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 8.2 m-20 -48.88 -50.49 34.72 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.991 -1.068 . . . . 0.0 108.728 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -56.04 -54.44 44.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.473 -0.767 . . . . 0.0 109.519 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.53 -66.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.261 -0.9 . . . . 0.0 110.04 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.482 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 49.2 mt-10 -47.46 -28.61 2.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.208 -0.932 . . . . 0.0 109.388 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.16 -54.51 5.92 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.36 -0.838 . . . . 0.0 109.297 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.78 -35.28 43.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.367 -1.458 . . . . 0.0 108.581 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -49.31 -49.14 45.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.385 -0.822 . . . . 0.0 110.289 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.782 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.62 -50.96 47.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.558 -1.339 . . . . 0.0 108.592 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.0 t -50.65 -58.81 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-O 121.482 0.658 . . . . 0.0 109.847 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.31 -23.72 54.31 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.67 -125.99 27.67 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -78.75 -14.0 59.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.384 -1.068 . . . . 0.0 110.463 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 22.7 mtt180 -58.07 -26.88 63.09 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.973 -1.079 . . . . 0.0 109.647 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.56 155.99 5.61 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.63 173.01 17.58 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.324 . . . . 0.0 110.413 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.62 140.18 49.68 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -80.49 170.24 16.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.8 t -65.01 175.6 1.5 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.995 -1.066 . . . . 0.0 110.219 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.52 150.22 0.54 Allowed Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 121.497 -0.752 . . . . 0.0 110.115 -178.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -78.25 -6.32 15.58 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 122.252 1.968 . . . . 0.0 110.658 179.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 32' ' ' GLY . 41.7 p -53.77 -40.99 66.7 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.039 -1.038 . . . . 0.0 111.169 -177.248 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.42 -15.95 0.39 Allowed Glycine 0 N--CA 1.494 2.501 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.432 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.27 -21.21 23.14 Favored Glycine 0 N--CA 1.5 2.914 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.494 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.15 54.43 0.17 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.582 -1.807 . . . . 0.0 108.582 179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.517 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 Cg_endo -68.75 -174.14 0.68 Allowed 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.985 1.79 . . . . 0.0 110.102 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 27' ' ' THR . 46.7 ttt180 -56.23 86.92 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.1 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.517 ' N ' ' O ' ' A' ' 34' ' ' PRO . 0.8 OUTLIER -59.15 -2.48 0.27 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.091 -1.006 . . . . 0.0 108.525 179.914 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -71.53 -25.62 74.85 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.15 -56.38 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.212 0 O-C-N 121.056 -1.261 . . . . 0.0 110.45 -179.714 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.524 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.1 t -62.42 -64.18 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.94 -1.1 . . . . 0.0 111.4 -177.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.517 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.9 mt-10 -55.8 -46.36 78.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.873 -1.142 . . . . 0.0 110.355 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 62.1 tp60 -47.99 -56.65 7.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.074 -1.016 . . . . 0.0 110.101 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.71 -28.25 26.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 111.072 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 52.4 t -83.49 -52.24 6.67 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.733 -1.229 . . . . 0.0 109.231 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.517 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t-80 -70.46 -27.89 64.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.346 -0.846 . . . . 0.0 109.231 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.9 m -136.92 159.85 40.63 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.437 -0.79 . . . . 0.0 109.431 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 7.7 mm -82.8 99.7 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.307 -0.87 . . . . 0.0 109.088 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.9 p -91.15 150.83 21.22 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.094 -1.003 . . . . 0.0 109.32 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.5 167.45 14.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.232 -0.918 . . . . 0.0 109.112 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.77 -34.81 67.97 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.06 -57.53 3.32 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.867 0.841 . . . . 0.0 110.025 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -59.73 -42.48 93.24 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -62.02 -32.25 72.71 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -69.91 -9.54 55.34 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -75.86 -28.56 58.22 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.824 -0.548 . . . . 0.0 109.702 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.457 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.4 m-85 -102.13 6.89 41.09 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.372 -0.83 . . . . 0.0 109.948 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.0 m -80.29 111.18 16.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.023 -1.048 . . . . 0.0 109.282 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.8 t30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.955 -1.021 . . . . 0.0 109.437 179.97 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -101.61 -91.93 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.383 -0.823 . . . . 0.0 110.851 -178.566 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -101.21 26.03 7.56 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.403 -0.811 . . . . 0.0 109.807 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.46 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.94 160.84 14.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.384 -0.822 . . . . 0.0 109.483 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.449 ' HB3' HD13 ' A' ' 46' ' ' ILE . 4.4 p-80 -95.95 136.77 35.95 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.577 -0.702 . . . . 0.0 110.092 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -98.38 136.11 39.0 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.597 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -150.16 124.76 9.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.933 . . . . 0.0 109.236 179.003 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.71 -147.34 41.66 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.6 m -45.94 -32.59 2.79 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.393 -1.063 . . . . 0.0 110.197 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.68 -49.99 35.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.978 -1.077 . . . . 0.0 108.753 179.866 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 38' ' ' ILE . 22.6 tp -57.33 -51.79 67.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.411 -0.805 . . . . 0.0 109.484 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.8 t -49.08 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 110.065 -179.335 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 53.2 mt-10 -47.47 -28.45 2.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.406 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.08 -54.94 5.5 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.377 -0.827 . . . . 0.0 109.206 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.37 -35.63 39.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.402 -1.436 . . . . 0.0 108.772 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -49.35 -50.02 41.74 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.355 -0.841 . . . . 0.0 110.422 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.794 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.68 -50.7 56.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.612 -1.305 . . . . 0.0 108.595 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -51.25 -59.19 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.485 0.66 . . . . 0.0 110.318 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 22.8 m -76.59 -23.26 53.46 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.419 -0.801 . . . . 0.0 109.932 -178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.11 -129.58 27.77 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.352 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -73.43 -16.71 61.31 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.437 -1.037 . . . . 0.0 110.589 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 49.0 mtp180 -54.95 -28.54 52.03 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 109.426 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.8 156.31 6.06 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 107.799 -2.12 . . . . 0.0 107.799 -178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -156.27 172.68 18.05 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.835 -1.391 . . . . 0.0 110.44 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.554 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -116.57 127.24 54.32 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -67.58 172.14 5.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.611 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.2 t -62.6 174.39 1.02 Allowed 'General case' 0 C--N 1.295 -1.762 0 O-C-N 120.641 -1.287 . . . . 0.0 109.359 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.58 150.74 0.51 Allowed Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.341 -0.849 . . . . 0.0 110.409 -177.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -77.82 -7.09 16.41 Favored 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.111 1.874 . . . . 0.0 110.421 179.297 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.1 p -53.99 -40.86 67.3 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.128 -0.983 . . . . 0.0 111.136 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.74 -15.78 0.45 Allowed Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.382 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.504 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.74 -23.89 17.08 Favored Glycine 0 N--CA 1.499 2.862 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.501 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -170.56 55.68 0.19 Allowed Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.054 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.501 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 30.8 Cg_endo -72.29 -175.01 1.57 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 121.914 1.742 . . . . 0.0 110.178 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.611 ' N ' ' OG1' ' A' ' 27' ' ' THR . 6.0 ttt-85 -61.53 85.48 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 178.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.477 ' O ' ' N ' ' A' ' 38' ' ' ILE . 12.0 ptt180 -59.33 -28.39 66.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.052 -1.03 . . . . 0.0 108.225 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.86 -22.98 0.11 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.56 -54.27 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 O-C-N 120.978 -1.307 . . . . 0.0 109.787 179.924 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.18 -64.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.057 -1.027 . . . . 0.0 111.76 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -58.57 -41.35 85.49 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.768 -1.208 . . . . 0.0 110.884 -178.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.2 tp60 -50.58 -55.95 13.95 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.972 -1.08 . . . . 0.0 109.553 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.459 ' SG ' HD21 ' A' ' 52' ' ' LEU . 81.6 m -85.23 -26.55 26.63 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 111.222 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.1 t -83.94 -52.62 6.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.604 -1.31 . . . . 0.0 109.821 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.6 t60 -68.99 -29.41 67.61 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.248 -0.907 . . . . 0.0 109.175 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -137.14 157.89 45.68 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.55 -0.719 . . . . 0.0 109.572 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.449 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.3 mm -78.96 119.07 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.38 -0.825 . . . . 0.0 108.822 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.9 p -111.03 156.57 21.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.364 -0.835 . . . . 0.0 109.687 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 p -88.97 166.79 13.68 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.37 -0.831 . . . . 0.0 109.395 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.7 mt -59.65 -32.53 70.54 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.53 -57.68 3.45 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.802 0.81 . . . . 0.0 110.123 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -60.82 -42.46 97.74 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 119.799 -0.76 . . . . 0.0 108.959 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.488 HD22 HD11 ' A' ' 11' ' ' LEU . 77.6 mt -61.42 -26.03 67.6 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.17 -8.55 57.28 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -79.8 -26.34 40.6 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.848 -0.532 . . . . 0.0 109.926 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -100.0 6.1 45.11 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.266 -0.896 . . . . 0.0 110.448 -179.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.425 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 85.1 m -76.39 111.6 12.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.921 -1.112 . . . . 0.0 109.403 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 25.5 t-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.457 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -105.13 -91.88 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.508 -0.745 . . . . 0.0 110.678 -178.514 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -98.98 25.41 6.72 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.303 -0.873 . . . . 0.0 109.745 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.483 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.99 160.47 14.44 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 109.512 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HB3' HD13 ' A' ' 46' ' ' ILE . 2.2 p-80 -96.2 138.7 33.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.613 -0.68 . . . . 0.0 110.101 -179.225 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -100.94 134.09 44.44 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -149.43 124.86 10.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -0.947 . . . . 0.0 109.203 179.065 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.74 -148.48 43.38 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -45.07 -32.26 1.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.322 -1.105 . . . . 0.0 110.22 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.2 m-20 -48.79 -50.3 34.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.944 -1.098 . . . . 0.0 108.755 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -57.04 -54.65 44.35 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.482 -0.762 . . . . 0.0 109.579 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.5 t -46.58 -66.3 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.303 -0.873 . . . . 0.0 110.067 -179.249 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 65.6 mt-10 -47.81 -27.83 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.65 -54.47 5.85 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.319 -0.863 . . . . 0.0 109.14 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.61 -35.3 41.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.402 -1.437 . . . . 0.0 108.626 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.44 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.6 t80 -49.32 -49.6 43.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.306 -0.871 . . . . 0.0 110.37 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.0 mp -68.36 -50.88 50.04 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.533 -1.355 . . . . 0.0 108.607 179.358 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.0 t -50.54 -58.72 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 CA-C-O 121.511 0.672 . . . . 0.0 109.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.03 -23.69 55.16 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.497 -0.752 . . . . 0.0 109.749 -179.004 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 52.91 -131.08 40.66 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -75.69 -11.52 60.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.345 -1.091 . . . . 0.0 110.158 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.409 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -58.21 -27.76 64.2 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.092 -1.005 . . . . 0.0 109.488 -179.453 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.72 155.22 5.28 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -156.51 172.73 18.03 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.936 -1.332 . . . . 0.0 110.277 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.8 p90 -115.74 137.39 52.13 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -77.13 171.13 15.31 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.573 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.0 t -63.89 175.02 1.27 Allowed 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.798 -1.189 . . . . 0.0 109.9 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -43.14 148.39 0.61 Allowed Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.494 -0.754 . . . . 0.0 110.229 -178.23 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -78.39 -6.5 15.56 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.128 1.885 . . . . 0.0 110.409 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 32' ' ' GLY . 38.1 p -54.04 -40.92 67.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.028 -1.045 . . . . 0.0 110.98 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.82 -15.7 0.47 Allowed Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.691 -1.243 . . . . 0.0 110.332 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.504 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.79 -17.26 36.16 Favored Glycine 0 N--CA 1.499 2.837 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.91 55.02 0.12 Allowed Glycine 0 N--CA 1.485 1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.7 Cg_endo -68.86 -175.19 0.88 Allowed 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 121.898 1.732 . . . . 0.0 110.231 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.573 ' N ' ' OG1' ' A' ' 27' ' ' THR . 41.4 ttt180 -58.04 86.47 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 34' ' ' PRO . 6.9 ptm180 -59.75 -2.01 0.33 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.023 -1.048 . . . . 0.0 108.667 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.52 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -72.7 -24.27 76.42 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.9 -55.3 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.261 0 O-C-N 121.098 -1.236 . . . . 0.0 110.349 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -63.54 -64.27 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.024 -1.047 . . . . 0.0 111.278 -177.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 44' ' ' HIS . 30.2 mt-10 -55.01 -45.74 75.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.373 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -48.74 -57.63 6.02 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.099 -1.0 . . . . 0.0 110.304 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.503 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.88 -25.36 28.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.173 -0.955 . . . . 0.0 111.435 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 48.3 t -84.24 -52.34 6.31 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.535 -1.353 . . . . 0.0 109.537 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.421 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.9 t60 -68.91 -26.77 65.26 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.22 -0.925 . . . . 0.0 109.195 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 12.6 t -136.71 173.32 11.83 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.458 -0.776 . . . . 0.0 109.473 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.407 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.0 mm -94.65 99.6 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.3 p -91.53 152.49 20.29 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.126 -0.984 . . . . 0.0 109.72 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -86.67 166.7 15.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.326 -0.859 . . . . 0.0 109.32 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.8 mt -57.39 -34.91 69.35 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -43.97 -57.19 3.46 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.862 0.839 . . . . 0.0 109.978 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.71 -42.59 93.41 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.503 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.4 mt -61.89 -32.36 72.73 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.98 -9.61 55.76 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -75.88 -28.15 58.02 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.799 -0.563 . . . . 0.0 109.664 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 7.9 m-85 -102.86 6.99 39.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.407 -0.808 . . . . 0.0 109.95 -179.616 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 62.2 m -79.26 108.23 12.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.984 -1.072 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.474 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 1.6 t30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.548 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -101.92 -91.69 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -0.812 . . . . 0.0 110.607 -178.738 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.3 m120 -101.73 26.08 7.82 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.351 -0.843 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.457 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -95.59 160.16 14.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 109.708 -179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -92.05 134.61 34.67 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.53 0.681 . . . . 0.0 110.541 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.4 mp -98.53 130.69 45.1 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.07 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.12 125.06 10.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.107 179.377 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.63 -148.34 43.36 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -45.02 -32.64 1.75 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.394 -1.062 . . . . 0.0 110.321 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.87 -50.31 35.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.004 -1.06 . . . . 0.0 108.745 179.841 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.534 HD21 HD12 ' A' ' 38' ' ' ILE . 18.5 tp -57.13 -55.05 39.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.404 -0.81 . . . . 0.0 109.562 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -46.31 -66.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.313 -0.867 . . . . 0.0 109.945 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 34.4 mt-10 -47.69 -26.67 1.62 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 -179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.07 -54.31 5.65 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.365 -0.834 . . . . 0.0 109.082 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.71 -34.48 39.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.372 -1.455 . . . . 0.0 108.658 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.8 t80 -50.49 -49.59 55.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.301 -0.874 . . . . 0.0 110.336 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.797 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.26 -50.29 54.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.591 -1.318 . . . . 0.0 108.556 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.5 t -50.68 -59.38 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.522 0.677 . . . . 0.0 109.745 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.05 -23.64 55.1 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 -178.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.48 -123.78 20.2 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -80.28 -16.56 54.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.355 -1.085 . . . . 0.0 110.584 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 15.8 mtt180 -55.92 -27.12 50.78 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.053 -1.029 . . . . 0.0 109.52 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.5 6.05 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -156.57 172.96 17.64 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.895 -1.356 . . . . 0.0 110.357 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.547 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.0 p90 -116.77 135.81 53.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -76.18 170.91 15.4 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.576 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.1 t -64.29 174.73 1.52 Allowed 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.807 -1.183 . . . . 0.0 110.027 -179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.28 148.58 0.82 Allowed Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.43 -0.794 . . . . 0.0 109.998 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -78.17 -6.43 15.71 Favored 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.118 1.878 . . . . 0.0 110.425 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 32' ' ' GLY . 39.6 p -54.05 -40.94 67.56 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.111 -0.993 . . . . 0.0 111.176 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.85 -15.86 0.47 Allowed Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.328 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.502 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.1 -18.55 31.21 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -173.99 54.89 0.14 Allowed Glycine 0 N--CA 1.485 1.952 0 N-CA-C 108.416 -1.874 . . . . 0.0 108.416 179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.3 Cg_endo -70.17 -175.19 1.17 Allowed 'Trans proline' 0 C--N 1.318 -1.052 0 C-N-CA 121.855 1.703 . . . . 0.0 110.127 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.576 ' N ' ' OG1' ' A' ' 27' ' ' THR . 4.6 ttt-85 -57.9 86.67 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 34' ' ' PRO . 45.0 mtm180 -59.37 -6.24 0.96 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.984 -1.072 . . . . 0.0 108.169 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.487 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.72 -25.89 73.94 Favored Glycine 0 N--CA 1.487 2.056 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.534 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -101.89 -56.28 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 O-C-N 121.026 -1.279 . . . . 0.0 110.559 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -61.98 -64.41 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 120.906 -1.121 . . . . 0.0 111.574 -177.1 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' HIS . 76.1 mt-10 -56.09 -46.17 79.16 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.932 -1.105 . . . . 0.0 110.341 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -48.31 -56.55 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.11 -0.993 . . . . 0.0 110.298 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.572 ' SG ' HD21 ' A' ' 52' ' ' LEU . 62.4 m -84.79 -27.16 27.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.135 -0.978 . . . . 0.0 111.331 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.1 t -83.01 -52.23 6.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.72 -1.238 . . . . 0.0 109.163 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.464 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.7 t-80 -69.32 -27.5 65.43 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.178 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 m -137.01 159.95 40.37 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.424 -0.797 . . . . 0.0 109.594 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.8 mm -83.41 99.59 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.264 -0.897 . . . . 0.0 108.933 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.0 p -90.63 147.31 23.38 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.059 -1.026 . . . . 0.0 109.482 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -81.62 166.56 20.08 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.6 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.4 mt -56.41 -34.24 66.55 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -44.31 -57.42 3.51 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.924 0.869 . . . . 0.0 109.982 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -60.0 -42.29 93.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.572 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.4 mt -62.36 -32.34 73.12 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -69.74 -9.51 54.76 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -75.7 -28.34 58.57 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.753 -0.592 . . . . 0.0 109.613 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.3 m-85 -101.48 6.0 42.19 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.35 -0.844 . . . . 0.0 110.035 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -80.45 110.52 15.99 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.933 -1.104 . . . . 0.0 109.217 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.409 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 1.8 t30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -99.55 -91.51 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.432 -0.793 . . . . 0.0 110.582 -178.756 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.1 m120 -103.86 27.14 7.84 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.491 -0.756 . . . . 0.0 109.798 -179.219 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.469 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -94.95 161.22 14.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.456 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -92.94 134.73 34.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.619 -0.676 . . . . 0.0 110.593 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.413 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -98.99 131.0 45.37 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.289 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.481 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.35 125.15 11.89 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.165 -0.96 . . . . 0.0 109.301 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.17 -149.24 43.86 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.2 m -44.91 -31.86 1.41 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.255 -1.144 . . . . 0.0 110.226 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.481 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.19 -50.5 28.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.064 -1.023 . . . . 0.0 108.824 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.14 -55.21 37.72 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.474 -0.766 . . . . 0.0 109.501 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.12 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.273 -0.892 . . . . 0.0 110.033 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.5 mt-10 -47.57 -29.12 2.63 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.78 -54.59 5.92 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.291 -0.881 . . . . 0.0 109.209 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.27 -35.67 38.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.433 -1.417 . . . . 0.0 108.71 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -49.31 -49.41 44.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.873 . . . . 0.0 110.403 -179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.811 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -68.82 -50.55 49.08 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.589 -1.319 . . . . 0.0 108.581 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -51.03 -59.14 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.503 0.668 . . . . 0.0 110.13 -179.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.2 m -76.42 -23.69 53.99 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.507 -0.746 . . . . 0.0 109.743 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.57 -133.44 46.96 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -74.87 -13.05 60.51 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.423 -1.045 . . . . 0.0 110.196 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.404 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.11 -26.77 51.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.166 -0.959 . . . . 0.0 109.258 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 155.75 5.58 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 108.462 -1.855 . . . . 0.0 108.462 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -156.43 172.52 18.37 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.982 -1.305 . . . . 0.0 110.091 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.0 p90 -115.8 133.45 56.02 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -72.66 171.9 11.67 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.586 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 8.3 t -63.36 174.53 1.22 Allowed 'General case' 0 C--N 1.298 -1.666 0 O-C-N 120.768 -1.207 . . . . 0.0 109.722 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.06 0.93 Allowed Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.483 -0.761 . . . . 0.0 110.231 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -77.64 -6.32 16.08 Favored 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 122.032 1.821 . . . . 0.0 110.3 179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.505 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.0 p -53.91 -41.0 67.18 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.181 -0.949 . . . . 0.0 110.839 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.48 -15.78 0.41 Allowed Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.433 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.8 -14.32 46.92 Favored Glycine 0 N--CA 1.499 2.882 0 N-CA-C 109.043 -1.623 . . . . 0.0 109.043 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.477 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -177.99 55.95 0.1 OUTLIER Glycine 0 N--CA 1.484 1.848 0 N-CA-C 108.173 -1.971 . . . . 0.0 108.173 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.477 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 18.2 Cg_endo -69.52 -175.54 1.13 Allowed 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.742 1.628 . . . . 0.0 110.206 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.586 ' N ' ' OG1' ' A' ' 27' ' ' THR . 4.3 ttt-85 -59.68 86.45 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.44 ' N ' ' O ' ' A' ' 34' ' ' PRO . 12.6 ptt180 -60.16 -1.01 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.04 -1.038 . . . . 0.0 108.746 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -75.43 -22.88 74.81 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 121.014 -1.286 . . . . 0.0 110.252 -179.702 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.7 t -62.59 -64.27 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.044 -1.035 . . . . 0.0 111.249 -177.29 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.495 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.0 mt-10 -54.99 -48.78 72.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.014 -1.054 . . . . 0.0 110.431 -178.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 52.7 tp60 -46.32 -57.2 4.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.075 -1.016 . . . . 0.0 110.458 -179.228 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.518 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -84.75 -26.48 27.58 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 111.278 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.3 t -83.19 -51.33 7.58 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.677 -1.264 . . . . 0.0 109.25 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.517 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.3 t-80 -72.61 -26.61 61.75 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.353 -0.842 . . . . 0.0 109.621 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.92 158.83 43.57 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.311 -0.868 . . . . 0.0 109.838 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 10.4 mm -81.25 99.51 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.347 -0.846 . . . . 0.0 109.171 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -92.17 149.9 21.22 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.018 -1.051 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -83.84 166.46 17.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.25 -0.906 . . . . 0.0 109.336 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.2 mt -57.63 -33.61 68.45 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -43.72 -57.85 3.0 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.917 0.865 . . . . 0.0 109.979 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -59.95 -42.68 94.58 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.518 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.8 mt -61.72 -27.2 68.54 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.25 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -75.33 -8.54 56.94 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -79.51 -26.33 41.57 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.811 -0.555 . . . . 0.0 109.995 -179.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 13.8 m-85 -101.05 5.67 43.08 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.283 -0.886 . . . . 0.0 110.398 -179.257 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.3 m -79.29 111.39 15.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.928 -1.108 . . . . 0.0 109.631 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.568 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 . . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.38 -91.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.479 -0.763 . . . . 0.0 110.572 -178.68 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -101.45 25.94 7.81 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.382 -0.824 . . . . 0.0 109.879 -179.267 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.64 159.82 14.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.356 -0.84 . . . . 0.0 109.671 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -92.2 137.17 32.59 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.483 0.659 . . . . 0.0 110.568 -179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -100.83 131.12 46.87 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.475 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.03 125.02 11.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 179.308 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -147.7 41.99 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -45.99 -32.3 2.7 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.328 -1.101 . . . . 0.0 110.225 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.475 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.9 OUTLIER -48.43 -50.08 32.54 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.054 -1.029 . . . . 0.0 108.722 179.805 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.493 HD11 HD22 ' A' ' 52' ' ' LEU . 20.2 tp -57.21 -54.39 47.36 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.45 -0.781 . . . . 0.0 109.519 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.7 t -46.93 -66.32 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.284 -0.885 . . . . 0.0 109.951 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 41.4 mt-10 -48.03 -24.41 1.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.139 -0.976 . . . . 0.0 109.377 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -83.29 -54.43 5.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.339 -0.851 . . . . 0.0 109.035 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -52.23 -33.26 40.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.429 -1.42 . . . . 0.0 108.542 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -51.17 -49.85 60.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.344 -0.848 . . . . 0.0 110.2 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.783 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.23 -50.55 53.27 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.578 -1.326 . . . . 0.0 108.597 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.1 t -50.54 -58.79 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.504 0.669 . . . . 0.0 109.723 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.03 -23.27 52.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.582 -0.699 . . . . 0.0 109.893 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.19 -126.27 18.33 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -77.39 -14.96 59.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.313 -1.11 . . . . 0.0 110.282 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.8 mtp180 -55.31 -27.95 50.33 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.088 -1.007 . . . . 0.0 109.424 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.66 154.55 4.83 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.509 -1.836 . . . . 0.0 108.509 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.79 173.01 17.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.897 -1.355 . . . . 0.0 110.372 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.4 p90 -117.96 136.46 53.49 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -77.25 170.37 16.65 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.587 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.3 t -64.62 175.34 1.45 Allowed 'General case' 0 C--N 1.298 -1.654 0 O-C-N 120.973 -1.079 . . . . 0.0 110.016 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -44.33 148.55 0.84 Allowed Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 109.967 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -77.35 -6.1 16.14 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.118 1.879 . . . . 0.0 110.3 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.511 ' C ' ' H ' ' A' ' 32' ' ' GLY . 48.8 p -53.79 -41.17 66.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.149 -0.969 . . . . 0.0 111.084 -177.288 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.28 -16.14 0.36 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.525 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -97.26 -18.52 28.53 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.5 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -172.97 55.49 0.16 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.382 -1.887 . . . . 0.0 108.382 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.6 Cg_endo -70.86 -175.25 1.35 Allowed 'Trans proline' 0 C--N 1.318 -1.067 0 C-N-CA 121.841 1.694 . . . . 0.0 110.189 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.587 ' N ' ' OG1' ' A' ' 27' ' ' THR . 7.5 ttt-85 -56.67 86.3 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 34' ' ' PRO . 10.9 ptt180 -60.1 0.16 0.18 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.984 -1.072 . . . . 0.0 108.843 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.538 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -75.2 -24.41 71.36 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.76 -56.41 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 121.024 -1.28 . . . . 0.0 110.287 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.34 -64.41 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.028 -1.045 . . . . 0.0 111.352 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -55.52 -45.45 77.15 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.056 -1.028 . . . . 0.0 110.457 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.5 tt0 -49.6 -56.45 9.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.087 -1.008 . . . . 0.0 110.212 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.543 ' SG ' HD21 ' A' ' 52' ' ' LEU . 64.5 m -84.99 -26.12 27.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.18 -0.95 . . . . 0.0 111.339 -178.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.06 -51.33 7.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.723 -1.236 . . . . 0.0 109.295 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.494 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.5 t-80 -72.1 -25.67 61.84 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.283 -0.885 . . . . 0.0 109.376 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -136.81 157.78 45.97 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.363 -0.836 . . . . 0.0 109.623 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 8.6 mm -82.11 99.22 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.374 -0.829 . . . . 0.0 108.891 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.5 p -91.28 150.62 21.24 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.097 -1.002 . . . . 0.0 109.54 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -84.1 166.83 17.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.199 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -57.44 -33.6 68.11 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.42 -57.81 3.33 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.811 0.815 . . . . 0.0 110.081 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -60.13 -41.86 93.55 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.543 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.9 mt -61.98 -31.99 72.41 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.031 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 49' ' ' LEU . 0.6 OUTLIER -70.04 -9.57 55.78 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 179.289 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -75.68 -28.33 58.63 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.759 -0.588 . . . . 0.0 109.557 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.437 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 12.9 m-85 -100.99 5.1 43.0 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.33 -0.856 . . . . 0.0 110.151 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.44 ' SG ' HG12 ' A' ' 18' ' ' VAL . 96.8 m -80.15 109.6 14.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.92 -1.112 . . . . 0.0 109.086 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.419 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 23.3 t-20 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.084 -0.96 . . . . 0.0 109.391 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.575 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -94.7 -91.36 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.373 -0.829 . . . . 0.0 110.791 -178.495 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.575 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -105.65 25.73 10.42 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.408 -0.807 . . . . 0.0 110.028 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.91 158.07 15.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.278 -0.889 . . . . 0.0 109.625 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.436 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 12.5 p80 -90.68 137.01 32.69 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.696 -0.627 . . . . 0.0 110.217 -179.275 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -96.21 122.57 39.21 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.8 m -139.69 125.65 19.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.291 -0.881 . . . . 0.0 109.331 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.38 -149.81 46.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -44.54 -29.55 0.74 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.353 -1.086 . . . . 0.0 110.235 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 9.9 m-20 -49.18 -51.24 33.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.034 -1.041 . . . . 0.0 108.874 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.515 HD11 HD22 ' A' ' 52' ' ' LEU . 21.7 tp -55.8 -51.36 67.72 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.401 -0.812 . . . . 0.0 109.365 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -49.61 -66.22 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 0.0 109.714 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.481 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 38.8 mt-10 -47.49 -26.91 1.53 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.379 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.53 -55.49 4.82 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.407 -0.808 . . . . 0.0 109.148 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.1 mt -51.3 -33.64 29.79 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.268 -1.52 . . . . 0.0 108.737 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.436 ' O ' ' N ' ' A' ' 20' ' ' GLY . 54.8 t80 -50.94 -50.35 57.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 110.228 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.776 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.6 mp -67.66 -50.53 57.35 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.575 -1.328 . . . . 0.0 108.605 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.434 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.5 t -50.42 -58.95 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.514 0.673 . . . . 0.0 109.816 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.8 m -76.71 -23.38 53.12 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.541 -0.724 . . . . 0.0 109.867 -178.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 48.42 -123.31 9.8 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -79.07 -13.28 59.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.304 -1.115 . . . . 0.0 110.298 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -57.81 -27.67 63.35 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.085 -1.009 . . . . 0.0 109.561 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 154.73 4.75 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.68 172.85 17.86 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.773 -1.428 . . . . 0.0 110.484 -179.328 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.9 p90 -118.14 129.98 55.84 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.3 t80 -70.69 171.12 10.97 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.591 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.8 t -64.12 174.91 1.39 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 120.826 -1.171 . . . . 0.0 109.644 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -42.29 150.38 0.4 Allowed Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.449 -0.782 . . . . 0.0 110.339 -178.075 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -78.35 -6.78 15.77 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.068 1.845 . . . . 0.0 110.439 179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.482 ' C ' ' H ' ' A' ' 32' ' ' GLY . 37.7 p -54.09 -40.68 67.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.128 -0.982 . . . . 0.0 111.166 -177.438 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.09 -15.45 0.54 Allowed Glycine 0 N--CA 1.493 2.475 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.347 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -94.95 -25.8 13.94 Favored Glycine 0 N--CA 1.5 2.902 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.505 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -169.91 54.9 0.2 Allowed Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.505 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 24.9 Cg_endo -70.89 -174.95 1.25 Allowed 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.041 1.828 . . . . 0.0 110.369 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.591 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.9 ttt-85 -57.6 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.621 HH11 ' CG ' ' A' ' 36' ' ' ARG . 0.6 OUTLIER -58.32 -30.77 66.95 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.918 -1.114 . . . . 0.0 108.368 -179.65 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.96 -24.53 0.09 OUTLIER Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.5 -55.55 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 120.977 -1.308 . . . . 0.0 109.91 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.8 t -62.49 -64.26 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.052 -1.03 . . . . 0.0 112.1 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -59.38 -37.71 78.64 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.832 -1.168 . . . . 0.0 110.856 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -54.49 -56.26 20.57 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.819 -1.175 . . . . 0.0 109.409 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.618 ' SG ' HD21 ' A' ' 52' ' ' LEU . 67.2 m -85.78 -24.03 27.0 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.324 -0.86 . . . . 0.0 111.297 -179.161 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.9 -52.62 6.21 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.635 -1.291 . . . . 0.0 109.771 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.515 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.4 t-80 -69.77 -26.3 64.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.203 -0.936 . . . . 0.0 109.278 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.88 161.17 36.74 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.376 -0.828 . . . . 0.0 109.483 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.7 mm -84.59 99.79 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.4 p -90.99 153.96 19.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.065 -1.022 . . . . 0.0 109.726 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.19 167.95 15.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.312 -0.867 . . . . 0.0 109.056 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.1 mt -59.74 -33.34 71.53 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.919 0.866 . . . . 0.0 108.669 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -44.34 -57.74 3.34 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.777 0.798 . . . . 0.0 110.286 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -61.06 -41.73 97.18 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 119.773 -0.771 . . . . 0.0 108.964 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.618 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.56 -31.31 71.34 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.64 -9.64 57.49 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -75.64 -28.06 58.64 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.746 -0.596 . . . . 0.0 109.569 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.429 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.8 m-85 -101.22 5.64 42.66 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.333 -0.854 . . . . 0.0 110.072 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.434 ' SG ' HG12 ' A' ' 18' ' ' VAL . 90.0 m -80.35 109.47 14.86 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.916 -1.115 . . . . 0.0 109.27 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.452 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 2.1 t30 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.454 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.553 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.3 OUTLIER -98.32 -91.29 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.366 -0.834 . . . . 0.0 110.503 -178.827 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.553 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.1 m-20 -106.35 27.53 8.64 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.534 -0.729 . . . . 0.0 109.899 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.447 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -94.79 159.96 14.82 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.343 -0.848 . . . . 0.0 109.335 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 14.8 p-80 -90.65 131.46 36.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.616 -0.677 . . . . 0.0 110.693 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.411 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -94.01 127.28 39.71 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.021 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.435 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.2 m -142.68 125.51 16.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.233 -0.917 . . . . 0.0 109.343 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.33 -150.45 47.06 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.9 m -43.67 -29.92 0.56 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -1.032 . . . . 0.0 110.383 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 24.4 m-20 -50.01 -51.31 42.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.991 -1.068 . . . . 0.0 108.951 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -54.8 -53.52 54.15 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.313 -0.867 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 t -47.91 -66.07 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.356 -0.84 . . . . 0.0 109.963 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 45.3 mt-10 -47.82 -28.51 2.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.349 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.72 -54.89 5.63 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.352 -0.843 . . . . 0.0 109.123 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.0 mt -51.64 -35.29 41.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.35 -1.469 . . . . 0.0 108.661 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.8 t80 -49.32 -49.53 43.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 110.298 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.748 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -68.53 -51.27 44.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.67 -1.269 . . . . 0.0 108.609 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.448 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.33 -58.41 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 121.525 0.678 . . . . 0.0 109.59 -179.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -76.58 -23.53 53.51 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.558 -0.714 . . . . 0.0 109.98 -178.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.91 -122.07 10.79 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.3 mt-10 -80.47 -16.47 54.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.307 -1.113 . . . . 0.0 110.357 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.43 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -55.89 -28.16 55.34 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.551 -179.524 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 156.25 5.68 Favored Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -156.58 172.73 18.05 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.842 -1.387 . . . . 0.0 110.477 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.0 p90 -117.76 139.46 51.03 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -78.47 170.97 15.79 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.586 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.5 t -64.6 174.55 1.72 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.869 -1.144 . . . . 0.0 110.523 -178.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -46.36 148.53 1.59 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.586 -0.696 . . . . 0.0 110.098 -178.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.69 -6.23 15.97 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.347 2.031 . . . . 0.0 110.962 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 32' ' ' GLY . 53.2 p -53.17 -40.93 64.71 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.921 -1.112 . . . . 0.0 110.844 -177.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.32 -16.18 0.36 Allowed Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.594 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.49 -14.08 45.55 Favored Glycine 0 N--CA 1.499 2.899 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.481 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.84 55.87 0.1 OUTLIER Glycine 0 N--CA 1.483 1.803 0 N-CA-C 108.132 -1.987 . . . . 0.0 108.132 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.7 Cg_endo -69.48 -175.29 1.04 Allowed 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 121.694 1.596 . . . . 0.0 109.927 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.586 ' N ' ' OG1' ' A' ' 27' ' ' THR . 1.1 ttt-85 -56.68 86.02 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.723 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.529 ' N ' ' O ' ' A' ' 34' ' ' PRO . 0.0 OUTLIER -60.63 0.66 0.18 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.005 -1.059 . . . . 0.0 108.857 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.537 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -77.6 -23.82 66.58 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.537 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.95 -56.41 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.234 0 O-C-N 121.096 -1.238 . . . . 0.0 110.393 -179.716 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.04 -64.35 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.026 . . . . 0.0 111.436 -177.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -55.04 -48.55 73.29 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.856 -1.152 . . . . 0.0 110.411 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -45.93 -58.32 3.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.195 -0.94 . . . . 0.0 110.451 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.6 m -85.34 -27.02 26.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.154 -0.966 . . . . 0.0 111.511 -178.573 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 42.6 t -83.38 -52.32 6.64 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.733 -1.229 . . . . 0.0 109.598 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.438 ' N ' ' O ' ' A' ' 40' ' ' GLU . 64.1 t-80 -70.94 -26.59 63.25 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.88 161.84 34.89 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.324 -0.86 . . . . 0.0 109.676 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.8 mm -83.36 99.69 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.585 -0.697 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -92.4 160.12 15.24 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.05 -1.031 . . . . 0.0 109.741 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.07 167.31 11.87 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.91 -32.58 69.67 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.517 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.35 -57.24 3.63 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.702 0.763 . . . . 0.0 110.14 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -61.35 -42.37 98.59 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.924 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.08 -31.93 71.59 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.42 -9.6 56.81 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.937 -1.135 . . . . 0.0 107.937 179.332 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -77.0 -27.67 54.78 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.778 -0.576 . . . . 0.0 109.689 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.1 m-85 -102.29 6.23 40.37 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.402 -0.811 . . . . 0.0 109.957 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.448 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -78.41 103.3 8.26 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.994 -1.066 . . . . 0.0 109.403 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.4 t-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.456 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -104.39 -91.67 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.616 -178.695 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.619 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.4 m120 -100.02 25.8 7.04 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.349 -0.844 . . . . 0.0 109.777 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.528 ' CD ' ' H2 ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.93 160.05 14.66 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.384 -0.823 . . . . 0.0 109.522 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -94.88 136.29 35.36 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.57 -0.706 . . . . 0.0 110.178 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.405 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -97.51 130.17 44.61 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.639 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 72.8 m -143.92 125.18 14.62 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.306 -0.871 . . . . 0.0 109.255 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.18 -150.62 47.58 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.9 m -43.77 -30.5 0.66 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.418 -1.048 . . . . 0.0 110.322 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 4.6 m-20 -48.94 -50.51 35.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.967 -1.083 . . . . 0.0 108.856 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 18.9 tp -55.42 -54.86 38.48 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.359 -0.838 . . . . 0.0 109.235 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.75 -66.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.391 -0.818 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.48 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 35.2 mt-10 -47.87 -27.85 2.32 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.191 -0.943 . . . . 0.0 109.341 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.69 -54.57 5.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.336 -0.852 . . . . 0.0 109.164 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.64 -34.96 40.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.364 -1.46 . . . . 0.0 108.599 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.9 t80 -49.64 -49.48 47.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.359 -0.838 . . . . 0.0 110.389 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.789 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.55 -50.76 49.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.525 -1.36 . . . . 0.0 108.578 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.6 -58.87 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-O 121.506 0.67 . . . . 0.0 109.718 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.48 -23.56 53.81 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.486 -0.759 . . . . 0.0 109.819 -178.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 53.51 -130.17 41.71 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -76.83 -13.07 60.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -1.105 . . . . 0.0 110.114 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.415 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.3 OUTLIER -56.69 -27.62 59.24 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.107 -0.996 . . . . 0.0 109.368 -179.533 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 155.59 5.5 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -156.54 172.93 17.7 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.932 -1.334 . . . . 0.0 110.074 -179.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.3 p90 -116.02 138.65 51.02 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -78.87 171.28 15.41 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.578 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 8.8 t -64.33 174.95 1.45 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.927 -1.108 . . . . 0.0 110.338 -178.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.92 149.95 1.44 Allowed Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.497 -0.752 . . . . 0.0 110.301 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -78.54 -6.31 15.33 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.206 1.937 . . . . 0.0 110.508 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 32' ' ' GLY . 42.8 p -53.76 -41.04 66.71 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.094 -1.004 . . . . 0.0 111.129 -177.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.63 -15.86 0.43 Allowed Glycine 0 N--CA 1.493 2.474 0 C-N-CA 119.638 -1.268 . . . . 0.0 110.309 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.62 -17.02 34.69 Favored Glycine 0 N--CA 1.499 2.844 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.49 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.55 54.91 0.12 Allowed Glycine 0 N--CA 1.484 1.836 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.508 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.2 Cg_endo -69.51 -175.58 1.14 Allowed 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.782 1.655 . . . . 0.0 109.996 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.578 ' N ' ' OG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -57.34 85.86 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.654 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.508 ' N ' ' O ' ' A' ' 34' ' ' PRO . 17.6 mtm-85 -59.64 -6.81 1.26 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.921 -1.112 . . . . 0.0 108.195 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.479 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.93 -25.66 74.2 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.18 -56.01 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.327 0 O-C-N 121.035 -1.273 . . . . 0.0 110.645 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.526 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -62.39 -63.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.946 -1.096 . . . . 0.0 111.495 -177.06 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' HIS . 70.1 mt-10 -55.97 -47.81 76.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.84 -1.163 . . . . 0.0 110.285 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -46.41 -57.44 4.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.999 -1.063 . . . . 0.0 110.426 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.559 ' SG ' HD21 ' A' ' 52' ' ' LEU . 61.0 m -84.69 -27.95 26.7 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.124 -0.985 . . . . 0.0 111.083 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.3 t -83.49 -52.1 6.79 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.809 -1.182 . . . . 0.0 109.349 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' GLU . 16.0 t60 -69.77 -28.23 65.59 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.241 -0.912 . . . . 0.0 109.077 179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 m -137.04 160.73 38.08 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.403 -0.811 . . . . 0.0 109.505 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -83.13 99.94 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 p -91.45 152.05 20.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.012 -1.055 . . . . 0.0 109.563 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.92 167.42 14.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.307 -0.871 . . . . 0.0 109.121 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.95 -34.51 68.09 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.625 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -44.15 -56.97 3.68 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.816 0.817 . . . . 0.0 109.979 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -60.33 -42.64 96.08 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.559 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.9 mt -62.05 -32.6 73.13 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.55 -9.47 54.1 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -76.06 -28.03 57.47 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.79 -0.569 . . . . 0.0 109.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.6 m-85 -102.57 6.71 39.97 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.368 -0.832 . . . . 0.0 109.992 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.464 ' SG ' HG12 ' A' ' 18' ' ' VAL . 67.3 m -79.81 104.01 10.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 109.33 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.431 ' O ' ' O ' ' A' ' 56' ' ' CYS . 24.9 t-20 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.511 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.584 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -100.28 -91.42 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.437 -0.789 . . . . 0.0 110.425 -178.938 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.584 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.0 m120 -104.54 27.64 7.73 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.477 -0.764 . . . . 0.0 109.801 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 1.9 pt20 -94.54 159.79 14.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.26 -0.9 . . . . 0.0 109.523 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.0 OUTLIER -90.26 131.94 35.8 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.602 0.715 . . . . 0.0 110.866 -178.637 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.51 132.56 43.08 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.957 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.98 124.89 10.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.15 -0.969 . . . . 0.0 109.222 179.287 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.43 -147.43 42.28 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.8 m -44.9 -33.17 1.87 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.376 -1.073 . . . . 0.0 110.205 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -49.3 -49.85 41.94 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.003 -1.061 . . . . 0.0 108.815 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.548 HD21 HD12 ' A' ' 38' ' ' ILE . 19.0 tp -58.08 -57.02 14.67 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 21.0 t -45.07 -65.94 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.34 -0.85 . . . . 0.0 109.974 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.491 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.7 mt-10 -47.54 -30.44 3.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -77.62 -54.58 6.22 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 109.223 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -50.92 -36.53 38.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.522 -1.361 . . . . 0.0 108.665 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -48.84 -49.8 37.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.399 -0.813 . . . . 0.0 110.396 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.841 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.6 mp -68.26 -50.73 51.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.524 -1.36 . . . . 0.0 108.579 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -50.89 -59.33 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.456 0.646 . . . . 0.0 110.087 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -23.45 54.21 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.512 -0.743 . . . . 0.0 109.809 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.98 -129.03 30.97 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.204 -1.159 . . . . 0.0 110.204 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -76.49 -15.04 59.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -1.106 . . . . 0.0 110.182 -179.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.514 ' NH1' ' OE2' ' A' ' 53' ' ' GLU . 33.8 mtp180 -54.69 -27.61 41.64 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.032 -1.043 . . . . 0.0 109.087 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.13 5.23 Favored Glycine 0 N--CA 1.486 2.0 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 -179.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.39 172.33 18.69 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.889 -1.36 . . . . 0.0 110.214 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.3 p90 -117.53 135.07 54.19 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -73.18 171.65 12.58 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.568 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 6.8 t -63.36 174.71 1.16 Allowed 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.773 -1.204 . . . . 0.0 109.749 -178.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.22 146.33 0.68 Allowed Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.201 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -77.05 -6.91 17.03 Favored 'Trans proline' 0 N--CA 1.484 0.92 0 C-N-CA 122.081 1.854 . . . . 0.0 110.723 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 32' ' ' GLY . 33.6 p -54.25 -40.9 68.18 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.023 -1.048 . . . . 0.0 110.842 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.59 -15.83 0.43 Allowed Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.822 -1.18 . . . . 0.0 110.512 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.09 -13.87 47.68 Favored Glycine 0 N--CA 1.5 2.925 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.479 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -177.79 56.22 0.1 OUTLIER Glycine 0 N--CA 1.484 1.877 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.479 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 18.5 Cg_endo -70.0 -175.22 1.14 Allowed 'Trans proline' 0 C--N 1.32 -0.973 0 C-N-CA 121.815 1.677 . . . . 0.0 110.352 -178.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.568 ' N ' ' OG1' ' A' ' 27' ' ' THR . 46.6 ttt180 -60.49 86.93 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 34' ' ' PRO . 1.3 ppt_? -59.31 -2.98 0.35 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.851 -1.155 . . . . 0.0 108.757 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -70.66 -24.21 77.1 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.548 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.09 -55.12 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.23 0 O-C-N 121.056 -1.261 . . . . 0.0 110.393 -179.635 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.522 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.12 -64.34 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.013 -1.054 . . . . 0.0 111.559 -177.091 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 44' ' ' HIS . 73.0 mt-10 -56.55 -44.78 81.26 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.95 -1.094 . . . . 0.0 110.483 -178.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.5 tp60 -48.86 -56.94 7.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.065 -1.022 . . . . 0.0 110.06 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.511 ' SG ' HD21 ' A' ' 52' ' ' LEU . 56.6 m -84.83 -27.26 26.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.105 -0.997 . . . . 0.0 111.08 -178.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.9 t -83.46 -52.35 6.58 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.672 -1.267 . . . . 0.0 109.448 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 40' ' ' GLU . 2.1 t-160 -70.14 -28.85 65.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.327 -0.858 . . . . 0.0 108.84 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.3 p -136.61 162.38 33.29 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.334 -0.853 . . . . 0.0 109.542 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.2 mm -84.09 99.75 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.608 -0.682 . . . . 0.0 109.662 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.0 p -92.28 146.53 23.64 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.13 -0.981 . . . . 0.0 109.342 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.72 167.61 18.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.232 -0.918 . . . . 0.0 109.212 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.593 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.3 mt -57.08 -34.25 68.1 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -43.67 -57.25 3.28 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.874 0.845 . . . . 0.0 110.138 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -60.33 -41.87 94.44 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.511 HD21 ' SG ' ' A' ' 42' ' ' CYS . 78.2 mt -62.73 -28.27 69.85 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.514 ' OE2' ' NH1' ' A' ' 22' ' ' ARG . 1.8 tm-20 -74.26 -8.72 57.2 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.184 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -78.84 -26.96 44.16 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.875 -0.515 . . . . 0.0 109.946 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.421 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 14.5 m-85 -100.31 5.63 44.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.253 -0.905 . . . . 0.0 110.38 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 72.7 m -82.69 111.27 18.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.843 -1.161 . . . . 0.0 109.462 179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 57' ' ' ASN . 62.7 t-20 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.819 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.594 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -101.13 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 110.697 -178.658 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.594 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -102.97 26.58 7.99 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 109.807 -179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.466 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.52 161.88 13.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.331 -0.855 . . . . 0.0 109.443 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -94.27 136.5 34.49 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.639 0.733 . . . . 0.0 110.32 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 0.8 OUTLIER -99.64 131.89 45.34 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.461 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.8 125.31 11.7 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.192 -0.943 . . . . 0.0 109.186 179.334 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -149.14 44.34 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.8 m -44.96 -31.61 1.34 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.373 -1.075 . . . . 0.0 110.335 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.461 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -48.73 -50.04 35.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.966 -1.084 . . . . 0.0 108.761 179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -57.0 -54.57 45.24 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.458 -0.776 . . . . 0.0 109.534 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.66 -66.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 110.096 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 50.8 mt-10 -47.67 -27.63 2.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.387 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.08 -54.49 5.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.392 -0.818 . . . . 0.0 109.17 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.92 -34.81 43.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.398 -1.439 . . . . 0.0 108.585 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 20' ' ' GLY . 57.2 t80 -49.94 -50.04 47.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.327 -0.858 . . . . 0.0 110.231 -179.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -67.68 -50.81 55.78 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.573 -1.329 . . . . 0.0 108.64 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.3 t -50.62 -58.98 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.543 0.687 . . . . 0.0 109.759 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.23 -23.76 54.57 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.528 -0.732 . . . . 0.0 109.768 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.8 -127.2 30.91 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -78.98 -11.67 60.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.409 -1.054 . . . . 0.0 110.028 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.407 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -57.61 -27.18 62.52 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.162 -0.961 . . . . 0.0 109.287 -179.568 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 154.8 5.01 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.225 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -156.47 172.52 18.38 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.859 -1.377 . . . . 0.0 110.278 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.2 p90 -116.95 132.57 56.67 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -72.26 171.44 12.11 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.8 t -63.73 174.56 1.36 Allowed 'General case' 0 C--N 1.297 -1.69 0 O-C-N 120.706 -1.246 . . . . 0.0 109.669 -179.074 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.35 0.89 Allowed Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.398 -0.814 . . . . 0.0 110.078 -178.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -77.69 -6.25 15.99 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 C-N-CA 122.102 1.868 . . . . 0.0 110.429 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.2 p -53.95 -40.91 67.23 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.083 -1.011 . . . . 0.0 110.984 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.57 -15.95 0.42 Allowed Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.409 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.502 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.88 -15.26 43.18 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.478 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.21 55.53 0.1 Allowed Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.8 Cg_endo -69.96 -175.62 1.27 Allowed 'Trans proline' 0 C--N 1.319 -1.016 0 C-N-CA 121.857 1.705 . . . . 0.0 110.239 -179.108 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.583 ' N ' ' OG1' ' A' ' 27' ' ' THR . 2.9 ttt-85 -58.96 86.08 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.704 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.469 ' N ' ' O ' ' A' ' 34' ' ' PRO . 13.5 mtm-85 -59.57 -5.49 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.97 -1.082 . . . . 0.0 108.367 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -69.43 -24.13 76.22 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.91 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 O-C-N 121.006 -1.291 . . . . 0.0 110.437 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.4 t -62.02 -64.18 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.038 -1.038 . . . . 0.0 111.521 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.443 ' O ' ' N ' ' A' ' 44' ' ' HIS . 83.9 mt-10 -55.84 -46.3 78.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.908 -1.12 . . . . 0.0 110.485 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.9 tp60 -48.14 -56.5 7.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.059 -1.026 . . . . 0.0 110.299 -179.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.552 ' SG ' HD21 ' A' ' 52' ' ' LEU . 58.5 m -85.15 -26.36 26.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.143 -0.973 . . . . 0.0 111.271 -178.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.9 t -83.4 -52.4 6.56 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.608 -1.307 . . . . 0.0 109.418 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.443 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.1 t-80 -69.47 -26.68 64.69 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.874 . . . . 0.0 109.339 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -137.04 173.31 11.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.338 -0.851 . . . . 0.0 109.827 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -93.17 100.04 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.4 p -93.78 145.03 24.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.016 -1.053 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -80.53 166.53 21.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.882 . . . . 0.0 109.35 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -56.81 -34.36 67.62 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.45 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -44.03 -57.29 3.44 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.904 0.859 . . . . 0.0 109.943 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -59.89 -42.94 94.89 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.552 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.9 mt -61.83 -31.91 72.19 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.23 -9.68 56.58 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -75.83 -28.33 58.23 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.803 -0.561 . . . . 0.0 109.598 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 6.9 m-85 -102.72 7.01 39.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.406 -0.808 . . . . 0.0 109.984 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 60.5 m -78.58 108.6 12.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.96 -1.087 . . . . 0.0 109.409 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 39.7 t30 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.483 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 . . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.622 HG23 ' H ' ' A' ' 3' ' ' ASN . 1.1 m -102.73 -91.99 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.506 -0.746 . . . . 0.0 110.762 -178.542 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.622 ' H ' HG23 ' A' ' 2' ' ' VAL . 3.7 m120 -99.59 25.3 7.24 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.232 -0.917 . . . . 0.0 109.883 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.492 ' CD ' ' H2 ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.95 157.35 15.94 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.83 . . . . 0.0 109.635 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.421 ' HB3' HD13 ' A' ' 46' ' ' ILE . 3.5 p-80 -92.69 135.9 33.7 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.574 0.702 . . . . 0.0 109.957 -179.189 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.418 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -97.53 136.03 38.52 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.472 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -151.67 125.16 8.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.303 179.4 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -146.49 40.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.7 m -47.84 -31.83 5.45 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -1.086 . . . . 0.0 110.209 -179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.472 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.2 m-20 -49.03 -49.83 39.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.881 -1.137 . . . . 0.0 108.645 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 38' ' ' ILE . 19.6 tp -56.67 -55.09 38.49 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.415 -0.803 . . . . 0.0 109.401 179.674 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -46.41 -66.04 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.283 -0.886 . . . . 0.0 110.001 -179.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.1 mt-10 -47.51 -28.8 2.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.368 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.02 -54.61 5.84 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 109.173 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.4 mt -51.26 -34.93 34.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.509 -1.369 . . . . 0.0 108.667 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.6 t80 -49.96 -48.79 51.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 110.394 -179.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.82 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.55 -50.71 42.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.495 -1.378 . . . . 0.0 108.529 179.315 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -50.86 -59.09 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 121.512 0.673 . . . . 0.0 110.02 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.4 m -76.04 -23.98 55.15 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.441 -0.787 . . . . 0.0 109.699 -178.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.42 -133.55 46.34 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -75.5 -12.13 60.17 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.325 -1.103 . . . . 0.0 109.963 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -56.32 -26.93 54.03 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.002 -179.544 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.86 154.72 5.11 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.5 172.91 17.72 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.999 -1.295 . . . . 0.0 110.079 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.546 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.6 p90 -117.38 139.79 50.41 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.48 170.43 16.59 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.564 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.5 t -64.73 174.94 1.61 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.947 -1.095 . . . . 0.0 110.069 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.54 148.56 0.52 Allowed Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.651 -0.655 . . . . 0.0 110.135 -178.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.47 -6.32 16.21 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.255 1.97 . . . . 0.0 110.995 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.497 ' C ' ' H ' ' A' ' 32' ' ' GLY . 52.0 p -53.49 -40.79 65.65 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.995 -1.065 . . . . 0.0 111.0 -177.237 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.64 -15.68 0.44 Allowed Glycine 0 N--CA 1.495 2.57 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.647 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.497 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.05 -20.02 27.01 Favored Glycine 0 N--CA 1.5 2.935 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.502 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -173.4 54.69 0.15 Allowed Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.277 -1.929 . . . . 0.0 108.277 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.516 ' O ' ' N ' ' A' ' 36' ' ' ARG . 17.4 Cg_endo -67.81 -173.95 0.54 Allowed 'Trans proline' 0 C--N 1.319 -1.026 0 C-N-CA 121.915 1.743 . . . . 0.0 110.5 -179.071 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.564 ' N ' ' OG1' ' A' ' 27' ' ' THR . 38.8 ttt180 -56.24 87.1 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.045 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.516 ' N ' ' O ' ' A' ' 34' ' ' PRO . 2.1 ptp180 -58.99 -1.55 0.18 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.107 -0.995 . . . . 0.0 108.68 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.542 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -73.0 -25.74 72.9 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.39 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.31 0 O-C-N 121.057 -1.261 . . . . 0.0 110.385 -179.601 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 2.9 t -63.46 -63.91 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.962 -1.086 . . . . 0.0 111.461 -177.332 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.444 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.4 mt-10 -55.62 -46.18 77.43 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.864 -1.147 . . . . 0.0 110.43 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -48.39 -56.77 7.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 110.204 -179.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.494 ' SG ' HD21 ' A' ' 52' ' ' LEU . 73.0 m -85.1 -28.07 25.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 111.427 -178.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 53.9 t -83.29 -52.33 6.66 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.66 -1.275 . . . . 0.0 109.295 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.444 ' N ' ' O ' ' A' ' 40' ' ' GLU . 5.8 t60 -69.55 -27.04 64.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.066 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.7 m -137.17 157.4 46.76 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.496 -0.753 . . . . 0.0 109.49 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.421 HD13 ' HB3' ' A' ' 5' ' ' HIS . 5.8 mm -81.55 99.73 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.6 p -89.51 163.84 15.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.998 -1.064 . . . . 0.0 109.697 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -96.18 166.84 11.55 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.416 -0.802 . . . . 0.0 109.186 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.601 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.59 -33.29 69.82 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -44.76 -57.86 3.45 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.791 0.805 . . . . 0.0 110.236 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -61.07 -40.84 95.22 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.061 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.494 HD21 ' SG ' ' A' ' 42' ' ' CYS . 76.1 mt -62.41 -25.09 67.76 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.66 -9.03 58.75 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -78.96 -26.82 43.51 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.783 -0.573 . . . . 0.0 109.705 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 17.2 m-85 -99.73 4.39 45.43 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.348 -0.845 . . . . 0.0 110.339 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.406 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 71.0 m -82.84 111.22 18.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.883 -1.136 . . . . 0.0 109.367 179.639 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.438 ' OXT' ' ND2' ' A' ' 57' ' ' ASN . 1.2 t30 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.058 -0.972 . . . . 0.0 109.377 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.598 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -102.85 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.445 -0.784 . . . . 0.0 110.536 -178.856 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.598 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.5 26.77 6.91 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.393 -0.817 . . . . 0.0 109.892 -179.318 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.472 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.0 pt20 -95.23 160.79 14.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -92.87 134.77 34.75 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.514 0.673 . . . . 0.0 110.67 -178.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -99.49 132.56 44.74 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.262 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.47 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -148.49 125.1 11.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.094 -1.004 . . . . 0.0 109.332 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -148.52 43.26 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.3 m -45.11 -32.28 1.72 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.347 -1.09 . . . . 0.0 110.245 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.47 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.54 -50.52 31.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.991 -1.068 . . . . 0.0 108.823 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.08 -54.79 42.76 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.434 -0.791 . . . . 0.0 109.505 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -46.56 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.294 -0.879 . . . . 0.0 109.991 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 46.9 mt-10 -47.59 -29.31 2.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.923 . . . . 0.0 109.397 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.42 -54.58 6.02 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.375 -0.828 . . . . 0.0 109.363 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.12 -36.1 38.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.456 -1.402 . . . . 0.0 108.794 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -49.43 -49.0 46.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.341 -0.849 . . . . 0.0 110.482 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.816 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -69.02 -50.32 49.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.61 -1.306 . . . . 0.0 108.496 179.381 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -51.03 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.504 0.669 . . . . 0.0 110.113 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.3 m -75.52 -23.63 56.72 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.495 -0.753 . . . . 0.0 109.821 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.47 -126.76 25.09 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -77.45 -15.49 59.29 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.395 -1.062 . . . . 0.0 110.186 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -54.85 -27.9 45.81 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.174 -0.953 . . . . 0.0 109.409 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.79 154.88 5.13 Favored Glycine 0 N--CA 1.487 2.033 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.38 172.53 18.34 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.918 -1.342 . . . . 0.0 110.269 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -118.01 129.28 55.49 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -68.62 171.45 7.62 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 178.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.59 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.0 t -63.41 174.45 1.27 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 120.74 -1.225 . . . . 0.0 109.468 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.59 147.64 1.03 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.182 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -78.18 -6.29 15.62 Favored 'Trans proline' 0 N--CA 1.483 0.883 0 C-N-CA 122.098 1.865 . . . . 0.0 110.158 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.491 ' C ' ' H ' ' A' ' 32' ' ' GLY . 39.0 p -53.85 -40.95 66.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 110.99 -177.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.73 -15.74 0.45 Allowed Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.773 -1.203 . . . . 0.0 110.399 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.491 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.54 -16.2 40.68 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.476 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -176.74 55.53 0.11 Allowed Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.476 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 17.7 Cg_endo -69.39 -175.44 1.07 Allowed 'Trans proline' 0 C--N 1.318 -1.037 0 C-N-CA 121.774 1.65 . . . . 0.0 110.143 -179.004 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.59 ' N ' ' OG1' ' A' ' 27' ' ' THR . 33.7 ttt180 -59.84 86.19 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 178.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 34' ' ' PRO . 1.8 ptp180 -61.58 3.08 0.14 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.054 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -79.59 -21.84 65.74 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.28 -55.53 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 O-C-N 121.024 -1.28 . . . . 0.0 110.052 -179.714 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -62.2 -63.84 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.023 -1.048 . . . . 0.0 111.094 -177.526 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.456 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.9 mt-10 -54.74 -48.49 72.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.989 -1.069 . . . . 0.0 110.557 -178.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -47.22 -56.58 6.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.069 -1.019 . . . . 0.0 110.493 -179.149 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.526 ' SG ' HD21 ' A' ' 52' ' ' LEU . 57.1 m -84.66 -26.51 27.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.228 -0.92 . . . . 0.0 111.363 -178.588 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.3 t -83.77 -52.39 6.44 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.642 -1.286 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.4 t-80 -68.96 -27.29 65.6 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.235 -0.916 . . . . 0.0 109.23 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.436 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.6 t -137.23 173.17 11.97 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.416 -0.803 . . . . 0.0 109.88 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 9.7 mm -92.3 99.85 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.561 -0.712 . . . . 0.0 109.315 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.8 p -93.0 143.3 26.37 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.014 -1.054 . . . . 0.0 109.39 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -79.39 166.45 22.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.447 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.0 mt -56.36 -34.11 66.33 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.06 -57.49 3.35 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 121.87 0.843 . . . . 0.0 109.971 179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -60.06 -42.15 93.9 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.526 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.8 mt -62.79 -29.05 70.41 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.127 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.11 -8.9 57.81 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -78.43 -26.89 46.41 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.853 -0.529 . . . . 0.0 109.864 -179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.422 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 15.3 m-85 -100.75 5.24 43.57 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.265 -0.897 . . . . 0.0 110.227 -179.281 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 71.6 m -83.35 111.48 19.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.97 -1.081 . . . . 0.0 109.49 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 52.6 t30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.441 179.959 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.998 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.59 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -101.99 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.421 -0.799 . . . . 0.0 110.678 -178.616 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.59 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -102.02 25.57 8.59 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.429 -0.794 . . . . 0.0 109.991 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.449 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.97 160.18 14.59 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.548 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 9.8 p80 -92.95 136.19 33.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.514 -0.741 . . . . 0.0 110.552 -178.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.35 127.06 42.99 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.304 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 82.2 m -142.89 125.29 15.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.296 -0.878 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.17 -149.31 45.61 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.5 m -44.92 -30.84 1.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.421 -1.047 . . . . 0.0 110.284 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.437 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 17.3 m-20 -48.7 -50.61 32.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.927 -1.108 . . . . 0.0 108.787 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.492 HD11 HD22 ' A' ' 52' ' ' LEU . 19.9 tp -55.42 -53.99 49.29 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -47.04 -66.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.837 . . . . 0.0 109.899 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 72.5 mt-10 -47.79 -26.77 1.74 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.371 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.998 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.02 -54.73 5.3 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.384 -0.823 . . . . 0.0 109.131 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.84 -34.28 39.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.406 -1.434 . . . . 0.0 108.581 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.6 t80 -50.16 -49.85 50.88 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.366 -0.834 . . . . 0.0 110.179 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.78 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.27 -50.76 51.59 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.584 -1.323 . . . . 0.0 108.681 179.407 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.6 t -50.52 -58.64 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.5 0.667 . . . . 0.0 109.757 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -77.0 -23.34 52.23 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 -178.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 46.95 -120.78 5.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.673 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -80.22 -13.7 59.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.299 -1.118 . . . . 0.0 110.15 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -57.95 -28.27 64.17 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.112 -0.992 . . . . 0.0 109.528 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.59 154.19 4.57 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -156.87 172.95 17.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.886 -1.361 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.8 p90 -119.15 139.51 51.68 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -80.52 169.82 17.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.931 -1.106 . . . . 0.0 108.143 179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.579 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.2 t -65.59 175.71 1.74 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.117 -0.989 . . . . 0.0 110.404 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -45.22 149.87 0.88 Allowed Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.459 -0.776 . . . . 0.0 109.895 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -78.4 -6.13 15.35 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.178 1.919 . . . . 0.0 110.581 179.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.512 ' C ' ' H ' ' A' ' 32' ' ' GLY . 42.5 p -53.67 -40.97 66.38 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.125 -0.985 . . . . 0.0 111.231 -177.155 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.57 -15.92 0.42 Allowed Glycine 0 N--CA 1.494 2.531 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.352 179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.52 -20.14 25.58 Favored Glycine 0 N--CA 1.499 2.852 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.508 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.82 54.3 0.16 Allowed Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.656 -1.778 . . . . 0.0 108.656 179.11 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.528 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.6 Cg_endo -69.17 -174.46 0.79 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 121.969 1.779 . . . . 0.0 110.075 -179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.579 ' N ' ' OG1' ' A' ' 27' ' ' THR . 2.8 ttt-85 -56.34 86.52 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' N ' ' O ' ' A' ' 34' ' ' PRO . 7.0 ptm180 -59.61 -1.73 0.28 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.049 -1.032 . . . . 0.0 108.722 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -72.92 -25.73 73.02 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.08 -56.33 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.061 -1.258 . . . . 0.0 110.46 -179.67 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -62.27 -64.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 120.961 -1.087 . . . . 0.0 111.637 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 44' ' ' HIS . 62.4 mt-10 -55.79 -46.79 77.9 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.85 -1.157 . . . . 0.0 110.331 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 -47.67 -57.49 5.45 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.086 -1.009 . . . . 0.0 110.167 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.598 ' SG ' HD21 ' A' ' 52' ' ' LEU . 63.1 m -84.77 -26.7 27.39 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.137 -0.977 . . . . 0.0 111.101 -178.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.0 t -83.25 -52.3 6.7 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.826 -1.171 . . . . 0.0 109.481 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.502 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.1 t-80 -71.24 -26.46 62.92 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.231 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.2 m -136.83 157.91 45.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.39 -0.819 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -82.27 99.73 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.242 -0.911 . . . . 0.0 109.013 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.7 p -90.75 151.62 21.14 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.137 -0.977 . . . . 0.0 109.375 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -85.08 166.49 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.02 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -56.54 -34.04 66.67 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -44.44 -57.5 3.52 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.855 0.835 . . . . 0.0 110.023 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -60.07 -42.35 94.37 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.598 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.9 mt -62.29 -31.8 72.44 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.13 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.89 -9.46 54.96 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -75.54 -28.37 59.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.799 -0.563 . . . . 0.0 109.712 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.1 m-85 -102.03 6.32 41.03 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.333 -0.854 . . . . 0.0 110.018 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 73.4 m -80.4 109.0 14.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.93 -1.106 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.417 ' OXT' ' OD1' ' A' ' 57' ' ' ASN . 53.7 t-20 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.514 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -104.04 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.407 -0.808 . . . . 0.0 110.726 -178.661 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -101.66 25.85 8.04 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.409 -0.807 . . . . 0.0 109.936 -179.06 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.447 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.88 160.2 14.59 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.321 -0.862 . . . . 0.0 109.85 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' A' ' 5' ' ' HIS . 0.1 OUTLIER -92.76 132.09 37.26 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.643 -0.661 . . . . 0.0 110.441 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -95.4 132.8 40.06 Favored 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.027 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.486 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -149.12 125.24 10.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.033 -1.042 . . . . 0.0 109.327 179.244 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.88 -147.4 41.49 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -45.89 -32.07 2.47 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.362 -1.081 . . . . 0.0 110.194 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.486 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.0 m-20 -49.27 -51.06 36.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.092 . . . . 0.0 108.762 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.512 HD21 HD12 ' A' ' 38' ' ' ILE . 21.3 tp -56.1 -51.64 67.16 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.4 -0.812 . . . . 0.0 109.391 179.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 t -49.44 -66.28 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.219 -0.926 . . . . 0.0 109.968 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.4 mt-10 -47.56 -26.42 1.44 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.412 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.03 -54.64 5.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.323 -0.861 . . . . 0.0 109.058 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.85 -33.94 38.4 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.412 -1.43 . . . . 0.0 108.635 179.452 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.2 t80 -50.58 -50.06 54.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.926 . . . . 0.0 110.236 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.78 -50.82 54.95 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.534 -1.354 . . . . 0.0 108.547 179.387 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.435 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.4 t -50.7 -59.01 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 CA-C-O 121.527 0.68 . . . . 0.0 109.668 -179.441 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -75.87 -23.54 55.63 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.48 -0.763 . . . . 0.0 109.819 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.02 -130.64 44.05 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -77.1 -14.44 59.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -1.094 . . . . 0.0 110.087 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.408 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.3 OUTLIER -54.88 -27.8 45.53 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.149 -0.969 . . . . 0.0 109.327 -179.628 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.76 156.39 6.07 Favored Glycine 0 N--CA 1.485 1.964 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.41 172.93 17.65 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.022 -1.281 . . . . 0.0 110.243 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.9 p90 -115.73 132.84 56.52 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -73.23 171.75 12.42 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.614 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.2 t -63.55 173.93 1.5 Allowed 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 118.578 -1.249 . . . . 0.0 109.302 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -44.41 148.82 0.81 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.199 -0.938 . . . . 0.0 110.139 -178.088 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -78.07 -6.54 15.87 Favored 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.086 1.857 . . . . 0.0 110.682 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.501 ' C ' ' H ' ' A' ' 32' ' ' GLY . 44.3 p -54.18 -40.86 67.93 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.949 -1.094 . . . . 0.0 111.186 -177.319 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.88 -15.76 0.48 Allowed Glycine 0 N--CA 1.493 2.439 0 C-N-CA 119.703 -1.237 . . . . 0.0 110.231 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.91 -15.93 37.66 Favored Glycine 0 N--CA 1.5 2.919 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.496 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -175.85 55.29 0.12 Allowed Glycine 0 N--CA 1.484 1.892 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.539 ' O ' ' N ' ' A' ' 36' ' ' ARG . 22.4 Cg_endo -71.14 -175.46 1.5 Allowed 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 121.833 1.688 . . . . 0.0 109.866 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.614 ' N ' ' OG1' ' A' ' 27' ' ' THR . 8.3 ttt-85 -57.05 86.26 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.539 ' N ' ' O ' ' A' ' 34' ' ' PRO . 6.8 ptm180 -62.25 6.31 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.138 -0.976 . . . . 0.0 109.181 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.571 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -85.02 -21.86 54.2 Favored Glycine 0 N--CA 1.491 2.36 0 O-C-N 121.133 -0.98 . . . . 0.0 110.911 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -100.31 -54.24 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 120.879 -1.366 . . . . 0.0 110.457 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.525 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -61.42 -63.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 111.704 -177.116 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -58.52 -38.15 77.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 111.079 -178.101 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -55.6 -53.68 53.43 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.833 -1.167 . . . . 0.0 109.195 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.63 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -85.76 -26.73 25.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 110.769 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.8 t -83.86 -52.5 6.32 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.701 -1.249 . . . . 0.0 109.541 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.412 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.6 t60 -71.39 -26.41 62.77 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.207 -0.933 . . . . 0.0 109.174 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.7 m -137.06 160.28 39.4 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.363 -0.835 . . . . 0.0 109.645 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.2 mm -83.21 100.28 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.49 -0.756 . . . . 0.0 109.221 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -93.0 147.75 22.57 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.105 -0.997 . . . . 0.0 109.683 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.7 167.76 17.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -58.4 -34.04 70.3 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -44.1 -57.12 3.57 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 121.797 0.808 . . . . 0.0 110.154 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -61.59 -41.63 97.7 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.63 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.0 mt -61.84 -31.69 71.97 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.48 -9.79 57.47 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -75.5 -28.31 59.13 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.816 -0.552 . . . . 0.0 109.571 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.438 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.5 m-85 -101.83 7.04 41.81 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.399 -0.813 . . . . 0.0 110.017 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.435 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -80.43 106.39 12.41 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.897 -1.127 . . . . 0.0 109.398 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.65 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.994 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.601 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.0 -91.83 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.476 -0.765 . . . . 0.0 110.34 -179.082 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.601 ' H ' HG23 ' A' ' 2' ' ' VAL . 24.6 p-10 -101.94 27.4 6.57 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.465 -0.772 . . . . 0.0 110.074 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.478 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 1.9 pt20 -95.28 157.66 15.8 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.232 -0.917 . . . . 0.0 109.166 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -90.2 132.05 35.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.582 -0.699 . . . . 0.0 110.718 -178.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -95.1 130.5 41.78 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.184 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.424 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.5 m -143.5 125.27 15.07 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.24 -0.913 . . . . 0.0 109.388 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.16 -150.04 46.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -44.66 -30.34 0.91 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.412 -1.052 . . . . 0.0 110.284 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.424 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.67 -50.14 34.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.953 -1.092 . . . . 0.0 108.791 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.51 HD21 HD12 ' A' ' 38' ' ' ILE . 20.3 tp -55.76 -55.71 29.18 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.451 -0.781 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 19.3 t -45.8 -65.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.385 -0.822 . . . . 0.0 109.946 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 84.8 mt-10 -47.73 -29.68 3.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.436 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.994 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.31 -54.45 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.84 . . . . 0.0 109.239 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -51.34 -35.88 40.32 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.496 -1.378 . . . . 0.0 108.712 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.6 t80 -49.4 -48.84 46.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.414 -0.804 . . . . 0.0 110.461 -179.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.832 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.38 -50.45 46.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.488 -1.383 . . . . 0.0 108.539 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -50.84 -59.23 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 CA-C-O 121.558 0.694 . . . . 0.0 110.23 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -24.04 54.23 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.402 -0.811 . . . . 0.0 109.804 -178.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.37 -126.19 23.2 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -77.32 -14.54 59.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -1.077 . . . . 0.0 110.28 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.406 ' HB3' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.52 -27.6 57.8 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.36 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.53 154.51 4.69 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -156.52 172.6 18.27 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.923 -1.34 . . . . 0.0 110.418 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.3 p90 -118.29 138.75 52.17 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -77.45 170.83 15.87 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.6 t -64.3 175.29 1.35 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.869 -1.144 . . . . 0.0 109.807 -179.276 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.15 148.03 0.52 Allowed Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.492 -0.755 . . . . 0.0 110.295 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -77.36 -6.52 16.45 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.091 1.861 . . . . 0.0 110.462 179.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.516 ' C ' ' H ' ' A' ' 32' ' ' GLY . 40.2 p -54.02 -41.16 67.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.095 -1.003 . . . . 0.0 111.096 -177.357 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.53 -15.89 0.41 Allowed Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.655 -1.259 . . . . 0.0 110.311 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.516 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.35 -19.05 31.36 Favored Glycine 0 N--CA 1.499 2.839 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.55 54.95 0.13 Allowed Glycine 0 N--CA 1.484 1.899 0 N-CA-C 108.449 -1.86 . . . . 0.0 108.449 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.491 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.3 Cg_endo -68.82 -174.71 0.77 Allowed 'Trans proline' 0 C--N 1.319 -0.993 0 C-N-CA 121.868 1.712 . . . . 0.0 110.416 -179.107 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.544 ' N ' ' OG1' ' A' ' 27' ' ' THR . 41.2 ttt180 -57.46 87.93 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.585 HH11 ' CG ' ' A' ' 36' ' ' ARG . 1.4 mtt-85 -59.1 -5.88 0.76 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.967 -1.083 . . . . 0.0 108.384 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.85 -25.99 74.02 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.52 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.21 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.315 0 O-C-N 121.002 -1.293 . . . . 0.0 110.436 -179.502 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.52 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.25 -64.52 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.133 . . . . 0.0 111.564 -177.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' HIS . 35.4 mt-10 -55.94 -45.74 78.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.854 -1.154 . . . . 0.0 110.295 -178.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 -47.48 -57.87 4.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.084 -1.01 . . . . 0.0 110.15 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.568 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.1 m -84.83 -27.0 27.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.156 -0.965 . . . . 0.0 111.02 -178.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.8 t -83.32 -51.44 7.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.845 -1.16 . . . . 0.0 109.429 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.519 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.0 t60 -73.47 -26.16 60.79 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.339 -0.851 . . . . 0.0 109.48 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -136.86 157.69 46.18 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.4 -0.813 . . . . 0.0 109.876 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.5 mm -79.95 99.56 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.461 -0.774 . . . . 0.0 109.229 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.6 p -92.57 154.9 18.14 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.056 -1.027 . . . . 0.0 109.637 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -88.85 166.5 13.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.296 -0.878 . . . . 0.0 108.988 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.7 mt -58.4 -32.78 68.94 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.39 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.28 -57.31 3.55 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.804 0.811 . . . . 0.0 110.159 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -61.68 -42.04 98.38 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.71 -0.796 . . . . 0.0 108.998 -179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.568 HD21 ' SG ' ' A' ' 42' ' ' CYS . 74.6 mt -61.29 -24.93 66.76 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.71 -8.74 58.39 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -79.67 -26.78 40.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.794 -0.566 . . . . 0.0 109.849 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 16.3 m-85 -99.06 4.62 47.12 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.282 -0.886 . . . . 0.0 110.31 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 70.9 m -81.26 111.34 17.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.939 -1.101 . . . . 0.0 109.496 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.64 179.993 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -99.77 -91.57 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.353 -0.842 . . . . 0.0 110.197 -179.124 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.3 p-10 -104.33 28.22 7.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.671 -0.643 . . . . 0.0 109.431 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.458 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 1.9 pt20 -94.75 157.41 15.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.163 -0.96 . . . . 0.0 109.123 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.6 p-80 -89.0 131.73 35.05 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.526 0.679 . . . . 0.0 110.713 -178.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.1 mp -97.16 132.44 42.94 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.483 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.24 125.36 10.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.189 -0.944 . . . . 0.0 109.278 179.286 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.72 -146.51 40.31 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.7 m -46.75 -32.5 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.365 -1.079 . . . . 0.0 110.155 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.483 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.0 -50.44 35.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.965 -1.084 . . . . 0.0 108.783 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.526 HD21 HD12 ' A' ' 38' ' ' ILE . 18.1 tp -56.9 -55.73 30.71 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.394 -0.816 . . . . 0.0 109.529 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 12' ' ' VAL . 15.6 t -46.13 -66.15 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.342 -0.849 . . . . 0.0 110.085 -179.41 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 75.8 mt-10 -47.94 -26.75 1.85 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.197 -0.939 . . . . 0.0 109.298 -179.644 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.08 -54.21 5.74 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.333 -0.854 . . . . 0.0 109.088 179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.87 -34.77 42.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.361 -1.462 . . . . 0.0 108.536 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 20' ' ' GLY . 58.0 t80 -49.82 -49.59 48.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.374 -0.828 . . . . 0.0 110.358 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.777 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.58 -50.66 49.99 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.584 -1.322 . . . . 0.0 108.598 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.428 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.67 -58.88 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.49 0.662 . . . . 0.0 109.703 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -76.51 -23.48 53.72 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.526 -0.734 . . . . 0.0 109.9 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.94 -127.08 31.16 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.12 -14.96 59.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.402 -1.057 . . . . 0.0 110.101 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.1 mtp180 -54.95 -28.99 55.61 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.098 -1.001 . . . . 0.0 109.171 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.91 5.73 Favored Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.5 172.72 18.05 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.907 -1.349 . . . . 0.0 110.174 -179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.09 137.65 51.94 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -75.96 171.95 13.56 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.571 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.0 t -63.13 174.37 1.17 Allowed 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.762 -1.211 . . . . 0.0 109.812 -178.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.45 147.37 1.03 Allowed Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.369 -0.832 . . . . 0.0 110.096 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -77.5 -6.48 16.3 Favored 'Trans proline' 0 N--CA 1.484 0.915 0 C-N-CA 122.107 1.871 . . . . 0.0 110.315 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.2 p -54.1 -41.06 67.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.104 -0.998 . . . . 0.0 110.904 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.25 -15.88 0.37 Allowed Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.389 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.35 -14.22 45.5 Favored Glycine 0 N--CA 1.498 2.808 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.52 ' O ' ' NH2' ' A' ' 36' ' ' ARG . . . -177.73 56.33 0.1 OUTLIER Glycine 0 N--CA 1.484 1.839 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.478 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 20.6 Cg_endo -70.7 -175.08 1.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 121.793 1.662 . . . . 0.0 109.886 -179.176 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.571 ' N ' ' OG1' ' A' ' 27' ' ' THR . 43.8 ttt180 -63.4 87.93 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.607 ' CD ' ' H ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER -58.63 -13.91 6.98 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.78 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.404 ' N ' ' C ' ' A' ' 35' ' ' ARG . . . -57.85 -26.66 58.19 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.437 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.93 -55.8 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.335 0 O-C-N 120.895 -1.356 . . . . 0.0 110.566 -179.461 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.8 t -63.26 -64.39 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.905 -1.122 . . . . 0.0 111.295 -177.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 44' ' ' HIS . 80.9 mt-10 -54.47 -47.54 72.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.89 -1.131 . . . . 0.0 110.277 -178.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -46.68 -58.52 3.77 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.155 -0.966 . . . . 0.0 110.417 -179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.47 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.7 m -84.87 -25.88 27.71 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.131 -0.981 . . . . 0.0 111.435 -178.644 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.3 t -83.61 -51.71 7.07 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.58 -1.325 . . . . 0.0 109.068 179.793 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.477 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t60 -68.13 -27.9 66.85 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.419 -0.8 . . . . 0.0 109.341 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 14.2 t -137.35 173.14 12.0 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.353 -0.842 . . . . 0.0 110.188 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.2 mm -91.82 99.43 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.0 p -93.92 152.99 18.46 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.074 -1.016 . . . . 0.0 109.548 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.28 167.54 13.47 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.902 . . . . 0.0 109.125 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.4 -34.53 68.98 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -43.67 -57.01 3.4 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.852 0.834 . . . . 0.0 110.038 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -60.1 -42.19 94.13 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.485 HD22 HD11 ' A' ' 11' ' ' LEU . 80.1 mt -62.54 -32.39 73.33 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.86 -9.24 54.12 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -76.34 -27.64 56.56 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.9 m-85 -102.11 6.64 40.99 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 95.7 m -80.95 105.2 12.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.842 -1.161 . . . . 0.0 109.154 179.567 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.431 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.4 t-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.633 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.9 OUTLIER -104.5 -91.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.751 . . . . 0.0 110.574 -178.767 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.633 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.0 m120 -99.95 25.82 6.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.283 -0.886 . . . . 0.0 109.742 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.483 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.72 159.14 15.13 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.308 -0.87 . . . . 0.0 109.494 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -93.36 134.46 35.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.616 -0.678 . . . . 0.0 110.283 -179.208 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -95.94 127.94 42.4 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.465 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.436 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.2 m -143.51 125.48 15.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.892 . . . . 0.0 109.263 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.11 -149.57 46.11 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -44.84 -30.21 0.94 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -1.032 . . . . 0.0 110.347 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.436 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.7 m-20 -49.12 -50.89 35.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.895 -1.128 . . . . 0.0 108.818 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.556 HD21 HD12 ' A' ' 38' ' ' ILE . 20.0 tp -55.16 -52.11 64.35 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.361 -0.837 . . . . 0.0 109.198 179.637 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 t -49.15 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 109.896 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 28.4 mt-10 -47.9 -25.75 1.44 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.447 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.57 -54.9 5.03 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.282 -0.887 . . . . 0.0 109.063 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.65 -34.35 37.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.335 -1.478 . . . . 0.0 108.595 179.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.422 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.5 t80 -50.23 -49.92 51.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.326 -0.859 . . . . 0.0 110.275 -179.494 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -67.91 -50.85 53.77 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.65 -1.281 . . . . 0.0 108.626 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.9 t -50.52 -58.68 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 CA-C-O 121.511 0.672 . . . . 0.0 109.854 -179.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -77.03 -23.12 52.13 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.483 -0.761 . . . . 0.0 109.997 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 47.7 -122.27 7.61 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -79.13 -15.3 58.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 0.0 110.275 -179.25 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.2 mtp180 -56.62 -28.35 60.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.123 -0.985 . . . . 0.0 109.491 -179.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.49 155.06 4.95 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.399 -1.881 . . . . 0.0 108.399 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -156.68 172.74 18.07 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.898 -1.354 . . . . 0.0 110.449 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 30.5 p90 -118.4 133.93 55.47 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -73.41 171.18 13.58 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.588 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.0 t -64.29 175.1 1.39 Allowed 'General case' 0 C--N 1.296 -1.756 0 O-C-N 120.961 -1.087 . . . . 0.0 109.698 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.51 151.87 0.45 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.423 -0.798 . . . . 0.0 110.121 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -78.69 -6.59 15.36 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.004 1.803 . . . . 0.0 110.259 179.421 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.7 p -53.64 -40.59 65.97 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.172 -0.955 . . . . 0.0 111.291 -177.384 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.14 -15.53 0.54 Allowed Glycine 0 N--CA 1.495 2.579 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.259 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -94.17 -31.82 7.81 Favored Glycine 0 N--CA 1.499 2.868 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.518 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -166.25 53.58 0.25 Allowed Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.83 -1.708 . . . . 0.0 108.83 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.528 ' O ' ' N ' ' A' ' 36' ' ' ARG . 24.5 Cg_endo -70.3 -173.6 0.83 Allowed 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 122.041 1.827 . . . . 0.0 109.924 -179.499 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.588 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.7 ttt-85 -57.01 85.95 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' N ' ' O ' ' A' ' 34' ' ' PRO . 16.6 mtm-85 -59.12 -29.54 67.46 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.045 -1.034 . . . . 0.0 108.281 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.9 -23.98 0.08 OUTLIER Glycine 0 N--CA 1.49 2.286 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.556 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.4 -55.61 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.152 -1.204 . . . . 0.0 109.97 179.674 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.7 t -62.69 -64.15 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.087 -1.008 . . . . 0.0 112.069 -176.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -59.93 -39.59 86.0 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.727 -1.233 . . . . 0.0 110.719 -178.241 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -51.26 -56.71 11.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.877 -1.139 . . . . 0.0 109.477 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.9 m -85.46 -26.58 26.25 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.381 -0.824 . . . . 0.0 111.045 -179.21 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.3 t -84.07 -52.4 6.32 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.706 -1.246 . . . . 0.0 109.673 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.427 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.2 t60 -69.99 -26.97 64.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.114 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -136.78 160.58 38.42 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.484 -0.76 . . . . 0.0 109.107 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.9 mm -84.65 99.73 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -90.42 164.18 14.39 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.065 -1.022 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -96.82 166.77 11.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.36 -0.838 . . . . 0.0 109.007 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -57.68 -34.34 69.31 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -44.08 -57.85 3.16 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.86 0.838 . . . . 0.0 110.014 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -59.8 -42.57 93.73 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.2 mt -62.21 -32.08 72.7 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.91 -9.26 54.35 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -76.21 -28.04 57.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.788 -0.57 . . . . 0.0 109.649 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.2 m-85 -101.83 6.21 41.45 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.354 -0.841 . . . . 0.0 110.102 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.462 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -79.8 106.74 12.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.939 -1.101 . . . . 0.0 109.323 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.41 179.967 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.62 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.6 -91.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.404 -0.81 . . . . 0.0 110.626 -178.68 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.62 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -101.05 25.6 7.92 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 -179.239 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.479 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -96.0 158.54 15.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.36 -0.837 . . . . 0.0 109.635 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.1 p-80 -92.04 135.89 33.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.635 -0.665 . . . . 0.0 110.255 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -97.05 126.55 42.27 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.425 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.5 m -142.35 125.14 16.0 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.292 -0.88 . . . . 0.0 109.241 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.9 -148.74 45.18 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.354 -1.098 . . . . 0.0 110.354 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -44.67 -31.08 1.05 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.383 -1.069 . . . . 0.0 110.349 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.425 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.01 -50.66 34.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.946 -1.097 . . . . 0.0 108.841 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 38' ' ' ILE . 19.1 tp -55.53 -54.01 49.32 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.405 -0.809 . . . . 0.0 109.283 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.415 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.7 t -47.43 -66.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.012 -179.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 52.0 mt-10 -47.72 -26.92 1.73 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.343 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.81 -54.93 5.17 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.467 -0.771 . . . . 0.0 109.188 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.54 -34.06 34.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.394 -1.441 . . . . 0.0 108.603 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.46 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.7 t80 -50.48 -50.75 51.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.276 -179.612 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.3 -50.8 58.76 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.532 -1.355 . . . . 0.0 108.658 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.457 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.43 -59.01 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.569 0.7 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.72 -23.27 53.08 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.539 -0.725 . . . . 0.0 109.92 -178.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.02 -123.2 10.55 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.57 -15.12 58.24 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -1.114 . . . . 0.0 110.084 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -55.15 -28.81 55.52 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.15 -0.969 . . . . 0.0 109.337 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.47 154.66 4.72 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -156.57 172.9 17.74 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 120.901 -1.352 . . . . 0.0 110.434 -179.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.541 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.7 p90 -118.11 138.27 52.37 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -77.67 170.61 16.27 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.565 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.3 t -64.68 175.0 1.56 Allowed 'General case' 0 C--N 1.299 -1.617 0 O-C-N 120.998 -1.064 . . . . 0.0 110.111 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -45.11 148.4 1.05 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.41 -0.806 . . . . 0.0 110.03 -178.678 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -77.73 -6.23 15.94 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.121 1.881 . . . . 0.0 110.573 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.509 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.0 p -53.88 -41.1 67.18 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.077 -1.014 . . . . 0.0 111.215 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.58 -15.76 0.43 Allowed Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.604 -1.284 . . . . 0.0 110.398 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.97 -17.71 31.63 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.501 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.58 54.64 0.13 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.157 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.2 Cg_endo -69.98 -174.61 0.98 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 121.866 1.711 . . . . 0.0 109.802 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.565 ' N ' ' OG1' ' A' ' 27' ' ' THR . 38.4 ttt180 -60.31 89.18 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.706 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.727 ' N ' ' HE ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER -58.52 -16.64 16.31 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.795 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.442 ' N ' ' HE ' ' A' ' 36' ' ' ARG . . . -56.23 -28.6 54.89 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.63 -55.98 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 O-C-N 120.929 -1.336 . . . . 0.0 110.704 -179.283 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.11 -64.24 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.911 -1.118 . . . . 0.0 111.421 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -54.46 -47.8 72.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.773 -1.204 . . . . 0.0 110.3 -178.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -47.13 -58.97 3.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.08 -1.013 . . . . 0.0 110.459 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.0 m -84.54 -25.56 28.65 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -0.946 . . . . 0.0 111.307 -178.736 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.96 -52.3 6.45 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.65 -1.281 . . . . 0.0 109.214 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.48 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.9 t-80 -67.44 -28.88 68.26 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.32 -0.863 . . . . 0.0 109.243 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -136.9 173.28 11.87 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.379 -0.826 . . . . 0.0 109.704 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 3.6 mm -92.56 99.66 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.6 p -91.75 151.68 20.51 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.063 -1.023 . . . . 0.0 109.632 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -84.97 166.34 16.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.233 -0.917 . . . . 0.0 109.223 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.2 -34.18 68.25 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.485 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -44.22 -57.42 3.46 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.914 0.864 . . . . 0.0 110.014 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.83 -42.67 94.08 Favored 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.0 mt -62.01 -32.39 72.87 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.046 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.6 -9.77 55.47 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -75.73 -27.85 58.31 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.781 -0.575 . . . . 0.0 109.584 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.9 m-85 -101.85 5.5 41.07 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.373 -0.829 . . . . 0.0 110.056 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.457 ' SG ' HG12 ' A' ' 18' ' ' VAL . 89.2 m -79.95 111.14 16.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.901 -1.124 . . . . 0.0 109.449 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.447 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -98.57 -91.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.369 -0.832 . . . . 0.0 110.803 -178.37 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -104.17 25.92 9.45 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.401 -0.812 . . . . 0.0 109.988 -179.086 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.465 ' OE1' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -95.85 157.95 15.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.247 -0.908 . . . . 0.0 109.672 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 3.0 p-80 -91.25 133.52 35.33 Favored 'General case' 0 N--CA 1.489 1.494 0 CA-C-O 121.405 0.622 . . . . 0.0 110.134 -179.335 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.408 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -92.9 125.22 37.39 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.519 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.1 m -140.79 125.45 17.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.907 . . . . 0.0 109.264 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.46 -150.75 47.32 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.9 m -44.21 -29.36 0.63 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -1.058 . . . . 0.0 110.263 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.77 -50.49 33.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.982 -1.074 . . . . 0.0 108.859 179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.495 HD11 HD22 ' A' ' 52' ' ' LEU . 20.4 tp -55.94 -54.48 44.22 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.438 -0.789 . . . . 0.0 109.207 179.736 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.71 -66.17 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.358 -0.839 . . . . 0.0 109.901 -179.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 86.7 mt-10 -47.63 -27.98 2.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.177 -0.952 . . . . 0.0 109.291 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.74 -55.32 5.09 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 109.181 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.47 -34.07 33.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.311 -1.493 . . . . 0.0 108.649 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -50.44 -49.27 55.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 110.165 -179.662 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.76 -51.06 45.22 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.535 -1.353 . . . . 0.0 108.619 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.418 HG12 ' SG ' ' A' ' 56' ' ' CYS . 39.9 t -50.39 -58.56 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 121.523 0.678 . . . . 0.0 109.698 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.3 -23.81 54.35 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.485 -0.759 . . . . 0.0 109.693 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.33 -131.83 45.89 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.799 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -76.62 -11.25 59.83 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.37 -1.077 . . . . 0.0 110.121 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -57.84 -26.98 62.77 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.076 -1.015 . . . . 0.0 109.35 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.87 155.68 5.72 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 -179.255 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.74 173.0 17.62 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.921 -1.341 . . . . 0.0 110.227 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.551 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 37.5 p90 -115.26 137.25 52.24 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -78.13 171.01 15.67 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.577 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.1 t -64.13 175.11 1.33 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.853 -1.154 . . . . 0.0 109.975 -179.088 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.42 147.71 0.58 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.521 -0.737 . . . . 0.0 110.3 -178.25 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -77.24 -6.41 16.47 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.18 1.92 . . . . 0.0 110.493 179.503 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.51 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.1 p -53.98 -41.06 67.47 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.137 -0.977 . . . . 0.0 110.96 -177.44 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.59 -15.83 0.43 Allowed Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.388 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.24 -18.38 31.4 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.497 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.04 55.04 0.14 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 179.229 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.497 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.6 Cg_endo -69.29 -175.03 0.92 Allowed 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.874 1.716 . . . . 0.0 110.423 -179.128 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.577 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.4 ttt-85 -56.93 86.58 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.488 ' N ' ' O ' ' A' ' 34' ' ' PRO . 7.1 ptm180 -59.71 -1.72 0.29 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.016 -1.052 . . . . 0.0 108.605 179.687 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -74.06 -24.41 73.81 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.41 -55.99 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.001 -1.293 . . . . 0.0 110.051 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.6 t -61.97 -64.38 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.01 -1.056 . . . . 0.0 111.32 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 51.2 mt-10 -55.24 -47.49 75.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.946 -1.096 . . . . 0.0 110.613 -178.725 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -47.3 -57.78 4.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.051 -1.03 . . . . 0.0 110.303 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.573 ' SG ' HD21 ' A' ' 52' ' ' LEU . 70.9 m -84.81 -26.0 27.76 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.203 -0.935 . . . . 0.0 111.177 -178.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.1 t -83.1 -52.27 6.78 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.746 -1.221 . . . . 0.0 109.42 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 11.8 t-80 -71.15 -26.08 62.84 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.357 -0.839 . . . . 0.0 109.39 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.94 157.85 45.81 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.443 -0.785 . . . . 0.0 109.625 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.2 mm -82.03 99.59 5.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.357 -0.839 . . . . 0.0 108.785 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.7 p -91.14 158.43 16.64 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.106 -0.996 . . . . 0.0 109.781 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.6 p -89.81 166.61 13.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.308 -0.87 . . . . 0.0 108.96 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.607 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -58.78 -33.27 70.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.54 -57.56 3.53 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 121.716 0.769 . . . . 0.0 110.238 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -61.06 -41.8 97.29 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 119.665 -0.814 . . . . 0.0 108.918 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.573 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.7 mt -61.28 -30.77 70.68 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.008 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.48 -9.72 58.64 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -75.99 -28.19 57.71 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.756 -0.59 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.426 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 9.9 m-85 -101.55 6.1 42.06 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.357 -0.839 . . . . 0.0 110.02 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 66.7 m -79.81 107.49 12.63 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.866 -1.147 . . . . 0.0 109.345 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 28.1 t-20 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.094 -0.955 . . . . 0.0 109.453 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.615 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.13 -91.6 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.45 -0.781 . . . . 0.0 110.608 -178.789 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.615 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.57 26.2 7.59 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.366 -0.834 . . . . 0.0 109.886 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.627 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -95.55 158.03 15.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.371 -0.831 . . . . 0.0 109.567 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.423 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.3 OUTLIER -91.57 132.0 36.61 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.66 -0.65 . . . . 0.0 110.587 -178.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -95.18 136.14 35.89 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.147 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.477 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -151.62 125.01 8.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.276 179.31 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.5 -146.65 40.91 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.1 m -46.85 -32.47 3.76 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.369 -1.077 . . . . 0.0 110.163 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.477 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 8.2 m-20 -48.88 -50.49 34.72 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.991 -1.068 . . . . 0.0 108.728 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -56.04 -54.44 44.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.473 -0.767 . . . . 0.0 109.519 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.53 -66.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.261 -0.9 . . . . 0.0 110.04 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.482 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 49.2 mt-10 -47.46 -28.61 2.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.208 -0.932 . . . . 0.0 109.388 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.16 -54.51 5.92 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.36 -0.838 . . . . 0.0 109.297 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.78 -35.28 43.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.367 -1.458 . . . . 0.0 108.581 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -49.31 -49.14 45.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.385 -0.822 . . . . 0.0 110.289 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.782 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.62 -50.96 47.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.558 -1.339 . . . . 0.0 108.592 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.0 t -50.65 -58.81 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-O 121.482 0.658 . . . . 0.0 109.847 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.31 -23.72 54.31 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.67 -125.99 27.67 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -78.75 -14.0 59.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.384 -1.068 . . . . 0.0 110.463 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 22.7 mtt180 -58.07 -26.88 63.09 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.973 -1.079 . . . . 0.0 109.647 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.56 155.99 5.61 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.63 173.01 17.58 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.324 . . . . 0.0 110.413 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.62 140.18 49.68 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -80.49 170.24 16.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 t -65.01 175.6 1.5 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.995 -1.066 . . . . 0.0 110.219 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.52 150.22 0.54 Allowed Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 121.497 -0.752 . . . . 0.0 110.115 -178.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo . . . . . 0 N--CA 1.484 0.93 0 C-N-CA 122.252 1.968 . . . . 0.0 110.658 179.478 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.53 -25.62 74.85 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.15 -56.38 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.212 0 O-C-N 121.056 -1.261 . . . . 0.0 110.45 -179.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.524 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.1 t -62.42 -64.18 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.94 -1.1 . . . . 0.0 111.4 -177.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.517 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.9 mt-10 -55.8 -46.36 78.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.873 -1.142 . . . . 0.0 110.355 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 62.1 tp60 -47.99 -56.65 7.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.074 -1.016 . . . . 0.0 110.101 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.71 -28.25 26.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 111.072 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 52.4 t -83.49 -52.24 6.67 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.733 -1.229 . . . . 0.0 109.231 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.517 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t-80 -70.46 -27.89 64.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.346 -0.846 . . . . 0.0 109.231 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.9 m -136.92 159.85 40.63 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.437 -0.79 . . . . 0.0 109.431 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 7.7 mm -82.8 99.7 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.307 -0.87 . . . . 0.0 109.088 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.9 p -91.15 150.83 21.22 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.094 -1.003 . . . . 0.0 109.32 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.5 167.45 14.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.232 -0.918 . . . . 0.0 109.112 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.77 -34.81 67.97 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.06 -57.53 3.32 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.867 0.841 . . . . 0.0 110.025 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -59.73 -42.48 93.24 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -62.02 -32.25 72.71 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -69.91 -9.54 55.34 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -75.86 -28.56 58.22 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.824 -0.548 . . . . 0.0 109.702 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.457 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.4 m-85 -102.13 6.89 41.09 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.372 -0.83 . . . . 0.0 109.948 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.0 m -80.29 111.18 16.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.023 -1.048 . . . . 0.0 109.282 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.955 -1.021 . . . . 0.0 109.437 179.97 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -101.61 -91.93 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.383 -0.823 . . . . 0.0 110.851 -178.566 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -101.21 26.03 7.56 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.403 -0.811 . . . . 0.0 109.807 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.94 160.84 14.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.384 -0.822 . . . . 0.0 109.483 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.449 ' HB3' HD13 ' A' ' 46' ' ' ILE . 4.4 p-80 -95.95 136.77 35.95 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.577 -0.702 . . . . 0.0 110.092 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -98.38 136.11 39.0 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.597 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -150.16 124.76 9.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.933 . . . . 0.0 109.236 179.003 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.71 -147.34 41.66 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.6 m -45.94 -32.59 2.79 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.393 -1.063 . . . . 0.0 110.197 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.68 -49.99 35.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.978 -1.077 . . . . 0.0 108.753 179.866 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 38' ' ' ILE . 22.6 tp -57.33 -51.79 67.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.411 -0.805 . . . . 0.0 109.484 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.8 t -49.08 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 110.065 -179.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 53.2 mt-10 -47.47 -28.45 2.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.406 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.08 -54.94 5.5 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.377 -0.827 . . . . 0.0 109.206 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.37 -35.63 39.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.402 -1.436 . . . . 0.0 108.772 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -49.35 -50.02 41.74 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.355 -0.841 . . . . 0.0 110.422 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.794 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.68 -50.7 56.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.612 -1.305 . . . . 0.0 108.595 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -51.25 -59.19 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.485 0.66 . . . . 0.0 110.318 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 22.8 m -76.59 -23.26 53.46 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.419 -0.801 . . . . 0.0 109.932 -178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.11 -129.58 27.77 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.352 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -73.43 -16.71 61.31 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.437 -1.037 . . . . 0.0 110.589 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 49.0 mtp180 -54.95 -28.54 52.03 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 109.426 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.8 156.31 6.06 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 107.799 -2.12 . . . . 0.0 107.799 -178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -156.27 172.68 18.05 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.835 -1.391 . . . . 0.0 110.44 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.554 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -116.57 127.24 54.32 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -67.58 172.14 5.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.2 t -62.6 174.39 1.02 Allowed 'General case' 0 C--N 1.295 -1.762 0 O-C-N 120.641 -1.287 . . . . 0.0 109.359 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.58 150.74 0.51 Allowed Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.341 -0.849 . . . . 0.0 110.409 -177.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo . . . . . 0 N--CA 1.484 0.947 0 C-N-CA 122.111 1.874 . . . . 0.0 110.421 179.297 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.477 ' O ' ' N ' ' A' ' 38' ' ' ILE . 12.0 ptt180 . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.86 -22.98 0.11 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.56 -54.27 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 O-C-N 120.978 -1.307 . . . . 0.0 109.787 179.924 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.18 -64.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.057 -1.027 . . . . 0.0 111.76 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -58.57 -41.35 85.49 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.768 -1.208 . . . . 0.0 110.884 -178.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.2 tp60 -50.58 -55.95 13.95 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.972 -1.08 . . . . 0.0 109.553 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.459 ' SG ' HD21 ' A' ' 52' ' ' LEU . 81.6 m -85.23 -26.55 26.63 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 111.222 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.1 t -83.94 -52.62 6.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.604 -1.31 . . . . 0.0 109.821 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.6 t60 -68.99 -29.41 67.61 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.248 -0.907 . . . . 0.0 109.175 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -137.14 157.89 45.68 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.55 -0.719 . . . . 0.0 109.572 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.449 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.3 mm -78.96 119.07 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.38 -0.825 . . . . 0.0 108.822 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.9 p -111.03 156.57 21.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.364 -0.835 . . . . 0.0 109.687 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 p -88.97 166.79 13.68 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.37 -0.831 . . . . 0.0 109.395 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.7 mt -59.65 -32.53 70.54 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.53 -57.68 3.45 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.802 0.81 . . . . 0.0 110.123 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -60.82 -42.46 97.74 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 119.799 -0.76 . . . . 0.0 108.959 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.488 HD22 HD11 ' A' ' 11' ' ' LEU . 77.6 mt -61.42 -26.03 67.6 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.17 -8.55 57.28 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -79.8 -26.34 40.6 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.848 -0.532 . . . . 0.0 109.926 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -100.0 6.1 45.11 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.266 -0.896 . . . . 0.0 110.448 -179.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.425 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 85.1 m -76.39 111.6 12.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.921 -1.112 . . . . 0.0 109.403 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 25.5 t-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.457 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -105.13 -91.88 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.508 -0.745 . . . . 0.0 110.678 -178.514 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -98.98 25.41 6.72 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.303 -0.873 . . . . 0.0 109.745 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.646 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.99 160.47 14.44 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 109.512 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HB3' HD13 ' A' ' 46' ' ' ILE . 2.2 p-80 -96.2 138.7 33.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.613 -0.68 . . . . 0.0 110.101 -179.225 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -100.94 134.09 44.44 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -149.43 124.86 10.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -0.947 . . . . 0.0 109.203 179.065 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.74 -148.48 43.38 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -45.07 -32.26 1.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.322 -1.105 . . . . 0.0 110.22 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.2 m-20 -48.79 -50.3 34.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.944 -1.098 . . . . 0.0 108.755 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -57.04 -54.65 44.35 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.482 -0.762 . . . . 0.0 109.579 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.5 t -46.58 -66.3 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.303 -0.873 . . . . 0.0 110.067 -179.249 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 65.6 mt-10 -47.81 -27.83 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.65 -54.47 5.85 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.319 -0.863 . . . . 0.0 109.14 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.61 -35.3 41.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.402 -1.437 . . . . 0.0 108.626 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.44 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.6 t80 -49.32 -49.6 43.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.306 -0.871 . . . . 0.0 110.37 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.0 mp -68.36 -50.88 50.04 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.533 -1.355 . . . . 0.0 108.607 179.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.0 t -50.54 -58.72 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 CA-C-O 121.511 0.672 . . . . 0.0 109.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.03 -23.69 55.16 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.497 -0.752 . . . . 0.0 109.749 -179.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 52.91 -131.08 40.66 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -75.69 -11.52 60.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.345 -1.091 . . . . 0.0 110.158 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.409 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -58.21 -27.76 64.2 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.092 -1.005 . . . . 0.0 109.488 -179.453 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.72 155.22 5.28 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -156.51 172.73 18.03 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.936 -1.332 . . . . 0.0 110.277 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.8 p90 -115.74 137.39 52.13 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -77.13 171.13 15.31 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -63.89 175.02 1.27 Allowed 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.798 -1.189 . . . . 0.0 109.9 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -43.14 148.39 0.61 Allowed Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.494 -0.754 . . . . 0.0 110.229 -178.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo . . . . . 0 N--CA 1.483 0.909 0 C-N-CA 122.128 1.885 . . . . 0.0 110.409 179.326 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.9 ptm180 . . . . . 0 N--CA 1.486 1.358 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.7 -24.27 76.42 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.9 -55.3 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.261 0 O-C-N 121.098 -1.236 . . . . 0.0 110.349 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -63.54 -64.27 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.024 -1.047 . . . . 0.0 111.278 -177.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 44' ' ' HIS . 30.2 mt-10 -55.01 -45.74 75.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.373 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -48.74 -57.63 6.02 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.099 -1.0 . . . . 0.0 110.304 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.503 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.88 -25.36 28.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.173 -0.955 . . . . 0.0 111.435 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 48.3 t -84.24 -52.34 6.31 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.535 -1.353 . . . . 0.0 109.537 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.421 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.9 t60 -68.91 -26.77 65.26 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.22 -0.925 . . . . 0.0 109.195 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 12.6 t -136.71 173.32 11.83 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.458 -0.776 . . . . 0.0 109.473 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.407 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.0 mm -94.65 99.6 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.3 p -91.53 152.49 20.29 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.126 -0.984 . . . . 0.0 109.72 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -86.67 166.7 15.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.326 -0.859 . . . . 0.0 109.32 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.8 mt -57.39 -34.91 69.35 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -43.97 -57.19 3.46 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.862 0.839 . . . . 0.0 109.978 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.71 -42.59 93.41 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.503 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.4 mt -61.89 -32.36 72.73 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.98 -9.61 55.76 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -75.88 -28.15 58.02 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.799 -0.563 . . . . 0.0 109.664 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 7.9 m-85 -102.86 6.99 39.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.407 -0.808 . . . . 0.0 109.95 -179.616 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 62.2 m -79.26 108.23 12.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.984 -1.072 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.548 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -101.92 -91.69 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -0.812 . . . . 0.0 110.607 -178.738 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.3 m120 -101.73 26.08 7.82 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.351 -0.843 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.59 160.16 14.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 109.708 -179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -92.05 134.61 34.67 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.53 0.681 . . . . 0.0 110.541 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.4 mp -98.53 130.69 45.1 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.12 125.06 10.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.107 179.377 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.63 -148.34 43.36 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -45.02 -32.64 1.75 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.394 -1.062 . . . . 0.0 110.321 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.87 -50.31 35.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.004 -1.06 . . . . 0.0 108.745 179.841 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.534 HD21 HD12 ' A' ' 38' ' ' ILE . 18.5 tp -57.13 -55.05 39.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.404 -0.81 . . . . 0.0 109.562 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -46.31 -66.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.313 -0.867 . . . . 0.0 109.945 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 34.4 mt-10 -47.69 -26.67 1.62 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 -179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.07 -54.31 5.65 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.365 -0.834 . . . . 0.0 109.082 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.71 -34.48 39.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.372 -1.455 . . . . 0.0 108.658 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.8 t80 -50.49 -49.59 55.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.301 -0.874 . . . . 0.0 110.336 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.797 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.26 -50.29 54.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.591 -1.318 . . . . 0.0 108.556 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.5 t -50.68 -59.38 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.522 0.677 . . . . 0.0 109.745 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.05 -23.64 55.1 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 -178.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.48 -123.78 20.2 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -80.28 -16.56 54.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.355 -1.085 . . . . 0.0 110.584 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 15.8 mtt180 -55.92 -27.12 50.78 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.053 -1.029 . . . . 0.0 109.52 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.5 6.05 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -156.57 172.96 17.64 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.895 -1.356 . . . . 0.0 110.357 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.547 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.0 p90 -116.77 135.81 53.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -76.18 170.91 15.4 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.1 t -64.29 174.73 1.52 Allowed 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.807 -1.183 . . . . 0.0 110.027 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.28 148.58 0.82 Allowed Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.43 -0.794 . . . . 0.0 109.998 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 C-N-CA 122.118 1.878 . . . . 0.0 110.425 179.385 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.0 mtm180 . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.72 -25.89 73.94 Favored Glycine 0 N--CA 1.487 2.056 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.534 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -101.89 -56.28 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 O-C-N 121.026 -1.279 . . . . 0.0 110.559 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -61.98 -64.41 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 120.906 -1.121 . . . . 0.0 111.574 -177.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' HIS . 76.1 mt-10 -56.09 -46.17 79.16 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.932 -1.105 . . . . 0.0 110.341 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 52.0 tt0 -48.31 -56.55 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.11 -0.993 . . . . 0.0 110.298 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.572 ' SG ' HD21 ' A' ' 52' ' ' LEU . 62.4 m -84.79 -27.16 27.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.135 -0.978 . . . . 0.0 111.331 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.1 t -83.01 -52.23 6.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.72 -1.238 . . . . 0.0 109.163 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.464 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.7 t-80 -69.32 -27.5 65.43 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.178 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 m -137.01 159.95 40.37 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.424 -0.797 . . . . 0.0 109.594 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.8 mm -83.41 99.59 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.264 -0.897 . . . . 0.0 108.933 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.0 p -90.63 147.31 23.38 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.059 -1.026 . . . . 0.0 109.482 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -81.62 166.56 20.08 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.6 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.4 mt -56.41 -34.24 66.55 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -44.31 -57.42 3.51 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.924 0.869 . . . . 0.0 109.982 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.0 -42.29 93.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.572 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.4 mt -62.36 -32.34 73.12 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -69.74 -9.51 54.76 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -75.7 -28.34 58.57 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.753 -0.592 . . . . 0.0 109.613 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.3 m-85 -101.48 6.0 42.19 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.35 -0.844 . . . . 0.0 110.035 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -80.45 110.52 15.99 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.933 -1.104 . . . . 0.0 109.217 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.405 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 17.3 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -99.55 -91.51 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.432 -0.793 . . . . 0.0 110.582 -178.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.1 m120 -103.86 27.14 7.84 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.491 -0.756 . . . . 0.0 109.798 -179.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.95 161.22 14.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.456 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.551 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 8.6 p80 -92.94 134.73 34.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.619 -0.676 . . . . 0.0 110.593 -178.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.413 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -98.99 131.0 45.37 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.289 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.481 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.35 125.15 11.89 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.165 -0.96 . . . . 0.0 109.301 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.17 -149.24 43.86 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.2 m -44.91 -31.86 1.41 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.255 -1.144 . . . . 0.0 110.226 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.481 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.19 -50.5 28.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.064 -1.023 . . . . 0.0 108.824 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.14 -55.21 37.72 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.474 -0.766 . . . . 0.0 109.501 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.12 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.273 -0.892 . . . . 0.0 110.033 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.5 mt-10 -47.57 -29.12 2.63 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.78 -54.59 5.92 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.291 -0.881 . . . . 0.0 109.209 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.27 -35.67 38.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.433 -1.417 . . . . 0.0 108.71 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -49.31 -49.41 44.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.873 . . . . 0.0 110.403 -179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.811 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -68.82 -50.55 49.08 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.589 -1.319 . . . . 0.0 108.581 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -51.03 -59.14 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.503 0.668 . . . . 0.0 110.13 -179.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.2 m -76.42 -23.69 53.99 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.507 -0.746 . . . . 0.0 109.743 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.57 -133.44 46.96 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -74.87 -13.05 60.51 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.423 -1.045 . . . . 0.0 110.196 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.404 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.11 -26.77 51.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.166 -0.959 . . . . 0.0 109.258 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 155.75 5.58 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 108.462 -1.855 . . . . 0.0 108.462 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -156.43 172.52 18.37 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.982 -1.305 . . . . 0.0 110.091 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.0 p90 -115.8 133.45 56.02 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -72.66 171.9 11.67 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.3 t -63.36 174.53 1.22 Allowed 'General case' 0 C--N 1.298 -1.666 0 O-C-N 120.768 -1.207 . . . . 0.0 109.722 -179.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.06 0.93 Allowed Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.483 -0.761 . . . . 0.0 110.231 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo . . . . . 0 N--CA 1.483 0.88 0 C-N-CA 122.032 1.821 . . . . 0.0 110.3 179.286 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.6 ptt180 . . . . . 0 N--CA 1.487 1.396 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.43 -22.88 74.81 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 121.014 -1.286 . . . . 0.0 110.252 -179.702 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.7 t -62.59 -64.27 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.044 -1.035 . . . . 0.0 111.249 -177.29 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.495 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.0 mt-10 -54.99 -48.78 72.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.014 -1.054 . . . . 0.0 110.431 -178.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 52.7 tp60 -46.32 -57.2 4.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.075 -1.016 . . . . 0.0 110.458 -179.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.518 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -84.75 -26.48 27.58 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 111.278 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.3 t -83.19 -51.33 7.58 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.677 -1.264 . . . . 0.0 109.25 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.517 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.3 t-80 -72.61 -26.61 61.75 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.353 -0.842 . . . . 0.0 109.621 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.92 158.83 43.57 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.311 -0.868 . . . . 0.0 109.838 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 10.4 mm -81.25 99.51 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.347 -0.846 . . . . 0.0 109.171 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -92.17 149.9 21.22 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.018 -1.051 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -83.84 166.46 17.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.25 -0.906 . . . . 0.0 109.336 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.2 mt -57.63 -33.61 68.45 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -43.72 -57.85 3.0 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.917 0.865 . . . . 0.0 109.979 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -59.95 -42.68 94.58 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.518 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.8 mt -61.72 -27.2 68.54 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -75.33 -8.54 56.94 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -79.51 -26.33 41.57 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.811 -0.555 . . . . 0.0 109.995 -179.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 13.8 m-85 -101.05 5.67 43.08 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.283 -0.886 . . . . 0.0 110.398 -179.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.3 m -79.29 111.39 15.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.928 -1.108 . . . . 0.0 109.631 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.568 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.38 -91.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.479 -0.763 . . . . 0.0 110.572 -178.68 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -101.45 25.94 7.81 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.382 -0.824 . . . . 0.0 109.879 -179.267 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.623 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.64 159.82 14.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.356 -0.84 . . . . 0.0 109.671 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -92.2 137.17 32.59 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.483 0.659 . . . . 0.0 110.568 -179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -100.83 131.12 46.87 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.475 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.03 125.02 11.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 179.308 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -147.7 41.99 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -45.99 -32.3 2.7 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.328 -1.101 . . . . 0.0 110.225 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.475 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.9 OUTLIER -48.43 -50.08 32.54 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.054 -1.029 . . . . 0.0 108.722 179.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.493 HD11 HD22 ' A' ' 52' ' ' LEU . 20.2 tp -57.21 -54.39 47.36 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.45 -0.781 . . . . 0.0 109.519 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.7 t -46.93 -66.32 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.284 -0.885 . . . . 0.0 109.951 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 41.4 mt-10 -48.03 -24.41 1.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.139 -0.976 . . . . 0.0 109.377 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -83.29 -54.43 5.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.339 -0.851 . . . . 0.0 109.035 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -52.23 -33.26 40.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.429 -1.42 . . . . 0.0 108.542 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -51.17 -49.85 60.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.344 -0.848 . . . . 0.0 110.2 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.783 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.23 -50.55 53.27 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.578 -1.326 . . . . 0.0 108.597 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.1 t -50.54 -58.79 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.504 0.669 . . . . 0.0 109.723 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.03 -23.27 52.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.582 -0.699 . . . . 0.0 109.893 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.19 -126.27 18.33 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -77.39 -14.96 59.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.313 -1.11 . . . . 0.0 110.282 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.8 mtp180 -55.31 -27.95 50.33 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.088 -1.007 . . . . 0.0 109.424 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.66 154.55 4.83 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.509 -1.836 . . . . 0.0 108.509 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.79 173.01 17.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.897 -1.355 . . . . 0.0 110.372 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.4 p90 -117.96 136.46 53.49 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -77.25 170.37 16.65 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 t -64.62 175.34 1.45 Allowed 'General case' 0 C--N 1.298 -1.654 0 O-C-N 120.973 -1.079 . . . . 0.0 110.016 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -44.33 148.55 0.84 Allowed Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 109.967 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo . . . . . 0 N--CA 1.484 0.939 0 C-N-CA 122.118 1.879 . . . . 0.0 110.3 179.415 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 . . . . . 0 N--CA 1.485 1.318 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.2 -24.41 71.36 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.76 -56.41 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 121.024 -1.28 . . . . 0.0 110.287 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.34 -64.41 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.028 -1.045 . . . . 0.0 111.352 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -55.52 -45.45 77.15 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.056 -1.028 . . . . 0.0 110.457 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -49.6 -56.45 9.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.087 -1.008 . . . . 0.0 110.212 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.543 ' SG ' HD21 ' A' ' 52' ' ' LEU . 64.5 m -84.99 -26.12 27.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.18 -0.95 . . . . 0.0 111.339 -178.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.06 -51.33 7.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.723 -1.236 . . . . 0.0 109.295 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.494 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.5 t-80 -72.1 -25.67 61.84 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.283 -0.885 . . . . 0.0 109.376 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -136.81 157.78 45.97 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.363 -0.836 . . . . 0.0 109.623 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 8.6 mm -82.11 99.22 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.374 -0.829 . . . . 0.0 108.891 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.5 p -91.28 150.62 21.24 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.097 -1.002 . . . . 0.0 109.54 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -84.1 166.83 17.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.199 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -57.44 -33.6 68.11 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.42 -57.81 3.33 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.811 0.815 . . . . 0.0 110.081 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 11.5 mt-30 -60.13 -41.86 93.55 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.543 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.9 mt -61.98 -31.99 72.41 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 49' ' ' LEU . 0.6 OUTLIER -70.04 -9.57 55.78 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 179.289 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -75.68 -28.33 58.63 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.759 -0.588 . . . . 0.0 109.557 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.437 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 12.9 m-85 -100.99 5.1 43.0 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.33 -0.856 . . . . 0.0 110.151 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.44 ' SG ' HG12 ' A' ' 18' ' ' VAL . 96.8 m -80.15 109.6 14.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.92 -1.112 . . . . 0.0 109.086 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.419 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 23.3 t-20 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.084 -0.96 . . . . 0.0 109.391 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.575 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -94.7 -91.36 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.373 -0.829 . . . . 0.0 110.791 -178.495 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.575 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -105.65 25.73 10.42 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.408 -0.807 . . . . 0.0 110.028 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 3.3 pt20 -95.91 158.07 15.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.278 -0.889 . . . . 0.0 109.625 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.436 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 12.5 p80 -90.68 137.01 32.69 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.696 -0.627 . . . . 0.0 110.217 -179.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -96.21 122.57 39.21 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.8 m -139.69 125.65 19.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.291 -0.881 . . . . 0.0 109.331 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.38 -149.81 46.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -44.54 -29.55 0.74 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.353 -1.086 . . . . 0.0 110.235 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 9.9 m-20 -49.18 -51.24 33.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.034 -1.041 . . . . 0.0 108.874 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.515 HD11 HD22 ' A' ' 52' ' ' LEU . 21.7 tp -55.8 -51.36 67.72 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.401 -0.812 . . . . 0.0 109.365 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -49.61 -66.22 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 0.0 109.714 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.481 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 38.8 mt-10 -47.49 -26.91 1.53 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.379 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.53 -55.49 4.82 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.407 -0.808 . . . . 0.0 109.148 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.1 mt -51.3 -33.64 29.79 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.268 -1.52 . . . . 0.0 108.737 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.436 ' O ' ' N ' ' A' ' 20' ' ' GLY . 54.8 t80 -50.94 -50.35 57.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 110.228 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.776 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.6 mp -67.66 -50.53 57.35 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.575 -1.328 . . . . 0.0 108.605 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.434 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.5 t -50.42 -58.95 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.514 0.673 . . . . 0.0 109.816 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.8 m -76.71 -23.38 53.12 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.541 -0.724 . . . . 0.0 109.867 -178.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 48.42 -123.31 9.8 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -79.07 -13.28 59.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.304 -1.115 . . . . 0.0 110.298 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -57.81 -27.67 63.35 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.085 -1.009 . . . . 0.0 109.561 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 154.73 4.75 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.68 172.85 17.86 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.773 -1.428 . . . . 0.0 110.484 -179.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.9 p90 -118.14 129.98 55.84 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.3 t80 -70.69 171.12 10.97 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 t -64.12 174.91 1.39 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 120.826 -1.171 . . . . 0.0 109.644 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -42.29 150.38 0.4 Allowed Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.449 -0.782 . . . . 0.0 110.339 -178.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo . . . . . 0 N--CA 1.484 0.961 0 C-N-CA 122.068 1.845 . . . . 0.0 110.439 179.377 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.621 HH11 ' CG ' ' A' ' 36' ' ' ARG . 0.6 OUTLIER . . . . . 0 N--CA 1.484 1.273 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.96 -24.53 0.09 OUTLIER Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.5 -55.55 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 120.977 -1.308 . . . . 0.0 109.91 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.8 t -62.49 -64.26 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.052 -1.03 . . . . 0.0 112.1 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -59.38 -37.71 78.64 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.832 -1.168 . . . . 0.0 110.856 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -54.49 -56.26 20.57 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.819 -1.175 . . . . 0.0 109.409 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.618 ' SG ' HD21 ' A' ' 52' ' ' LEU . 67.2 m -85.78 -24.03 27.0 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.324 -0.86 . . . . 0.0 111.297 -179.161 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.9 -52.62 6.21 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.635 -1.291 . . . . 0.0 109.771 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.515 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.4 t-80 -69.77 -26.3 64.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.203 -0.936 . . . . 0.0 109.278 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.88 161.17 36.74 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.376 -0.828 . . . . 0.0 109.483 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.7 mm -84.59 99.79 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.4 p -90.99 153.96 19.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.065 -1.022 . . . . 0.0 109.726 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.19 167.95 15.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.312 -0.867 . . . . 0.0 109.056 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.1 mt -59.74 -33.34 71.53 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.919 0.866 . . . . 0.0 108.669 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -44.34 -57.74 3.34 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.777 0.798 . . . . 0.0 110.286 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -61.06 -41.73 97.18 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 119.773 -0.771 . . . . 0.0 108.964 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.618 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.56 -31.31 71.34 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.64 -9.64 57.49 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -75.64 -28.06 58.64 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.746 -0.596 . . . . 0.0 109.569 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.429 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.8 m-85 -101.22 5.64 42.66 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.333 -0.854 . . . . 0.0 110.072 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.434 ' SG ' HG12 ' A' ' 18' ' ' VAL . 90.0 m -80.35 109.47 14.86 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.916 -1.115 . . . . 0.0 109.27 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.454 -179.961 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.553 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.3 OUTLIER -98.32 -91.29 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.366 -0.834 . . . . 0.0 110.503 -178.827 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.553 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.1 m-20 -106.35 27.53 8.64 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.534 -0.729 . . . . 0.0 109.899 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.63 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.79 159.96 14.82 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.343 -0.848 . . . . 0.0 109.335 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 14.8 p-80 -90.65 131.46 36.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.616 -0.677 . . . . 0.0 110.693 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.411 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -94.01 127.28 39.71 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.021 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.435 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.2 m -142.68 125.51 16.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.233 -0.917 . . . . 0.0 109.343 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.33 -150.45 47.06 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.9 m -43.67 -29.92 0.56 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -1.032 . . . . 0.0 110.383 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 24.4 m-20 -50.01 -51.31 42.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.991 -1.068 . . . . 0.0 108.951 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -54.8 -53.52 54.15 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.313 -0.867 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 t -47.91 -66.07 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.356 -0.84 . . . . 0.0 109.963 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 45.3 mt-10 -47.82 -28.51 2.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.349 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.72 -54.89 5.63 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.352 -0.843 . . . . 0.0 109.123 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.0 mt -51.64 -35.29 41.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.35 -1.469 . . . . 0.0 108.661 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.8 t80 -49.32 -49.53 43.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 110.298 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.748 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -68.53 -51.27 44.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.67 -1.269 . . . . 0.0 108.609 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.448 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.33 -58.41 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 121.525 0.678 . . . . 0.0 109.59 -179.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -76.58 -23.53 53.51 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.558 -0.714 . . . . 0.0 109.98 -178.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.91 -122.07 10.79 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.3 mt-10 -80.47 -16.47 54.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.307 -1.113 . . . . 0.0 110.357 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.43 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -55.89 -28.16 55.34 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.551 -179.524 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 156.25 5.68 Favored Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -156.58 172.73 18.05 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.842 -1.387 . . . . 0.0 110.477 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.0 p90 -117.76 139.46 51.03 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -78.47 170.97 15.79 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t -64.6 174.55 1.72 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.869 -1.144 . . . . 0.0 110.523 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -46.36 148.53 1.59 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.586 -0.696 . . . . 0.0 110.098 -178.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo . . . . . 0 N--CA 1.486 1.071 0 C-N-CA 122.347 2.031 . . . . 0.0 110.962 179.715 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.52 HH11 ' HG2' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.6 -23.82 66.58 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.537 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.95 -56.41 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.234 0 O-C-N 121.096 -1.238 . . . . 0.0 110.393 -179.716 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.04 -64.35 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.026 . . . . 0.0 111.436 -177.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -55.04 -48.55 73.29 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.856 -1.152 . . . . 0.0 110.411 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -45.93 -58.32 3.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.195 -0.94 . . . . 0.0 110.451 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.6 m -85.34 -27.02 26.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.154 -0.966 . . . . 0.0 111.511 -178.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 42.6 t -83.38 -52.32 6.64 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.733 -1.229 . . . . 0.0 109.598 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.438 ' N ' ' O ' ' A' ' 40' ' ' GLU . 12.3 t60 -70.94 -26.59 63.25 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.88 161.84 34.89 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.324 -0.86 . . . . 0.0 109.676 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.8 mm -83.36 99.69 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.585 -0.697 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -92.4 160.12 15.24 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.05 -1.031 . . . . 0.0 109.741 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.07 167.31 11.87 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.91 -32.58 69.67 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.35 -57.24 3.63 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.702 0.763 . . . . 0.0 110.14 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -61.35 -42.37 98.59 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.924 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.08 -31.93 71.59 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.42 -9.6 56.81 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.937 -1.135 . . . . 0.0 107.937 179.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -77.0 -27.67 54.78 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.778 -0.576 . . . . 0.0 109.689 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.1 m-85 -102.29 6.23 40.37 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.402 -0.811 . . . . 0.0 109.957 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.448 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -78.41 103.3 8.26 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.994 -1.066 . . . . 0.0 109.403 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.4 t-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.456 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -104.39 -91.67 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.616 -178.695 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.619 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.4 m120 -100.02 25.8 7.04 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.349 -0.844 . . . . 0.0 109.777 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.638 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.93 160.05 14.66 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.384 -0.823 . . . . 0.0 109.522 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -94.88 136.29 35.36 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.57 -0.706 . . . . 0.0 110.178 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.405 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -97.51 130.17 44.61 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.639 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 72.8 m -143.92 125.18 14.62 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.306 -0.871 . . . . 0.0 109.255 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.18 -150.62 47.58 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.9 m -43.77 -30.5 0.66 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.418 -1.048 . . . . 0.0 110.322 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 4.6 m-20 -48.94 -50.51 35.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.967 -1.083 . . . . 0.0 108.856 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 18.9 tp -55.42 -54.86 38.48 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.359 -0.838 . . . . 0.0 109.235 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.75 -66.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.391 -0.818 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.48 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 35.2 mt-10 -47.87 -27.85 2.32 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.191 -0.943 . . . . 0.0 109.341 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.69 -54.57 5.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.336 -0.852 . . . . 0.0 109.164 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.64 -34.96 40.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.364 -1.46 . . . . 0.0 108.599 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.9 t80 -49.64 -49.48 47.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.359 -0.838 . . . . 0.0 110.389 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.789 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.55 -50.76 49.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.525 -1.36 . . . . 0.0 108.578 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.6 -58.87 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-O 121.506 0.67 . . . . 0.0 109.718 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.48 -23.56 53.81 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.486 -0.759 . . . . 0.0 109.819 -178.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 53.51 -130.17 41.71 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -76.83 -13.07 60.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -1.105 . . . . 0.0 110.114 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.415 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.3 OUTLIER -56.69 -27.62 59.24 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.107 -0.996 . . . . 0.0 109.368 -179.533 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 155.59 5.5 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -156.54 172.93 17.7 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.932 -1.334 . . . . 0.0 110.074 -179.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.3 p90 -116.02 138.65 51.02 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -78.87 171.28 15.41 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -64.33 174.95 1.45 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.927 -1.108 . . . . 0.0 110.338 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.92 149.95 1.44 Allowed Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.497 -0.752 . . . . 0.0 110.301 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 N--CA 1.484 0.965 0 C-N-CA 122.206 1.937 . . . . 0.0 110.508 179.276 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.429 ' HG3' HH11 ' A' ' 36' ' ' ARG . 17.6 mtm-85 . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.93 -25.66 74.2 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.18 -56.01 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.327 0 O-C-N 121.035 -1.273 . . . . 0.0 110.645 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.526 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -62.39 -63.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.946 -1.096 . . . . 0.0 111.495 -177.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' HIS . 70.1 mt-10 -55.97 -47.81 76.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.84 -1.163 . . . . 0.0 110.285 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.3 tt0 -46.41 -57.44 4.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.999 -1.063 . . . . 0.0 110.426 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.559 ' SG ' HD21 ' A' ' 52' ' ' LEU . 61.0 m -84.69 -27.95 26.7 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.124 -0.985 . . . . 0.0 111.083 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.3 t -83.49 -52.1 6.79 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.809 -1.182 . . . . 0.0 109.349 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' GLU . 16.0 t60 -69.77 -28.23 65.59 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.241 -0.912 . . . . 0.0 109.077 179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 m -137.04 160.73 38.08 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.403 -0.811 . . . . 0.0 109.505 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -83.13 99.94 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 p -91.45 152.05 20.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.012 -1.055 . . . . 0.0 109.563 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.92 167.42 14.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.307 -0.871 . . . . 0.0 109.121 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.95 -34.51 68.09 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.625 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -44.15 -56.97 3.68 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.816 0.817 . . . . 0.0 109.979 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.3 mt-30 -60.33 -42.64 96.08 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.559 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.9 mt -62.05 -32.6 73.13 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.55 -9.47 54.1 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -76.06 -28.03 57.47 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.79 -0.569 . . . . 0.0 109.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.6 m-85 -102.57 6.71 39.97 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.368 -0.832 . . . . 0.0 109.992 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.464 ' SG ' HG12 ' A' ' 18' ' ' VAL . 67.3 m -79.81 104.01 10.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 109.33 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.431 ' O ' ' O ' ' A' ' 56' ' ' CYS . 24.9 t-20 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.511 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.584 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -100.28 -91.42 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.437 -0.789 . . . . 0.0 110.425 -178.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.584 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.0 m120 -104.54 27.64 7.73 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.477 -0.764 . . . . 0.0 109.801 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.54 159.79 14.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.26 -0.9 . . . . 0.0 109.523 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.0 OUTLIER -90.26 131.94 35.8 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.602 0.715 . . . . 0.0 110.866 -178.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.51 132.56 43.08 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.98 124.89 10.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.15 -0.969 . . . . 0.0 109.222 179.287 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.43 -147.43 42.28 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.8 m -44.9 -33.17 1.87 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.376 -1.073 . . . . 0.0 110.205 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -49.3 -49.85 41.94 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.003 -1.061 . . . . 0.0 108.815 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.548 HD21 HD12 ' A' ' 38' ' ' ILE . 19.0 tp -58.08 -57.02 14.67 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 21.0 t -45.07 -65.94 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.34 -0.85 . . . . 0.0 109.974 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.491 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.7 mt-10 -47.54 -30.44 3.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -77.62 -54.58 6.22 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 109.223 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -50.92 -36.53 38.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.522 -1.361 . . . . 0.0 108.665 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -48.84 -49.8 37.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.399 -0.813 . . . . 0.0 110.396 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.841 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.6 mp -68.26 -50.73 51.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.524 -1.36 . . . . 0.0 108.579 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -50.89 -59.33 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.456 0.646 . . . . 0.0 110.087 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -23.45 54.21 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.512 -0.743 . . . . 0.0 109.809 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.98 -129.03 30.97 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.204 -1.159 . . . . 0.0 110.204 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -76.49 -15.04 59.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -1.106 . . . . 0.0 110.182 -179.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.514 ' NH1' ' OE2' ' A' ' 53' ' ' GLU . 33.8 mtp180 -54.69 -27.61 41.64 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.032 -1.043 . . . . 0.0 109.087 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.13 5.23 Favored Glycine 0 N--CA 1.486 2.0 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 -179.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.39 172.33 18.69 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.889 -1.36 . . . . 0.0 110.214 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.3 p90 -117.53 135.07 54.19 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -73.18 171.65 12.58 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.8 t -63.36 174.71 1.16 Allowed 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.773 -1.204 . . . . 0.0 109.749 -178.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.22 146.33 0.68 Allowed Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.201 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo . . . . . 0 N--CA 1.484 0.92 0 C-N-CA 122.081 1.854 . . . . 0.0 110.723 179.688 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.66 -24.21 77.1 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.548 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.09 -55.12 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.23 0 O-C-N 121.056 -1.261 . . . . 0.0 110.393 -179.635 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.522 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.12 -64.34 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.013 -1.054 . . . . 0.0 111.559 -177.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 44' ' ' HIS . 73.0 mt-10 -56.55 -44.78 81.26 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.95 -1.094 . . . . 0.0 110.483 -178.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.5 tp60 -48.86 -56.94 7.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.065 -1.022 . . . . 0.0 110.06 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.511 ' SG ' HD21 ' A' ' 52' ' ' LEU . 56.6 m -84.83 -27.26 26.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.105 -0.997 . . . . 0.0 111.08 -178.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.9 t -83.46 -52.35 6.58 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.672 -1.267 . . . . 0.0 109.448 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 40' ' ' GLU . 2.1 t-160 -70.14 -28.85 65.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.327 -0.858 . . . . 0.0 108.84 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.3 p -136.61 162.38 33.29 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.334 -0.853 . . . . 0.0 109.542 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.2 mm -84.09 99.75 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.608 -0.682 . . . . 0.0 109.662 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.0 p -92.28 146.53 23.64 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.13 -0.981 . . . . 0.0 109.342 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.72 167.61 18.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.232 -0.918 . . . . 0.0 109.212 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.593 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.3 mt -57.08 -34.25 68.1 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -43.67 -57.25 3.28 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.874 0.845 . . . . 0.0 110.138 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -60.33 -41.87 94.44 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.511 HD21 ' SG ' ' A' ' 42' ' ' CYS . 78.2 mt -62.73 -28.27 69.85 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.514 ' OE2' ' NH1' ' A' ' 22' ' ' ARG . 1.8 tm-20 -74.26 -8.72 57.2 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -78.84 -26.96 44.16 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.875 -0.515 . . . . 0.0 109.946 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.421 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 14.5 m-85 -100.31 5.63 44.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.253 -0.905 . . . . 0.0 110.38 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 72.7 m -82.69 111.27 18.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.843 -1.161 . . . . 0.0 109.462 179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 57' ' ' ASN . 62.7 t-20 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.819 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.594 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -101.13 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 110.697 -178.658 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.594 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -102.97 26.58 7.99 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 109.807 -179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.52 161.88 13.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.331 -0.855 . . . . 0.0 109.443 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -94.27 136.5 34.49 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.639 0.733 . . . . 0.0 110.32 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 0.8 OUTLIER -99.64 131.89 45.34 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.461 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.8 125.31 11.7 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.192 -0.943 . . . . 0.0 109.186 179.334 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -149.14 44.34 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.8 m -44.96 -31.61 1.34 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.373 -1.075 . . . . 0.0 110.335 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.461 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -48.73 -50.04 35.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.966 -1.084 . . . . 0.0 108.761 179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -57.0 -54.57 45.24 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.458 -0.776 . . . . 0.0 109.534 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.411 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.66 -66.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 110.096 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 50.8 mt-10 -47.67 -27.63 2.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.387 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.08 -54.49 5.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.392 -0.818 . . . . 0.0 109.17 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.92 -34.81 43.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.398 -1.439 . . . . 0.0 108.585 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 20' ' ' GLY . 57.2 t80 -49.94 -50.04 47.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.327 -0.858 . . . . 0.0 110.231 -179.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -67.68 -50.81 55.78 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.573 -1.329 . . . . 0.0 108.64 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.3 t -50.62 -58.98 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.543 0.687 . . . . 0.0 109.759 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.23 -23.76 54.57 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.528 -0.732 . . . . 0.0 109.768 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.8 -127.2 30.91 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -78.98 -11.67 60.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.409 -1.054 . . . . 0.0 110.028 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.407 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -57.61 -27.18 62.52 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.162 -0.961 . . . . 0.0 109.287 -179.568 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 154.8 5.01 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.225 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -156.47 172.52 18.38 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.859 -1.377 . . . . 0.0 110.278 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.2 p90 -116.95 132.57 56.67 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -72.26 171.44 12.11 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.8 t -63.73 174.56 1.36 Allowed 'General case' 0 C--N 1.297 -1.69 0 O-C-N 120.706 -1.246 . . . . 0.0 109.669 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.35 0.89 Allowed Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.398 -0.814 . . . . 0.0 110.078 -178.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo . . . . . 0 N--CA 1.484 0.951 0 C-N-CA 122.102 1.868 . . . . 0.0 110.429 179.474 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.424 ' HG3' HH11 ' A' ' 36' ' ' ARG . 13.5 mtm-85 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.43 -24.13 76.22 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.91 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 O-C-N 121.006 -1.291 . . . . 0.0 110.437 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.4 t -62.02 -64.18 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.038 -1.038 . . . . 0.0 111.521 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.443 ' O ' ' N ' ' A' ' 44' ' ' HIS . 83.9 mt-10 -55.84 -46.3 78.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.908 -1.12 . . . . 0.0 110.485 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.9 tp60 -48.14 -56.5 7.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.059 -1.026 . . . . 0.0 110.299 -179.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.552 ' SG ' HD21 ' A' ' 52' ' ' LEU . 58.5 m -85.15 -26.36 26.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.143 -0.973 . . . . 0.0 111.271 -178.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.9 t -83.4 -52.4 6.56 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.608 -1.307 . . . . 0.0 109.418 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.443 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.1 t-80 -69.47 -26.68 64.69 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.874 . . . . 0.0 109.339 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -137.04 173.31 11.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.338 -0.851 . . . . 0.0 109.827 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -93.17 100.04 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.4 p -93.78 145.03 24.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.016 -1.053 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -80.53 166.53 21.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.882 . . . . 0.0 109.35 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -56.81 -34.36 67.62 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.45 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -44.03 -57.29 3.44 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.904 0.859 . . . . 0.0 109.943 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -59.89 -42.94 94.89 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.552 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.9 mt -61.83 -31.91 72.19 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.23 -9.68 56.58 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -75.83 -28.33 58.23 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.803 -0.561 . . . . 0.0 109.598 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 6.9 m-85 -102.72 7.01 39.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.406 -0.808 . . . . 0.0 109.984 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 60.5 m -78.58 108.6 12.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.96 -1.087 . . . . 0.0 109.409 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 57' ' ' ASN . 2.1 t-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.483 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.622 HG23 ' H ' ' A' ' 3' ' ' ASN . 1.1 m -102.73 -91.99 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.506 -0.746 . . . . 0.0 110.762 -178.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.622 ' H ' HG23 ' A' ' 2' ' ' VAL . 3.7 m120 -99.59 25.3 7.24 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.232 -0.917 . . . . 0.0 109.883 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.95 157.35 15.94 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.83 . . . . 0.0 109.635 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.421 ' HB3' HD13 ' A' ' 46' ' ' ILE . 3.5 p-80 -92.69 135.9 33.7 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.574 0.702 . . . . 0.0 109.957 -179.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.418 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -97.53 136.03 38.52 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.472 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -151.67 125.16 8.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.303 179.4 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -146.49 40.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.7 m -47.84 -31.83 5.45 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -1.086 . . . . 0.0 110.209 -179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.472 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.2 m-20 -49.03 -49.83 39.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.881 -1.137 . . . . 0.0 108.645 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 38' ' ' ILE . 19.6 tp -56.67 -55.09 38.49 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.415 -0.803 . . . . 0.0 109.401 179.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -46.41 -66.04 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.283 -0.886 . . . . 0.0 110.001 -179.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.1 mt-10 -47.51 -28.8 2.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.368 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.02 -54.61 5.84 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 109.173 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.4 mt -51.26 -34.93 34.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.509 -1.369 . . . . 0.0 108.667 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.6 t80 -49.96 -48.79 51.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 110.394 -179.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.82 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.55 -50.71 42.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.495 -1.378 . . . . 0.0 108.529 179.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -50.86 -59.09 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 121.512 0.673 . . . . 0.0 110.02 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.4 m -76.04 -23.98 55.15 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.441 -0.787 . . . . 0.0 109.699 -178.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.42 -133.55 46.34 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -75.5 -12.13 60.17 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.325 -1.103 . . . . 0.0 109.963 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -56.32 -26.93 54.03 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.002 -179.544 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.86 154.72 5.11 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.5 172.91 17.72 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.999 -1.295 . . . . 0.0 110.079 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.546 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.6 p90 -117.38 139.79 50.41 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.48 170.43 16.59 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.5 t -64.73 174.94 1.61 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.947 -1.095 . . . . 0.0 110.069 -179.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.54 148.56 0.52 Allowed Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.651 -0.655 . . . . 0.0 110.135 -178.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 N--CA 1.487 1.091 0 C-N-CA 122.255 1.97 . . . . 0.0 110.995 179.911 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.0 -25.74 72.9 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.39 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.31 0 O-C-N 121.057 -1.261 . . . . 0.0 110.385 -179.601 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 2.9 t -63.46 -63.91 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.962 -1.086 . . . . 0.0 111.461 -177.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.444 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.4 mt-10 -55.62 -46.18 77.43 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.864 -1.147 . . . . 0.0 110.43 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -48.39 -56.77 7.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 110.204 -179.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.494 ' SG ' HD21 ' A' ' 52' ' ' LEU . 73.0 m -85.1 -28.07 25.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 111.427 -178.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 53.9 t -83.29 -52.33 6.66 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.66 -1.275 . . . . 0.0 109.295 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.444 ' N ' ' O ' ' A' ' 40' ' ' GLU . 5.8 t60 -69.55 -27.04 64.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.066 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.7 m -137.17 157.4 46.76 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.496 -0.753 . . . . 0.0 109.49 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.421 HD13 ' HB3' ' A' ' 5' ' ' HIS . 5.8 mm -81.55 99.73 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.6 p -89.51 163.84 15.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.998 -1.064 . . . . 0.0 109.697 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -96.18 166.84 11.55 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.416 -0.802 . . . . 0.0 109.186 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.601 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.59 -33.29 69.82 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -44.76 -57.86 3.45 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.791 0.805 . . . . 0.0 110.236 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -61.07 -40.84 95.22 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.061 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.494 HD21 ' SG ' ' A' ' 42' ' ' CYS . 76.1 mt -62.41 -25.09 67.76 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.66 -9.03 58.75 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -78.96 -26.82 43.51 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.783 -0.573 . . . . 0.0 109.705 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 17.2 m-85 -99.73 4.39 45.43 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.348 -0.845 . . . . 0.0 110.339 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.406 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 71.0 m -82.84 111.22 18.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.883 -1.136 . . . . 0.0 109.367 179.639 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.406 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.9 t-20 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.058 -0.972 . . . . 0.0 109.377 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.598 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -102.85 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.445 -0.784 . . . . 0.0 110.536 -178.856 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.598 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.5 26.77 6.91 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.393 -0.817 . . . . 0.0 109.892 -179.318 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.642 ' NE2' ' H2 ' ' A' ' 1' ' ' PHE . 2.0 pt20 -95.23 160.79 14.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -92.87 134.77 34.75 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.514 0.673 . . . . 0.0 110.67 -178.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -99.49 132.56 44.74 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.262 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.47 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -148.49 125.1 11.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.094 -1.004 . . . . 0.0 109.332 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -148.52 43.26 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.3 m -45.11 -32.28 1.72 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.347 -1.09 . . . . 0.0 110.245 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.47 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.54 -50.52 31.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.991 -1.068 . . . . 0.0 108.823 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.08 -54.79 42.76 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.434 -0.791 . . . . 0.0 109.505 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -46.56 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.294 -0.879 . . . . 0.0 109.991 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 46.9 mt-10 -47.59 -29.31 2.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.923 . . . . 0.0 109.397 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.42 -54.58 6.02 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.375 -0.828 . . . . 0.0 109.363 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.12 -36.1 38.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.456 -1.402 . . . . 0.0 108.794 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -49.43 -49.0 46.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.341 -0.849 . . . . 0.0 110.482 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.816 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -69.02 -50.32 49.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.61 -1.306 . . . . 0.0 108.496 179.381 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -51.03 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.504 0.669 . . . . 0.0 110.113 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.3 m -75.52 -23.63 56.72 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.495 -0.753 . . . . 0.0 109.821 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.47 -126.76 25.09 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -77.45 -15.49 59.29 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.395 -1.062 . . . . 0.0 110.186 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -54.85 -27.9 45.81 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.174 -0.953 . . . . 0.0 109.409 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.79 154.88 5.13 Favored Glycine 0 N--CA 1.487 2.033 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.38 172.53 18.34 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.918 -1.342 . . . . 0.0 110.269 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -118.01 129.28 55.49 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -68.62 171.45 7.62 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 178.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -63.41 174.45 1.27 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 120.74 -1.225 . . . . 0.0 109.468 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.59 147.64 1.03 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.182 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo . . . . . 0 N--CA 1.483 0.883 0 C-N-CA 122.098 1.865 . . . . 0.0 110.158 179.179 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 . . . . . 0 N--CA 1.488 1.435 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.59 -21.84 65.74 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.28 -55.53 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 O-C-N 121.024 -1.28 . . . . 0.0 110.052 -179.714 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -62.2 -63.84 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.023 -1.048 . . . . 0.0 111.094 -177.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.456 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.9 mt-10 -54.74 -48.49 72.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.989 -1.069 . . . . 0.0 110.557 -178.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.0 tt0 -47.22 -56.58 6.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.069 -1.019 . . . . 0.0 110.493 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.526 ' SG ' HD21 ' A' ' 52' ' ' LEU . 57.1 m -84.66 -26.51 27.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.228 -0.92 . . . . 0.0 111.363 -178.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.3 t -83.77 -52.39 6.44 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.642 -1.286 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.4 t-80 -68.96 -27.29 65.6 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.235 -0.916 . . . . 0.0 109.23 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.436 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.6 t -137.23 173.17 11.97 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.416 -0.803 . . . . 0.0 109.88 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 9.7 mm -92.3 99.85 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.561 -0.712 . . . . 0.0 109.315 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.8 p -93.0 143.3 26.37 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.014 -1.054 . . . . 0.0 109.39 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -79.39 166.45 22.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.447 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.0 mt -56.36 -34.11 66.33 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.06 -57.49 3.35 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 121.87 0.843 . . . . 0.0 109.971 179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.9 mt-30 -60.06 -42.15 93.9 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.526 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.8 mt -62.79 -29.05 70.41 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.11 -8.9 57.81 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -78.43 -26.89 46.41 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.853 -0.529 . . . . 0.0 109.864 -179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.422 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 15.3 m-85 -100.75 5.24 43.57 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.265 -0.897 . . . . 0.0 110.227 -179.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 71.6 m -83.35 111.48 19.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.97 -1.081 . . . . 0.0 109.49 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.441 179.959 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.998 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.59 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -101.99 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.421 -0.799 . . . . 0.0 110.678 -178.616 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.59 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -102.02 25.57 8.59 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.429 -0.794 . . . . 0.0 109.991 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.97 160.18 14.59 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.548 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 9.8 p80 -92.95 136.19 33.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.514 -0.741 . . . . 0.0 110.552 -178.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.35 127.06 42.99 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.304 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 82.2 m -142.89 125.29 15.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.296 -0.878 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.17 -149.31 45.61 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.5 m -44.92 -30.84 1.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.421 -1.047 . . . . 0.0 110.284 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.437 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 17.3 m-20 -48.7 -50.61 32.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.927 -1.108 . . . . 0.0 108.787 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.492 HD11 HD22 ' A' ' 52' ' ' LEU . 19.9 tp -55.42 -53.99 49.29 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -47.04 -66.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.837 . . . . 0.0 109.899 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 72.5 mt-10 -47.79 -26.77 1.74 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.371 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.998 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.02 -54.73 5.3 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.384 -0.823 . . . . 0.0 109.131 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.84 -34.28 39.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.406 -1.434 . . . . 0.0 108.581 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.6 t80 -50.16 -49.85 50.88 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.366 -0.834 . . . . 0.0 110.179 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.78 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.27 -50.76 51.59 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.584 -1.323 . . . . 0.0 108.681 179.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.6 t -50.52 -58.64 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.5 0.667 . . . . 0.0 109.757 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -77.0 -23.34 52.23 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 -178.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 46.95 -120.78 5.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -80.22 -13.7 59.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.299 -1.118 . . . . 0.0 110.15 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -57.95 -28.27 64.17 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.112 -0.992 . . . . 0.0 109.528 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.59 154.19 4.57 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -156.87 172.95 17.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.886 -1.361 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.8 p90 -119.15 139.51 51.68 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -80.52 169.82 17.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.931 -1.106 . . . . 0.0 108.143 179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.2 t -65.59 175.71 1.74 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.117 -0.989 . . . . 0.0 110.404 -179.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -45.22 149.87 0.88 Allowed Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.459 -0.776 . . . . 0.0 109.895 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo . . . . . 0 N--CA 1.484 0.95 0 C-N-CA 122.178 1.919 . . . . 0.0 110.581 179.421 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.92 -25.73 73.02 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.08 -56.33 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.061 -1.258 . . . . 0.0 110.46 -179.67 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -62.27 -64.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 120.961 -1.087 . . . . 0.0 111.637 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 44' ' ' HIS . 62.4 mt-10 -55.79 -46.79 77.9 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.85 -1.157 . . . . 0.0 110.331 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.0 tt0 -47.67 -57.49 5.45 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.086 -1.009 . . . . 0.0 110.167 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.598 ' SG ' HD21 ' A' ' 52' ' ' LEU . 63.1 m -84.77 -26.7 27.39 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.137 -0.977 . . . . 0.0 111.101 -178.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.0 t -83.25 -52.3 6.7 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.826 -1.171 . . . . 0.0 109.481 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.502 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.1 t-80 -71.24 -26.46 62.92 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.231 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.2 m -136.83 157.91 45.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.39 -0.819 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -82.27 99.73 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.242 -0.911 . . . . 0.0 109.013 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.7 p -90.75 151.62 21.14 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.137 -0.977 . . . . 0.0 109.375 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -85.08 166.49 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.02 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -56.54 -34.04 66.67 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -44.44 -57.5 3.52 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.855 0.835 . . . . 0.0 110.023 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.07 -42.35 94.37 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.598 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.9 mt -62.29 -31.8 72.44 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.13 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.89 -9.46 54.96 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -75.54 -28.37 59.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.799 -0.563 . . . . 0.0 109.712 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.1 m-85 -102.03 6.32 41.03 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.333 -0.854 . . . . 0.0 110.018 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 73.4 m -80.4 109.0 14.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.93 -1.106 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.417 ' OXT' ' OD1' ' A' ' 57' ' ' ASN . 53.7 t-20 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.514 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -104.04 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.407 -0.808 . . . . 0.0 110.726 -178.661 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -101.66 25.85 8.04 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.409 -0.807 . . . . 0.0 109.936 -179.06 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.635 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.88 160.2 14.59 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.321 -0.862 . . . . 0.0 109.85 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' A' ' 5' ' ' HIS . 0.1 OUTLIER -92.76 132.09 37.26 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.643 -0.661 . . . . 0.0 110.441 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -95.4 132.8 40.06 Favored 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.027 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.486 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -149.12 125.24 10.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.033 -1.042 . . . . 0.0 109.327 179.244 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.88 -147.4 41.49 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -45.89 -32.07 2.47 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.362 -1.081 . . . . 0.0 110.194 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.486 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.0 m-20 -49.27 -51.06 36.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.092 . . . . 0.0 108.762 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.512 HD21 HD12 ' A' ' 38' ' ' ILE . 21.3 tp -56.1 -51.64 67.16 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.4 -0.812 . . . . 0.0 109.391 179.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 t -49.44 -66.28 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.219 -0.926 . . . . 0.0 109.968 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.4 mt-10 -47.56 -26.42 1.44 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.412 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.03 -54.64 5.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.323 -0.861 . . . . 0.0 109.058 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.85 -33.94 38.4 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.412 -1.43 . . . . 0.0 108.635 179.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.2 t80 -50.58 -50.06 54.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.926 . . . . 0.0 110.236 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.78 -50.82 54.95 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.534 -1.354 . . . . 0.0 108.547 179.387 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.435 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.4 t -50.7 -59.01 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 CA-C-O 121.527 0.68 . . . . 0.0 109.668 -179.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -75.87 -23.54 55.63 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.48 -0.763 . . . . 0.0 109.819 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.02 -130.64 44.05 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -77.1 -14.44 59.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -1.094 . . . . 0.0 110.087 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.408 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.3 OUTLIER -54.88 -27.8 45.53 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.149 -0.969 . . . . 0.0 109.327 -179.628 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.76 156.39 6.07 Favored Glycine 0 N--CA 1.485 1.964 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.41 172.93 17.65 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.022 -1.281 . . . . 0.0 110.243 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.9 p90 -115.73 132.84 56.52 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -73.23 171.75 12.42 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 t -63.55 173.93 1.5 Allowed 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 118.578 -1.249 . . . . 0.0 109.302 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -44.41 148.82 0.81 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.199 -0.938 . . . . 0.0 110.139 -178.088 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo . . . . . 0 N--CA 1.484 0.958 0 C-N-CA 122.086 1.857 . . . . 0.0 110.682 179.577 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.02 -21.86 54.2 Favored Glycine 0 N--CA 1.491 2.36 0 O-C-N 121.133 -0.98 . . . . 0.0 110.911 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -100.31 -54.24 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 120.879 -1.366 . . . . 0.0 110.457 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.525 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -61.42 -63.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 111.704 -177.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -58.52 -38.15 77.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 111.079 -178.101 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -55.6 -53.68 53.43 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.833 -1.167 . . . . 0.0 109.195 -179.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.63 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -85.76 -26.73 25.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 110.769 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.8 t -83.86 -52.5 6.32 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.701 -1.249 . . . . 0.0 109.541 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.412 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.6 t60 -71.39 -26.41 62.77 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.207 -0.933 . . . . 0.0 109.174 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.7 m -137.06 160.28 39.4 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.363 -0.835 . . . . 0.0 109.645 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.2 mm -83.21 100.28 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.49 -0.756 . . . . 0.0 109.221 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -93.0 147.75 22.57 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.105 -0.997 . . . . 0.0 109.683 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.7 167.76 17.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -58.4 -34.04 70.3 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -44.1 -57.12 3.57 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 121.797 0.808 . . . . 0.0 110.154 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 9.8 mt-30 -61.59 -41.63 97.7 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.63 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.0 mt -61.84 -31.69 71.97 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.48 -9.79 57.47 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -75.5 -28.31 59.13 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.816 -0.552 . . . . 0.0 109.571 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.438 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.5 m-85 -101.83 7.04 41.81 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.399 -0.813 . . . . 0.0 110.017 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.435 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -80.43 106.39 12.41 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.897 -1.127 . . . . 0.0 109.398 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.65 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.994 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.601 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.0 -91.83 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.476 -0.765 . . . . 0.0 110.34 -179.082 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.79 HD22 ' H ' ' A' ' 3' ' ' ASN . 0.0 OUTLIER -101.94 27.4 6.57 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.465 -0.772 . . . . 0.0 110.074 -179.323 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.7 pt20 -95.28 157.66 15.8 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.232 -0.917 . . . . 0.0 109.166 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -90.2 132.05 35.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.582 -0.699 . . . . 0.0 110.718 -178.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -95.1 130.5 41.78 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.184 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.424 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.5 m -143.5 125.27 15.07 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.24 -0.913 . . . . 0.0 109.388 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.16 -150.04 46.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -44.66 -30.34 0.91 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.412 -1.052 . . . . 0.0 110.284 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.424 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.67 -50.14 34.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.953 -1.092 . . . . 0.0 108.791 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.51 HD21 HD12 ' A' ' 38' ' ' ILE . 20.3 tp -55.76 -55.71 29.18 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.451 -0.781 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 19.3 t -45.8 -65.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.385 -0.822 . . . . 0.0 109.946 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 84.8 mt-10 -47.73 -29.68 3.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.436 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.994 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.31 -54.45 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.84 . . . . 0.0 109.239 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -51.34 -35.88 40.32 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.496 -1.378 . . . . 0.0 108.712 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.6 t80 -49.4 -48.84 46.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.414 -0.804 . . . . 0.0 110.461 -179.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.832 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.38 -50.45 46.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.488 -1.383 . . . . 0.0 108.539 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -50.84 -59.23 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 CA-C-O 121.558 0.694 . . . . 0.0 110.23 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -24.04 54.23 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.402 -0.811 . . . . 0.0 109.804 -178.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.37 -126.19 23.2 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -77.32 -14.54 59.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -1.077 . . . . 0.0 110.28 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.406 ' HB3' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.52 -27.6 57.8 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.36 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.53 154.51 4.69 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -156.52 172.6 18.27 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.923 -1.34 . . . . 0.0 110.418 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.3 p90 -118.29 138.75 52.17 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -77.45 170.83 15.87 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.6 t -64.3 175.29 1.35 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.869 -1.144 . . . . 0.0 109.807 -179.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.15 148.03 0.52 Allowed Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.492 -0.755 . . . . 0.0 110.295 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo . . . . . 0 N--CA 1.484 0.952 0 C-N-CA 122.091 1.861 . . . . 0.0 110.462 179.469 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.585 HH11 ' CG ' ' A' ' 36' ' ' ARG . 1.4 mtt-85 . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.85 -25.99 74.02 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.52 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.21 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.315 0 O-C-N 121.002 -1.293 . . . . 0.0 110.436 -179.502 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.52 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.25 -64.52 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.133 . . . . 0.0 111.564 -177.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' HIS . 35.4 mt-10 -55.94 -45.74 78.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.854 -1.154 . . . . 0.0 110.295 -178.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.461 ' NE2' ' OE1' ' A' ' 51' ' ' GLN . 53.0 tt0 -47.48 -57.87 4.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.084 -1.01 . . . . 0.0 110.15 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.568 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.1 m -84.83 -27.0 27.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.156 -0.965 . . . . 0.0 111.02 -178.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.8 t -83.32 -51.44 7.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.845 -1.16 . . . . 0.0 109.429 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.519 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.0 t60 -73.47 -26.16 60.79 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.339 -0.851 . . . . 0.0 109.48 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -136.86 157.69 46.18 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.4 -0.813 . . . . 0.0 109.876 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.5 mm -79.95 99.56 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.461 -0.774 . . . . 0.0 109.229 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.6 p -92.57 154.9 18.14 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.056 -1.027 . . . . 0.0 109.637 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -88.85 166.5 13.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.296 -0.878 . . . . 0.0 108.988 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.7 mt -58.4 -32.78 68.94 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.39 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.28 -57.31 3.55 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.804 0.811 . . . . 0.0 110.159 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.461 ' OE1' ' NE2' ' A' ' 41' ' ' GLN . 24.6 mt-30 -61.68 -42.04 98.38 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.71 -0.796 . . . . 0.0 108.998 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.568 HD21 ' SG ' ' A' ' 42' ' ' CYS . 74.6 mt -61.29 -24.93 66.76 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.71 -8.74 58.39 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -79.67 -26.78 40.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.794 -0.566 . . . . 0.0 109.849 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 16.3 m-85 -99.06 4.62 47.12 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.282 -0.886 . . . . 0.0 110.31 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 70.9 m -81.26 111.34 17.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.939 -1.101 . . . . 0.0 109.496 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.64 179.993 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -99.77 -91.57 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.353 -0.842 . . . . 0.0 110.197 -179.124 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.3 p-10 -104.33 28.22 7.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.671 -0.643 . . . . 0.0 109.431 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.628 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.75 157.41 15.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.163 -0.96 . . . . 0.0 109.123 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.477 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 16.4 p80 -89.0 131.73 35.05 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.526 0.679 . . . . 0.0 110.713 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.1 mp -97.16 132.44 42.94 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.483 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.24 125.36 10.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.189 -0.944 . . . . 0.0 109.278 179.286 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.72 -146.51 40.31 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.7 m -46.75 -32.5 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.365 -1.079 . . . . 0.0 110.155 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.483 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.0 -50.44 35.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.965 -1.084 . . . . 0.0 108.783 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.526 HD21 HD12 ' A' ' 38' ' ' ILE . 18.1 tp -56.9 -55.73 30.71 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.394 -0.816 . . . . 0.0 109.529 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 12' ' ' VAL . 15.6 t -46.13 -66.15 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.342 -0.849 . . . . 0.0 110.085 -179.41 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 75.8 mt-10 -47.94 -26.75 1.85 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.197 -0.939 . . . . 0.0 109.298 -179.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.08 -54.21 5.74 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.333 -0.854 . . . . 0.0 109.088 179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.87 -34.77 42.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.361 -1.462 . . . . 0.0 108.536 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 20' ' ' GLY . 58.0 t80 -49.82 -49.59 48.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.374 -0.828 . . . . 0.0 110.358 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.777 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.58 -50.66 49.99 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.584 -1.322 . . . . 0.0 108.598 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.428 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.67 -58.88 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.49 0.662 . . . . 0.0 109.703 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -76.51 -23.48 53.72 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.526 -0.734 . . . . 0.0 109.9 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.94 -127.08 31.16 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.12 -14.96 59.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.402 -1.057 . . . . 0.0 110.101 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.1 mtp180 -54.95 -28.99 55.61 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.098 -1.001 . . . . 0.0 109.171 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.91 5.73 Favored Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.5 172.72 18.05 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.907 -1.349 . . . . 0.0 110.174 -179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.09 137.65 51.94 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -75.96 171.95 13.56 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -63.13 174.37 1.17 Allowed 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.762 -1.211 . . . . 0.0 109.812 -178.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.45 147.37 1.03 Allowed Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.369 -0.832 . . . . 0.0 110.096 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo . . . . . 0 N--CA 1.484 0.915 0 C-N-CA 122.107 1.871 . . . . 0.0 110.315 179.352 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.525 HH11 ' HG2' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.85 -26.66 58.19 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.93 -55.8 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.335 0 O-C-N 120.895 -1.356 . . . . 0.0 110.566 -179.461 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.8 t -63.26 -64.39 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.905 -1.122 . . . . 0.0 111.295 -177.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 44' ' ' HIS . 80.9 mt-10 -54.47 -47.54 72.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.89 -1.131 . . . . 0.0 110.277 -178.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 48.5 tt0 -46.68 -58.52 3.77 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.155 -0.966 . . . . 0.0 110.417 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.47 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.7 m -84.87 -25.88 27.71 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.131 -0.981 . . . . 0.0 111.435 -178.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.3 t -83.61 -51.71 7.07 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.58 -1.325 . . . . 0.0 109.068 179.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.477 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t60 -68.13 -27.9 66.85 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.419 -0.8 . . . . 0.0 109.341 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 14.2 t -137.35 173.14 12.0 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.353 -0.842 . . . . 0.0 110.188 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.2 mm -91.82 99.43 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.0 p -93.92 152.99 18.46 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.074 -1.016 . . . . 0.0 109.548 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.28 167.54 13.47 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.902 . . . . 0.0 109.125 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.4 -34.53 68.98 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -43.67 -57.01 3.4 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.852 0.834 . . . . 0.0 110.038 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.1 mt-30 -60.1 -42.19 94.13 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.485 HD22 HD11 ' A' ' 11' ' ' LEU . 80.1 mt -62.54 -32.39 73.33 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.86 -9.24 54.12 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -76.34 -27.64 56.56 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.9 m-85 -102.11 6.64 40.99 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 95.7 m -80.95 105.2 12.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.842 -1.161 . . . . 0.0 109.154 179.567 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.431 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.4 t-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.633 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.9 OUTLIER -104.5 -91.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.751 . . . . 0.0 110.574 -178.767 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.633 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.0 m120 -99.95 25.82 6.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.283 -0.886 . . . . 0.0 109.742 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.635 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.72 159.14 15.13 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.308 -0.87 . . . . 0.0 109.494 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -93.36 134.46 35.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.616 -0.678 . . . . 0.0 110.283 -179.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -95.94 127.94 42.4 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.465 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.436 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.2 m -143.51 125.48 15.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.892 . . . . 0.0 109.263 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.11 -149.57 46.11 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -44.84 -30.21 0.94 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -1.032 . . . . 0.0 110.347 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.436 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.7 m-20 -49.12 -50.89 35.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.895 -1.128 . . . . 0.0 108.818 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.556 HD21 HD12 ' A' ' 38' ' ' ILE . 20.0 tp -55.16 -52.11 64.35 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.361 -0.837 . . . . 0.0 109.198 179.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 t -49.15 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 109.896 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 28.4 mt-10 -47.9 -25.75 1.44 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.447 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.57 -54.9 5.03 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.282 -0.887 . . . . 0.0 109.063 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.65 -34.35 37.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.335 -1.478 . . . . 0.0 108.595 179.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.422 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.5 t80 -50.23 -49.92 51.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.326 -0.859 . . . . 0.0 110.275 -179.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -67.91 -50.85 53.77 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.65 -1.281 . . . . 0.0 108.626 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.9 t -50.52 -58.68 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 CA-C-O 121.511 0.672 . . . . 0.0 109.854 -179.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -77.03 -23.12 52.13 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.483 -0.761 . . . . 0.0 109.997 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 47.7 -122.27 7.61 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -79.13 -15.3 58.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 0.0 110.275 -179.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.2 mtp180 -56.62 -28.35 60.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.123 -0.985 . . . . 0.0 109.491 -179.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.49 155.06 4.95 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.399 -1.881 . . . . 0.0 108.399 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -156.68 172.74 18.07 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.898 -1.354 . . . . 0.0 110.449 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 30.5 p90 -118.4 133.93 55.47 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -73.41 171.18 13.58 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -64.29 175.1 1.39 Allowed 'General case' 0 C--N 1.296 -1.756 0 O-C-N 120.961 -1.087 . . . . 0.0 109.698 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.51 151.87 0.45 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.423 -0.798 . . . . 0.0 110.121 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 N--CA 1.484 0.94 0 C-N-CA 122.004 1.803 . . . . 0.0 110.259 179.421 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 38' ' ' ILE . 16.6 mtm-85 . . . . . 0 N--CA 1.484 1.257 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.9 -23.98 0.08 OUTLIER Glycine 0 N--CA 1.49 2.286 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.556 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.4 -55.61 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.152 -1.204 . . . . 0.0 109.97 179.674 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.7 t -62.69 -64.15 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.087 -1.008 . . . . 0.0 112.069 -176.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -59.93 -39.59 86.0 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.727 -1.233 . . . . 0.0 110.719 -178.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.2 tt0 -51.26 -56.71 11.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.877 -1.139 . . . . 0.0 109.477 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.9 m -85.46 -26.58 26.25 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.381 -0.824 . . . . 0.0 111.045 -179.21 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.3 t -84.07 -52.4 6.32 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.706 -1.246 . . . . 0.0 109.673 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.427 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.2 t60 -69.99 -26.97 64.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.114 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -136.78 160.58 38.42 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.484 -0.76 . . . . 0.0 109.107 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.9 mm -84.65 99.73 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -90.42 164.18 14.39 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.065 -1.022 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -96.82 166.77 11.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.36 -0.838 . . . . 0.0 109.007 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -57.68 -34.34 69.31 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -44.08 -57.85 3.16 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.86 0.838 . . . . 0.0 110.014 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 7.8 mt-30 -59.8 -42.57 93.73 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -179.78 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.2 mt -62.21 -32.08 72.7 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.91 -9.26 54.35 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -76.21 -28.04 57.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.788 -0.57 . . . . 0.0 109.649 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.2 m-85 -101.83 6.21 41.45 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.354 -0.841 . . . . 0.0 110.102 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.462 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -79.8 106.74 12.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.939 -1.101 . . . . 0.0 109.323 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.41 179.967 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.62 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.6 -91.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.404 -0.81 . . . . 0.0 110.626 -178.68 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.62 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -101.05 25.6 7.92 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 -179.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.628 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -96.0 158.54 15.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.36 -0.837 . . . . 0.0 109.635 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.1 p-80 -92.04 135.89 33.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.635 -0.665 . . . . 0.0 110.255 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -97.05 126.55 42.27 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.425 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.5 m -142.35 125.14 16.0 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.292 -0.88 . . . . 0.0 109.241 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.9 -148.74 45.18 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.354 -1.098 . . . . 0.0 110.354 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -44.67 -31.08 1.05 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.383 -1.069 . . . . 0.0 110.349 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.425 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.01 -50.66 34.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.946 -1.097 . . . . 0.0 108.841 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 38' ' ' ILE . 19.1 tp -55.53 -54.01 49.32 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.405 -0.809 . . . . 0.0 109.283 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.415 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.7 t -47.43 -66.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.012 -179.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 52.0 mt-10 -47.72 -26.92 1.73 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.343 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.81 -54.93 5.17 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.467 -0.771 . . . . 0.0 109.188 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.54 -34.06 34.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.394 -1.441 . . . . 0.0 108.603 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.46 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.7 t80 -50.48 -50.75 51.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.276 -179.612 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.3 -50.8 58.76 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.532 -1.355 . . . . 0.0 108.658 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.457 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.43 -59.01 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.569 0.7 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.72 -23.27 53.08 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.539 -0.725 . . . . 0.0 109.92 -178.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.02 -123.2 10.55 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.57 -15.12 58.24 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -1.114 . . . . 0.0 110.084 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -55.15 -28.81 55.52 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.15 -0.969 . . . . 0.0 109.337 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.47 154.66 4.72 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -156.57 172.9 17.74 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 120.901 -1.352 . . . . 0.0 110.434 -179.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.541 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.7 p90 -118.11 138.27 52.37 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -77.67 170.61 16.27 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 t -64.68 175.0 1.56 Allowed 'General case' 0 C--N 1.299 -1.617 0 O-C-N 120.998 -1.064 . . . . 0.0 110.111 -179.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -45.11 148.4 1.05 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.41 -0.806 . . . . 0.0 110.03 -178.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo . . . . . 0 N--CA 1.484 0.964 0 C-N-CA 122.121 1.881 . . . . 0.0 110.573 179.465 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.727 ' N ' ' HE ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.442 ' N ' ' HE ' ' A' ' 36' ' ' ARG . . . -56.23 -28.6 54.89 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.63 -55.98 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 O-C-N 120.929 -1.336 . . . . 0.0 110.704 -179.283 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.11 -64.24 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.911 -1.118 . . . . 0.0 111.421 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -54.46 -47.8 72.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.773 -1.204 . . . . 0.0 110.3 -178.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -47.13 -58.97 3.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.08 -1.013 . . . . 0.0 110.459 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.0 m -84.54 -25.56 28.65 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -0.946 . . . . 0.0 111.307 -178.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.96 -52.3 6.45 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.65 -1.281 . . . . 0.0 109.214 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.48 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.9 t-80 -67.44 -28.88 68.26 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.32 -0.863 . . . . 0.0 109.243 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -136.9 173.28 11.87 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.379 -0.826 . . . . 0.0 109.704 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 3.6 mm -92.56 99.66 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.6 p -91.75 151.68 20.51 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.063 -1.023 . . . . 0.0 109.632 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -84.97 166.34 16.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.233 -0.917 . . . . 0.0 109.223 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.2 -34.18 68.25 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -44.22 -57.42 3.46 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.914 0.864 . . . . 0.0 110.014 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.83 -42.67 94.08 Favored 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.0 mt -62.01 -32.39 72.87 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.6 -9.77 55.47 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -75.73 -27.85 58.31 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.781 -0.575 . . . . 0.0 109.584 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.9 m-85 -101.85 5.5 41.07 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.373 -0.829 . . . . 0.0 110.056 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.457 ' SG ' HG12 ' A' ' 18' ' ' VAL . 89.2 m -79.95 111.14 16.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.901 -1.124 . . . . 0.0 109.449 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.447 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -98.57 -91.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.369 -0.832 . . . . 0.0 110.803 -178.37 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -104.17 25.92 9.45 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.401 -0.812 . . . . 0.0 109.988 -179.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . 0.626 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 3.2 pt20 -95.85 157.95 15.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.247 -0.908 . . . . 0.0 109.672 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 3.0 p-80 -91.25 133.52 35.33 Favored 'General case' 0 N--CA 1.489 1.494 0 CA-C-O 121.405 0.622 . . . . 0.0 110.134 -179.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.408 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -92.9 125.22 37.39 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.519 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.1 m -140.79 125.45 17.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.907 . . . . 0.0 109.264 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.46 -150.75 47.32 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.9 m -44.21 -29.36 0.63 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -1.058 . . . . 0.0 110.263 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.77 -50.49 33.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.982 -1.074 . . . . 0.0 108.859 179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.495 HD11 HD22 ' A' ' 52' ' ' LEU . 20.4 tp -55.94 -54.48 44.22 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.438 -0.789 . . . . 0.0 109.207 179.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.71 -66.17 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.358 -0.839 . . . . 0.0 109.901 -179.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 86.7 mt-10 -47.63 -27.98 2.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.177 -0.952 . . . . 0.0 109.291 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.74 -55.32 5.09 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 109.181 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.47 -34.07 33.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.311 -1.493 . . . . 0.0 108.649 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -50.44 -49.27 55.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 110.165 -179.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.76 -51.06 45.22 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.535 -1.353 . . . . 0.0 108.619 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.418 HG12 ' SG ' ' A' ' 56' ' ' CYS . 39.9 t -50.39 -58.56 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 121.523 0.678 . . . . 0.0 109.698 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.3 -23.81 54.35 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.485 -0.759 . . . . 0.0 109.693 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.33 -131.83 45.89 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -76.62 -11.25 59.83 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.37 -1.077 . . . . 0.0 110.121 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -57.84 -26.98 62.77 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.076 -1.015 . . . . 0.0 109.35 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.87 155.68 5.72 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 -179.255 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.74 173.0 17.62 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.921 -1.341 . . . . 0.0 110.227 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.551 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 37.5 p90 -115.26 137.25 52.24 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -78.13 171.01 15.67 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t -64.13 175.11 1.33 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.853 -1.154 . . . . 0.0 109.975 -179.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.42 147.71 0.58 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.521 -0.737 . . . . 0.0 110.3 -178.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo . . . . . 0 N--CA 1.484 0.946 0 C-N-CA 122.18 1.92 . . . . 0.0 110.493 179.503 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 . . . . . 0 N--CA 1.486 1.375 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.06 -24.41 73.81 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.41 -55.99 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.001 -1.293 . . . . 0.0 110.051 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.6 t -61.97 -64.38 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.01 -1.056 . . . . 0.0 111.32 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 51.2 mt-10 -55.24 -47.49 75.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.946 -1.096 . . . . 0.0 110.613 -178.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -47.3 -57.78 4.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.051 -1.03 . . . . 0.0 110.303 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.573 ' SG ' HD21 ' A' ' 52' ' ' LEU . 70.9 m -84.81 -26.0 27.76 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.203 -0.935 . . . . 0.0 111.177 -178.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.1 t -83.1 -52.27 6.78 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.746 -1.221 . . . . 0.0 109.42 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 11.8 t-80 -71.15 -26.08 62.84 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.357 -0.839 . . . . 0.0 109.39 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.94 157.85 45.81 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.443 -0.785 . . . . 0.0 109.625 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.2 mm -82.03 99.59 5.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.357 -0.839 . . . . 0.0 108.785 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.7 p -91.14 158.43 16.64 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.106 -0.996 . . . . 0.0 109.781 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.6 p -89.81 166.61 13.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.308 -0.87 . . . . 0.0 108.96 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.607 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -58.78 -33.27 70.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.54 -57.56 3.53 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 121.716 0.769 . . . . 0.0 110.238 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -61.06 -41.8 97.29 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 119.665 -0.814 . . . . 0.0 108.918 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.573 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.7 mt -61.28 -30.77 70.68 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.008 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.48 -9.72 58.64 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -75.99 -28.19 57.71 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.756 -0.59 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.426 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 9.9 m-85 -101.55 6.1 42.06 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.357 -0.839 . . . . 0.0 110.02 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 66.7 m -79.81 107.49 12.63 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.866 -1.147 . . . . 0.0 109.345 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 28.1 t-20 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.094 -0.955 . . . . 0.0 109.453 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.615 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.13 -91.6 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.45 -0.781 . . . . 0.0 110.608 -178.789 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.615 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.57 26.2 7.59 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.366 -0.834 . . . . 0.0 109.886 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.627 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.1 pt20 -95.55 158.03 15.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.371 -0.831 . . . . 0.0 109.567 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.423 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.3 OUTLIER -91.57 132.0 36.61 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.66 -0.65 . . . . 0.0 110.587 -178.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -95.18 136.14 35.89 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.147 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.477 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -151.62 125.01 8.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.276 179.31 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.5 -146.65 40.91 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.1 m -46.85 -32.47 3.76 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.369 -1.077 . . . . 0.0 110.163 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.477 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 8.2 m-20 -48.88 -50.49 34.72 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.991 -1.068 . . . . 0.0 108.728 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -56.04 -54.44 44.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.473 -0.767 . . . . 0.0 109.519 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.53 -66.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.261 -0.9 . . . . 0.0 110.04 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.482 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 49.2 mt-10 -47.46 -28.61 2.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.208 -0.932 . . . . 0.0 109.388 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.16 -54.51 5.92 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.36 -0.838 . . . . 0.0 109.297 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.78 -35.28 43.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.367 -1.458 . . . . 0.0 108.581 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -49.31 -49.14 45.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.385 -0.822 . . . . 0.0 110.289 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.782 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.62 -50.96 47.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.558 -1.339 . . . . 0.0 108.592 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.0 t -50.65 -58.81 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-O 121.482 0.658 . . . . 0.0 109.847 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.31 -23.72 54.31 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.67 -125.99 27.67 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -78.75 -14.0 59.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.384 -1.068 . . . . 0.0 110.463 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 22.7 mtt180 -58.07 -26.88 63.09 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.973 -1.079 . . . . 0.0 109.647 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.56 155.99 5.61 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.63 173.01 17.58 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.324 . . . . 0.0 110.413 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.62 140.18 49.68 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -80.49 170.24 16.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.8 t -65.01 175.6 1.5 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.995 -1.066 . . . . 0.0 110.219 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.52 150.22 0.54 Allowed Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 121.497 -0.752 . . . . 0.0 110.115 -178.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -78.25 -6.32 15.58 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 122.252 1.968 . . . . 0.0 110.658 179.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 32' ' ' GLY . 41.7 p -53.77 -40.99 66.7 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.039 -1.038 . . . . 0.0 111.169 -177.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.42 -15.95 0.39 Allowed Glycine 0 N--CA 1.494 2.501 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.432 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.27 -21.21 23.14 Favored Glycine 0 N--CA 1.5 2.914 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.494 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.15 54.43 0.17 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.582 -1.807 . . . . 0.0 108.582 179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.517 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 Cg_endo -68.75 -174.14 0.68 Allowed 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.985 1.79 . . . . 0.0 110.102 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 27' ' ' THR . 46.7 ttt180 -56.23 86.92 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.517 ' N ' ' O ' ' A' ' 34' ' ' PRO . 0.8 OUTLIER -59.15 -2.48 0.27 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.091 -1.006 . . . . 0.0 108.525 179.914 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -71.53 -25.62 74.85 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.15 -56.38 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.212 0 O-C-N 121.056 -1.261 . . . . 0.0 110.45 -179.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.524 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.1 t -62.42 -64.18 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.94 -1.1 . . . . 0.0 111.4 -177.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.517 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.9 mt-10 -55.8 -46.36 78.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.873 -1.142 . . . . 0.0 110.355 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 62.1 tp60 -47.99 -56.65 7.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.074 -1.016 . . . . 0.0 110.101 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.71 -28.25 26.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 111.072 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 52.4 t -83.49 -52.24 6.67 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.733 -1.229 . . . . 0.0 109.231 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.517 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t-80 -70.46 -27.89 64.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.346 -0.846 . . . . 0.0 109.231 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.9 m -136.92 159.85 40.63 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.437 -0.79 . . . . 0.0 109.431 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 7.7 mm -82.8 99.7 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.307 -0.87 . . . . 0.0 109.088 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.9 p -91.15 150.83 21.22 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.094 -1.003 . . . . 0.0 109.32 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.5 167.45 14.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.232 -0.918 . . . . 0.0 109.112 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.77 -34.81 67.97 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.06 -57.53 3.32 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.867 0.841 . . . . 0.0 110.025 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -59.73 -42.48 93.24 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -62.02 -32.25 72.71 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -69.91 -9.54 55.34 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -75.86 -28.56 58.22 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.824 -0.548 . . . . 0.0 109.702 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.457 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.4 m-85 -102.13 6.89 41.09 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.372 -0.83 . . . . 0.0 109.948 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.0 m -80.29 111.18 16.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.023 -1.048 . . . . 0.0 109.282 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.955 -1.021 . . . . 0.0 109.437 179.97 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -101.61 -91.93 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.383 -0.823 . . . . 0.0 110.851 -178.566 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -101.21 26.03 7.56 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.403 -0.811 . . . . 0.0 109.807 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.94 160.84 14.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.384 -0.822 . . . . 0.0 109.483 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.449 ' HB3' HD13 ' A' ' 46' ' ' ILE . 4.4 p-80 -95.95 136.77 35.95 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.577 -0.702 . . . . 0.0 110.092 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.404 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -98.38 136.11 39.0 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.597 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -150.16 124.76 9.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.933 . . . . 0.0 109.236 179.003 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.71 -147.34 41.66 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.6 m -45.94 -32.59 2.79 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.393 -1.063 . . . . 0.0 110.197 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.68 -49.99 35.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.978 -1.077 . . . . 0.0 108.753 179.866 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 38' ' ' ILE . 22.6 tp -57.33 -51.79 67.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.411 -0.805 . . . . 0.0 109.484 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.8 t -49.08 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 110.065 -179.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 53.2 mt-10 -47.47 -28.45 2.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.406 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.08 -54.94 5.5 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.377 -0.827 . . . . 0.0 109.206 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.37 -35.63 39.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.402 -1.436 . . . . 0.0 108.772 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -49.35 -50.02 41.74 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.355 -0.841 . . . . 0.0 110.422 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.794 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.68 -50.7 56.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.612 -1.305 . . . . 0.0 108.595 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -51.25 -59.19 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.485 0.66 . . . . 0.0 110.318 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 22.8 m -76.59 -23.26 53.46 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.419 -0.801 . . . . 0.0 109.932 -178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.11 -129.58 27.77 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.352 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -73.43 -16.71 61.31 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.437 -1.037 . . . . 0.0 110.589 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 49.0 mtp180 -54.95 -28.54 52.03 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 109.426 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.8 156.31 6.06 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 107.799 -2.12 . . . . 0.0 107.799 -178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -156.27 172.68 18.05 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.835 -1.391 . . . . 0.0 110.44 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.554 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -116.57 127.24 54.32 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -67.58 172.14 5.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.611 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.2 t -62.6 174.39 1.02 Allowed 'General case' 0 C--N 1.295 -1.762 0 O-C-N 120.641 -1.287 . . . . 0.0 109.359 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.58 150.74 0.51 Allowed Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.341 -0.849 . . . . 0.0 110.409 -177.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -77.82 -7.09 16.41 Favored 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.111 1.874 . . . . 0.0 110.421 179.297 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.1 p -53.99 -40.86 67.3 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.128 -0.983 . . . . 0.0 111.136 -177.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.74 -15.78 0.45 Allowed Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.382 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.504 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.74 -23.89 17.08 Favored Glycine 0 N--CA 1.499 2.862 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.501 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -170.56 55.68 0.19 Allowed Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.501 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 30.8 Cg_endo -72.29 -175.01 1.57 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 121.914 1.742 . . . . 0.0 110.178 -179.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.611 ' N ' ' OG1' ' A' ' 27' ' ' THR . 6.0 ttt-85 -61.53 85.48 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 178.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.477 ' O ' ' N ' ' A' ' 38' ' ' ILE . 12.0 ptt180 -59.33 -28.39 66.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.052 -1.03 . . . . 0.0 108.225 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.86 -22.98 0.11 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.56 -54.27 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 O-C-N 120.978 -1.307 . . . . 0.0 109.787 179.924 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.18 -64.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.057 -1.027 . . . . 0.0 111.76 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -58.57 -41.35 85.49 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.768 -1.208 . . . . 0.0 110.884 -178.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.2 tp60 -50.58 -55.95 13.95 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.972 -1.08 . . . . 0.0 109.553 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.459 ' SG ' HD21 ' A' ' 52' ' ' LEU . 81.6 m -85.23 -26.55 26.63 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 111.222 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.1 t -83.94 -52.62 6.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.604 -1.31 . . . . 0.0 109.821 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.6 t60 -68.99 -29.41 67.61 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.248 -0.907 . . . . 0.0 109.175 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -137.14 157.89 45.68 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.55 -0.719 . . . . 0.0 109.572 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.449 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.3 mm -78.96 119.07 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.38 -0.825 . . . . 0.0 108.822 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.9 p -111.03 156.57 21.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.364 -0.835 . . . . 0.0 109.687 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 p -88.97 166.79 13.68 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.37 -0.831 . . . . 0.0 109.395 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.7 mt -59.65 -32.53 70.54 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.53 -57.68 3.45 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.802 0.81 . . . . 0.0 110.123 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -60.82 -42.46 97.74 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 119.799 -0.76 . . . . 0.0 108.959 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.488 HD22 HD11 ' A' ' 11' ' ' LEU . 77.6 mt -61.42 -26.03 67.6 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.17 -8.55 57.28 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -79.8 -26.34 40.6 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.848 -0.532 . . . . 0.0 109.926 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -100.0 6.1 45.11 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.266 -0.896 . . . . 0.0 110.448 -179.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.425 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 85.1 m -76.39 111.6 12.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.921 -1.112 . . . . 0.0 109.403 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 25.5 t-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.457 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -105.13 -91.88 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.508 -0.745 . . . . 0.0 110.678 -178.514 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -98.98 25.41 6.72 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.303 -0.873 . . . . 0.0 109.745 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.646 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.99 160.47 14.44 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 109.512 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HB3' HD13 ' A' ' 46' ' ' ILE . 2.2 p-80 -96.2 138.7 33.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.613 -0.68 . . . . 0.0 110.101 -179.225 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -100.94 134.09 44.44 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -149.43 124.86 10.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -0.947 . . . . 0.0 109.203 179.065 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.74 -148.48 43.38 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -45.07 -32.26 1.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.322 -1.105 . . . . 0.0 110.22 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.2 m-20 -48.79 -50.3 34.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.944 -1.098 . . . . 0.0 108.755 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.9 tp -57.04 -54.65 44.35 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.482 -0.762 . . . . 0.0 109.579 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.5 t -46.58 -66.3 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.303 -0.873 . . . . 0.0 110.067 -179.249 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 65.6 mt-10 -47.81 -27.83 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.65 -54.47 5.85 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.319 -0.863 . . . . 0.0 109.14 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.61 -35.3 41.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.402 -1.437 . . . . 0.0 108.626 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.44 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.6 t80 -49.32 -49.6 43.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.306 -0.871 . . . . 0.0 110.37 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.0 mp -68.36 -50.88 50.04 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.533 -1.355 . . . . 0.0 108.607 179.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.0 t -50.54 -58.72 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 CA-C-O 121.511 0.672 . . . . 0.0 109.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.03 -23.69 55.16 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.497 -0.752 . . . . 0.0 109.749 -179.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 52.91 -131.08 40.66 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -75.69 -11.52 60.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.345 -1.091 . . . . 0.0 110.158 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.409 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -58.21 -27.76 64.2 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.092 -1.005 . . . . 0.0 109.488 -179.453 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.72 155.22 5.28 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -156.51 172.73 18.03 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.936 -1.332 . . . . 0.0 110.277 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.8 p90 -115.74 137.39 52.13 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -77.13 171.13 15.31 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.573 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.0 t -63.89 175.02 1.27 Allowed 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.798 -1.189 . . . . 0.0 109.9 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -43.14 148.39 0.61 Allowed Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.494 -0.754 . . . . 0.0 110.229 -178.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -78.39 -6.5 15.56 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.128 1.885 . . . . 0.0 110.409 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 32' ' ' GLY . 38.1 p -54.04 -40.92 67.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.028 -1.045 . . . . 0.0 110.98 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.82 -15.7 0.47 Allowed Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.691 -1.243 . . . . 0.0 110.332 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.504 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.79 -17.26 36.16 Favored Glycine 0 N--CA 1.499 2.837 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.91 55.02 0.12 Allowed Glycine 0 N--CA 1.485 1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.7 Cg_endo -68.86 -175.19 0.88 Allowed 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 121.898 1.732 . . . . 0.0 110.231 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.573 ' N ' ' OG1' ' A' ' 27' ' ' THR . 41.4 ttt180 -58.04 86.47 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 34' ' ' PRO . 6.9 ptm180 -59.75 -2.01 0.33 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.023 -1.048 . . . . 0.0 108.667 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.52 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -72.7 -24.27 76.42 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.9 -55.3 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.261 0 O-C-N 121.098 -1.236 . . . . 0.0 110.349 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -63.54 -64.27 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.024 -1.047 . . . . 0.0 111.278 -177.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 44' ' ' HIS . 30.2 mt-10 -55.01 -45.74 75.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.373 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -48.74 -57.63 6.02 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.099 -1.0 . . . . 0.0 110.304 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.503 ' SG ' HD21 ' A' ' 52' ' ' LEU . 59.0 m -84.88 -25.36 28.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.173 -0.955 . . . . 0.0 111.435 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 48.3 t -84.24 -52.34 6.31 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.535 -1.353 . . . . 0.0 109.537 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.421 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.9 t60 -68.91 -26.77 65.26 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.22 -0.925 . . . . 0.0 109.195 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 12.6 t -136.71 173.32 11.83 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.458 -0.776 . . . . 0.0 109.473 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.407 HD13 ' HB3' ' A' ' 5' ' ' HIS . 6.0 mm -94.65 99.6 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.3 p -91.53 152.49 20.29 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.126 -0.984 . . . . 0.0 109.72 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -86.67 166.7 15.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.326 -0.859 . . . . 0.0 109.32 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.8 mt -57.39 -34.91 69.35 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -43.97 -57.19 3.46 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.862 0.839 . . . . 0.0 109.978 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.71 -42.59 93.41 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.503 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.4 mt -61.89 -32.36 72.73 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.98 -9.61 55.76 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -75.88 -28.15 58.02 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.799 -0.563 . . . . 0.0 109.664 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 7.9 m-85 -102.86 6.99 39.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.407 -0.808 . . . . 0.0 109.95 -179.616 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 62.2 m -79.26 108.23 12.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.984 -1.072 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.548 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.0 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.605 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -101.92 -91.69 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -0.812 . . . . 0.0 110.607 -178.738 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.605 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.3 m120 -101.73 26.08 7.82 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.351 -0.843 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.3 pt20 -95.59 160.16 14.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 109.708 -179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -92.05 134.61 34.67 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.53 0.681 . . . . 0.0 110.541 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.4 mp -98.53 130.69 45.1 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.473 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.12 125.06 10.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.107 179.377 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.63 -148.34 43.36 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -45.02 -32.64 1.75 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.394 -1.062 . . . . 0.0 110.321 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.473 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.7 OUTLIER -48.87 -50.31 35.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.004 -1.06 . . . . 0.0 108.745 179.841 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.534 HD21 HD12 ' A' ' 38' ' ' ILE . 18.5 tp -57.13 -55.05 39.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.404 -0.81 . . . . 0.0 109.562 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -46.31 -66.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.313 -0.867 . . . . 0.0 109.945 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 34.4 mt-10 -47.69 -26.67 1.62 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 -179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.0 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.07 -54.31 5.65 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.365 -0.834 . . . . 0.0 109.082 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.71 -34.48 39.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.372 -1.455 . . . . 0.0 108.658 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.8 t80 -50.49 -49.59 55.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.301 -0.874 . . . . 0.0 110.336 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.797 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.26 -50.29 54.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.591 -1.318 . . . . 0.0 108.556 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 42.5 t -50.68 -59.38 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.522 0.677 . . . . 0.0 109.745 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.05 -23.64 55.1 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 -178.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.48 -123.78 20.2 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 90.5 mt-10 -80.28 -16.56 54.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.355 -1.085 . . . . 0.0 110.584 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 15.8 mtt180 -55.92 -27.12 50.78 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.053 -1.029 . . . . 0.0 109.52 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.5 6.05 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -156.57 172.96 17.64 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.895 -1.356 . . . . 0.0 110.357 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.547 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.0 p90 -116.77 135.81 53.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -76.18 170.91 15.4 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.576 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.1 t -64.29 174.73 1.52 Allowed 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.807 -1.183 . . . . 0.0 110.027 -179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.28 148.58 0.82 Allowed Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.43 -0.794 . . . . 0.0 109.998 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -78.17 -6.43 15.71 Favored 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.118 1.878 . . . . 0.0 110.425 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 32' ' ' GLY . 39.6 p -54.05 -40.94 67.56 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.111 -0.993 . . . . 0.0 111.176 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.85 -15.86 0.47 Allowed Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.328 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.502 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.1 -18.55 31.21 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -173.99 54.89 0.14 Allowed Glycine 0 N--CA 1.485 1.952 0 N-CA-C 108.416 -1.874 . . . . 0.0 108.416 179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.3 Cg_endo -70.17 -175.19 1.17 Allowed 'Trans proline' 0 C--N 1.318 -1.052 0 C-N-CA 121.855 1.703 . . . . 0.0 110.127 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.576 ' N ' ' OG1' ' A' ' 27' ' ' THR . 4.6 ttt-85 -57.9 86.67 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 34' ' ' PRO . 45.0 mtm180 -59.37 -6.24 0.96 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.984 -1.072 . . . . 0.0 108.169 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.487 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.72 -25.89 73.94 Favored Glycine 0 N--CA 1.487 2.056 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.534 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -101.89 -56.28 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 O-C-N 121.026 -1.279 . . . . 0.0 110.559 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -61.98 -64.41 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 120.906 -1.121 . . . . 0.0 111.574 -177.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' HIS . 76.1 mt-10 -56.09 -46.17 79.16 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.932 -1.105 . . . . 0.0 110.341 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 52.0 tt0 -48.31 -56.55 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.11 -0.993 . . . . 0.0 110.298 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.572 ' SG ' HD21 ' A' ' 52' ' ' LEU . 62.4 m -84.79 -27.16 27.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.135 -0.978 . . . . 0.0 111.331 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.1 t -83.01 -52.23 6.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.72 -1.238 . . . . 0.0 109.163 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.464 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.7 t-80 -69.32 -27.5 65.43 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.178 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 m -137.01 159.95 40.37 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.424 -0.797 . . . . 0.0 109.594 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.8 mm -83.41 99.59 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.264 -0.897 . . . . 0.0 108.933 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.0 p -90.63 147.31 23.38 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.059 -1.026 . . . . 0.0 109.482 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -81.62 166.56 20.08 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.6 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.4 mt -56.41 -34.24 66.55 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -44.31 -57.42 3.51 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.924 0.869 . . . . 0.0 109.982 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.564 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.0 -42.29 93.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.572 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.4 mt -62.36 -32.34 73.12 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -69.74 -9.51 54.76 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -75.7 -28.34 58.57 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.753 -0.592 . . . . 0.0 109.613 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.3 m-85 -101.48 6.0 42.19 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.35 -0.844 . . . . 0.0 110.035 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -80.45 110.52 15.99 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.933 -1.104 . . . . 0.0 109.217 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.405 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 17.3 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -99.55 -91.51 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.432 -0.793 . . . . 0.0 110.582 -178.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.1 m120 -103.86 27.14 7.84 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.491 -0.756 . . . . 0.0 109.798 -179.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.95 161.22 14.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.456 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.551 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 8.6 p80 -92.94 134.73 34.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.619 -0.676 . . . . 0.0 110.593 -178.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.413 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -98.99 131.0 45.37 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.289 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.481 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.35 125.15 11.89 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.165 -0.96 . . . . 0.0 109.301 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.17 -149.24 43.86 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.2 m -44.91 -31.86 1.41 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.255 -1.144 . . . . 0.0 110.226 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.481 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.19 -50.5 28.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.064 -1.023 . . . . 0.0 108.824 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.14 -55.21 37.72 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.474 -0.766 . . . . 0.0 109.501 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.12 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.273 -0.892 . . . . 0.0 110.033 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.5 mt-10 -47.57 -29.12 2.63 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.78 -54.59 5.92 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.291 -0.881 . . . . 0.0 109.209 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.27 -35.67 38.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.433 -1.417 . . . . 0.0 108.71 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -49.31 -49.41 44.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.873 . . . . 0.0 110.403 -179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.811 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -68.82 -50.55 49.08 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.589 -1.319 . . . . 0.0 108.581 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -51.03 -59.14 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.503 0.668 . . . . 0.0 110.13 -179.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.2 m -76.42 -23.69 53.99 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.507 -0.746 . . . . 0.0 109.743 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.57 -133.44 46.96 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -74.87 -13.05 60.51 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.423 -1.045 . . . . 0.0 110.196 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.404 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.11 -26.77 51.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.166 -0.959 . . . . 0.0 109.258 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.68 155.75 5.58 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 108.462 -1.855 . . . . 0.0 108.462 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -156.43 172.52 18.37 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.982 -1.305 . . . . 0.0 110.091 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.0 p90 -115.8 133.45 56.02 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -72.66 171.9 11.67 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.586 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 8.3 t -63.36 174.53 1.22 Allowed 'General case' 0 C--N 1.298 -1.666 0 O-C-N 120.768 -1.207 . . . . 0.0 109.722 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.06 0.93 Allowed Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.483 -0.761 . . . . 0.0 110.231 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -77.64 -6.32 16.08 Favored 'Trans proline' 0 N--CA 1.483 0.88 0 C-N-CA 122.032 1.821 . . . . 0.0 110.3 179.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.505 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.0 p -53.91 -41.0 67.18 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.181 -0.949 . . . . 0.0 110.839 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.48 -15.78 0.41 Allowed Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.433 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.8 -14.32 46.92 Favored Glycine 0 N--CA 1.499 2.882 0 N-CA-C 109.043 -1.623 . . . . 0.0 109.043 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.477 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -177.99 55.95 0.1 OUTLIER Glycine 0 N--CA 1.484 1.848 0 N-CA-C 108.173 -1.971 . . . . 0.0 108.173 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.477 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 18.2 Cg_endo -69.52 -175.54 1.13 Allowed 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.742 1.628 . . . . 0.0 110.206 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.586 ' N ' ' OG1' ' A' ' 27' ' ' THR . 4.3 ttt-85 -59.68 86.45 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.44 ' N ' ' O ' ' A' ' 34' ' ' PRO . 12.6 ptt180 -60.16 -1.01 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.04 -1.038 . . . . 0.0 108.746 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -75.43 -22.88 74.81 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 121.014 -1.286 . . . . 0.0 110.252 -179.702 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.7 t -62.59 -64.27 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.044 -1.035 . . . . 0.0 111.249 -177.29 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.495 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.0 mt-10 -54.99 -48.78 72.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.014 -1.054 . . . . 0.0 110.431 -178.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 52.7 tp60 -46.32 -57.2 4.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.075 -1.016 . . . . 0.0 110.458 -179.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.518 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -84.75 -26.48 27.58 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 111.278 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.3 t -83.19 -51.33 7.58 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.677 -1.264 . . . . 0.0 109.25 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.517 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.3 t-80 -72.61 -26.61 61.75 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.353 -0.842 . . . . 0.0 109.621 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.92 158.83 43.57 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.311 -0.868 . . . . 0.0 109.838 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 10.4 mm -81.25 99.51 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.347 -0.846 . . . . 0.0 109.171 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -92.17 149.9 21.22 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.018 -1.051 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -83.84 166.46 17.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.25 -0.906 . . . . 0.0 109.336 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.2 mt -57.63 -33.61 68.45 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -43.72 -57.85 3.0 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.917 0.865 . . . . 0.0 109.979 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -59.95 -42.68 94.58 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.518 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.8 mt -61.72 -27.2 68.54 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -75.33 -8.54 56.94 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -79.51 -26.33 41.57 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.811 -0.555 . . . . 0.0 109.995 -179.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 13.8 m-85 -101.05 5.67 43.08 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.283 -0.886 . . . . 0.0 110.398 -179.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 89.3 m -79.29 111.39 15.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.928 -1.108 . . . . 0.0 109.631 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.568 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.38 -91.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.479 -0.763 . . . . 0.0 110.572 -178.68 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.2 m120 -101.45 25.94 7.81 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.382 -0.824 . . . . 0.0 109.879 -179.267 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.623 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.64 159.82 14.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.356 -0.84 . . . . 0.0 109.671 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -92.2 137.17 32.59 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.483 0.659 . . . . 0.0 110.568 -179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CE1' ' A' ' 1' ' ' PHE . 1.2 mp -100.83 131.12 46.87 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.475 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.03 125.02 11.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 179.308 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -147.7 41.99 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -45.99 -32.3 2.7 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.328 -1.101 . . . . 0.0 110.225 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.475 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 0.9 OUTLIER -48.43 -50.08 32.54 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.054 -1.029 . . . . 0.0 108.722 179.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.493 HD11 HD22 ' A' ' 52' ' ' LEU . 20.2 tp -57.21 -54.39 47.36 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.45 -0.781 . . . . 0.0 109.519 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.7 t -46.93 -66.32 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.284 -0.885 . . . . 0.0 109.951 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 41.4 mt-10 -48.03 -24.41 1.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.139 -0.976 . . . . 0.0 109.377 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -83.29 -54.43 5.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.339 -0.851 . . . . 0.0 109.035 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -52.23 -33.26 40.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.429 -1.42 . . . . 0.0 108.542 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -51.17 -49.85 60.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.344 -0.848 . . . . 0.0 110.2 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.783 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.23 -50.55 53.27 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.578 -1.326 . . . . 0.0 108.597 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.1 t -50.54 -58.79 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.504 0.669 . . . . 0.0 109.723 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.03 -23.27 52.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.582 -0.699 . . . . 0.0 109.893 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.19 -126.27 18.33 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -77.39 -14.96 59.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.313 -1.11 . . . . 0.0 110.282 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.8 mtp180 -55.31 -27.95 50.33 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.088 -1.007 . . . . 0.0 109.424 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.66 154.55 4.83 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.509 -1.836 . . . . 0.0 108.509 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.79 173.01 17.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.897 -1.355 . . . . 0.0 110.372 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.4 p90 -117.96 136.46 53.49 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -77.25 170.37 16.65 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.587 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.3 t -64.62 175.34 1.45 Allowed 'General case' 0 C--N 1.298 -1.654 0 O-C-N 120.973 -1.079 . . . . 0.0 110.016 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -44.33 148.55 0.84 Allowed Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 109.967 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -77.35 -6.1 16.14 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.118 1.879 . . . . 0.0 110.3 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.511 ' C ' ' H ' ' A' ' 32' ' ' GLY . 48.8 p -53.79 -41.17 66.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.149 -0.969 . . . . 0.0 111.084 -177.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.28 -16.14 0.36 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.525 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -97.26 -18.52 28.53 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.5 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -172.97 55.49 0.16 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.382 -1.887 . . . . 0.0 108.382 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.6 Cg_endo -70.86 -175.25 1.35 Allowed 'Trans proline' 0 C--N 1.318 -1.067 0 C-N-CA 121.841 1.694 . . . . 0.0 110.189 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.587 ' N ' ' OG1' ' A' ' 27' ' ' THR . 7.5 ttt-85 -56.67 86.3 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 34' ' ' PRO . 10.9 ptt180 -60.1 0.16 0.18 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.984 -1.072 . . . . 0.0 108.843 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.538 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -75.2 -24.41 71.36 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.76 -56.41 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 121.024 -1.28 . . . . 0.0 110.287 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.34 -64.41 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.028 -1.045 . . . . 0.0 111.352 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -55.52 -45.45 77.15 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.056 -1.028 . . . . 0.0 110.457 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -49.6 -56.45 9.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.087 -1.008 . . . . 0.0 110.212 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.543 ' SG ' HD21 ' A' ' 52' ' ' LEU . 64.5 m -84.99 -26.12 27.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.18 -0.95 . . . . 0.0 111.339 -178.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.06 -51.33 7.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.723 -1.236 . . . . 0.0 109.295 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.494 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.5 t-80 -72.1 -25.67 61.84 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.283 -0.885 . . . . 0.0 109.376 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -136.81 157.78 45.97 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.363 -0.836 . . . . 0.0 109.623 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 8.6 mm -82.11 99.22 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.374 -0.829 . . . . 0.0 108.891 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.5 p -91.28 150.62 21.24 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.097 -1.002 . . . . 0.0 109.54 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -84.1 166.83 17.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.199 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -57.44 -33.6 68.11 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -44.42 -57.81 3.33 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.811 0.815 . . . . 0.0 110.081 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.547 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 11.5 mt-30 -60.13 -41.86 93.55 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.543 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.9 mt -61.98 -31.99 72.41 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 49' ' ' LEU . 0.6 OUTLIER -70.04 -9.57 55.78 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 179.289 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -75.68 -28.33 58.63 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.759 -0.588 . . . . 0.0 109.557 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.437 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 12.9 m-85 -100.99 5.1 43.0 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.33 -0.856 . . . . 0.0 110.151 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.44 ' SG ' HG12 ' A' ' 18' ' ' VAL . 96.8 m -80.15 109.6 14.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.92 -1.112 . . . . 0.0 109.086 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.419 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 23.3 t-20 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.084 -0.96 . . . . 0.0 109.391 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.575 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -94.7 -91.36 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.373 -0.829 . . . . 0.0 110.791 -178.495 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.575 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -105.65 25.73 10.42 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.408 -0.807 . . . . 0.0 110.028 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 3.3 pt20 -95.91 158.07 15.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.278 -0.889 . . . . 0.0 109.625 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.436 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 12.5 p80 -90.68 137.01 32.69 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.696 -0.627 . . . . 0.0 110.217 -179.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -96.21 122.57 39.21 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.8 m -139.69 125.65 19.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.291 -0.881 . . . . 0.0 109.331 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.38 -149.81 46.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -44.54 -29.55 0.74 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.353 -1.086 . . . . 0.0 110.235 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 9.9 m-20 -49.18 -51.24 33.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.034 -1.041 . . . . 0.0 108.874 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.515 HD11 HD22 ' A' ' 52' ' ' LEU . 21.7 tp -55.8 -51.36 67.72 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.401 -0.812 . . . . 0.0 109.365 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -49.61 -66.22 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 0.0 109.714 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.481 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 38.8 mt-10 -47.49 -26.91 1.53 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.379 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.53 -55.49 4.82 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.407 -0.808 . . . . 0.0 109.148 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.1 mt -51.3 -33.64 29.79 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.268 -1.52 . . . . 0.0 108.737 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.436 ' O ' ' N ' ' A' ' 20' ' ' GLY . 54.8 t80 -50.94 -50.35 57.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 110.228 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.776 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.6 mp -67.66 -50.53 57.35 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.575 -1.328 . . . . 0.0 108.605 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.434 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.5 t -50.42 -58.95 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 CA-C-O 121.514 0.673 . . . . 0.0 109.816 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.8 m -76.71 -23.38 53.12 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.541 -0.724 . . . . 0.0 109.867 -178.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 48.42 -123.31 9.8 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -79.07 -13.28 59.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.304 -1.115 . . . . 0.0 110.298 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -57.81 -27.67 63.35 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.085 -1.009 . . . . 0.0 109.561 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 154.73 4.75 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.68 172.85 17.86 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.773 -1.428 . . . . 0.0 110.484 -179.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 36.9 p90 -118.14 129.98 55.84 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.3 t80 -70.69 171.12 10.97 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.591 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.8 t -64.12 174.91 1.39 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 120.826 -1.171 . . . . 0.0 109.644 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -42.29 150.38 0.4 Allowed Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.449 -0.782 . . . . 0.0 110.339 -178.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -78.35 -6.78 15.77 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.068 1.845 . . . . 0.0 110.439 179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.482 ' C ' ' H ' ' A' ' 32' ' ' GLY . 37.7 p -54.09 -40.68 67.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.128 -0.982 . . . . 0.0 111.166 -177.438 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.09 -15.45 0.54 Allowed Glycine 0 N--CA 1.493 2.475 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.347 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -94.95 -25.8 13.94 Favored Glycine 0 N--CA 1.5 2.902 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.505 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -169.91 54.9 0.2 Allowed Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.505 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 24.9 Cg_endo -70.89 -174.95 1.25 Allowed 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.041 1.828 . . . . 0.0 110.369 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.591 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.9 ttt-85 -57.6 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.621 HH11 ' CG ' ' A' ' 36' ' ' ARG . 0.6 OUTLIER -58.32 -30.77 66.95 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.918 -1.114 . . . . 0.0 108.368 -179.65 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.96 -24.53 0.09 OUTLIER Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.5 -55.55 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 120.977 -1.308 . . . . 0.0 109.91 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.8 t -62.49 -64.26 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.052 -1.03 . . . . 0.0 112.1 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -59.38 -37.71 78.64 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.832 -1.168 . . . . 0.0 110.856 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -54.49 -56.26 20.57 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.819 -1.175 . . . . 0.0 109.409 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.618 ' SG ' HD21 ' A' ' 52' ' ' LEU . 67.2 m -85.78 -24.03 27.0 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.324 -0.86 . . . . 0.0 111.297 -179.161 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.9 -52.62 6.21 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.635 -1.291 . . . . 0.0 109.771 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.515 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 9.4 t-80 -69.77 -26.3 64.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.203 -0.936 . . . . 0.0 109.278 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.88 161.17 36.74 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.376 -0.828 . . . . 0.0 109.483 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.7 mm -84.59 99.79 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.4 p -90.99 153.96 19.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.065 -1.022 . . . . 0.0 109.726 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.19 167.95 15.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.312 -0.867 . . . . 0.0 109.056 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.1 mt -59.74 -33.34 71.53 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.919 0.866 . . . . 0.0 108.669 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -44.34 -57.74 3.34 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.777 0.798 . . . . 0.0 110.286 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -61.06 -41.73 97.18 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 119.773 -0.771 . . . . 0.0 108.964 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.618 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.56 -31.31 71.34 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.64 -9.64 57.49 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -75.64 -28.06 58.64 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.746 -0.596 . . . . 0.0 109.569 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.429 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.8 m-85 -101.22 5.64 42.66 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.333 -0.854 . . . . 0.0 110.072 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.434 ' SG ' HG12 ' A' ' 18' ' ' VAL . 90.0 m -80.35 109.47 14.86 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.916 -1.115 . . . . 0.0 109.27 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.454 -179.961 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.553 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.3 OUTLIER -98.32 -91.29 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.366 -0.834 . . . . 0.0 110.503 -178.827 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.553 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.1 m-20 -106.35 27.53 8.64 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.534 -0.729 . . . . 0.0 109.899 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.63 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.2 pt20 -94.79 159.96 14.82 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.343 -0.848 . . . . 0.0 109.335 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 14.8 p-80 -90.65 131.46 36.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.616 -0.677 . . . . 0.0 110.693 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.411 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -94.01 127.28 39.71 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.021 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.435 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 77.2 m -142.68 125.51 16.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.233 -0.917 . . . . 0.0 109.343 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.33 -150.45 47.06 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.9 m -43.67 -29.92 0.56 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -1.032 . . . . 0.0 110.383 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 24.4 m-20 -50.01 -51.31 42.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.991 -1.068 . . . . 0.0 108.951 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.521 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -54.8 -53.52 54.15 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.313 -0.867 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 t -47.91 -66.07 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.356 -0.84 . . . . 0.0 109.963 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 45.3 mt-10 -47.82 -28.51 2.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.349 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.72 -54.89 5.63 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.352 -0.843 . . . . 0.0 109.123 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 18.0 mt -51.64 -35.29 41.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.35 -1.469 . . . . 0.0 108.661 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.8 t80 -49.32 -49.53 43.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 110.298 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.748 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -68.53 -51.27 44.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.67 -1.269 . . . . 0.0 108.609 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.448 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.33 -58.41 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 121.525 0.678 . . . . 0.0 109.59 -179.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.1 m -76.58 -23.53 53.51 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.558 -0.714 . . . . 0.0 109.98 -178.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.91 -122.07 10.79 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.3 mt-10 -80.47 -16.47 54.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.307 -1.113 . . . . 0.0 110.357 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.43 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -55.89 -28.16 55.34 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.551 -179.524 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.46 156.25 5.68 Favored Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -156.58 172.73 18.05 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.842 -1.387 . . . . 0.0 110.477 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.535 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.0 p90 -117.76 139.46 51.03 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -78.47 170.97 15.79 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.586 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.5 t -64.6 174.55 1.72 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.869 -1.144 . . . . 0.0 110.523 -178.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -46.36 148.53 1.59 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.586 -0.696 . . . . 0.0 110.098 -178.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.69 -6.23 15.97 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.347 2.031 . . . . 0.0 110.962 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 32' ' ' GLY . 53.2 p -53.17 -40.93 64.71 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.921 -1.112 . . . . 0.0 110.844 -177.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.32 -16.18 0.36 Allowed Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.594 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.49 -14.08 45.55 Favored Glycine 0 N--CA 1.499 2.899 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.481 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.84 55.87 0.1 OUTLIER Glycine 0 N--CA 1.483 1.803 0 N-CA-C 108.132 -1.987 . . . . 0.0 108.132 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.7 Cg_endo -69.48 -175.29 1.04 Allowed 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 121.694 1.596 . . . . 0.0 109.927 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.586 ' N ' ' OG1' ' A' ' 27' ' ' THR . 1.1 ttt-85 -56.68 86.02 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.529 ' N ' ' O ' ' A' ' 34' ' ' PRO . 0.0 OUTLIER -60.63 0.66 0.18 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.005 -1.059 . . . . 0.0 108.857 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.537 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -77.6 -23.82 66.58 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.537 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.95 -56.41 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.234 0 O-C-N 121.096 -1.238 . . . . 0.0 110.393 -179.716 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.3 t -62.04 -64.35 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.026 . . . . 0.0 111.436 -177.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -55.04 -48.55 73.29 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.856 -1.152 . . . . 0.0 110.411 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -45.93 -58.32 3.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.195 -0.94 . . . . 0.0 110.451 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.6 m -85.34 -27.02 26.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.154 -0.966 . . . . 0.0 111.511 -178.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 42.6 t -83.38 -52.32 6.64 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.733 -1.229 . . . . 0.0 109.598 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.438 ' N ' ' O ' ' A' ' 40' ' ' GLU . 12.3 t60 -70.94 -26.59 63.25 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.88 161.84 34.89 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.324 -0.86 . . . . 0.0 109.676 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.8 mm -83.36 99.69 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.585 -0.697 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -92.4 160.12 15.24 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.05 -1.031 . . . . 0.0 109.741 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.07 167.31 11.87 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.91 -32.58 69.67 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -44.35 -57.24 3.63 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.702 0.763 . . . . 0.0 110.14 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -61.35 -42.37 98.59 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.924 -179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.3 mt -61.08 -31.93 71.59 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.42 -9.6 56.81 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.937 -1.135 . . . . 0.0 107.937 179.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -77.0 -27.67 54.78 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.778 -0.576 . . . . 0.0 109.689 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.1 m-85 -102.29 6.23 40.37 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.402 -0.811 . . . . 0.0 109.957 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.448 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -78.41 103.3 8.26 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.994 -1.066 . . . . 0.0 109.403 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.4 t-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.456 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -104.39 -91.67 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.616 -178.695 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.619 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.4 m120 -100.02 25.8 7.04 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.349 -0.844 . . . . 0.0 109.777 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.638 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.7 pt20 -95.93 160.05 14.66 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.384 -0.823 . . . . 0.0 109.522 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -94.88 136.29 35.36 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.57 -0.706 . . . . 0.0 110.178 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.405 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.7 OUTLIER -97.51 130.17 44.61 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.639 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 72.8 m -143.92 125.18 14.62 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.306 -0.871 . . . . 0.0 109.255 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.18 -150.62 47.58 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.9 m -43.77 -30.5 0.66 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.418 -1.048 . . . . 0.0 110.322 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 4.6 m-20 -48.94 -50.51 35.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.967 -1.083 . . . . 0.0 108.856 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 38' ' ' ILE . 18.9 tp -55.42 -54.86 38.48 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.359 -0.838 . . . . 0.0 109.235 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.75 -66.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.391 -0.818 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.48 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 35.2 mt-10 -47.87 -27.85 2.32 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.191 -0.943 . . . . 0.0 109.341 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.69 -54.57 5.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.336 -0.852 . . . . 0.0 109.164 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.64 -34.96 40.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.364 -1.46 . . . . 0.0 108.599 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.9 t80 -49.64 -49.48 47.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.359 -0.838 . . . . 0.0 110.389 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.789 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -68.55 -50.76 49.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.525 -1.36 . . . . 0.0 108.578 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.3 t -50.6 -58.87 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-O 121.506 0.67 . . . . 0.0 109.718 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.48 -23.56 53.81 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.486 -0.759 . . . . 0.0 109.819 -178.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 53.51 -130.17 41.71 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -76.83 -13.07 60.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -1.105 . . . . 0.0 110.114 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.415 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.3 OUTLIER -56.69 -27.62 59.24 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.107 -0.996 . . . . 0.0 109.368 -179.533 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 155.59 5.5 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -156.54 172.93 17.7 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.932 -1.334 . . . . 0.0 110.074 -179.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.3 p90 -116.02 138.65 51.02 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -78.87 171.28 15.41 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.578 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 8.8 t -64.33 174.95 1.45 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.927 -1.108 . . . . 0.0 110.338 -178.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.92 149.95 1.44 Allowed Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.497 -0.752 . . . . 0.0 110.301 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -78.54 -6.31 15.33 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.206 1.937 . . . . 0.0 110.508 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 32' ' ' GLY . 42.8 p -53.76 -41.04 66.71 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.094 -1.004 . . . . 0.0 111.129 -177.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.63 -15.86 0.43 Allowed Glycine 0 N--CA 1.493 2.474 0 C-N-CA 119.638 -1.268 . . . . 0.0 110.309 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.62 -17.02 34.69 Favored Glycine 0 N--CA 1.499 2.844 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.49 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -175.55 54.91 0.12 Allowed Glycine 0 N--CA 1.484 1.836 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.508 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.2 Cg_endo -69.51 -175.58 1.14 Allowed 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.782 1.655 . . . . 0.0 109.996 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.578 ' N ' ' OG1' ' A' ' 27' ' ' THR . 0.3 OUTLIER -57.34 85.86 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.654 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.508 ' N ' ' O ' ' A' ' 34' ' ' PRO . 17.6 mtm-85 -59.64 -6.81 1.26 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.921 -1.112 . . . . 0.0 108.195 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.479 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.93 -25.66 74.2 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -102.18 -56.01 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.327 0 O-C-N 121.035 -1.273 . . . . 0.0 110.645 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.526 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -62.39 -63.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.946 -1.096 . . . . 0.0 111.495 -177.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' HIS . 70.1 mt-10 -55.97 -47.81 76.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.84 -1.163 . . . . 0.0 110.285 -178.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.3 tt0 -46.41 -57.44 4.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.999 -1.063 . . . . 0.0 110.426 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.559 ' SG ' HD21 ' A' ' 52' ' ' LEU . 61.0 m -84.69 -27.95 26.7 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.124 -0.985 . . . . 0.0 111.083 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 49.3 t -83.49 -52.1 6.79 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.809 -1.182 . . . . 0.0 109.349 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' GLU . 16.0 t60 -69.77 -28.23 65.59 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.241 -0.912 . . . . 0.0 109.077 179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 m -137.04 160.73 38.08 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.403 -0.811 . . . . 0.0 109.505 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -83.13 99.94 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 p -91.45 152.05 20.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.012 -1.055 . . . . 0.0 109.563 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -86.92 167.42 14.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.307 -0.871 . . . . 0.0 109.121 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.2 mt -56.95 -34.51 68.09 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.625 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -44.15 -56.97 3.68 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.816 0.817 . . . . 0.0 109.979 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.624 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.3 mt-30 -60.33 -42.64 96.08 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.559 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.9 mt -62.05 -32.6 73.13 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.55 -9.47 54.1 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -76.06 -28.03 57.47 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.79 -0.569 . . . . 0.0 109.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 8.6 m-85 -102.57 6.71 39.97 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.368 -0.832 . . . . 0.0 109.992 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.464 ' SG ' HG12 ' A' ' 18' ' ' VAL . 67.3 m -79.81 104.01 10.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 109.33 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.431 ' O ' ' O ' ' A' ' 56' ' ' CYS . 24.9 t-20 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.511 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.584 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -100.28 -91.42 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.437 -0.789 . . . . 0.0 110.425 -178.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.584 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.0 m120 -104.54 27.64 7.73 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.477 -0.764 . . . . 0.0 109.801 -179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.54 159.79 14.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.26 -0.9 . . . . 0.0 109.523 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 0.0 OUTLIER -90.26 131.94 35.8 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.602 0.715 . . . . 0.0 110.866 -178.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.51 132.56 43.08 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.476 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -148.98 124.89 10.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.15 -0.969 . . . . 0.0 109.222 179.287 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.43 -147.43 42.28 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.8 m -44.9 -33.17 1.87 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.376 -1.073 . . . . 0.0 110.205 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.476 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -49.3 -49.85 41.94 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.003 -1.061 . . . . 0.0 108.815 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.548 HD21 HD12 ' A' ' 38' ' ' ILE . 19.0 tp -58.08 -57.02 14.67 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 12' ' ' VAL . 21.0 t -45.07 -65.94 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.34 -0.85 . . . . 0.0 109.974 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.491 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.7 mt-10 -47.54 -30.44 3.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -77.62 -54.58 6.22 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 109.223 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -50.92 -36.53 38.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.522 -1.361 . . . . 0.0 108.665 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -48.84 -49.8 37.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.399 -0.813 . . . . 0.0 110.396 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.841 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.6 mp -68.26 -50.73 51.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.524 -1.36 . . . . 0.0 108.579 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -50.89 -59.33 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.456 0.646 . . . . 0.0 110.087 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -23.45 54.21 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.512 -0.743 . . . . 0.0 109.809 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.98 -129.03 30.97 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.204 -1.159 . . . . 0.0 110.204 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -76.49 -15.04 59.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -1.106 . . . . 0.0 110.182 -179.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.514 ' NH1' ' OE2' ' A' ' 53' ' ' GLU . 33.8 mtp180 -54.69 -27.61 41.64 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.032 -1.043 . . . . 0.0 109.087 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.13 5.23 Favored Glycine 0 N--CA 1.486 2.0 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 -179.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.39 172.33 18.69 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.889 -1.36 . . . . 0.0 110.214 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 34.3 p90 -117.53 135.07 54.19 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -73.18 171.65 12.58 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.568 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 6.8 t -63.36 174.71 1.16 Allowed 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.773 -1.204 . . . . 0.0 109.749 -178.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.22 146.33 0.68 Allowed Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.201 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -77.05 -6.91 17.03 Favored 'Trans proline' 0 N--CA 1.484 0.92 0 C-N-CA 122.081 1.854 . . . . 0.0 110.723 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 32' ' ' GLY . 33.6 p -54.25 -40.9 68.18 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.023 -1.048 . . . . 0.0 110.842 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.59 -15.83 0.43 Allowed Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.822 -1.18 . . . . 0.0 110.512 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.09 -13.87 47.68 Favored Glycine 0 N--CA 1.5 2.925 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.479 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -177.79 56.22 0.1 OUTLIER Glycine 0 N--CA 1.484 1.877 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.479 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 18.5 Cg_endo -70.0 -175.22 1.14 Allowed 'Trans proline' 0 C--N 1.32 -0.973 0 C-N-CA 121.815 1.677 . . . . 0.0 110.352 -178.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.568 ' N ' ' OG1' ' A' ' 27' ' ' THR . 46.6 ttt180 -60.49 86.93 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 34' ' ' PRO . 1.3 ppt_? -59.31 -2.98 0.35 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.851 -1.155 . . . . 0.0 108.757 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -70.66 -24.21 77.1 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.548 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.09 -55.12 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.23 0 O-C-N 121.056 -1.261 . . . . 0.0 110.393 -179.635 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.522 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.1 t -63.12 -64.34 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.013 -1.054 . . . . 0.0 111.559 -177.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 44' ' ' HIS . 73.0 mt-10 -56.55 -44.78 81.26 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.95 -1.094 . . . . 0.0 110.483 -178.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.5 tp60 -48.86 -56.94 7.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.065 -1.022 . . . . 0.0 110.06 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.511 ' SG ' HD21 ' A' ' 52' ' ' LEU . 56.6 m -84.83 -27.26 26.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.105 -0.997 . . . . 0.0 111.08 -178.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.9 t -83.46 -52.35 6.58 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.672 -1.267 . . . . 0.0 109.448 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 40' ' ' GLU . 2.1 t-160 -70.14 -28.85 65.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.327 -0.858 . . . . 0.0 108.84 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.3 p -136.61 162.38 33.29 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.334 -0.853 . . . . 0.0 109.542 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.2 mm -84.09 99.75 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.608 -0.682 . . . . 0.0 109.662 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.0 p -92.28 146.53 23.64 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.13 -0.981 . . . . 0.0 109.342 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.72 167.61 18.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.232 -0.918 . . . . 0.0 109.212 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.593 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.3 mt -57.08 -34.25 68.1 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -43.67 -57.25 3.28 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.874 0.845 . . . . 0.0 110.138 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -60.33 -41.87 94.44 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.511 HD21 ' SG ' ' A' ' 42' ' ' CYS . 78.2 mt -62.73 -28.27 69.85 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.514 ' OE2' ' NH1' ' A' ' 22' ' ' ARG . 1.8 tm-20 -74.26 -8.72 57.2 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -78.84 -26.96 44.16 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.875 -0.515 . . . . 0.0 109.946 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.421 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 14.5 m-85 -100.31 5.63 44.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.253 -0.905 . . . . 0.0 110.38 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 72.7 m -82.69 111.27 18.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.843 -1.161 . . . . 0.0 109.462 179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 57' ' ' ASN . 62.7 t-20 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.819 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.594 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -101.13 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 110.697 -178.658 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.594 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.8 m120 -102.97 26.58 7.99 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 109.807 -179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.633 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.52 161.88 13.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.331 -0.855 . . . . 0.0 109.443 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -94.27 136.5 34.49 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.639 0.733 . . . . 0.0 110.32 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.402 HD21 ' CE1' ' A' ' 1' ' ' PHE . 0.8 OUTLIER -99.64 131.89 45.34 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.461 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -147.8 125.31 11.7 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.192 -0.943 . . . . 0.0 109.186 179.334 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -149.14 44.34 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.8 m -44.96 -31.61 1.34 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.373 -1.075 . . . . 0.0 110.335 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.461 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -48.73 -50.04 35.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.966 -1.084 . . . . 0.0 108.761 179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 38' ' ' ILE . 19.5 tp -57.0 -54.57 45.24 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.458 -0.776 . . . . 0.0 109.534 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' H ' HG23 ' A' ' 12' ' ' VAL . 17.3 t -46.66 -66.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 110.096 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 50.8 mt-10 -47.67 -27.63 2.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.387 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.08 -54.49 5.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.392 -0.818 . . . . 0.0 109.17 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.7 mt -51.92 -34.81 43.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.398 -1.439 . . . . 0.0 108.585 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 20' ' ' GLY . 57.2 t80 -49.94 -50.04 47.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.327 -0.858 . . . . 0.0 110.231 -179.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -67.68 -50.81 55.78 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.573 -1.329 . . . . 0.0 108.64 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.3 t -50.62 -58.98 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.543 0.687 . . . . 0.0 109.759 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.23 -23.76 54.57 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.528 -0.732 . . . . 0.0 109.768 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.8 -127.2 30.91 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -78.98 -11.67 60.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.409 -1.054 . . . . 0.0 110.028 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.407 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -57.61 -27.18 62.52 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.162 -0.961 . . . . 0.0 109.287 -179.568 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.71 154.8 5.01 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.225 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -156.47 172.52 18.38 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.859 -1.377 . . . . 0.0 110.278 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 35.2 p90 -116.95 132.57 56.67 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -72.26 171.44 12.11 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.8 t -63.73 174.56 1.36 Allowed 'General case' 0 C--N 1.297 -1.69 0 O-C-N 120.706 -1.246 . . . . 0.0 109.669 -179.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -43.88 147.35 0.89 Allowed Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.398 -0.814 . . . . 0.0 110.078 -178.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -77.69 -6.25 15.99 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 C-N-CA 122.102 1.868 . . . . 0.0 110.429 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.2 p -53.95 -40.91 67.23 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.083 -1.011 . . . . 0.0 110.984 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.57 -15.95 0.42 Allowed Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.409 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.502 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.88 -15.26 43.18 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.478 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -177.21 55.53 0.1 Allowed Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.8 Cg_endo -69.96 -175.62 1.27 Allowed 'Trans proline' 0 C--N 1.319 -1.016 0 C-N-CA 121.857 1.705 . . . . 0.0 110.239 -179.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.583 ' N ' ' OG1' ' A' ' 27' ' ' THR . 2.9 ttt-85 -58.96 86.08 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.469 ' N ' ' O ' ' A' ' 34' ' ' PRO . 13.5 mtm-85 -59.57 -5.49 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.97 -1.082 . . . . 0.0 108.367 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -69.43 -24.13 76.22 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.8 -55.91 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 O-C-N 121.006 -1.291 . . . . 0.0 110.437 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.4 t -62.02 -64.18 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.038 -1.038 . . . . 0.0 111.521 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.443 ' O ' ' N ' ' A' ' 44' ' ' HIS . 83.9 mt-10 -55.84 -46.3 78.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.908 -1.12 . . . . 0.0 110.485 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.9 tp60 -48.14 -56.5 7.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.059 -1.026 . . . . 0.0 110.299 -179.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.552 ' SG ' HD21 ' A' ' 52' ' ' LEU . 58.5 m -85.15 -26.36 26.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.143 -0.973 . . . . 0.0 111.271 -178.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 43.9 t -83.4 -52.4 6.56 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.608 -1.307 . . . . 0.0 109.418 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.443 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.1 t-80 -69.47 -26.68 64.69 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.874 . . . . 0.0 109.339 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -137.04 173.31 11.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.338 -0.851 . . . . 0.0 109.827 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.8 mm -93.17 100.04 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.4 p -93.78 145.03 24.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.016 -1.053 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -80.53 166.53 21.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.882 . . . . 0.0 109.35 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -56.81 -34.36 67.62 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.45 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -44.03 -57.29 3.44 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.904 0.859 . . . . 0.0 109.943 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -59.89 -42.94 94.89 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.552 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.9 mt -61.83 -31.91 72.19 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -70.23 -9.68 56.58 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -75.83 -28.33 58.23 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.803 -0.561 . . . . 0.0 109.598 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 6.9 m-85 -102.72 7.01 39.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.406 -0.808 . . . . 0.0 109.984 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.446 ' SG ' HG12 ' A' ' 18' ' ' VAL . 60.5 m -78.58 108.6 12.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.96 -1.087 . . . . 0.0 109.409 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 57' ' ' ASN . 2.1 t-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.483 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.622 HG23 ' H ' ' A' ' 3' ' ' ASN . 1.1 m -102.73 -91.99 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.506 -0.746 . . . . 0.0 110.762 -178.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.622 ' H ' HG23 ' A' ' 2' ' ' VAL . 3.7 m120 -99.59 25.3 7.24 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.232 -0.917 . . . . 0.0 109.883 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.644 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.6 pt20 -95.95 157.35 15.94 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.83 . . . . 0.0 109.635 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.421 ' HB3' HD13 ' A' ' 46' ' ' ILE . 3.5 p-80 -92.69 135.9 33.7 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.574 0.702 . . . . 0.0 109.957 -179.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.418 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -97.53 136.03 38.52 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.472 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -151.67 125.16 8.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.303 179.4 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.79 -146.49 40.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.7 m -47.84 -31.83 5.45 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -1.086 . . . . 0.0 110.209 -179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.472 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.2 m-20 -49.03 -49.83 39.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.881 -1.137 . . . . 0.0 108.645 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 38' ' ' ILE . 19.6 tp -56.67 -55.09 38.49 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.415 -0.803 . . . . 0.0 109.401 179.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -46.41 -66.04 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.283 -0.886 . . . . 0.0 110.001 -179.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.1 mt-10 -47.51 -28.8 2.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.368 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.02 -54.61 5.84 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 109.173 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.4 mt -51.26 -34.93 34.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.509 -1.369 . . . . 0.0 108.667 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.6 t80 -49.96 -48.79 51.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 110.394 -179.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.82 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.55 -50.71 42.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.495 -1.378 . . . . 0.0 108.529 179.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -50.86 -59.09 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 121.512 0.673 . . . . 0.0 110.02 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.4 m -76.04 -23.98 55.15 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.441 -0.787 . . . . 0.0 109.699 -178.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.42 -133.55 46.34 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -75.5 -12.13 60.17 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.325 -1.103 . . . . 0.0 109.963 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -56.32 -26.93 54.03 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.002 -179.544 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.86 154.72 5.11 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -156.5 172.91 17.72 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.999 -1.295 . . . . 0.0 110.079 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.546 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.6 p90 -117.38 139.79 50.41 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.48 170.43 16.59 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.564 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.5 t -64.73 174.94 1.61 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.947 -1.095 . . . . 0.0 110.069 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.54 148.56 0.52 Allowed Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.651 -0.655 . . . . 0.0 110.135 -178.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.47 -6.32 16.21 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.255 1.97 . . . . 0.0 110.995 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.497 ' C ' ' H ' ' A' ' 32' ' ' GLY . 52.0 p -53.49 -40.79 65.65 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.995 -1.065 . . . . 0.0 111.0 -177.237 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.64 -15.68 0.44 Allowed Glycine 0 N--CA 1.495 2.57 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.647 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.497 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.05 -20.02 27.01 Favored Glycine 0 N--CA 1.5 2.935 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.502 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -173.4 54.69 0.15 Allowed Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.277 -1.929 . . . . 0.0 108.277 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.516 ' O ' ' N ' ' A' ' 36' ' ' ARG . 17.4 Cg_endo -67.81 -173.95 0.54 Allowed 'Trans proline' 0 C--N 1.319 -1.026 0 C-N-CA 121.915 1.743 . . . . 0.0 110.5 -179.071 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.564 ' N ' ' OG1' ' A' ' 27' ' ' THR . 38.8 ttt180 -56.24 87.1 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.516 ' N ' ' O ' ' A' ' 34' ' ' PRO . 2.1 ptp180 -58.99 -1.55 0.18 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.107 -0.995 . . . . 0.0 108.68 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.542 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -73.0 -25.74 72.9 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.39 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.31 0 O-C-N 121.057 -1.261 . . . . 0.0 110.385 -179.601 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 2.9 t -63.46 -63.91 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.962 -1.086 . . . . 0.0 111.461 -177.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.444 ' O ' ' N ' ' A' ' 44' ' ' HIS . 60.4 mt-10 -55.62 -46.18 77.43 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.864 -1.147 . . . . 0.0 110.43 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -48.39 -56.77 7.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 110.204 -179.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.494 ' SG ' HD21 ' A' ' 52' ' ' LEU . 73.0 m -85.1 -28.07 25.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 111.427 -178.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 53.9 t -83.29 -52.33 6.66 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.66 -1.275 . . . . 0.0 109.295 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.444 ' N ' ' O ' ' A' ' 40' ' ' GLU . 5.8 t60 -69.55 -27.04 64.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.066 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.7 m -137.17 157.4 46.76 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.496 -0.753 . . . . 0.0 109.49 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.421 HD13 ' HB3' ' A' ' 5' ' ' HIS . 5.8 mm -81.55 99.73 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.6 p -89.51 163.84 15.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.998 -1.064 . . . . 0.0 109.697 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -96.18 166.84 11.55 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.416 -0.802 . . . . 0.0 109.186 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.601 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.2 mt -58.59 -33.29 69.82 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -44.76 -57.86 3.45 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.791 0.805 . . . . 0.0 110.236 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -61.07 -40.84 95.22 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.061 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.494 HD21 ' SG ' ' A' ' 42' ' ' CYS . 76.1 mt -62.41 -25.09 67.76 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.66 -9.03 58.75 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -78.96 -26.82 43.51 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.783 -0.573 . . . . 0.0 109.705 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 17.2 m-85 -99.73 4.39 45.43 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.348 -0.845 . . . . 0.0 110.339 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.406 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 71.0 m -82.84 111.22 18.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.883 -1.136 . . . . 0.0 109.367 179.639 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.406 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.9 t-20 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.058 -0.972 . . . . 0.0 109.377 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.598 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -102.85 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.445 -0.784 . . . . 0.0 110.536 -178.856 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.598 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -101.5 26.77 6.91 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.393 -0.817 . . . . 0.0 109.892 -179.318 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.642 ' NE2' ' H2 ' ' A' ' 1' ' ' PHE . 2.0 pt20 -95.23 160.79 14.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -92.87 134.77 34.75 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.514 0.673 . . . . 0.0 110.67 -178.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -99.49 132.56 44.74 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.262 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.47 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.8 OUTLIER -148.49 125.1 11.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.094 -1.004 . . . . 0.0 109.332 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.86 -148.52 43.26 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.3 m -45.11 -32.28 1.72 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.347 -1.09 . . . . 0.0 110.245 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.47 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.8 m-20 -48.54 -50.52 31.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.991 -1.068 . . . . 0.0 108.823 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.522 HD21 HD12 ' A' ' 38' ' ' ILE . 19.8 tp -57.08 -54.79 42.76 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.434 -0.791 . . . . 0.0 109.505 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -46.56 -66.06 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.294 -0.879 . . . . 0.0 109.991 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 46.9 mt-10 -47.59 -29.31 2.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.923 . . . . 0.0 109.397 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.42 -54.58 6.02 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.375 -0.828 . . . . 0.0 109.363 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.6 mt -51.12 -36.1 38.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.456 -1.402 . . . . 0.0 108.794 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -49.43 -49.0 46.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.341 -0.849 . . . . 0.0 110.482 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.816 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.9 mp -69.02 -50.32 49.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.61 -1.306 . . . . 0.0 108.496 179.381 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -51.03 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.504 0.669 . . . . 0.0 110.113 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.3 m -75.52 -23.63 56.72 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.495 -0.753 . . . . 0.0 109.821 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.47 -126.76 25.09 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -77.45 -15.49 59.29 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.395 -1.062 . . . . 0.0 110.186 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -54.85 -27.9 45.81 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.174 -0.953 . . . . 0.0 109.409 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.79 154.88 5.13 Favored Glycine 0 N--CA 1.487 2.033 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.38 172.53 18.34 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.918 -1.342 . . . . 0.0 110.269 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 31.5 p90 -118.01 129.28 55.49 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -68.62 171.45 7.62 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 178.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.59 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.0 t -63.41 174.45 1.27 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 120.74 -1.225 . . . . 0.0 109.468 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.59 147.64 1.03 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.182 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -78.18 -6.29 15.62 Favored 'Trans proline' 0 N--CA 1.483 0.883 0 C-N-CA 122.098 1.865 . . . . 0.0 110.158 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.491 ' C ' ' H ' ' A' ' 32' ' ' GLY . 39.0 p -53.85 -40.95 66.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 110.99 -177.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.73 -15.74 0.45 Allowed Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.773 -1.203 . . . . 0.0 110.399 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.491 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.54 -16.2 40.68 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.476 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -176.74 55.53 0.11 Allowed Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.476 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 17.7 Cg_endo -69.39 -175.44 1.07 Allowed 'Trans proline' 0 C--N 1.318 -1.037 0 C-N-CA 121.774 1.65 . . . . 0.0 110.143 -179.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.59 ' N ' ' OG1' ' A' ' 27' ' ' THR . 33.7 ttt180 -59.84 86.19 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 178.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 34' ' ' PRO . 1.8 ptp180 -61.58 3.08 0.14 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.054 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -79.59 -21.84 65.74 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.28 -55.53 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 O-C-N 121.024 -1.28 . . . . 0.0 110.052 -179.714 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.9 t -62.2 -63.84 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.023 -1.048 . . . . 0.0 111.094 -177.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.456 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.9 mt-10 -54.74 -48.49 72.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.989 -1.069 . . . . 0.0 110.557 -178.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.0 tt0 -47.22 -56.58 6.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.069 -1.019 . . . . 0.0 110.493 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.526 ' SG ' HD21 ' A' ' 52' ' ' LEU . 57.1 m -84.66 -26.51 27.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.228 -0.92 . . . . 0.0 111.363 -178.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.3 t -83.77 -52.39 6.44 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.642 -1.286 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.4 t-80 -68.96 -27.29 65.6 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.235 -0.916 . . . . 0.0 109.23 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.436 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.6 t -137.23 173.17 11.97 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.416 -0.803 . . . . 0.0 109.88 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 9.7 mm -92.3 99.85 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.561 -0.712 . . . . 0.0 109.315 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 9.8 p -93.0 143.3 26.37 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.014 -1.054 . . . . 0.0 109.39 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 p -79.39 166.45 22.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.447 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.598 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 13.0 mt -56.36 -34.11 66.33 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.06 -57.49 3.35 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 121.87 0.843 . . . . 0.0 109.971 179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.625 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.9 mt-30 -60.06 -42.15 93.9 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.526 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.8 mt -62.79 -29.05 70.41 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.11 -8.9 57.81 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -78.43 -26.89 46.41 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.853 -0.529 . . . . 0.0 109.864 -179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.422 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 15.3 m-85 -100.75 5.24 43.57 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.265 -0.897 . . . . 0.0 110.227 -179.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 71.6 m -83.35 111.48 19.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.97 -1.081 . . . . 0.0 109.49 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.441 179.959 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.998 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.59 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -101.99 -91.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.421 -0.799 . . . . 0.0 110.678 -178.616 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.59 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.7 m120 -102.02 25.57 8.59 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.429 -0.794 . . . . 0.0 109.991 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.631 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.8 pt20 -95.97 160.18 14.59 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.548 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 9.8 p80 -92.95 136.19 33.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.514 -0.741 . . . . 0.0 110.552 -178.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.407 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.0 OUTLIER -97.35 127.06 42.99 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.304 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 82.2 m -142.89 125.29 15.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.296 -0.878 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.17 -149.31 45.61 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.5 m -44.92 -30.84 1.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.421 -1.047 . . . . 0.0 110.284 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.437 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 17.3 m-20 -48.7 -50.61 32.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.927 -1.108 . . . . 0.0 108.787 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.492 HD11 HD22 ' A' ' 52' ' ' LEU . 19.9 tp -55.42 -53.99 49.29 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.1 t -47.04 -66.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.837 . . . . 0.0 109.899 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 72.5 mt-10 -47.79 -26.77 1.74 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.371 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.998 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.02 -54.73 5.3 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.384 -0.823 . . . . 0.0 109.131 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.84 -34.28 39.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.406 -1.434 . . . . 0.0 108.581 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.6 t80 -50.16 -49.85 50.88 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.366 -0.834 . . . . 0.0 110.179 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.78 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.27 -50.76 51.59 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.584 -1.323 . . . . 0.0 108.681 179.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.6 t -50.52 -58.64 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.5 0.667 . . . . 0.0 109.757 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -77.0 -23.34 52.23 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 -178.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 46.95 -120.78 5.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -80.22 -13.7 59.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.299 -1.118 . . . . 0.0 110.15 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -57.95 -28.27 64.17 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.112 -0.992 . . . . 0.0 109.528 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.59 154.19 4.57 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -156.87 172.95 17.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.886 -1.361 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.8 p90 -119.15 139.51 51.68 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -80.52 169.82 17.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.931 -1.106 . . . . 0.0 108.143 179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.579 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.2 t -65.59 175.71 1.74 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.117 -0.989 . . . . 0.0 110.404 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -45.22 149.87 0.88 Allowed Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.459 -0.776 . . . . 0.0 109.895 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -78.4 -6.13 15.35 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.178 1.919 . . . . 0.0 110.581 179.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.512 ' C ' ' H ' ' A' ' 32' ' ' GLY . 42.5 p -53.67 -40.97 66.38 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.125 -0.985 . . . . 0.0 111.231 -177.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.57 -15.92 0.42 Allowed Glycine 0 N--CA 1.494 2.531 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.352 179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.52 -20.14 25.58 Favored Glycine 0 N--CA 1.499 2.852 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.508 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -172.82 54.3 0.16 Allowed Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.656 -1.778 . . . . 0.0 108.656 179.11 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.528 ' O ' ' N ' ' A' ' 36' ' ' ARG . 18.6 Cg_endo -69.17 -174.46 0.79 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 121.969 1.779 . . . . 0.0 110.075 -179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.579 ' N ' ' OG1' ' A' ' 27' ' ' THR . 2.8 ttt-85 -56.34 86.52 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' N ' ' O ' ' A' ' 34' ' ' PRO . 7.0 ptm180 -59.61 -1.73 0.28 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.049 -1.032 . . . . 0.0 108.722 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -72.92 -25.73 73.02 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -102.08 -56.33 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.061 -1.258 . . . . 0.0 110.46 -179.67 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -62.27 -64.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 120.961 -1.087 . . . . 0.0 111.637 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 44' ' ' HIS . 62.4 mt-10 -55.79 -46.79 77.9 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.85 -1.157 . . . . 0.0 110.331 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.0 tt0 -47.67 -57.49 5.45 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.086 -1.009 . . . . 0.0 110.167 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.598 ' SG ' HD21 ' A' ' 52' ' ' LEU . 63.1 m -84.77 -26.7 27.39 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.137 -0.977 . . . . 0.0 111.101 -178.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.0 t -83.25 -52.3 6.7 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.826 -1.171 . . . . 0.0 109.481 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.502 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 10.1 t-80 -71.24 -26.46 62.92 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.231 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.2 m -136.83 157.91 45.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.39 -0.819 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.5 mm -82.27 99.73 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.242 -0.911 . . . . 0.0 109.013 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.7 p -90.75 151.62 21.14 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.137 -0.977 . . . . 0.0 109.375 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -85.08 166.49 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.02 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -56.54 -34.04 66.67 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -44.44 -57.5 3.52 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.855 0.835 . . . . 0.0 110.023 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.593 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.8 mt-30 -60.07 -42.35 94.37 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.598 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.9 mt -62.29 -31.8 72.44 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.13 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -69.89 -9.46 54.96 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -75.54 -28.37 59.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.799 -0.563 . . . . 0.0 109.712 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.1 m-85 -102.03 6.32 41.03 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.333 -0.854 . . . . 0.0 110.018 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.452 ' SG ' HG12 ' A' ' 18' ' ' VAL . 73.4 m -80.4 109.0 14.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.93 -1.106 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.417 ' OXT' ' OD1' ' A' ' 57' ' ' ASN . 53.7 t-20 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.514 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.002 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.583 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -104.04 -91.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.407 -0.808 . . . . 0.0 110.726 -178.661 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.583 ' H ' HG23 ' A' ' 2' ' ' VAL . 5.2 m120 -101.66 25.85 8.04 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.409 -0.807 . . . . 0.0 109.936 -179.06 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.635 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.88 160.2 14.59 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.321 -0.862 . . . . 0.0 109.85 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' A' ' 5' ' ' HIS . 0.1 OUTLIER -92.76 132.09 37.26 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.643 -0.661 . . . . 0.0 110.441 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -95.4 132.8 40.06 Favored 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.027 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.486 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.6 OUTLIER -149.12 125.24 10.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.033 -1.042 . . . . 0.0 109.327 179.244 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.88 -147.4 41.49 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -45.89 -32.07 2.47 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.362 -1.081 . . . . 0.0 110.194 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.486 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 7.0 m-20 -49.27 -51.06 36.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.092 . . . . 0.0 108.762 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.512 HD21 HD12 ' A' ' 38' ' ' ILE . 21.3 tp -56.1 -51.64 67.16 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.4 -0.812 . . . . 0.0 109.391 179.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 t -49.44 -66.28 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.219 -0.926 . . . . 0.0 109.968 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 47.4 mt-10 -47.56 -26.42 1.44 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.412 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.002 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.03 -54.64 5.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.323 -0.861 . . . . 0.0 109.058 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.85 -33.94 38.4 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.412 -1.43 . . . . 0.0 108.635 179.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 55.2 t80 -50.58 -50.06 54.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.926 . . . . 0.0 110.236 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.78 -50.82 54.95 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.534 -1.354 . . . . 0.0 108.547 179.387 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.435 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.4 t -50.7 -59.01 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 CA-C-O 121.527 0.68 . . . . 0.0 109.668 -179.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -75.87 -23.54 55.63 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.48 -0.763 . . . . 0.0 109.819 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.02 -130.64 44.05 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -77.1 -14.44 59.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -1.094 . . . . 0.0 110.087 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.408 HH11 ' HB3' ' A' ' 22' ' ' ARG . 0.3 OUTLIER -54.88 -27.8 45.53 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.149 -0.969 . . . . 0.0 109.327 -179.628 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.76 156.39 6.07 Favored Glycine 0 N--CA 1.485 1.964 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.41 172.93 17.65 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.022 -1.281 . . . . 0.0 110.243 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.9 p90 -115.73 132.84 56.52 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -73.23 171.75 12.42 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.614 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.2 t -63.55 173.93 1.5 Allowed 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 118.578 -1.249 . . . . 0.0 109.302 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -44.41 148.82 0.81 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.199 -0.938 . . . . 0.0 110.139 -178.088 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -78.07 -6.54 15.87 Favored 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.086 1.857 . . . . 0.0 110.682 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.501 ' C ' ' H ' ' A' ' 32' ' ' GLY . 44.3 p -54.18 -40.86 67.93 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.949 -1.094 . . . . 0.0 111.186 -177.319 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.88 -15.76 0.48 Allowed Glycine 0 N--CA 1.493 2.439 0 C-N-CA 119.703 -1.237 . . . . 0.0 110.231 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.91 -15.93 37.66 Favored Glycine 0 N--CA 1.5 2.919 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.496 ' N ' ' HD3' ' A' ' 34' ' ' PRO . . . -175.85 55.29 0.12 Allowed Glycine 0 N--CA 1.484 1.892 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.539 ' O ' ' N ' ' A' ' 36' ' ' ARG . 22.4 Cg_endo -71.14 -175.46 1.5 Allowed 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 121.833 1.688 . . . . 0.0 109.866 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.614 ' N ' ' OG1' ' A' ' 27' ' ' THR . 8.3 ttt-85 -57.05 86.26 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.539 ' N ' ' O ' ' A' ' 34' ' ' PRO . 6.8 ptm180 -62.25 6.31 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.138 -0.976 . . . . 0.0 109.181 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.571 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -85.02 -21.86 54.2 Favored Glycine 0 N--CA 1.491 2.36 0 O-C-N 121.133 -0.98 . . . . 0.0 110.911 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -100.31 -54.24 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 120.879 -1.366 . . . . 0.0 110.457 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.525 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.2 t -61.42 -63.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 111.704 -177.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -58.52 -38.15 77.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 111.079 -178.101 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 50.1 tt0 -55.6 -53.68 53.43 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.833 -1.167 . . . . 0.0 109.195 -179.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.63 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.3 m -85.76 -26.73 25.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 110.769 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 51.8 t -83.86 -52.5 6.32 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.701 -1.249 . . . . 0.0 109.541 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.412 ' N ' ' O ' ' A' ' 40' ' ' GLU . 11.6 t60 -71.39 -26.41 62.77 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.207 -0.933 . . . . 0.0 109.174 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.7 m -137.06 160.28 39.4 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.363 -0.835 . . . . 0.0 109.645 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 6.2 mm -83.21 100.28 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.49 -0.756 . . . . 0.0 109.221 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 p -93.0 147.75 22.57 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.105 -0.997 . . . . 0.0 109.683 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.7 167.76 17.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.605 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.6 mt -58.4 -34.04 70.3 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -44.1 -57.12 3.57 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 121.797 0.808 . . . . 0.0 110.154 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.536 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 9.8 mt-30 -61.59 -41.63 97.7 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.63 HD21 ' SG ' ' A' ' 42' ' ' CYS . 79.0 mt -61.84 -31.69 71.97 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.48 -9.79 57.47 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -75.5 -28.31 59.13 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.816 -0.552 . . . . 0.0 109.571 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.438 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.5 m-85 -101.83 7.04 41.81 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.399 -0.813 . . . . 0.0 110.017 -179.568 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.435 ' SG ' HG12 ' A' ' 18' ' ' VAL . 65.4 m -80.43 106.39 12.41 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.897 -1.127 . . . . 0.0 109.398 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.65 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.994 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.601 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -103.0 -91.83 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.476 -0.765 . . . . 0.0 110.34 -179.082 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.79 HD22 ' H ' ' A' ' 3' ' ' ASN . 0.0 OUTLIER -101.94 27.4 6.57 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.465 -0.772 . . . . 0.0 110.074 -179.323 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.632 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.7 pt20 -95.28 157.66 15.8 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.232 -0.917 . . . . 0.0 109.166 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -90.2 132.05 35.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.582 -0.699 . . . . 0.0 110.718 -178.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.412 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.6 OUTLIER -95.1 130.5 41.78 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.184 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.424 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.5 m -143.5 125.27 15.07 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.24 -0.913 . . . . 0.0 109.388 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.16 -150.04 46.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -44.66 -30.34 0.91 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.412 -1.052 . . . . 0.0 110.284 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.424 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.67 -50.14 34.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.953 -1.092 . . . . 0.0 108.791 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.51 HD21 HD12 ' A' ' 38' ' ' ILE . 20.3 tp -55.76 -55.71 29.18 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.451 -0.781 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.408 ' H ' HG23 ' A' ' 12' ' ' VAL . 19.3 t -45.8 -65.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.385 -0.822 . . . . 0.0 109.946 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.497 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 84.8 mt-10 -47.73 -29.68 3.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.436 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.994 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -78.31 -54.45 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.84 . . . . 0.0 109.239 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.5 mt -51.34 -35.88 40.32 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.496 -1.378 . . . . 0.0 108.712 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 56.6 t80 -49.4 -48.84 46.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.414 -0.804 . . . . 0.0 110.461 -179.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.832 HD12 ' H ' ' A' ' 17' ' ' LEU . 3.7 mp -69.38 -50.45 46.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.488 -1.383 . . . . 0.0 108.539 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -50.84 -59.23 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 CA-C-O 121.558 0.694 . . . . 0.0 110.23 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.1 m -76.34 -24.04 54.23 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.402 -0.811 . . . . 0.0 109.804 -178.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 50.37 -126.19 23.2 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -77.32 -14.54 59.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -1.077 . . . . 0.0 110.28 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.406 ' HB3' HH11 ' A' ' 22' ' ' ARG . 0.2 OUTLIER -56.52 -27.6 57.8 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.36 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.53 154.51 4.69 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -156.52 172.6 18.27 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.923 -1.34 . . . . 0.0 110.418 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 33.3 p90 -118.29 138.75 52.17 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -77.45 170.83 15.87 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.6 t -64.3 175.29 1.35 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.869 -1.144 . . . . 0.0 109.807 -179.276 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.15 148.03 0.52 Allowed Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.492 -0.755 . . . . 0.0 110.295 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -77.36 -6.52 16.45 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.091 1.861 . . . . 0.0 110.462 179.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.516 ' C ' ' H ' ' A' ' 32' ' ' GLY . 40.2 p -54.02 -41.16 67.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.095 -1.003 . . . . 0.0 111.096 -177.357 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.53 -15.89 0.41 Allowed Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.655 -1.259 . . . . 0.0 110.311 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.516 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -95.35 -19.05 31.36 Favored Glycine 0 N--CA 1.499 2.839 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.55 54.95 0.13 Allowed Glycine 0 N--CA 1.484 1.899 0 N-CA-C 108.449 -1.86 . . . . 0.0 108.449 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.491 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.3 Cg_endo -68.82 -174.71 0.77 Allowed 'Trans proline' 0 C--N 1.319 -0.993 0 C-N-CA 121.868 1.712 . . . . 0.0 110.416 -179.107 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.544 ' N ' ' OG1' ' A' ' 27' ' ' THR . 41.2 ttt180 -57.46 87.93 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.585 HH11 ' CG ' ' A' ' 36' ' ' ARG . 1.4 mtt-85 -59.1 -5.88 0.76 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.967 -1.083 . . . . 0.0 108.384 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -67.85 -25.99 74.02 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.52 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.92 -55.21 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.315 0 O-C-N 121.002 -1.293 . . . . 0.0 110.436 -179.502 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.52 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.25 -64.52 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.133 . . . . 0.0 111.564 -177.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' HIS . 35.4 mt-10 -55.94 -45.74 78.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.854 -1.154 . . . . 0.0 110.295 -178.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.461 ' NE2' ' OE1' ' A' ' 51' ' ' GLN . 53.0 tt0 -47.48 -57.87 4.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.084 -1.01 . . . . 0.0 110.15 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.568 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.1 m -84.83 -27.0 27.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.156 -0.965 . . . . 0.0 111.02 -178.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.8 t -83.32 -51.44 7.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.845 -1.16 . . . . 0.0 109.429 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.519 ' N ' ' O ' ' A' ' 40' ' ' GLU . 17.0 t60 -73.47 -26.16 60.79 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.339 -0.851 . . . . 0.0 109.48 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -136.86 157.69 46.18 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.4 -0.813 . . . . 0.0 109.876 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.5 mm -79.95 99.56 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.461 -0.774 . . . . 0.0 109.229 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 12.6 p -92.57 154.9 18.14 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.056 -1.027 . . . . 0.0 109.637 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -88.85 166.5 13.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.296 -0.878 . . . . 0.0 108.988 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 14.7 mt -58.4 -32.78 68.94 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.39 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.28 -57.31 3.55 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.804 0.811 . . . . 0.0 110.159 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.461 ' OE1' ' NE2' ' A' ' 41' ' ' GLN . 24.6 mt-30 -61.68 -42.04 98.38 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.71 -0.796 . . . . 0.0 108.998 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.568 HD21 ' SG ' ' A' ' 42' ' ' CYS . 74.6 mt -61.29 -24.93 66.76 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.71 -8.74 58.39 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -79.67 -26.78 40.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.794 -0.566 . . . . 0.0 109.849 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 16.3 m-85 -99.06 4.62 47.12 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.282 -0.886 . . . . 0.0 110.31 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . . . . . . . . . 70.9 m -81.26 111.34 17.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.939 -1.101 . . . . 0.0 109.496 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.64 179.993 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.003 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.614 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.5 OUTLIER -99.77 -91.57 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.353 -0.842 . . . . 0.0 110.197 -179.124 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.614 ' H ' HG23 ' A' ' 2' ' ' VAL . 1.3 p-10 -104.33 28.22 7.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.671 -0.643 . . . . 0.0 109.431 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.628 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 1.8 pt20 -94.75 157.41 15.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.163 -0.96 . . . . 0.0 109.123 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.477 ' H ' ' CD2' ' A' ' 5' ' ' HIS . 16.4 p80 -89.0 131.73 35.05 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.526 0.679 . . . . 0.0 110.713 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.406 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.1 mp -97.16 132.44 42.94 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.483 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 0.7 OUTLIER -149.24 125.36 10.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.189 -0.944 . . . . 0.0 109.278 179.286 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.72 -146.51 40.31 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.7 m -46.75 -32.5 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.365 -1.079 . . . . 0.0 110.155 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.483 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.0 -50.44 35.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.965 -1.084 . . . . 0.0 108.783 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.526 HD21 HD12 ' A' ' 38' ' ' ILE . 18.1 tp -56.9 -55.73 30.71 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.394 -0.816 . . . . 0.0 109.529 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 12' ' ' VAL . 15.6 t -46.13 -66.15 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.342 -0.849 . . . . 0.0 110.085 -179.41 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.493 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 75.8 mt-10 -47.94 -26.75 1.85 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.197 -0.939 . . . . 0.0 109.298 -179.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.003 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.08 -54.21 5.74 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.333 -0.854 . . . . 0.0 109.088 179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.87 -34.77 42.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.361 -1.462 . . . . 0.0 108.536 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 20' ' ' GLY . 58.0 t80 -49.82 -49.59 48.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.374 -0.828 . . . . 0.0 110.358 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.777 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.2 mp -68.58 -50.66 49.99 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.584 -1.322 . . . . 0.0 108.598 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.428 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.67 -58.88 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.49 0.662 . . . . 0.0 109.703 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -76.51 -23.48 53.72 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.526 -0.734 . . . . 0.0 109.9 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 51.94 -127.08 31.16 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.12 -14.96 59.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.402 -1.057 . . . . 0.0 110.101 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.1 mtp180 -54.95 -28.99 55.61 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.098 -1.001 . . . . 0.0 109.171 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.73 155.91 5.73 Favored Glycine 0 N--CA 1.485 1.931 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -156.5 172.72 18.05 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.907 -1.349 . . . . 0.0 110.174 -179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.542 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.3 p90 -116.09 137.65 51.94 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -75.96 171.95 13.56 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.571 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 10.0 t -63.13 174.37 1.17 Allowed 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.762 -1.211 . . . . 0.0 109.812 -178.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -44.45 147.37 1.03 Allowed Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.369 -0.832 . . . . 0.0 110.096 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -77.5 -6.48 16.3 Favored 'Trans proline' 0 N--CA 1.484 0.915 0 C-N-CA 122.107 1.871 . . . . 0.0 110.315 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.2 p -54.1 -41.06 67.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.104 -0.998 . . . . 0.0 110.904 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.25 -15.88 0.37 Allowed Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.389 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.35 -14.22 45.5 Favored Glycine 0 N--CA 1.498 2.808 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.52 ' O ' ' NH2' ' A' ' 36' ' ' ARG . . . -177.73 56.33 0.1 OUTLIER Glycine 0 N--CA 1.484 1.839 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.478 ' HD3' ' N ' ' A' ' 33' ' ' GLY . 20.6 Cg_endo -70.7 -175.08 1.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 121.793 1.662 . . . . 0.0 109.886 -179.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.571 ' N ' ' OG1' ' A' ' 27' ' ' THR . 43.8 ttt180 -63.4 87.93 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.607 ' CD ' ' H ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER -58.63 -13.91 6.98 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.78 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.404 ' N ' ' C ' ' A' ' 35' ' ' ARG . . . -57.85 -26.66 58.19 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.93 -55.8 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.335 0 O-C-N 120.895 -1.356 . . . . 0.0 110.566 -179.461 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.8 t -63.26 -64.39 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.905 -1.122 . . . . 0.0 111.295 -177.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 44' ' ' HIS . 80.9 mt-10 -54.47 -47.54 72.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.89 -1.131 . . . . 0.0 110.277 -178.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 48.5 tt0 -46.68 -58.52 3.77 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.155 -0.966 . . . . 0.0 110.417 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.47 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.7 m -84.87 -25.88 27.71 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.131 -0.981 . . . . 0.0 111.435 -178.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 47.3 t -83.61 -51.71 7.07 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.58 -1.325 . . . . 0.0 109.068 179.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.477 ' N ' ' O ' ' A' ' 40' ' ' GLU . 10.2 t60 -68.13 -27.9 66.85 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.419 -0.8 . . . . 0.0 109.341 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 42' ' ' CYS . 14.2 t -137.35 173.14 12.0 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.353 -0.842 . . . . 0.0 110.188 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 11.2 mm -91.82 99.43 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 10.0 p -93.92 152.99 18.46 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.074 -1.016 . . . . 0.0 109.548 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.28 167.54 13.47 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.902 . . . . 0.0 109.125 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.606 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.4 -34.53 68.98 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.7 t80 -43.67 -57.01 3.4 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.852 0.834 . . . . 0.0 110.038 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.611 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 8.1 mt-30 -60.1 -42.19 94.13 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.485 HD22 HD11 ' A' ' 11' ' ' LEU . 80.1 mt -62.54 -32.39 73.33 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.86 -9.24 54.12 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -76.34 -27.64 56.56 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 11.9 m-85 -102.11 6.64 40.99 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.431 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 95.7 m -80.95 105.2 12.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.842 -1.161 . . . . 0.0 109.154 179.567 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.431 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 14.4 t-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.999 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.633 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.9 OUTLIER -104.5 -91.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.751 . . . . 0.0 110.574 -178.767 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.633 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.0 m120 -99.95 25.82 6.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.283 -0.886 . . . . 0.0 109.742 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.635 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.4 pt20 -95.72 159.14 15.13 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.308 -0.87 . . . . 0.0 109.494 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -93.36 134.46 35.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.616 -0.678 . . . . 0.0 110.283 -179.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.9 OUTLIER -95.94 127.94 42.4 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.465 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.436 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.2 m -143.51 125.48 15.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.892 . . . . 0.0 109.263 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.11 -149.57 46.11 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -44.84 -30.21 0.94 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -1.032 . . . . 0.0 110.347 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.436 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.7 m-20 -49.12 -50.89 35.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.895 -1.128 . . . . 0.0 108.818 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.556 HD21 HD12 ' A' ' 38' ' ' ILE . 20.0 tp -55.16 -52.11 64.35 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.361 -0.837 . . . . 0.0 109.198 179.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 t -49.15 -66.29 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 109.896 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.487 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 28.4 mt-10 -47.9 -25.75 1.44 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.447 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.999 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -81.57 -54.9 5.03 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.282 -0.887 . . . . 0.0 109.063 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.65 -34.35 37.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.335 -1.478 . . . . 0.0 108.595 179.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.422 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.5 t80 -50.23 -49.92 51.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.326 -0.859 . . . . 0.0 110.275 -179.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.779 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.5 mp -67.91 -50.85 53.77 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.65 -1.281 . . . . 0.0 108.626 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG12 ' SG ' ' A' ' 56' ' ' CYS . 40.9 t -50.52 -58.68 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 CA-C-O 121.511 0.672 . . . . 0.0 109.854 -179.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.2 m -77.03 -23.12 52.13 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.483 -0.761 . . . . 0.0 109.997 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 47.7 -122.27 7.61 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -79.13 -15.3 58.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 0.0 110.275 -179.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 47.2 mtp180 -56.62 -28.35 60.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.123 -0.985 . . . . 0.0 109.491 -179.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.49 155.06 4.95 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.399 -1.881 . . . . 0.0 108.399 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -156.68 172.74 18.07 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.898 -1.354 . . . . 0.0 110.449 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 30.5 p90 -118.4 133.93 55.47 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -73.41 171.18 13.58 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.588 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.0 t -64.29 175.1 1.39 Allowed 'General case' 0 C--N 1.296 -1.756 0 O-C-N 120.961 -1.087 . . . . 0.0 109.698 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.51 151.87 0.45 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.423 -0.798 . . . . 0.0 110.121 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -78.69 -6.59 15.36 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.004 1.803 . . . . 0.0 110.259 179.421 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.7 p -53.64 -40.59 65.97 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.172 -0.955 . . . . 0.0 111.291 -177.384 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.14 -15.53 0.54 Allowed Glycine 0 N--CA 1.495 2.579 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.259 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -94.17 -31.82 7.81 Favored Glycine 0 N--CA 1.499 2.868 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.518 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -166.25 53.58 0.25 Allowed Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.83 -1.708 . . . . 0.0 108.83 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.528 ' O ' ' N ' ' A' ' 36' ' ' ARG . 24.5 Cg_endo -70.3 -173.6 0.83 Allowed 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 122.041 1.827 . . . . 0.0 109.924 -179.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.588 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.7 ttt-85 -57.01 85.95 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' N ' ' O ' ' A' ' 34' ' ' PRO . 16.6 mtm-85 -59.12 -29.54 67.46 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.045 -1.034 . . . . 0.0 108.281 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 36' ' ' ARG . . . -40.9 -23.98 0.08 OUTLIER Glycine 0 N--CA 1.49 2.286 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.556 HD12 HD21 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -102.4 -55.61 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.152 -1.204 . . . . 0.0 109.97 179.674 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.53 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 4.7 t -62.69 -64.15 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.087 -1.008 . . . . 0.0 112.069 -176.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 1.7 pp20? -59.93 -39.59 86.0 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.727 -1.233 . . . . 0.0 110.719 -178.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 51' ' ' GLN . 49.2 tt0 -51.26 -56.71 11.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.877 -1.139 . . . . 0.0 109.477 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.576 ' SG ' HD21 ' A' ' 52' ' ' LEU . 68.9 m -85.46 -26.58 26.25 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.381 -0.824 . . . . 0.0 111.045 -179.21 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 46.3 t -84.07 -52.4 6.32 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.706 -1.246 . . . . 0.0 109.673 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.427 ' N ' ' O ' ' A' ' 40' ' ' GLU . 6.2 t60 -69.99 -26.97 64.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.114 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -136.78 160.58 38.42 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.484 -0.76 . . . . 0.0 109.107 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 4.9 mm -84.65 99.73 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.3 p -90.42 164.18 14.39 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.065 -1.022 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -96.82 166.77 11.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.36 -0.838 . . . . 0.0 109.007 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.3 mt -57.68 -34.34 69.31 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -44.08 -57.85 3.16 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.86 0.838 . . . . 0.0 110.014 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.618 ' NE2' ' NE2' ' A' ' 41' ' ' GLN . 7.8 mt-30 -59.8 -42.57 93.73 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -179.78 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.576 HD21 ' SG ' ' A' ' 42' ' ' CYS . 81.2 mt -62.21 -32.08 72.7 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.91 -9.26 54.35 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -76.21 -28.04 57.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.788 -0.57 . . . . 0.0 109.649 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.448 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.2 m-85 -101.83 6.21 41.45 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.354 -0.841 . . . . 0.0 110.102 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.462 ' SG ' HG12 ' A' ' 18' ' ' VAL . 88.6 m -79.8 106.74 12.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.939 -1.101 . . . . 0.0 109.323 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.41 179.967 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.62 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.8 OUTLIER -102.6 -91.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.404 -0.81 . . . . 0.0 110.626 -178.68 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.62 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -101.05 25.6 7.92 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 -179.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.628 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 2.5 pt20 -96.0 158.54 15.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.36 -0.837 . . . . 0.0 109.635 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.1 p-80 -92.04 135.89 33.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.635 -0.665 . . . . 0.0 110.255 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.41 HD21 ' CB ' ' A' ' 14' ' ' ALA . 1.2 mp -97.05 126.55 42.27 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.425 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 76.5 m -142.35 125.14 16.0 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.292 -0.88 . . . . 0.0 109.241 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.9 -148.74 45.18 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.354 -1.098 . . . . 0.0 110.354 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.0 m -44.67 -31.08 1.05 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.383 -1.069 . . . . 0.0 110.349 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.425 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 1.3 m-20 -49.01 -50.66 34.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.946 -1.097 . . . . 0.0 108.841 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 38' ' ' ILE . 19.1 tp -55.53 -54.01 49.32 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.405 -0.809 . . . . 0.0 109.283 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.415 ' H ' HG23 ' A' ' 12' ' ' VAL . 16.7 t -47.43 -66.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.012 -179.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.485 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 52.0 mt-10 -47.72 -26.92 1.73 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.343 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -80.81 -54.93 5.17 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.467 -0.771 . . . . 0.0 109.188 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.8 mt -51.54 -34.06 34.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.394 -1.441 . . . . 0.0 108.603 179.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.46 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.7 t80 -50.48 -50.75 51.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.276 -179.612 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.802 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.3 mp -67.3 -50.8 58.76 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.532 -1.355 . . . . 0.0 108.658 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.457 HG12 ' SG ' ' A' ' 56' ' ' CYS . 41.6 t -50.43 -59.01 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-O 121.569 0.7 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.0 m -76.72 -23.27 53.08 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.539 -0.725 . . . . 0.0 109.92 -178.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 49.02 -123.2 10.55 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.57 -15.12 58.24 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -1.114 . . . . 0.0 110.084 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -55.15 -28.81 55.52 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.15 -0.969 . . . . 0.0 109.337 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.47 154.66 4.72 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -156.57 172.9 17.74 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 120.901 -1.352 . . . . 0.0 110.434 -179.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.541 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 32.7 p90 -118.11 138.27 52.37 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -77.67 170.61 16.27 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.565 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 9.3 t -64.68 175.0 1.56 Allowed 'General case' 0 C--N 1.299 -1.617 0 O-C-N 120.998 -1.064 . . . . 0.0 110.111 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -45.11 148.4 1.05 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.41 -0.806 . . . . 0.0 110.03 -178.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -77.73 -6.23 15.94 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.121 1.881 . . . . 0.0 110.573 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.509 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.0 p -53.88 -41.1 67.18 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.077 -1.014 . . . . 0.0 111.215 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.58 -15.76 0.43 Allowed Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.604 -1.284 . . . . 0.0 110.398 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.97 -17.71 31.63 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.501 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.58 54.64 0.13 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.157 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 19.2 Cg_endo -69.98 -174.61 0.98 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 121.866 1.711 . . . . 0.0 109.802 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.565 ' N ' ' OG1' ' A' ' 27' ' ' THR . 38.4 ttt180 -60.31 89.18 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.727 ' N ' ' HE ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER -58.52 -16.64 16.31 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.795 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.442 ' N ' ' HE ' ' A' ' 36' ' ' ARG . . . -56.23 -28.6 54.89 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -101.63 -55.98 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 O-C-N 120.929 -1.336 . . . . 0.0 110.704 -179.283 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.521 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.5 t -63.11 -64.24 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.911 -1.118 . . . . 0.0 111.421 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 44' ' ' HIS . 42.2 mt-10 -54.46 -47.8 72.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.773 -1.204 . . . . 0.0 110.3 -178.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -47.13 -58.97 3.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.08 -1.013 . . . . 0.0 110.459 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.566 ' SG ' HD21 ' A' ' 52' ' ' LEU . 60.0 m -84.54 -25.56 28.65 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -0.946 . . . . 0.0 111.307 -178.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 45.4 t -83.96 -52.3 6.45 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.65 -1.281 . . . . 0.0 109.214 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.48 ' N ' ' O ' ' A' ' 40' ' ' GLU . 9.9 t-80 -67.44 -28.88 68.26 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.32 -0.863 . . . . 0.0 109.243 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.432 ' O ' ' O ' ' A' ' 42' ' ' CYS . 13.2 t -136.9 173.28 11.87 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.379 -0.826 . . . . 0.0 109.704 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 3.6 mm -92.56 99.66 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.6 p -91.75 151.68 20.51 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.063 -1.023 . . . . 0.0 109.632 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 p -84.97 166.34 16.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.233 -0.917 . . . . 0.0 109.223 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.7 mt -57.2 -34.18 68.25 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -44.22 -57.42 3.46 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.914 0.864 . . . . 0.0 110.014 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 8.5 mt-30 -59.83 -42.67 94.08 Favored 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.566 HD21 ' SG ' ' A' ' 42' ' ' CYS . 80.0 mt -62.01 -32.39 72.87 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.6 -9.77 55.47 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -75.73 -27.85 58.31 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.781 -0.575 . . . . 0.0 109.584 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.443 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 10.9 m-85 -101.85 5.5 41.07 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.373 -0.829 . . . . 0.0 110.056 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.457 ' SG ' HG12 ' A' ' 18' ' ' VAL . 89.2 m -79.95 111.14 16.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.901 -1.124 . . . . 0.0 109.449 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.447 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 1.001 ' CZ ' ' HB1' ' A' ' 14' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.595 HG23 ' H ' ' A' ' 3' ' ' ASN . 0.7 OUTLIER -98.57 -91.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.369 -0.832 . . . . 0.0 110.803 -178.37 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.595 ' H ' HG23 ' A' ' 2' ' ' VAL . 4.6 m120 -104.17 25.92 9.45 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.401 -0.812 . . . . 0.0 109.988 -179.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.626 ' NE2' ' N ' ' A' ' 1' ' ' PHE . 3.2 pt20 -95.85 157.95 15.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.247 -0.908 . . . . 0.0 109.672 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 5' ' ' HIS . 3.0 p-80 -91.25 133.52 35.33 Favored 'General case' 0 N--CA 1.489 1.494 0 CA-C-O 121.405 0.622 . . . . 0.0 110.134 -179.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.408 HD21 ' CB ' ' A' ' 14' ' ' ALA . 0.8 OUTLIER -92.9 125.22 37.39 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.519 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.422 ' H ' ' HB2' ' A' ' 10' ' ' ASP . 83.1 m -140.79 125.45 17.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.907 . . . . 0.0 109.264 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.46 -150.75 47.32 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 72.9 m -44.21 -29.36 0.63 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.401 -1.058 . . . . 0.0 110.263 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 7' ' ' CYS . 2.5 m-20 -48.77 -50.49 33.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.982 -1.074 . . . . 0.0 108.859 179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.495 HD11 HD22 ' A' ' 52' ' ' LEU . 20.4 tp -55.94 -54.48 44.22 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.438 -0.789 . . . . 0.0 109.207 179.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.3 t -46.71 -66.17 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.358 -0.839 . . . . 0.0 109.901 -179.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.486 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 86.7 mt-10 -47.63 -27.98 2.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.177 -0.952 . . . . 0.0 109.291 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 1.001 ' HB1' ' CZ ' ' A' ' 1' ' ' PHE . . . -79.74 -55.32 5.09 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 109.181 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 17.9 mt -51.47 -34.07 33.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.311 -1.493 . . . . 0.0 108.649 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 20' ' ' GLY . 56.1 t80 -50.44 -49.27 55.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 110.165 -179.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 17' ' ' LEU . 4.4 mp -68.76 -51.06 45.22 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.535 -1.353 . . . . 0.0 108.619 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.418 HG12 ' SG ' ' A' ' 56' ' ' CYS . 39.9 t -50.39 -58.56 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 121.523 0.678 . . . . 0.0 109.698 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.9 m -76.3 -23.81 54.35 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.485 -0.759 . . . . 0.0 109.693 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 16' ' ' TYR . . . 54.33 -131.83 45.89 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -76.62 -11.25 59.83 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.37 -1.077 . . . . 0.0 110.121 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -57.84 -26.98 62.77 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.076 -1.015 . . . . 0.0 109.35 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.87 155.68 5.72 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 -179.255 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 51.3 p90 -156.74 173.0 17.62 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.921 -1.341 . . . . 0.0 110.227 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.551 ' O ' ' CD1' ' A' ' 25' ' ' PHE . 37.5 p90 -115.26 137.25 52.24 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -78.13 171.01 15.67 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.577 ' OG1' ' N ' ' A' ' 35' ' ' ARG . 7.1 t -64.13 175.11 1.33 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.853 -1.154 . . . . 0.0 109.975 -179.088 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -42.42 147.71 0.58 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.521 -0.737 . . . . 0.0 110.3 -178.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -77.24 -6.41 16.47 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.18 1.92 . . . . 0.0 110.493 179.503 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.51 ' C ' ' H ' ' A' ' 32' ' ' GLY . 43.1 p -53.98 -41.06 67.47 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.137 -0.977 . . . . 0.0 110.96 -177.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 67.59 -15.83 0.43 Allowed Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.388 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 30' ' ' THR . . . -96.24 -18.38 31.4 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.497 ' N ' ' CD ' ' A' ' 34' ' ' PRO . . . -174.04 55.04 0.14 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 179.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.497 ' CD ' ' N ' ' A' ' 33' ' ' GLY . 18.6 Cg_endo -69.29 -175.03 0.92 Allowed 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.874 1.716 . . . . 0.0 110.423 -179.128 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.577 ' N ' ' OG1' ' A' ' 27' ' ' THR . 5.4 ttt-85 -56.93 86.58 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.488 ' N ' ' O ' ' A' ' 34' ' ' PRO . 7.1 ptm180 -59.71 -1.72 0.29 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.016 -1.052 . . . . 0.0 108.605 179.687 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 35' ' ' ARG . . . -74.06 -24.41 73.81 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -101.41 -55.99 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.001 -1.293 . . . . 0.0 110.051 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 3.6 t -61.97 -64.38 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.01 -1.056 . . . . 0.0 111.32 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 44' ' ' HIS . 51.2 mt-10 -55.24 -47.49 75.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.946 -1.096 . . . . 0.0 110.613 -178.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -47.3 -57.78 4.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.051 -1.03 . . . . 0.0 110.303 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.573 ' SG ' HD21 ' A' ' 52' ' ' LEU . 70.9 m -84.81 -26.0 27.76 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.203 -0.935 . . . . 0.0 111.177 -178.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 39' ' ' VAL . 43.1 t -83.1 -52.27 6.78 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.746 -1.221 . . . . 0.0 109.42 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' A' ' 44' ' ' HIS . 11.8 t-80 -71.15 -26.08 62.84 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.357 -0.839 . . . . 0.0 109.39 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -136.94 157.85 45.81 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.443 -0.785 . . . . 0.0 109.625 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 5.2 mm -82.03 99.59 5.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.357 -0.839 . . . . 0.0 108.785 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.7 p -91.14 158.43 16.64 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.106 -0.996 . . . . 0.0 109.781 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.6 p -89.81 166.61 13.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.308 -0.87 . . . . 0.0 108.96 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.607 ' CD2' ' CE1' ' A' ' 1' ' ' PHE . 12.9 mt -58.78 -33.27 70.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -44.54 -57.56 3.53 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 121.716 0.769 . . . . 0.0 110.238 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -61.06 -41.8 97.29 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 119.665 -0.814 . . . . 0.0 108.918 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.573 HD21 ' SG ' ' A' ' 42' ' ' CYS . 77.7 mt -61.28 -30.77 70.68 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.008 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.48 -9.72 58.64 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -75.99 -28.19 57.71 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.756 -0.59 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.426 ' CD1' ' N ' ' A' ' 55' ' ' TYR . 9.9 m-85 -101.55 6.1 42.06 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.357 -0.839 . . . . 0.0 110.02 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' CYS . . . . . 0.422 ' O ' ' OXT' ' A' ' 57' ' ' ASN . 66.7 m -79.81 107.49 12.63 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.866 -1.147 . . . . 0.0 109.345 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.422 ' OXT' ' O ' ' A' ' 56' ' ' CYS . 28.1 t-20 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.094 -0.955 . . . . 0.0 109.453 -179.958 . . . . . . . . 1 1 . 1 stop_ save_